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Abstract	  
Reversible	  phosphorylation	  of	  tyrosine	  residues	  on	  proteins	   is	  a	  cornerstone	  of	  cell	  
to	   cell	   signalling,	   and	   is	   achieved	   through	   the	   concerted	  action	  of	  protein	   tyrosine	  
kinases	  (PTKs)	  and	  protein	  tyrosine	  phosphatases	  (PTPs),	  which	  catalyse	  the	  addition	  
and	  removal	  of	  phosphate	  moieties	  respectively.	  	  While	  the	  contribution	  of	  PTKs	  to	  
oncogenesis	   and	   tumour	   maintenance	   has	   been	   well	   documented	   in	   a	   range	   of	  
human	  cancers,	  knowledge	  of	  the	  specific	  role	  of	  PTPs	  has	  generally	  lagged	  behind.	  
This	   thesis	   examines	   that	   role	   in	   neuroblastoma,	   a	   common	   and	   deadly	  
sympathoadrenal	  tumour	  of	  infancy.	  	  We	  provide	  evidence	  that	  vanadium-­‐based	  PTP	  
inhibitors	   cause	   synergistic	   hyperactivation	   of	   Akt	   and	   Erk,	   which	   drives	   an	  
irreversible	   differentiation	   and	   senescence	   program	   that	   is	   independent	   of	   p53,	  
p16INK4A	  and	  PTEN.	  It	  is	  then	  shown	  that	  in	  another	  group	  of	  tumour	  cell	  lines,	  such	  
compounds	   used	   alone	   can	   induce	   selective	   caspase-­‐dependent,	   p53-­‐independent	  
apoptosis	   that	   is	   associated	  with	   activation	   of	   Akt	   and	   altered	   redox	   homeostasis.	  
Lastly	   we	   examine	   the	   expression	   profile	   of	   the	   PTPome	   in	   a	   wide	   panel	   of	  
neuroblastoma	   cell	   lines,	   providing	   preliminary	   evidence	   for	   candidate	   PTP	  













	   9	  
Acknowledgements	  
This	   work	   would	   not	   have	   been	   possible	   without	   the	   contributions	   of	   others,	   for	  
which	  I	  am	  extremely	  grateful.	  Of	  special	  mention	  are	  Jonathan	  Ham	  for	  generously	  
agreeing	   to	   perform	   microinjection	   studies;	   Charlotte	   Cole	   for	   her	   expert	  
construction	   of	   plasmid	   expression	   vectors;	   Mauritzio	  Mangolini	   for	   his	   efforts	   at	  
resolving	   problems	   with	   troublesome	   antibodies;	   Simon	   Picker	   for	   lending	   his	  
expertise	   in	   bioinformatics;	   Aris	   Tagalakis	   and	   Stephen	   Hart	   for	   their	   numerous	  
donations	   of	   time	   and	   transfection	   reagents;	   Ayad	   Eddaoudi	   for	   his	   unending	  
knowledge	  of	  flow	  cytometry;	  Fanny	  Schmidt	  for	  her	  generous	  efforts	  at	  conducting	  
expression	   analyses;	   and	   Olesya	   Chayka	   for	   her	   uncanny	   ability	   to	   acquire	   things	  
exactly	  when	  I	  need	  them…	  
Of	   course	   much	   help	   has	   come	   from	   the	   members	   of	   the	   ICH	   Neural	  
Development	  Unit,	   of	  which	   I	   have	  had	   the	   great	  pleasure	  of	  working	   in	   for	   three	  
years.	  First	  the	  group	  leaders;	  my	  supervisor	  Andy	  Stoker,	  the	  most	  patient	  man	  on	  
earth,	  who	  has	  put	  up	  with	  more	  of	  my	  catastrophes	  than	  I	  can	  remember…	  (As	  well	  
as	  providing	  constant	   intellectual	   insights	  of	  course);	  my	  secondary	  supervisor	  Alan	  
Burns,	  always	  on	  hand	  for	  useful	  advice;	  The	  head	  of	  the	  unit	  Andy	  Copp,	  who	  would	  
always	  lend	  an	  ear	  to	  my	  problems	  despite	  running	  an	  entire	  institute;	  And	  of	  course	  
JP,	  who	  has	  and	  will	  always	  provide	  me	  with	  constant	  challenges	  to	  my	  arguments	  to	  
the	  point	  that	  I	  end	  up	  forgetting	  what	  they	  were…	  	  The	  PhD	  students	  and	  postdocs	  
are	  obviously	  the	  heart	  and	  soul	  of	  the	  unit,	  and	  no	  doubt	  each	  and	  every	  one	  will	  
have	   lent	   their	   encouragement	   at	   some	   point;	   but	   special	  mention	   goes	   to	   Carles	  
and	   Valentina,	   for	   their	   invaluable	   advice	   and	   support,	   and	   for	   putting	   the	  words	  
‘and	  the	  Nobel	  prize	  goes	  to	  Owen	  Clark	  and	  Carles	  Gaston-­‐Massuet’	  in	  the	  back	  of	  
my	  mind;	  and	  Sandra	  and	  Sophie,	  for	  keeping	  me	  sane	  (almost).	  	  
Lastly,	   and	   for	   whom	   I	   owe	   the	   most	   gratitude,	   my	   family.	   My	   sister	   for	  
probably	  believing	   in	  me	  more	  than	   I	  do	  myself,	  and	  for	  always	  validating	  my	  hard	  
work;	   and	  my	  parents,	   for	   their	  unending	   support	  and	  commitment,	  especially	  my	  
dad,	  whose	  enthusiasm	  for	  teaching	  me	  the	  wonders	  of	  science	  (including	  basement	  
electroplating	  and	  home	  made	  explosives)	  helped	  spur	  me	  on	  to	  scientific	  research.	  	  
	  
	   10	  
Abbreviations	  
NBL	   	   Neuroblastoma	  
SNS	  	   	   Sympathetic	  nervous	  system	  
EFS	   	   Event-­‐free	  survival	  
SA	   	   Sympathoadrenal	  
NCC	  	   	   Neural	  crest	  cells	  
ALK	  	   	   Anaplastic	  lymphoma	  kinase	  
RA	   	   Retinoic	  acid	  
NF1	  	   	   Neurofibromin	  1	  	  
Trks	   	   Tropomyosin	  related	  kinases	  
NGF	   	   Nerve	  growth	  factor	  
BDNF	   	   Brain-­‐derived	  neurotrophic	  factor	  
NT-­‐3	   	   Neurotrophin	  3	  
MRD	   	   Minimal	  residual	  disease	  
DM	   	   Double	  minute	  bodies	  
HSRs	   	   Homogenously	  staining	  regions	  
FAK	   	   Focal	  adhesion	  kinase	  
Tsc2	   	   Tuberous	  sclerosis	  2	  
PTKs	   	   Protein	  tyrosine	  kinases	  
PTPs	   	   Protein	  tyrosine	  phosphatases	  
SH2	   	   Src	  homology	  2	  
PTB	  	   	   Phosphotyrosine	  binding	  
RTKs	   	   Receptor	  tyrosine	  kinases	  
EGFR	   	   Epidermal	  growth	  factor	  receptor	  
ECM	   	   Extracellular	  matrix	  
MAPK	   	   Mitogen	  activated	  protein	  kinase	  
Erk	   	   Extracellular	  signal-­‐related	  kinase	  
PI3K	   	   Phosphatidylinositol-­‐3-­‐kinase	  
PIP2	   	   Phosphatidylinositol-­‐4,-­‐5-­‐bisphosphate	  (Ptpins(4,5)P2	  
PIP3	   	   Phosphatidylinositol-­‐4,-­‐5-­‐bisphosphate	  (Ptpins(3,4,5)P3	  
PH	   	   Plekstrin-­‐homology	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PDK1	   	   Phosphoinositide-­‐dependent	  kinase	  1	  
PTEN	   	   Phosphate	  and	  tensin	  homologue	  deleted	  on	  chromosome	  10	  
CREB	   	   Cyclic-­‐AMP-­‐response	  element	  binding	  protein	  
mTOR	   	   Mammalian	  target	  of	  rapamycin	  
4EBPs	  	  	   4E-­‐binding	  proteins	  
ROS	   	   Reactive	  oxygen	  species	  
CSC	   	   Cancer	  stem	  cell	  
TIC	   	   Tumour-­‐initiating	  cell	  
IGF-­‐1R	  	   Insulin-­‐like	  growth	  factor	  I	  receptor	  
ARF	   	   ADP	  ribosylation	  factor	  
OIS	   	   Oncogene-­‐induced	  senescence	  
PIN	   	   Prostrate	  intraepithelial	  neoplasia	  
SA-­‐β-­‐gal	   Senescence-­‐associated	  β-­‐galactosidase	  
MEFs	   	   Mouse	  embryonic	  fibroblasts	  
PICS	   	   PTEN-­‐loss-­‐induced	  senescence	  
pTyr	   	   Phosphotyrosine	  
RPTPs	   	   Receptor-­‐type	  PTPs	  
CAMs	   	   Cell	  adhesion	  molecules	  
DSP	   	   Dual	  specificity	  phosphatase	  
pSer	   	   Phosphoserine	  
pThr	   	   Phosphothreonine	  
Asp	   	   Aspartic	  acid	  
Cys	   	   Cysteine	  
Glu	   	   Glutamine	  
PDGF-­‐R	   Platelet-­‐derived	  growth	  factor	  
IR	   	   Insulin	  receptor	  
LOH	   	   Loss	  of	  heterozygosity	  
UTR	   	   Untranslated	  region	  
V	   	   Vanadium	  
BMOV	   	   Bis(maltolato)oxovanadium(IV)	  
BEOV	   	   Bis(ethylmaltolato)oxovanadium(IV)	  
VO-­‐OH	  Pic	   3-­‐hydroxypicolinate	  vanadium(IV)	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NAC	   	   N-­‐acetyl-­‐L-­‐cysteine	  
FDA	   	   Food	  and	  drug	  administration	  
SOD	   	   Superoxide	  dismutase	  
NADPH	   Nicotinamide	  adenine	  dinucleotide	  phosphate	  
GSH	   	   Reduced	  glutathione	  
GSSG	   	   Oxidised	  glutathione	  
BSO	   	   Buthionine	  sulfoximine	  
PKC	   	   Protein	  kinase	  C	  
LB	   	   Luria	  Bertani	  
RT	   	   Room	  temperature	  
CIP	   	   Calf	  intestinal	  phosphatase	  
TAE	   	   Tris-­‐acetate-­‐EDTA	  
PCR	   	   Polymerase	  chain	  reaction	  
dNTPs	   	   Deoxynucleotide	  triphosphates	  
MW	   	   Molecular	  weight	  
Tm	   	   Melting	  temperature	  
Ct	   	   Cross	  point	  values	  
CMV	   	   Cytomegalovirus	  
SV40	   	   Simian	  vacuolating	  virus	  40	  
GFP	   	   Green	  fluorescent	  protein	  
LC3	   	   Microtubule-­‐associated	  protein	  1A/1B-­‐light	  chain	  3	  
CAβ	   	   Chick	  beta-­‐actin	  
PCD	   	   Programmed	  cell	  death	  
DMEM	  	   Dulbecco’s	  modified	  Eagle’s	  Medium	  
MEM	   	   Eagle’s	  Minimum	  Essential	  Medium	  
RPMI	   	   Roswell	  Park	  Memorial	  Institute	  
HEPES	   	   4-­‐(2-­‐hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	  acid	  
FBS	   	   Fetal	  bovine	  serum	   	  
P/S	   	   Penicillin/streptomycin	  
PBS	   	   Phosphate-­‐buffered	  saline	  
HEK	   	   human	  embryonic-­‐kidney	  
dfp	   	   Days	  post	  fertilisation	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IgG	   	   Immunoglobulin	  type	  G	  
BSA	   	   Bovine	  serum	  albumin	  
DAPI	   	   4',6-­‐diamidino-­‐2-­‐phenylindole	  
PEI	   	   Polyethyleneimine	  
DOTMA	   N-­‐[1-­‐2(2,3-­‐dioleyloxy)propyl]-­‐n,n,n-­‐trimethylammonium	  chloride	  
DOPE	   	   Dioleoyl	  phophotidylethanolamine	  
RPM	   	   Revolutions	  per	  minute	  
SDS-­‐PAGE	   Sodium	  dodecyl	  sulfate	  polyacrylamide	  electrophoresis	  
APS	   	   Ammonium	  persulfate	  
TEMED	  	   Tetramethylethylenediamine	  
PVDF	   	   Polyvinyldiflouride	  
TBS	   	   Tris-­‐buffered	  saline	  
TBS-­‐T	   	   Tris-­‐buffered	  saline-­‐tween	  20	  
ECL	   	   Electrochemiluminescence	  
MTS	   3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐5-­‐(3-­‐carboxymethoxyphenyl)-­‐2-­‐(4-­‐
sulfophenyl)-­‐2H-­‐tetrazolium	  
DCFADA	   2’,7’-­‐di-­‐chlorodihydrofluorescein	  diacetate	  
DCF	   2’,7’-­‐Di-­‐chlorofluorescein	  
DMSO	   Dimethyl	  sulfoxide	  
HBSS	   Hank’s	  balanced	  salt	  solution	  
LAR	   Leukocyte	  common	  antigen	  related	  
FN	   Fibronectin	  
IG	   Immunoglobulin	  
IRES	   Internal	  ribosome	  entry	  site	  
ICC	   Immunocytochemistry	  
IB	   Immunoblotting	  
WT	   Wild	  type	  
NCAM	   Neural	  cell	  adhesion	  molecule	  
STAT3	   Signal	  transducer	  and	  activator	  of	  transcription	  3	  
VA	   Sodium	  orthovanadate	  
RET	   Rearranged	  during	  transfection	  tyrosine	  kinase	  
SEM	   Standard	  error	  of	  the	  mean	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SD	   Standard	  deviation	  
EHDH	   Sodium	  etidronate	  
PAO	   Phenylarsine	  oxide	  
pV(phen)	   Sodium	  oxodiperoxo(1,10-­‐phenanthroline)vanadate(V)	  
qPCR	   	   Quantitative	  PCR	  
CML	   	   Chronic	  myeloid	  leukaemia	  
NEM	   	   N-­‐ethylmaleomide	  
tTA	   	   Tetracycline	  transactivator	  
TRE	   	   Tetracycline	  response	  element	  
4-­‐OHT	   	   4-­‐Hydroxytamoxifen	  
DHR	   	   Dihydrorhodamine	  
PE	   	   Phosphatidylenimine	  
GSK3β	  	   Glycogen	  synthase	  kinase	  3β	  
PP2A	   	   Protein	  phosphatase	  2A	  
S6K1	   	   S6	  kinase	  1	  
TET	   	   Tetracycline	  
TRAIL	   	   Tumour	  necrosis	  factor	  (TNF)-­‐related	  apoptosis-­‐inducing	  ligand	  
MCB	   	   Monochlorobimane	  
Myr	   	   Myristoylated	  
DN	   	   Dominant	  negative	  
RT-­‐qPCR	   Real-­‐time	  qPCR	  
HKGs	   	   House-­‐keeping	  genes	  
CRC	   	   Colorectal	  cancer	  
GBM	   	   Glioblastoma	  multiforme	  
DNA	   	   Deoxyribonucleic	  acid	  
RNA	   	   Ribonucleic	  acid	  
RNAi	   	   RNA	  interference	  
siRNA	   	   Short-­‐interfering	  RNA	  
TH	   	   Tyrosine	  hydroxylase	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  activates	  Akt	  in	  the	  presence	  of	  LY294002	  
Figure	  4.11.	  BMOV/LY294002	  inhibits	  S6	  kinase	  
Figure	  4.12.	  Tetracycline	  treatment	  enhances	  BMOV	  induced-­‐cytotoxicity	  in	  the	  
isogenic	  cell	  line	  Tet21N	  without	  inducing	  MYCN	  
Figure	  4.13.	  The	  non-­‐Mycn-­‐amplified	  cell	  line	  ACN	  is	  sensitive	  to	  BMOV,	  which	  is	  not	  
enhanced	  by	  forced	  expression	  of	  Mycn	  
Figure	  4.14.	  Forced	  expression	  of	  Mycn	  in	  an	  isogenic	  version	  of	  SK-­‐N-­‐AS	  cells	  does	  
not	  cause	  sensitivity	  to	  BMOV	  
Figure	  4.15.	  Conditional	  suppression	  of	  Mycn	  in	  Tet21N	  cells	  does	  not	  induce	  
sensitive	  to	  BMOV	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Figure	  4.16.	  MEK	  inhibition	  and	  Akt	  stimulation	  enhance	  BMOV-­‐induced	  cytotoxicity	  
Figure	  4.17.	  Inhibition	  of	  PI3K	  and	  mTOR	  enhance	  BMOV-­‐induced	  cell	  death	  
Figure	  4.18.	  BMOV	  induces	  increases	  in	  ROS	  
Figure	  4.19.	  BMOV	  and	  LY29	  cause	  significant	  increases	  in	  ROS	  
Figure	  4.20.	  BMOV,	  LY29	  and	  BSO	  cause	  reductions	  in	  the	  level	  of	  GSH	  as	  measured	  
by	  decreases	  in	  fluorescence	  intensity	  of	  MCB	  
Figure	  4.21.	  Preventing	  ROS	  production	  NAC	  attenuates	  BMOV-­‐induced	  increases	  in	  
apoptosis	  
Figure	  4.22.	  BMOV-­‐induced	  toxicity	  in	  KCNR	  cells	  is	  augmented	  by	  inhibition	  of	  GSH	  
synthesis	  
Figure	  4.23.	  LC3-­‐GFP	  revealing	  a	  lack	  of	  autophagy	  in	  both	  U87	  glioma	  and	  Kelly	  
neuroblastoma	  cells	  in	  response	  to	  PI3K/mTOR	  inhibition	  
Figure	  4.24.	  BMOV	  may	  suppress	  autophagy	  as	  shown	  by	  acridine	  orange	  staining	  
Figure	  4.25.	  BMOV	  inhibits	  PI-­‐103/Rapamycin-­‐induced	  LC3-­‐II	  increases	  
Figure	  4.26.	  The	  PTEN	  inhibitor	  VO-­‐OH	  Pic	  induces	  cytotoxicity	  similar	  to	  BMOV,	  but	  
only	  above	  2.5µM	  
Figure	  4.27.	  BSO	  treatment	  fails	  to	  neither	  inactivate	  PTEN	  by	  oxidation	  nor	  increase	  
Akt	  stimulation	  
Figure	  4.28.	  Immunoblotting	  for	  phosphorylated	  Akt	  and	  HA	  
Figure	  4.29.	  	  Overexpression	  of	  constitutively	  active	  Akt	  does	  not	  significantly	  
sensitise	  BMOV-­‐resistant	  SK-­‐N-­‐AS	  cells	  to	  apoptosis	  
	  
Chapter	  5.	  
Figure	  5.1.	  Two-­‐dimensional	  graph	  depicting	  differential	  expression	  of	  PTP	  gene	  
family	  in	  non-­‐neoplastic	  nervous	  system,	  glioblastoma	  and	  neuroblastoma	  cell	  line	  
Table	  5.1.	  Expression	  profile	  of	  PTPs	  in	  glioblastoma	  and	  NBL	  as	  well	  as	  in	  brain	  and	  
cerebellar	  tissue	  
Figure	  5.2.	  Highly	  expressed	  PTPs	  in	  NBL	  versus	  non-­‐neoplastic	  neural	  tissue	  
Figure	  5.3.	  Highly	  expressed	  PTPs	  in	  multiple	  NBL	  cell	  lines	  
Figure	  5.4.	  Low-­‐level	  expression	  of	  PTPs	  in	  NBL	  
Figure	  5.5.	  Clustering	  dendrogram	  of	  qPCR	  expression	  from	  92	  PTP	  genes	  
Figure	  5.6.	  Significantly	  differential	  expression	  of	  PTPs	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Table	  5.2.	  Expression	  alteration	  of	  PTPs	  in	  NBL	  qPCR	  screen	  and	  their	  relation	  to	  
published	  alterations/functional	  analyses	  in	  other	  cancers	  
	  
Chapter	  6.	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1.1. Neuroblastoma:	  Clinical	  presentation	  and	  biological	  attributes	  
1.1.1. Incidence	  and	  outcome	  
Neuroblastoma	   (NBL)	  was	   first	  described	   independently	  over	  a	   century	  ago	  by	   the	  
physicians	  Robert	  Hutchison,	  William	  Pepper	  and	  James	  Homer	  Wright	  (Rothenberg	  
et	  al.,	  2009)	  and	  has	  been	  the	  subject	  of	  an	  intense	  amount	  of	  research	  culminating	  
in	   fascinating	   key	   discoveries	   (See	   timeline	   accompanying	   (Maris,	   2010)),	   expertly	  
reviewed	   elsewhere	   (Brodeur,	   2003;	   Janoueix-­‐Lerosey	   et	   al.,	   2010;	   Maris,	   2010;	  
Maris	  et	  al.,	  2007).	  
	   NBL	  is	  the	  most	  common	  and	  deadly	  extracranial	  solid	  tumour	  of	  childhood,	  
accounting	   for	   7.8%	  of	   paediatric	   cancers	   diagnosed	  under	   the	   age	   of	   15,	  with	   an	  
incidence	  rate	  of	  10.2	  cases	  per	  million	  children	  in	  this	  age	  bracket	  (Goodman	  et	  al.,	  
1999).	  NBL	   is	  also	   the	  most	  common	  cancer	  diagnosed	  within	   the	   first	  year	  of	   life,	  
accounting	   for	   28%	   of	   infant	   cancers	   with	   an	   incidence	   of	   65	   per	   million	   infants	  
(Figure	  1.1.1)	  (Smith	  et	  al.,	  1999)	  	  
	  
Figure	  1.1.1.	  NBL	  is	  the	  most	  commonly	  occurring	  tumour	  of	  infancy.	  Graph	  shows	  annual	  
incidence	   of	   tumours	   occurring	  within	   the	   1st	   year	   of	   life	   in	   the	   US.	   Taken	   from	   (Gurney,	  
Smith,	  Ross).	  (1999).	  
	  
NBL	   is	   a	   malignancy	   of	   the	   sympathetic	   nervous	   system	   (SNS)	   (see	   below)	   and	  
accounts	   for	   97%	   of	   total	   SNS	   malignancies,	   representing	   650	   of	   700	   newly	  
diagnosed	  children	   less	   than	  20	  years	  of	  age	   in	   the	  US	  each	  year	   (Goodman	  et	  al.,	  
1999),	  with	  a	  prevalence	  of	  around	  1	  in	  7000	  live	  births	  (Brodeur,	  2003).	  The	  median	  
	   22	  
age	  of	  diagnosis	  of	  NBL	   is	  17	  months	   (London	  et	  al.,	  2005),	  although	  the	   incidence	  
rate	  of	  NBL	  more	  than	  doubles	  from	  29/million	  to	  64/million	  children	  diagnosed	   in	  
the	  2nd	  and	  1st	  year	  of	  life	  respectively.	  Similarly,	  overall	  16%	  of	  cases	  are	  diagnosed	  
within	   the	   first	  month	  of	   life,	   and	  41%	  within	   the	   first	   3	  months	   (Goodman	  et	   al.,	  
1999).	  
	   NBL	  is	  also	  frequently	  deadly,	  accounting	  for	  15%	  of	  fatalities	  resulting	  from	  
paediatric	   malignancies	   (Brodeur,	   2003).	   Event-­‐free	   survival	   (EFS)	   rates	   have	  
however	   improved	   from	   52%	   between	   1975-­‐1977	   to	   74%	   between	   1999-­‐2005	  
(www.seer.cancer.gov).	   However,	   improvements	   in	   cure	   rates	   are	   most	   likely	  
accounted	   for	   by	   the	   more	   benign	   forms	   of	   the	   disease,	   which	   present	   with	  
favourable	   prognoses	   and	   require	   only	   surgical	   intervention	   and	   treatment	   of	  
minimal	  residual	  disease.	  	  In	  fact,	  patient	  survival	  in	  those	  presenting	  with	  metastatic	  
disease	   over	   the	   age	   of	   1	   is	   less	   than	   40%	   (Matthay	   et	   al.,	   1999).	   Furthermore	  
intensive	  multimodal	  therapy	  required	  in	  the	  case	  of	  treatment-­‐resistant,	  aggressive	  
disease	   frequently	   results	   in	   significant	   morbidities,	   including	   increased	   mortality	  
rates	  and	  secondary	  neoplasms,	   infertility,	  as	  well	  as	  chronic	  health	  conditions	  and	  
lowered	  rates	  of	  employment,	  marriage	  and	  socioeconomic	  status	  (Laverdiere	  et	  al.,	  
2009).	  	  
	  
1.1.2.	  Neural	  crest	  origin	  and	  clinical	  presentation	  	  
NBL	   has	   a	   sympathoadrenal	   (SA)	   lineage,	   where	   neural	   crest	   cells	   (NCC)	   are	   the	  
putative	  cell	  of	  origin	  (Acosta	  et	  al.,	  2009;	  De	  Preter	  et	  al.,	  2006).	  The	  neural	  crest	  is	  
a	   transitory	   population	   of	   cells	   that	   forms	   during	   development	   of	   the	   nervous	  
system	   between	   the	   neural	   plate	   and	   the	   non-­‐neural	   ectoderm.	   NCC	   are	   formed	  
during	   the	   process	   of	   neurulation,	   when	   neural	   tissue	   folds	   inward	   to	   form	   the	  
neural	  tube,	  generating	  regions	  at	  the	  borders	  of	  the	  neural	  plate	  referred	  to	  as	  the	  
neural	   folds.	  A	  subset	  of	  cells	  at	  the	  dorsal	  region	  of	  the	  neural	   folds	  subsequently	  
form	   a	  migratory	   cell	   population,	   the	   NCC,	   which	  migrates	   in	   particular	   routes	   to	  
form	   a	   diverse	   lineage	   including	   craniofacial	   cartilage	   and	   bone,	   melanocytes,	  
smooth	  muscle	  and	  the	  peripheral	  and	  enteric	  nervous	  system.	  	  
	   The	  fate	  of	  NCC	  is	  determined	  by	  a	  complex	  and	  dynamic	  interplay	  of	  intrinsic	  
and	   extrinsic	   factors	   (reviewed	  by	   (Bronner	   Fraser,	   1994).	   The	   trunk	   of	   the	   neural	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tube	   gives	   rise	   to	   a	   subset	   of	   ventrally	   migrating	   NCCs	   that	   migrate	   through	   the	  
anterior	  parts	  of	  the	  somites	  to	  form	  sensory	  and	  sympathetic	  neurons,	  chromaffin	  
cells	  of	  the	  adrenal	  gland,	  peripheral	  glial	  cells	  and	  melanocytes	  (Loring	  and	  Erickson,	  
1987).	   Sympathetic	  neural	   cells	   and	   chromaffin	   cells	  develop	   from	  a	  putative	   fate-­‐
restricted	  SA	  progenitor	  that	  receives	  specification	  signals	  from	  bone-­‐morphogenetic	  
proteins	  in	  the	  dorsal	  aorta	  wall	  (Anderson	  and	  Axel,	  1986).	  	  NCC	  that	  aggregate	  at	  
the	   dorsal	   aorta	   undergo	   neuronal	   and	   catecholinergic	   differentiation	   resulting	   in	  
the	  expression	  of	   tyrosine	  hydroxylase	   (TH)	  and	  dopamine	  β-­‐hydroxylase,	   required	  
for	  the	  synthesis	  of	  noradrenaline,	  and	  neuronal	  markers	  such	  as	  neurofilament	  and	  
neuronal	   tubulin.	   SA	   cells	   are	   further	   specified	   by	   a	   host	   of	   transcription	   factors	  
including	   the	   mammalian	   achaete-­‐scute	   homolog	   1,	   the	   paired	   homeodomain	  
proteins	   Phox2a	   and	   Phox2b,	   Hand2	   and	   GATA	   2/3	   (for	   reviews	   see	   (Cane	   and	  
Anderson,	  2009;	  Howard,	  2005;	  Huber	  et	  al.,	  2009).	  
	   Thus	   the	  SA	   lineage	   is	   formed	   in	  a	  multistep	  process	  eventually	   resulting	   in	  
paraspinal	  and	  extra-­‐adrenal	  sympathetic	  ganglia,	  containing	  neurons	  characterized	  
by	  the	  catecholaminergic	  neurotransmitter	  noradrenaline,	  of	  which	  NBL	   is	  believed	  
to	  be	  an	  undifferentiated	  precursor.	  As	  a	   result,	  primary	  NBL	   tumours	  can	  present	  
anywhere	  along	  the	  sympathetic	  chain	  (Figure	  1.1.2,	  A).	  However	  the	  most	  common	  
site	   of	   presentation	   is	   the	   abdomen	   (65%),	   normally	   centring	   on	   the	   adrenal	  
medulla.	  Other	  sites	  include	  paraspinal	  sympathetic	  ganglia,	  at	  sites	  within	  the	  neck	  
(5%),	  chest	  (20%)	  and	  pelvis	  (5%)	  (Janoueix-­‐Lerosey	  et	  al.,	  2010).	  	  
	   The	   region	   of	   primary	   tumour	   formation	   often	   affects	   clinical	   presentation	  
and	  side	  effects	   (Maris,	  2010).	  For	   instance,	  paraspinal	   tumours	   frequently	  expand	  
through	   the	   intraforaminal	   space	   resulting	   in	   compression	   of	   the	   spinal	   cord	   and	  
paralysis	  (Figure	  1.1.2,	  B).	  Tumours	  presenting	  in	  the	  neck	  or	  upper	  chest	  can	  cause	  
damage	  to	  the	  SNS	  leading	  to	  Horner’s	  syndrome,	  associated	  with	  ptosis	  (drooping	  
of	   the	   eyelid),	   miosis	   (permanent-­‐pupil	   contraction)	   and	   anhidrosis	   (decreased	  
sweating	  on	  the	  affected	  side	  of	  the	  face).	  Furthermore,	  loco-­‐regional	  invasion	  often	  
results	   in	   tumours	  surrounding	  critical	  nerves	  and	  vessels	  such	  as	   the	  celiac-­‐axis	   (a	  
branch	  of	  the	  abdominal	  artery),	  preventing	  resection.	  Lastly,	  metastasis	  through	  the	  
lymph	   nodes	   and	   hematopoietic	   system	   can	   result	   in	   colonization	   of	   secondary	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tumours	  within	  the	  bone	  marrow	  and	  infiltration	  of	  bone	  cortex,	  as	  well	  as	  tumour	  
formation	  in	  the	  liver	  (Figure	  1.1.2,	  C).	  
	  
1.1.3.	  Stratification	  and	  staging	  
Perhaps	   one	   of	   the	  most	   striking	   features	   of	   NBL	   is	   its	   extreme	   heterogeneity	   of	  
presentation,	   with	   roughly	   an	   equal	   proportion	   of	   cases	   presenting	  with	   confined	  
primary	   tumours	   easily	   treatable	   with	   surgical	   resection	   and	   minimal	   cycles	   of	  
chemotherapy	   and	   cases	   presenting	   with	   advanced	   stage	   metastatic	   disease	   with	  
unrelenting	  progression	  despite	  intense	  multimodal	  therapy.	  This	  clinical	  enigma	  has	  
been	   recognized	   for	   40	   years,	   leading	   to	   the	   establishment	   of	   staging	   systems	  
designed	  to	  stratify	  patients	  into	  risk	  group	  in	  order	  to	  base	  prognosis	  on	  clinical	  and	  
biological	  factors	  (Evans	  et	  al.,	  1971).	  	  
	   Until	  recently,	  the	  most	  commonly	  used	  staging	  system	  was	  the	  International	  
Neuroblastoma	   Staging	   System	   (INSS),	  which	   stratified	   patient	   prognosis	   based	   on	  
clinical	   presentation	   and	   age,	   forming	   five	   subgroups	   of	   localised	   (stage	   1	   and	   2),	  
advanced	   locoregional	   (stage	   3)	   and	  metastatic	   (stage	   4	   and	   4S)	   (Figure	   1.1.3,	   A)	  
(Brodeur	   et	   al.,	   1993;	   Brodeur	   et	   al.,	   1988).	   Importantly	   stage	   4S	   or	   ‘the	   special	  
stage’	  was	  recognized	  based	  on	  the	  bizarrely	  favourable	  prognosis	  (~75%	  5	  year	  EFS	  
rate)	   of	   a	   subset	   (~5%)	   of	   advanced	   metastatic	   tumours,	   generally	   due	   to	  
spontaneous	   remission	   (Evans	   et	   al.,	   1971).	   Notably	   patients	   under	   the	   age	   of	   1	  
generally	  present	  with	  a	  favourable	  prognosis	  and	  low	  stage	  tumours,	  whereas	  those	  
over	   one	   generally	   present	  with	  metastatic,	   treatment-­‐resistant	  NBL	   (Figure	   1.1.3,	  
B).	  	  
Thus	   broadly	   speaking	   tumours	   commonly	   present	   as	   either	   locally	  
manageable,	  low-­‐risk	  with	  a	  favourable	  prognosis	  or	  highly	  malignant,	  high-­‐risk	  with	  
an	   unfavourable	   prognosis,	   aptly	   termed	   by	   the	   preeminent	   paediatric	   oncologist	  
Audrey	  Evans	  as	  ‘the	  goodies	  and	  the	  baddies’	  (Wellstein	  and	  Toretsky,	  2011).	  Thus	  
the	  basis	  of	  this	  clinical	  heterogeneity	  has	  focused	  on	  biological	  and	  genetic	  events	  
stratifying	  these	  distinct	  subgroups.	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Figure	  1.1.2.	  Clinical	  presentation	  of	  NBL.	  Primary	  NBL	  tumours	  occur	  anywhere	  within	  the	  
sympathetic	   chain	   (e.g.	   adrenal	   medulla)	   (A).	   Primary	   tumours	   commonly	   result	   in	  
secondary	   risk	   factors	   including	   surrounding	   vessels/nerves,	   spinal	   cord	   compression	   and	  
degeneration	  of	  the	  SNS	  causing	  Horner’s	  syndrome	  (B).	  Tumour	  metastases	  infiltrate	  bone	  
marrow/cortex	  via	  the	  hematopoietic	  system	  and	  liver	  especially	  in	  stage	  4S	  (see	  below)	  (C).	  




	   26	  
	  
Figure	  1.1.3.	  Prognostic	  stratification	  in	  NBL.	  Kaplan-­‐Meier	  survival	  curve	  illustrating	  EFS	  of	  
NBL	   tumours	   divided	   into	   stages	   (A).	   Prognosis	   also	   differs	   dramatically	   based	   on	   age	   at	  
presentation	  (B).	  Taken	  from	  (Janoueix-­‐Lerosey	  et	  al.,	  2010).	  	  
	  
1.1.4.	  Genomic	  aberrations	  
The	   broad	   heterogeneity	   exhibited	   by	   NBL	   likely	   reflects	   underlying	   differences	   in	  
tumour	  biology.	  For	   instance,	  cytogenetic	  abnormalities	   reflected	   in	  gross	  genomic	  
patterns	   are	   highly	   predictive	   of	   patient	   outcome	   (Janoueix-­‐Lerosey	   et	   al.,	   2009).	  
Large-­‐scale	  genomic	  application	  of	  the	  MYCN	  proto-­‐oncogene	  at	  2p24,	  observed	   in	  
around	  20%	  of	  NBL,	  is	  associated	  with	  treatment	  failure	  and	  unfavourable	  prognosis	  
(Brodeur	   et	   al.,	   1984;	   Seeger	   et	   al.,	   1985),	   and	   is	   currently	   the	  only	   genetic-­‐based	  
prognostic	  marker	  allowing	  patient	  stratification	  (see	  below).	  	  
	   Numerical	   alterations	   resulting	   in	   whole-­‐chromosome	   gains	   and	   losses	  
(ploidy	   variations)	   are	   also	   an	   established	   means	   of	   stratification	   (Figure	   1.1.4).	  
Whole	  chromosomal	  gains	  resulting	  in	  a	  near-­‐triploid	  or	  even	  pentaploid	  DNA	  index	  
are	  associated	  with	  favourable	  tumours,	  whereas	  diploid	  DNA	  indices	  are	  associated	  
with	  unfavourable	  tumours	  and	  treatment	  failure,	  with	  the	  former	  constituting	  >90%	  
survival	   rates	   in	  patients	  below	   the	  age	  of	  2	  years	   (Look	  et	  al.,	   1991).	  Whole	  copy	  
number	   variations	   occur	   exclusively	  without	   associated	   segmental	   alterations	   (see	  
below)	  or	  genomic	  amplification	  (Janoueix-­‐Lerosey	  et	  al.,	  2009;	  Kaneko	  et	  al.,	  1999).	  
Triploidy	   has	   been	   suggested	   to	   result	   from	   endoreduplication	   or	   endomitosis,	  
generating	   cells	   with	   one	   or	   two	   normal	   alleles	   of	   a	   tumour-­‐suppressor	   gene	  
homozygously	  deleted	   in	  diploid	  cells,	  exerting	  a	   suppressor	  effect	   resulting	   in	   low	  
malignancy	  (Kaneko	  and	  Knudson,	  2000).	  
	   One	   of	   the	   main	   features	   of	   unfavourable	   tumours	   is	   the	   presence	   of	  
structural	   chromosomal	   aberrations	   (Figure	   1.1.4)	   (Stallings	   et	   al.,	   2007)	   that	   are	  
again	   correlated	   with	   amplification	   of	   Mycn,	   patient	   age	   and	   treatment	   failure	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strongly	  predicting	  relapse	  (Janoueix-­‐Lerosey	  et	  al.,	  2009).	  The	  best	  characterized	  of	  
these	   are	   deletions	   of	   1p36	   and	   11q23	   (Schleiermacher	   et	   al.,	   1994)	   and	   gain	   of	  
17q23	   (Bown	   et	   al.,	   1999),	   resulting	   from	   focal,	   acquired	   copy	   number	   variations	  
associated	   with	   unbalanced	   translocation.	   Loss	   of	   11q	   generally	   occurs	   in	   the	  












Figure	  1.1.4.	  Genomic	  aberrations	  and	  prognosis.	  Good	  and	  poor	  prognosis	  are	  associated	  
with	   whole	   chromosome	   gains	   and	   an	   absence	   of	   structural	   variations	   and	   diploidy	   with	  
segmental	  alterations,	  respectively.	  Taken	  from	  (Maris,	  2010).	  	  
	  
1.1.5.	  Specific	  genetic	  lesions	  
Despite	   the	   evidence	   of	   chromosomal	   aberrations	   largely	   accounting	   for	   clinical	  
behaviour	  of	  NBL,	  to	  date	  very	  few	  bona	  fide	  mutations	  in	  cancer	  genes	  have	  been	  
identified.	   Thus	   the	   discovery	   by	   4	   independent	   groups	   of	   activating	  mutations	   in	  
anaplastic	  lymphoma	  kinase	  (ALK)	  occuring	  in	  both	  familial	  and	  sporadic	  cases	  of	  NBL	  
represents	  an	  exciting	   step	   in	   the	  understanding	  of	  NBL	  pathogenesis	   (Chen	  et	  al.,	  
2008;	  George	  et	  al.,	  2008;	  Janoueix-­‐Lerosey	  et	  al.,	  2008;	  Mossé	  et	  al.,	  2008).	  	  
These	  studies	  confirmed	  germline	  and	  somatically	  acquired	  mutations	  in	  the	  
ALK	  gene,	  identifying	  3	  types	  of	  missense	  mutation,	  with	  the	  most	  frequent	  R1275Q,	  
since	  shown	  to	  impair	  receptor	  trafficking	  (Mazot	  et	  al.,	  2011).	  Since	  then	  more	  than	  
50	   mutations	   have	   been	   characterized	   in	   680	   sporadic	   cases,	   representing	   8%	   of	  
examined	  tumours	  (Janoueix-­‐Lerosey	  et	  al.,	  2010),	  occurring	  at	  higher	  frequency	   in	  
advanced	  stage	  disease	  and	  associated	  with	  Mycn	  amplification	  (De	  Brouwer	  et	  al.,	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2010).	   ALK	   is	   upregulated	   in	   metastatic/highly	   malignant	   tumours	   (Passoni	   et	   al.,	  
2009)	  and	  downregulated	  by	  retinoic	  acid	  (RA)	  treatment	  correlating	  with	  apoptosis	  
(Futami	  and	  Sakai,	  2010),	  making	  it	  an	  attractive	  target	  for	  selective	  therapy	  in	  NBL	  
(Wellstein	  and	  Toretsky,	  2011).	  	  
	   Another	   gene	   shown	   to	   be	   mutated	   in	   familial	   NBL	   is	   the	   paired	   like	  
homoebox	   gene	   PHOX2B	   located	   at	   4p12.	   Numerous	   missense	   and	   frameshift	  
mutations	   have	   been	   identified	   as	   predisposing	  mutations	   in	   cases	   of	   familial	  NBL	  
(Perri	   et	   al.,	   2005;	   Raabe	   et	   al.,	   2008).	   Although	   PHOX2B	   has	   been	   shown	   to	  
contribute	   to	  a	  proliferative/undifferentiated	  phenotype	   in	  SA	  progenitors	   (Reiff	  et	  
al.,	   2010),	   its	   contribution	   to	  NBL	   remains	  unclear	  due	   to	   the	   rare	   rate	  of	   somatic	  
mutations.	   Lastly,	   the	   gene	   encoding	   neurofibromin	   1	   (NF1)	   represents	   an	   NBL	  
tumour	  suppressor	  (Hölzel	  et	  al.,	  2010),	  where	  loss	  of	  NF1	  predicts	  insensitivity	  to	  RA	  
and	  poor	  outcome	  in	  vivo	  by	  repressing	  the	  activity	  of	  the	  transcriptional	  coactivator	  
of	  RA	  receptors	  ZNF423	  through	  activation	  of	  Ras-­‐MEK	  signalling.	  	  
	   In	  sum	  only	  a	  handful	  of	  genes	  have	  been	  shown	  to	  functionally	  play	  a	  role	  in	  
NBL	   pathogenesis,	   thus	   highlighting	   a	   need	   for	   increased	   identification	   of	   genetic	  
contributing	  factors	  and	  treatment	  targets.	  
	  
1.1.6.	  Trks	  and	  NBL	  prognosis	  
The	   tropomyosin	   related	   kinases	   (Trks)	   are	   a	   family	   of	   receptor	   tyrosine	   kinases	  
consisting	  of	  TrkA,	  TrkB	  and	  TrkC.	  The	  Trks	  signal	  through	  their	  ligands	  nerve-­‐growth	  
factor	   (NGF),	   brain-­‐derived	  neurotrophic	   factor	   (BDNF)	   and	  neurotrophin	   3	   (NT-­‐3),	  
respectively,	   controlling	   a	   diverse	   range	   of	   functions	   responsible	   for	   neuronal	  
differentiation	  (Benitogutierrez	  et	  al.,	  2006).	  Trks	  are	  well-­‐established	  mediators	  of	  
biological	  response	  in	  NBL,	  whose	  expression	  pattern	  is	  significantly	  associated	  with	  
outcome	  (Brodeur	  et	  al.,	  2009;	  Eggert	  et	  al.,	  2000;	  Schramm	  et	  al.,	  2005).	  
	   High	   expression	   of	   TrkA	   is	   strongly	   associated	   with	   favourable	   factors	  
including	   young	   age	   and	   absence	   of	  Mycn	   amplification	   (Nakagawara	   et	   al.,	   1992;	  
Nakagawara	  et	  al.,	  1993).	  Expression	  of	  TrkA	  is	  commonly	  seen	  in	  low	  stage	  tumours,	  
and	  can	  inhibit	  growth	  (Lucarelli	  et	  al.,	  1997),	  decrease	  the	  expression	  of	  Mycn	  (Woo	  
et	   al.,	   2004)	   and	   cause	   differentiation	   in	   the	   presence	   of	   NGF	   (Nakagawara	   and	  
Brodeur,	  1997).	  Here	  culturing	  explanted	  TrkA-­‐expressing	  NBL	  cells	  in	  the	  absence	  of	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NGF	  led	  to	  apoptosis	  after	  7	  days,	  suggestive	  of	  TrkA	  expression	  as	  a	  determinant	  of	  
NBL	   spontaneous	   regression	   (Nakagawara,	   1998).	   A	   truncated	   version	   of	   TrkA	  
(TrkAIII),	  resulting	  from	  alternative	  mRNA	  splicing,	  actually	  promotes	  tumorigenesis,	  
antagonizing	  TrkAI/NGF	  signalling	  (Tacconelli	  et	  al.,	  2004).	  
	   Conversely,	   expression	   of	   TrkB	   is	   strongly	   associated	   with	   unfavourable	  
prognostic	  markers	  and	  poor	  response,	  where	  the	  addition	  of	  the	  TrkB	  ligand	  BDNF	  
promotes	   the	   survival	   of	   undifferentiated	   neuroblasts	   (Nakagawara	   et	   al.,	   1994).	  
High	  TrkB	  expression	  contributes	   to	  chemotherapy	  resistance	   (Ho	  et	  al.,	  2002)	  and	  
promotes	   tumour	  angiogenesis	   (Eggert	  et	  al.,	  2002)	  and	   invasiveness	   (Hecht	  et	  al.,	  
2005).	   Thus	   the	   expression	   pattern	   of	   Trks	   conforms	   to	   the	   notion	   of	   stratified	  
biological	   markers	   underlying	   differences	   between	   unfavourable	   and	   favourable	  
prognosis	  in	  NBL	  (Figure	  1.1.5).	  
	  
Figure	   1.1.5.	   Trk	   expression	   stratifies	   with	   biological	   and	   clinical	   features	   of	   prognosis.	  
Taken	  from	  (Maris	  et	  al.,	  2007).	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TrkC	  likely	  functions	  in	  a	  similar	  manner	  to	  TrkA,	  and	  is	  expressed	  in	  a	  subset	  (25%)	  
of	  TrkA	  expressing	  tumours	  and	  weakly	  associated	  with	  positive	  outcome	  (Brodeur	  
et	   al.,	   1997).	   Thus	   Trk	   receptors	   represent	   an	   attractive	   therapeutic	   target	   given	  
their	   ability	   to	   confer	   survival	   in	   the	   case	   of	   TrkB.	   As	   such	   multiple	   selective	   Trk	  
inhibitors	  have	  been	  developed	   including	  AZ623	  and	  CEP-­‐751,	  with	  efficacy	  against	  
NBL	  xenografts	  in	  preclinical	  testing,	  and	  are	  currently	  in	  phase	  1	  trials	  (Evans	  et	  al.,	  
2001;	   Evans	   et	   al.,	   1999;	   Zage	   et	   al.,	   2010a).	   In	   sum	   the	   overall	   biology	   of	   NBL	  
suggests	  a	  model	  whereby	  at	  least	  two	  subtypes	  of	  disease	  exist	  (Figure	  1.1.6).	  
	  
Figure	   1.1.6.	   Unfavourable	   and	   favourable	   NBL	   tumours	   represent	   distinct	   biological	  
subtypes.	   Tumours	   with	   favourable	   prognoses	   harbour	   few	   structural	   chromosomal	  
abnormalities	  but	  do	  exhibit	  whole	   chromosome	  gains.	   These	   tumours	  often	  express	  TrkA	  
making	   them	  prone	   to	  differentiation	  or	  apoptosis.	  Conversely	   tumours	  with	  unfavourable	  
prognoses	  exhibit	  gross	  chromosomal	  abnormalities	  including	  loss	  of	  1p,	  gain	  of	  11q	  and	  17q	  
and	  amplification	  of	  Mycn,	  as	  well	  as	  expression	  of	  TrkB.	  Taken	  from	  (Brodeur,	  2003).	  	  
	  
1.1.7.	  The	  status	  of	  the	  p53	  pathway	  	  
Mutation	  or	   functional	   inactivation	  of	   the	   tumour	   suppressor	   gene	  TP53	   encoding	  
p53	  are	  synonymous	  with	  human	  cancer,	  occurring	   in	  practically	  all	  known	  cancers	  
at	   a	   very	   high	   frequency	   (Goh	   et	   al.,	   2010;	   Junttila	   and	   Evan,	   2009).	   A	   surprising	  
feature	   of	   NBL	   is	   that	   p53	   mutations	   are	   very	   rare	   (<2%)	   at	   diagnosis	   (Tweddle,	  
2003),	   and	  p53	   remains	   functional	   in	  both	  differentiated	  and	  undifferentiated	  NBL	  
(Chen	  et	  al.,	  2007)	  as	  well	  as	  contributing	   to	  chemotherapy-­‐induced	  apoptosis	  and	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tumour	  regression	   in	  vivo	   (Chesler	  et	  al.,	  2008).	  However,	  NBL	  cells	  can	  circumvent	  
the	   p53-­‐driven	   tumour	   barrier	   by	   deregulation	   of	   the	   p14ARF-­‐MDM2-­‐p53	   axis,	  
including	  upregulation	  of	  MDM2	  and	  BMI1	  and	  cytoplasmic	  sequestration	  of	  p53,	  all	  
of	  which	  negatively	  regulate	  the	  activity	  of	  p53	  (Van	  Maerken	  et	  al.,	  2009).	  Similarly,	  
mutational	   inactivation	   of	   p53	   occurs	   frequently	   following	   cytotoxic	   therapy	  
(Tweddle	   et	   al.,	   2001)	   and	   represents	   a	   mechanism	   of	   patient	   relapse	   (Carr-­‐
Wilkinson	  et	  al.,	  2010),	  causing	  resistance	  to	  therapy	  (Keshelava	  et	  al.,	  2000).	  
	   Thus	   reactivating	   the	   p53	   pathway	   is	   considered	   a	   therapeutic	   strategy	   in	  
NBL.	  For	  example,	  positively	   increasing	   the	  activity	  of	  p53	  with	   the	  small	  molecule	  
MDM2	  inhibitor	  nutlin-­‐3	  causes	  cytotoxicity	  and	  growth	  arrest	  (Van	  Maerken	  et	  al.,	  
2006).	   However	   this	   approach	   may	   only	   be	   applicable	   to	   tumours	   with	   wild-­‐type	  
p53,	   and	   may	   require	   increased	   activity	   of	   p14ARF	   to	   achieve	   full	   effects	   (Van	  
Maerken	  et	  al.,	  2011).	  Lastly,	  it	  should	  be	  pointed	  out	  that	  activation	  of	  p53	  has	  also	  
been	   suggested	   to	   be	   responsible	   for	   toxic	   side	   effects	   of	   chemotherapy	   where	  
inhibiting	  its	  function	  may	  actually	  be	  desirable	  (Komarov	  et	  al.,	  1999;	  Morita	  et	  al.,	  
2010).	  
	  
1.1.8.	  Retinoic	  acid	  treatment	  	  
The	  carboxylic	  acid	  lipophillic	  small	  molecule	  RA	  is	  a	  derivative	  of	  the	  alcohol	  form	  of	  
vitamin	   A	   (retinol),	   and	   is	   crucial	   for	   cellular	   differentiation	   during	   embryogenesis	  
(Duester,	  2008;	  Niederreither	  and	  Dollé,	  2008).	  RA	  exerts	  its	  effects	  through	  binding	  
to	  nuclear	  receptors	  of	   the	  retinoic	  acid	   (RARα,	  RARβ,	  RARγ)	  and	  retinoid	  X	   (RXRα,	  
RXRβ,	  RXRγ)	  families	  of	  retinoic	  acid	  receptors.	  Here	  receptor-­‐ligand	  binding	  initiates	  
DNA	  binding,	  directly	  regulating	  the	  transcription	  of	  target	  genes.	  	  
	   Seminal	  studies	  by	  Neil	  Sidell	  in	  the	  1980s	  revealed	  RA	  to	  be	  a	  highly	  effective	  
differentiation	  agent	  in	  NBL	  cells,	  where	  treatment	  for	  as	  little	  as	  48	  hours	  can	  give	  
rise	  to	  highly	  differentiated	  neuronal-­‐like	  cells	  (Abemayor	  and	  Sidell,	  1989;	  Sidell	  et	  
al.,	  1983)	  and	  is	  considered	  a	  gold	  standard	  in	  NBL	  differentiation	  (Clagett-­‐Dame	  et	  
al.,	   2006).	   RA	   was	   later	   shown	   to	   mediate	   neuronal	   differentiation	   by	   inducing	  
expression	   of	   TrkB	   and	   TrkA	   at	   nano	   and	  micromolar	   concentrations,	   respectively	  
(Kaplan	  et	  al.,	  1993;	  Lucarelli	  et	  al.,	  1995),	  and	  sequential	   treatment	  with	  TrkB	  can	  
enhance	  differentiation	  (Encinas	  et	  al.,	  2000b).	  RA	  also	  decreases	  the	  expression	  of	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Mycn	  (Thiele	  et	  al.,	  1985),	  and	  effectively	  inhibits	  growth	  (Shea	  et	  al.,	  1985),	  causing	  
decreased	   proliferation	   and	   mitotic	   arrest	   (Melino	   et	   al.,	   1997).	   In	   some	  
circumstances	  RA	  has	  also	  been	  shown	  to	  cause	  apoptosis,	   for	   instance	   in	  SK-­‐N-­‐DZ	  
NBL	  cells,	  due	  to	  constitutively	  high	  expression	  of	  RARα	  (Melino	  et	  al.,	  1997;	  Nagai	  et	  
al.,	  2004).	  
	   Clinical	  trials	  conducted	  over	  the	  past	  ten	  years	  with	  RA	  on	  minimal	  residual	  
disease	  (MRD),	  Showed	  that	  administration	  of	  RA	  following	  chemotherapy	  or	  bone	  
marrow	  transplantation	  significantly	   improved	  EFS	   in	  children	  with	  progressive	  NBL	  
(Matthay	  et	  al.,	  1999;	  Park	  et	  al.,	  2009;	  Villablanca	  et	  al.,	  1995).	  Thus	  RA	  has	  become	  
a	  standard	   inclusion	  of	   the	  NBL	  therapeutic	   regimen,	  and	  retinoid	  derivatives	  have	  
been	  developed	  to	  build	  on	  the	  success	  of	  RA	  (Reynolds	  et	  al.,	  2003;	  Villablanca	  et	  
al.,	  2006).	  	  
	   However,	   there	   are	   still	   unresolved	   issues	   over	   RA	   dosage,	   toxicity	   and	  
resistance	   (Maris,	   2010),	   and	   its	   biological	   mediators	   are	   still	   unclear	   despite	  
examinations	  of	  both	   transcriptional	   (Yuza	  et	  al.,	  2003)	  and	  signalling	   (Niles,	  2004)	  
changes	   following	   RA	   treatment.	   Among	   these	   studies,	   RA-­‐induced	   differentiation	  
has	  been	  shown	  to	  require	  PI3K/Akt	  (López-­‐Carballo	  et	  al.,	  2002),	  PKC	  (Miloso	  et	  al.,	  
2004),	  mTOR	  (Zeng	  and	  Zhou,	  2008),	  JNK	  (Yu	  et	  al.,	  2003),	  presilin	  1/Wnt	  (Uemura	  et	  
al.,	  2003),	  GSK-­‐3β	  (Castaño	  et	  al.,	  2010)	  and	  RET	  (Oppenheimer	  et	  al.,	  2007).	  RA	  also	  
either	   upregulates	   or	   activates	   tissue	   transglutaminase/Rho	   GTPases	   (Joshi	   et	   al.,	  
2006;	   Singh	   et	   al.,	   2003)	   and	   Erk	   (Singh	   et	   al.,	   2003),	   although	   the	   latter	  may	   be	  
redundant	   (Miloso	   et	   al.,	   2004).	   Lastly,	   other	   transcriptional	   changes	   such	   as	  
decreased	   expression	   of	   cyclin	   D1	   and	   increased	   expression	   of	   cyclin-­‐dependent	  
kinase	   inhibitors	   such	   as	   p27KIP1	   are	   important	   for	   RA	   mediated	   growth	   arrest	  
(Matsuo	  and	  Thiele,	  1998;	  Niles,	  2004).	   In	  sum,	  RA	  alters	  the	  expression/activation	  
of	   multiple	   signalling	   pathways	   and	   genes	   involved	   in	   cell-­‐cycle	   control	   (Figure	  
1.1.7).	  	  
Given	  that	  a	  number	  of	  transcriptional/transcriptional	  changes	  are	  crucial	  for	  
RA-­‐induced	   differentiation,	   genetic	   downregulation	   of	   such	   components	   may	  
underlie	  therapeutic	  resistance	  to	  RA.	  For	  example,	  a	  recent	  RNAi	  screen	  found	  that	  
the	   transcription	   factor	   ZNF423	   is	   crucially	   required	   for	   RA	   differentiation	   by	  
associating	   with	   RARα/RXRα	   (Huang	   et	   al.,	   2009),	   with	   low	   ZNF423	   expression	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underlying	   treatment	   resistance	   in	   NBL	   patients	   with	   poor	   prognosis.	   The	   same	  
group	  showed	  that	  loss	  of	  the	  tumour-­‐suppressor	  NF1	  causes	  activation	  of	  Ras/MEK	  
signalling	  suppressing	  ZNF423	  (Huang	  et	  al.,	  2009).	  Combined	  loss	  leads	  to	  very	  poor	  
prognosis,	   and	   responsiveness	   to	  RA	  can	  be	   improved	  with	   combined	   inhibition	  of	  
MEK	  signalling.	  In	  addition	  to	  overcoming	  resistance	  to	  RA	  with	  targeted	  therapy,	  an	  
alternative	   approach	   has	   been	   to	   augment	   the	   effects	   of	   RA	   with	   combination	  
differentiation	   agent	   treatment.	   For	   instance	   phenylacetate	   (Sidell	   et	   al.,	   1995),	  
vasoactive	  intestinal	  peptide	  (Chevrier	  et	  al.,	  2008),	  BDNF	  (Encinas	  et	  al.,	  2000a)	  and	  
Notch-­‐blocking	   gamma	   secretase	   inhibitors	   (Ferrari-­‐Toninelli	   et	   al.,	   2010)	   all	  
synergise	  with	  RA.	  	  
	  
	  
Figure	  1.1.7.	  Alteration	  of	  signalling	  pathways	  by	  RA	   in	  human	  cancers.	  The	  activation	  or	  
inhibition	  (upwards	  and	  downwards	  arrows	  respectively)	  of	  major	  signalling	  pathways	  is	  cell	  
type	  dependent.	  	  
	  
In	   sum,	   though	   RA	   is	   a	   highly	   effective	   differentiation	   agent	   in	   vitro	   as	   well	   as	   a	  
significant	  component	  of	  NBL	  therapy	  in	  the	  treatment	  of	  MRD,	  a	  number	  of	  issues	  
such	  as	   failure	   to	   fully	   eradicate	  undifferentiated	  NBL	   cells,	   toxicity	   and	   treatment	  
resistance	   have	   initiated	   efforts	   to	   improve	   its	   action,	   such	   as	   targeting	   of	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1.2. Amplification	  of	  Mycn	  is	  the	  major	  negative	  prognostic	  marker	  in	  
neuroblastoma	  
Among	   the	   genetic	   markers	   available	   for	   stratification	   of	   NBL	   prognosis,	  
amplification	  of	  Mycn	   is	  by	   far	   the	  most	   robust	   (Figure	  2.1.1)	   (Cohn	  and	  Tweddle,	  
2004).	   Mycn	   amplification	   was	   originally	   identified	   as	   correlative	   with	   advanced	  
stage	  disease	  and	  tumour	  aggressiveness	  (Brodeur	  et	  al.,	  1984;	  Seeger	  et	  al.,	  1985),	  
and	   extensive	   research	   has	   demonstrated	  mechanisms	   of	   amplification,	   biological	  
consequences,	  and	  oncoprotein	  targets.	  
	  
Figure	   1.2.1.	   Amplification	   of	   Mycn	   and	   prognosis.	   Kaplan-­‐Meier	   survival	   curve	   showing	  
patients	  under	  the	  age	  of	  1	  with	  metastatic	  NBL.	  Taken	  from	  (Brodeur,	  2003).	  	  
	  
1.2.1. Mechanisms	  and	  adverse	  consequences	  of	  Mycn	  amplification	  
Genomic	   amplification	   of	   chromosomal	   DNA	   harbouring	   the	  MYCN	   gene	   on	   the	  
distal	  short	  arm	  of	  chromosome	  2	  (2p)	  generates	  amplicons	  up	  to	  1mb,	  and	  results	  
in	   dramatically	   increased	   gene	   and	   protein	   expression.	   Amplification	  manifests	   as	  
extrachromosomal	   double	   minute	   (DM)	   bodies	   or	   chromosomally	   integrated	  
homogenously	   staining	   regions	   (HSRs)	   (Figure	   1.2.1)	   (Brodeur	   and	   Seeger,	   1986;	  
Tanaka	  and	  Yao,	  2009).	  
	  
Figure	   1.2.2.	   Manifestation	   of	   Mycn	  
amplification.	   Increases	   in	   gene	   copy	  
number	   result	   in	   homogenously	   staining	  
regions	   and	   extrachromosomal	   double-­‐
minute	   bodies	   when	   visualized	   with	  
fluorescence	  in	  situ	  hybridization).	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MYCN	   encodes	   a	   60-­‐63kDa	   protein	   that	   functions	   as	   a	   basic	   helix-­‐loop-­‐helix	  
transcription	  factor,	   forming	  heterodimeric	  complexes	  with	  MAX	  family	  proteins	  to	  
regulate	   transcription	   of	   numerous	   target	   genes	   (Adhikary	   and	   Eilers,	   2005).	   The	  
adverse	   effects	   of	  Mycn	   amplification	   are	  well	   documented	   (Schwab,	   2004).	  Mycn	  
directly	   promotes	   tumorigenesis,	   causing	   oncogenic	   transformation	   of	  mammalian	  
cells	   (Schwab	  et	  al.,	  1985)	  and	  stimulating	  autocrine	  survival	   loops	  by	  upregulating	  
growth-­‐factor	   receptors.	   This	   induces	   proliferation	   (Schweigerer	   et	   al.,	   1990),	  
inhibition	  of	   cell-­‐cycle	  arrest	   (Bell	  et	  al.,	  2006),	  genomic	   instability	   (Sugihara	  et	  al.,	  
2004),	   cellular	   motility	   and	   invasiveness	   (Goodman	   et	   al.,	   1997),	   promotion	   of	  
tumour	  angiogenesis	  (Fotsis	  et	  al.,	  1999),	  circumvention	  of	  immune	  response	  (Song	  
et	  al.,	  2007),	  and	  therapeutic	  resistance	  (de	  Tudela	  et	  al.,	  2010).	  Furthermore,	  Mycn	  
can	   directly	   drive	   NBL	   tumour	   formation,	   where	   transgenic	   mice	   conditionally	  
expressing	   Mycn	   under	   the	   control	   of	   the	   TH	   promoter	   form	   tumours	   of	   the	  
sympathetic	   nervous	   system	   that	   highly	   recapitulate	   human	  NBL	   in	   terms	   of	   both	  
histology	   and	   pathology	   (Weiss	   et	   al.,	   1997).	   Here	   tumours	   form	   at	   a	   high	  
penetrance	   (~33%	  hemizygous;	   100%	  homozygous	   on	   a	   129SvJ	   background)	   albeit	  
exhibiting	  strain-­‐dependent	  variable	  penetrance	  (Teitz	  et	  al.,	  2011).	  	  TH-­‐Mycn-­‐driven	  
tumours	  arise	   in	  sympathoadrenal	  paraspinal	  ganglia,	  however	  surprisingly	  primary	  
tumours	  are	  never	  observed	  in	  the	  adrenal	  medulla,	  in	  contrast	  to	  human	  tumours,	  a	  
caveat	  that	  remains	  to	  be	  explained	  (Teitz	  et	  al.,	  2011).	  The	  TH-­‐Mycn	  mouse	  is	  used	  
as	   an	   important	   tool	   in	   the	   validation	   of	   novel	   therapies,	   in	   that	   tumours	   are	  
reminiscent	  of	  aggressive	  NBL	  and	  retain	  many	  of	  the	  associated	  genetic	  aberrations	  
of	  high-­‐stage	  disease	  (Chesler	  and	  Weiss,	  2011).	  Lastly	  the	  TH-­‐Mycn	  mouse	  exhibits	  
neuroblast	  hyperplasia	  one	  week	  after	  birth,	  which	  in	  contrast	  to	  mice	  with	  a	  normal	  
background	   fails	   to	   regress,	   forming	   tumours	   by	   6	   weeks	   and	   showing	   a	   strong	  
resistance	   to	   neurotrophin	   withdrawal,	   suggesting	   a	   lack	   of	   normal	   neural	   crest	  
deletion	  underlying	  tumour	  formation	  (Hansford	  et	  al.,	  2004).	  
	  
1.2.2. Survival	  and	  death:	  The	  paradox	  of	  Mycn	  
It	  is	  well	  accepted	  that	  Mycn	  can	  induce	  apoptosis	  both	  in	  embryonic	  development	  
and	   in	   cancer,	   likely	  depending	  on	   signal	   intensity	  and	  cellular	   context	   (Murphy	  et	  
al.,	   2008;	   Soucek	   and	   Evan,	   2010).	   In	   NBL,	   overexpression	   of	   Mycn	   in	   non-­‐Mycn	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amplified	  cells	  enhances	  sensitivity	  to	  chemotherapeutic	  induced-­‐cytotoxicity	  (Fulda	  
et	  al.,	  2000;	  Fulda	  et	  al.,	  1999).	  Thus	  concomitant	  inactivation	  of	  apoptotic	  signalling	  
is	   a	   prerequisite	   for	   tumour	   cell	   survival	   in	   the	   presence	   of	   increased	   Mycn	  
expression	  (Hogarty,	  2003).	  Mycn-­‐induced	  apoptosis	  occurs	  through	  a	  putative	  DNA	  
damage	   response,	   where	   Mycn	   stabilizes	   the	   p53	   kinase	   HIPK2,	   causing	  
phosphorylation	  of	   p53	   (Petroni	   et	   al.,	   2011),	   implying	   that	   reactivating	   p53	   could	  
engage	  this	  response.	  Conversely,	  Mycn	  expression	  in	  non	  Mycn-­‐amplified	  NBL	  cells	  
results	   from	   reactivation	   of	   p53	   signalling	   by	   MDM2	   inhibition	   using	   nutlin-­‐3,	  
resulting	   in	  cytotoxicity	   induced	  by	  doxorubicin	   (Peirce,	  2009).	  p53	   itself	   is	  a	  direct	  
transcriptional	  target	  of	  Mycn	  (Chen	  et	  al.,	  2010a),	  although	  the	  negative	  regulator	  
of	  p53	  MDM2	  is	  also	  positively	  upregulated	  by	  Mycn	  (Slack	  et	  al.,	  2005).	  	  
	  
1.2.3. 	  	  	  Targets	  of	  Mycn	  and	  the	  search	  for	  negative	  regulators	  
The	   Mycn	   transcription	   factor	   is	   clearly	   an	   obvious	   therapeutic	   target,	   but	   it	   has	  
historically	  been	  regarded	  as	  undruggable	  given	  the	  difficulty	  of	  disrupting	  protein-­‐
protein	   or	   protein-­‐DNA	   interactions.	   Instead	   efforts	   have	   focused	   on	   the	  
identification	   of	  Mycn	   targets	   themselves	   (Bell	   et	   al.,	   2010),	   as	   well	   as	   enzymatic	  
regulators	   of	   Mycn	   stability	   and	   expression	   (Gustafson	   and	   Weiss,	   2010).	   This	  
approach	  is	  particularly	  appealing	  due	  to	  the	  plethora	  of	  kinase	  inhibitors	  developed	  
in	  recent	  years.	  
	   Mycn	  controls	  the	  expression	  of	  numerous	  genes	  related	  to	  clinical	  behaviour	  
in	   NBL.	   Among	   these	  Mycn	   increases	   the	   expression	   of	   the	   cellular	   retinoic	   acid-­‐
binding	   protein	   II	   (CRABP-­‐II),	   thus	   promoting	   motility	   (Gupta	   et	   al.,	   2006),	  
downregulates	   Dickkopf-­‐1,	   thereby	   inhibiting	   proliferation	   (Koppen	   et	   al.,	   2007),	  
upregulates	  microRNAs	  capable	  of	  repressing	  oestrogen	  receptor	  (alpha)	  expression	  
and	  suppressing	  differentiation	  (Lovén	  et	  al.,	  2010),	  and	  increases	  the	  expression	  of	  
the	   oncogenic	   survival	   factor	   focal	   adhesion	   kinase	   (FAK)	   (Beierle	   et	   al.,	   2007).	  
However,	   while	   inhibiting	  Mycn	   targets	   may	   in	   some	   circumstances	   abrogate	   the	  
effects	  of	  Mycn	  overexpression,	  there	  is	  likely	  to	  be	  a	  high	  level	  of	  redundancy	  given	  
the	   very	  high	  number	  of	   potential	  Myc/Max	  dimer	   target	   genes	   (possibly	   ~25%	  of	  
known	  promoters).	   Thus	   reducing	  Mycn	  protein	   levels	   is	   perhaps	   a	  more	  effective	  
strategy.	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   The	   stability	   of	   Mycn	   depends	   on	   reversible	   phosphorylation	   by	   multiple	  
enzymes	   (Figure	   1.2.3)	   (Gustafson	   and	   Weiss,	   2010).	   Mycn	   is	   stabilized	   by	  
phosphorylation	   at	   S62,	   controlled	   by	   the	   cyclin-­‐dependent	   kinase	   1	   (CDK1)	  	  
(Sjostrom,	   05).	   Phosphorylation	   at	   S62	   promotes	   interactions	   with	   a	   complex	  
containing	   Axin1,	   Pim1,	   PP2A	   and	  GSK3β	   (Arnold	   et	   al.,	   2009).	   Phosphorylation	   of	  
Mycn	   at	   T58	   is	   achieved	   by	   GSK3β,	   downstream	   of	   PI3K/Akt/mTOR.	   Protein-­‐
phosphatase	  2A	  (PP2A)	  dephosphorylates	  Mycn	  at	  S62,	  where	  monophosphorylated	  
T58	   targets	   Mycn	   for	   ubiquitination	   and	   degradation	   (Arnold	   et	   al.,	   2009).	   The	  
PI3K/Akt/mTOR	   pathway	   has	   several	   roles	   in	   contributing	   to	   the	   stabilization	   of	  
Mycn.	  Firstly	  Akt,	  which	  is	  activated	  by	  PI3K,	  phosphorylates	  and	  inactivates	  GSK3β	  
and	   stabilizes	   Mycn	   through	   blockage	   of	   T58	   phosphorylation.	   Akt	   also	  
phosphorylates	   and	   inhibits	   tuberous	   sclerosis	   2	   (Tsc2)	   that	  binds	   to	  Tsc1	  allowing	  
the	  GTPase	   Rheb	   to	   stimulate	  mTOR	   as	   part	   of	   the	  mTORC1	   complex,	   resulting	   in	  
downregulation	   of	   PP2A	   and	   further	   stabilizing	   Mycn.	   Inhibitors	   of	   PI3K	   result	   in	  
Mycn	  degradation,	  a	  process	  dependent	  on	  phosphorylation	  (Chesler	  et	  al.,	  2006).	  
The	  cell	  cycle	  and	  spindle	  assembly	  regulator	  Aurora	  A	  kinase	  also	  stabilizes	  
Mycn	   through	   both	   direct	   and	   ubiquitin	   ligase-­‐mediated	   interactions	   (Otto	   et	   al.,	  
2009),	  although	  this	  function	  is	  independent	  of	  Aurora	  A	  kinase	  activity	  and	  thus	  not	  
directly	   affected	   by	   Aurora	   A	   inhibitors	   (Maris,	   2009).	   Significantly,	   RA	  
downregulates	  Mycn	  (Thiele	  et	  al.,	  1985),	  however	  clearly	  Mycn	  amplified	  tumours	  
can	   circumvent	   RA	   induced-­‐growth	   arrest	   as	   this	   drug	   fails	   to	   achieve	   tumour	  
remission	   and	   prevention	   of	   relapse	   in	   all	   cases.	   Thus	   while	   targeting	   of	   Mycn	   is	  
undoubtedly	   an	   important	   strategy	   in	   NBL	   therapy,	   it	   may	   prove	   disappointing,	  
especially	   if	   addiction	   to	   Mycn	   does	   not	   underlie	   Mycn	   amplification	   in	   NBL	  
(Weinstein,	  2002;	  Weinstein	  and	  Joe,	  2008).	  
	  
1.3. Aberrant	  regulation	  of	  protein	  phosphorylation	  in	  human	  cancer	  
and	  neuroblastoma	  
1.3.1. Constitutive	  activation	  of	  kinases	  as	  a	  hallmark	  of	  cancer	  
Deregulated	  cell	  growth	  resulting	  from	  aberrant	  intracellular	  signal	  transduction	  is	  a	  
hallmark	  of	  all	  neoplasms	  (Hanahan	  and	  Weinberg,	  2000).	  Constitutive	  activation	  of	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protein	   tyrosine-­‐kinases	   (PTKs)	   represents	   an	   overwhelming	   majority	   of	   such	  
perturbations	   (Blume-­‐Jensen	  and	  Hunter,	   2001).	  Over-­‐activation	  of	  PTKs	   can	  occur	  
by	  gene	  amplification,	  overexpression	  or	  genetic	  mutations,	  but	  generally	  results	  in	  
constitutive	   enzyme	   activity	   and	   loss	   of	   autoinhibitory	   mechanisms	   that	   normally	  
safeguard	  cells	  from	  neoplastic	  transformation.	  Among	  deregulated	  PTKs,	  receptor-­‐
tyrosine	   kinases	   (RTKs)	   form	   a	  major	   contributor,	   becoming	   activated	   often	   in	   the	  
presence	   of	   increased	   amounts	   of	   their	   cognate	   ligand	   to	   generate	   autocrine	  
growth-­‐	  factor	  loops.	  
	  
Figure	  1.2.3.	  Signal	  transduction	  cascades	  regulating	  Mycn	  stability.	  	  Signalling	  downstream	  
of	   receptor	   tyrosine	   kinases	   (RTKs)	   results	   in	   a	   number	   of	   changes	   altering	   Mycn	  
phosphorylation.	  For	   instance	  Akt/mTOR-­‐mediated	   inhibition	  of	  PP2A	  results	   in	  prevention	  
of	  monophosphorylation	  at	  T58,	  an	  event	  that	  primes	  Mycn	  for	  degradation.	  Similarly	  Akt-­‐
mediated	  inhibition	  of	  GSK3β	  prevents	  phosphorylation	  at	  T58,	  also	  stabilizing	  Mycn.	  	  
	  
RTKs	  recruit	  adaptor	  proteins	  containing	  SRC	  homology	  2	  (SH2)	  and	  phosphotyrosine	  
binding	   (PTB)	   domains,	   and	   also	   activate	   downstream	   PTKs,	   triggering	   signal	  
transduction	  cascades	  (Zwick	  et	  al.,	  2001).	  As	  a	  result	  a	  wealth	  of	  research	  has	  been	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conducted	  on	   the	   role	  of	   aberrant	  PTK	   signalling,	   identifying	   key	  enzymes	   suitable	  
for	  therapeutic	  intervention	  (Gschwind	  et	  al.,	  2004;	  Tibes	  et	  al.,	  2005;	  Traxler,	  2003).	  
	  
1.3.2. FAK	  and	  SRC	  as	  regulators	  of	  cell	  survival	  	  
Both	  the	  FAK	  family	  and	  c-­‐SRC	  (SRC)	  non-­‐receptor	  tyrosine	  kinases	  have	  been	  heavily	  
implicated	   in	   human	   cancer,	   controlling	   vital	   processes	   such	   as	   cell	   motility	   and	  
invasiveness,	   proliferation	   and	   survival	   (Brunton	   and	   Frame,	   2008;	   Mitra	   and	  
Schlaepfer,	  2006)	  (Figure	  1.3.1).	  c-­‐SRC	  is	  the	  cellular	  orthologue	  of	  viral-­‐(v)-­‐SRC,	  the	  
first	   viral	   oncogene	   to	   be	   identified	   (Moore	   and	   Chang,	   2010),	   and	   has	   been	  
implicated	   in	   numerous	   processes	   contributing	   to	   tumour	   maintenance	   and	  
progression	  (Yeatman,	  2004).	  It	  is	  commonly	  overexpressed	  and	  activated	  in	  cancers,	  
most	   notably	   breast	   and	   colorectal	   tumours	   (Irby	   and	   Yeatman,	   2000).	   SRC	  
cooperates	  with	  growth	   factor	   receptors	  such	  as	  epidermal	  growth	   factor	   receptor	  
(EGFR)	   to	   increase	   proliferation	   and	   invasiveness	   (Brunton	   et	   al.,	   1997),	   and	  
stimulates	   cell	   spreading	   and	  motility	   by	   influencing	   integrin	   attachment	   (Jones	   et	  
al.,	   2002).	   Recently	   SRC	   activation	   was	   observed	   to	   occur	   as	   a	   compensatory	  
mechanism	   of	   resistance	   to	   chemotherapeutic	   inhibition	   of	   alternative	   oncogenic	  
survival	   pathways	   after	   prolonged	   treatment	   with	   the	   commonly	   used	   ERBB2	  
inhibitor	  trastuzumab	  (Zhang	  et	  al.,	  2011).	  Here	  one	  of	  the	  causes	  of	  SRC	  activation	  
was	   by	  mutational	   inactivation	   of	   PTEN,	   a	   common	   feature	   in	   cancer	   (see	   below),	  
suggesting	   that	   this	   tumour-­‐suppressive	   phosphatase	   is	   capable	   of	   negatively	  
regulating	  SRC	  activity.	  	  
	   	  SRC	   is	   regulated	   by	   multiple	   protein	   tyrosine-­‐phosphatases	   (PTPs).	   The	  
receptor	   type	   PTPα	   dephosphorylates	   SRC	   at	   its	   terminal	   tyrosine,	   positively	  
regulating	   its	   activity	   (Zheng	  et	   al.,	   1992).	   SRC	   is	   also	  activated	  by	   the	   cytoplasmic	  
PTPs	   Shp1	   (Frank	  et	   al.,	   2004),	   Shp2	   (Zhang	  et	   al.,	   2004)	   and	  PTP1B	   (Bjorge	  et	   al.,	  
2000).	   In	   fact	   PTP1B	  was	   recently	   demonstrated	   to	   be	   crucial	   for	   ErbB2-­‐mediated	  
transformation	   due	   to	   its	   ability	   to	   activate	   SRC	   in	   breast	   epithelial	   cells	   (Arias-­‐
Romero	  et	  al.,	   2009).	  PTP-­‐PEST	  has	  also	  been	  shown	   to	  negatively	   regulate	  events	  
downstream	   of	   SRC	   activation	   by	   dephosphorylating	   Y416	   preventing	   the	  
phosphorylation	  of	  villin	  1	  (Mathew	  et	  al.,	  2008).	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   FAK	   is	   expressed	   at	   sites	   of	   integrin	   clustering	   or	   focal	   adhesions	  where	   it	  
carries	   out	   protein-­‐protein	   adaptor	   functions	   regulating	   scaffolding	   to	   the	  
extracellular	   matrix	   (ECM).	   FAK	   regulates	   integrin	   adhesions,	   control	   of	   the	   actin-­‐
cytoskeleton	   and	   stimulation	   of	   cell	   migration	   by	   assembly/disassembly	   of	   focal	  
adhesion	   complexes	   at	   cell	   leading	   and	   trailing	   edges,	   as	   well	   as	   growth	   factor	  
signalling	   and	   proliferation/survival	   (Mclean	   et	   al.,	   2005).	   	   In	   line	   with	   this	   FAK	   is	  
commonly	   upregulated	   and	   activated	   in	   human	   cancers	   (Weiner	   et	   al.,	   1993),	  
correlating	  with	  metastasis	  and	  malignancy	  as	  well	  as	  patient	  prognosis.	  The	  roles	  of	  
FAK	   are	   closely	   intertwined	  with	   that	   of	   SRC.	  Autophosphorylation	  of	   FAK	   at	   Y397	  
leads	   to	   recruitment	  and	  binding	  of	  SH2	  domain	  containing	  proteins,	  most	  notably	  
SRC	   itself	   causing	   SRC	   kinase	   activity	   (Schaller	   et	   al.,	   1994).	   Binding	   of	   SRC	   causes	  
phosphorylation	   of	   FAK	   at	   Y576/77	   further	   increasing	   its	   activity,	   as	   well	   as	  
phosphorylating	  other	  tyrosine	  residues	  including	  Y925	  allowing	  the	  binding	  of	  Grb2	  
and	   concomitant	   activation	   of	   the	   Ras/MAPK	   pathway	   (Schlaepfer	   and	   Hunter,	  
1996).	  	  
	   The	   best-­‐documented	   consequence	   of	   FAK	   stimulation	   is	   the	   turnover	   of	  
focal	   adhesions	   and	   cell-­‐cell	   cadherin	   junctions,	   and	   control	   of	   dynamic	   actin	  
structures,	   all	   contributing	   to	   enhanced	   cell	   motility	   and	   invasiveness.	   However,	  
upregulation	   of	   FAK	   also	   prevents	   apoptosis	   following	   detachment	   from	   the	   ECM	  
(anoikis)	  in	  kidney	  epithelial	  cells.	  This	  provides	  indirect	  evidence	  for	  a	  role	  of	  FAK	  in	  
promoting	   the	   survival	   of	   cancer	   cells	   following	   epithelial	   to	   mesenchymal	  
transitions	  (EMT),	  which	  occurs	  prior	  to	  metastatic	  spread	  (Frisch	  et	  al.,	  1996).	  







Figure	  1.3.1.	  Generalized	  role	  of	  FAK	  and	  SRC	  in	  human	  cancer.	  Co-­‐activation	  of	  FAK/SRC,	  
both	   positively	   contributes	   to	   cell	   survival	   and	  motility	   by	   controlling	   adhesion	   dynamics.	  
Taken	  from	  (Mclean	  et	  al.,	  2005).	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Multiple	   lines	   of	   evidence	   have	   linked	   FAK/SRC	   to	   survival	   signalling	   in	   NBL.	   Dual	  
inhibition	  of	  FAK	  and	  SRC	  increases	  NBL	  cell	  death	  by	  stimulating	  anoikis	  (Beierle	  et	  
al.,	   2010).	   The	   same	   group	   demonstrated	   that	   FAK	   was	   a	   direct	   target	   of	   Mycn,	  
which	   acted	   as	   a	   transcriptional	   activator	   causing	   upregulation	   of	   FAK	   after	  
conditional	  expression	  of	  Mycn	  (Beierle	  et	  al.,	  2007;	  Madonna,	  2010).	  As	  such,	  FAK	  is	  
considered	   a	  promising	   target	   in	  NBL	   therapy	   (Gillory	   and	  Beierle,	   2010).	   FAK	   also	  
activates	   SRC/p130Cas	   to	   engage	   α5β1	   and	   α4β1	   integrin-­‐mediated	  
motility/invasion	   in	  NBL	   (Wu	  et	   al.,	   2008).	   SRC	   is	   involved	   in	   the	  differentiation	  of	  
NBL	  cells	  (Bjelfman	  et	  al.,	  1990;	  den	  Hertog	  et	  al.,	  1993).	  Indeed,	  ligand	  independent	  
activation	   of	   Trk	   receptors	   is	   blocked	   by	   SRC	   inhibition	   (Lee	   and	  Chao,	   2001),	   and	  
constitutively	   active	   SRC	   can	   enhance	   activation	   of	   TrkA	   by	  NGF	   and	   the	   resulting	  
Erk-­‐dependent	   differentiation	   (Tsuruda	   et	   al.,	   2004).	   However	   SRC	   dependent	  
adhesion	  has	  been	   suggested	   to	  be	   facilitated	  by	   caspase	  8-­‐expression	   (Finlay	   and	  
Vuori,	   2007),	   which	   positively	   contributes	   to	   migration	   and	   metastasis	   in	   NBL	  
(Barbero	  et	  al.,	  2009).	  
	  
1.3.3. The	  Ras/RAF/MEK/Erk	  and	  PI3K/Akt	  pathways	  
Among	   the	   many	   intracellular	   signalling	   cascades	   aberrantly	   regulated	   in	   human	  
cancer,	   both	   the	   Ras/RAF/MEK/Erk	   (McCubrey	   et	   al.,	   2007)	   and	   the	   PI3K/Akt	  
(Hennessy	   et	   al.,	   2005)	   pathways	   have	   perhaps	   the	   most	   crucial	   and	   broad	  
involvement	   in	   neoplastic	   transformation	   and	   tumour	   maintenance.	   Indeed	  
activating	  mutations	   in	  Ras,	   the	   first	  proto-­‐oncogene	   to	  be	   identified	   (Tabin	  et	   al.,	  
1982),	   occur	   in	   20-­‐30%	   of	   tumours	   (Downward,	   2003).	   Similarly,	  mutations	   in	   the	  
negative	  regulator	  of	  PI3K/Akt	  signalling	  PTEN	  occur	  in	  50-­‐80%	  of	  sporadic	  tumours	  
(Salmena	   et	   al.,	   2008).	   Mutations	   in	   the	   downstream	   effectors	   of	   Ras,	   RAF	   and	  
mitogen-­‐activated	   protein	   kinases	   (MAPK)/Extracellular	   signal-­‐related	   kinases	   (Erk)	  
kinase	  (MEK),	  are	  frequently	  observed	  in	  a	  range	  of	  cancers,	  and	  the	  gene	  encoding	  
PI3K	   PIK3CA	   is	   similarly	   subject	   to	   activating	   mutations	   as	   well	   as	   amplification,	  
making	   multiple	   components	   of	   both	   pathways	   a	   dominant	   feature	   in	   cancer	  
biology.	  
Activation	  of	  Ras	  GTPases	  by	  upstream	  activation	  of	  growth	  factor	  receptors	  
such	  as	  EGFR	  can	  stimulate	  multiple	  effectors,	   including	  PI3K	  and	  the	  RAF	  family	  of	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serine/threonine	   kinases,	   which	   in	   turn	   activate	   MEK	   1/2	   dual-­‐specificity	   kinases,	  
resulting	   in	   Erk	   stimulation	   (Figure	   1.3.2).	   Phosphorylation	   and	   activation	   of	   Erk	  
results	   in	   both	   cytoplasmic	   enzymatic	   interactions	   and	   nuclear-­‐
translocation/transcription	   factor	   binding.	   Erk	   has	   at	   least	   160	   substrates,	  with	   its	  
activation	  resulting	  in	  diverse	  consequences	  of	  proliferation,	  survival,	  apoptosis	  and	  
differentiation	  depending	  on	  cellular	  context	  (von	  Kriegsheim	  et	  al.,	  2009).	  
The	  phosphatidylinositol-­‐3-­‐kinase	  (PI3K)	   family	  of	   lipid	  and	  serine/threonine	  
kinases	   have	   similarly	   diverse	   functions.	   Class	   IA	   PI3K	   enzymes	   form	  heterodimers	  
with	  an	   inhibitory	  adaptor/regulator	  p85	  and	  catalytic	  p110	  subunit.	  The	   former	   is	  
capable	  of	  binding	  and	  integrating	  signals	  from	  upstream	  RTKs	  as	  well	  as	  intracellular	  
enzymes	  such	  as	  PKC,	  SHP1,	  Ras	  and	  SRC.	  PI3K	  phosphorylates	  phosphatidylinositol-­‐
4,-­‐5-­‐bisphosphate	   (Ptpins(4,5)P2;	   PIP2),,	   generating	   the	   second	   messenger	  
Ptpins(3,4,5)P3	   (PIP3),	   which	   binds	   plekstrin-­‐homology	   (PH)	   domain-­‐containing	  
proteins,	   most	   notably	   Akt.	   Akt	   is	   then	   recruited	   to	   the	   membrane,	   undergoes	  
conformational	   change	   and	   phosphorylation	   of	   T308	   by	   phosphoinositide-­‐
dependent	   kinase	   1	   (PDK1)	   and	   phosphorylation	   at	   S473	   by	   PDK2,	   causing	   full	  
activation	  (Figure	  1.3.2).	  Phosphate	  and	  tensin	  homologue	  deleted	  on	  chromosome	  
10	   (PTEN)	   dephosphorylates	   the	   3’OH	   group	   of	   PIP3,	   representing	   the	   negative	  
regulator	  of	  Akt	  activity.	  Class	   IA	  PI3K	  has	  4	   isoforms	  (p110α,	  β,	  γ	  and	  δ),	  of	  which	  
only	   α	   is	   mutated	   in	   cancer,	   although	   all	   are	   capable	   of	   sustaining	   proliferation	  
(Foukas	  et	  al.,	  2010).	  	  
Akt1,	  Akt2,	  Akt3	  are	  each	  activated	  by	  PI3K	  signalling	  with	  similar	  substrate	  
preferences.	   However,	   each	   may	   serve	   different	   functions	   contributing	   to	  
motility/invasion	   (Akt2),	   hormone	   independence	   (Akt3)	   and	   general	   cell	   growth	  
(Arboleda	   et	   al.,	   2003).	   Akt	   can	   regulate	   cell	   survival	   by	   inactivating	   proapoptotic	  
factors	   including	   the	  mitochondrial	   apoptotic	   enzyme	  BAD,	   Forkhead	   transcription	  
factors	   and	   caspase	   9,	   as	   well	   as	   upregulating	   antiapoptotic	   genes	   such	   as	   cyclic-­‐
AMP-­‐response	  element	  binding	  protein	  (CREB)	  (Paez	  and	  Sellers,	  2003).	  Akt	  can	  also	  
stimulate	   mammalian	   target	   of	   rapamycin	   (mTOR)	   (Figure	   1.3.2)	   to	   engage	  
proliferation	   (Wendel	   et	   al.,	   2004).	   mTOR	   activates	   protein-­‐synthesis	   machinery	  
including	   ribosomal	   protein	   S6	   kinases	   (p70S6K)	   and	   4E-­‐binding	   proteins	   (4EBPs),	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resulting	   in	   the	   release	   of	   the	   translation	   initiation	   factor	   eIF4E	   itself	   capable	   of	  
antiapoptotic/transforming	  functions	  (Schmelzle	  and	  Hall,	  2000).	  	  
Unlike	  many	  cancers	  of	  adulthood,	  mutations	  in	  RAS	  and	  hyperactivity	  of	  Erk	  
have	   not	   been	   described	   in	   NBL	   (Maris	   et	   al.,	   2007).	   In	   fact	   H-­‐Ras	   is	   generally	  
regarded	   as	   a	   favourable	   marker	   in	   NBL,	   and	   has	   been	   suggested	   to	   cause	  
autophagic	  cell	  death	  (see	  below)	  and	  thus	  spontaneous	  regression	  (Kitanaka	  et	  al.,	  
2002).	  Similarly,	  Ras-­‐mediated	  activation	  of	  Erk	   is	   responsible	   for	  p53-­‐independent	  
cell	   death	   occurring	   after	   treatment	   with	   the	   platinum	   based	   chemotherapeutic	  
cisplatin	   (Woessmann	   et	   al.,	   2002),	   and	   in	   hydrogen	   peroxide-­‐induced	   cell	   death	  
(Ruffels	   et	   al.,	   2004).	   However,	   the	   fatty	   acid	   based-­‐protein	   tyrosine	   phosphatase	  
(PTP)	   inhibitor	   docasahexaenoic	   acid	   causes	   neuritogenesis	   of	   NBL	   cells	   via	   Erk	  
activation	  mediated	  by	  reactive	  oxygen	  species	  (ROS)	  (Wu	  et	  al.,	  2009).	  
	  
Figure	   1.3.2.	   The	   Ras/RAF/MEK/Erk	   and	   PI3K/Akt/mTOR	   pathways.	   Growth	   factor	  
mediated	   activation	   of	   RTKs	   leads	   to	   activation	   of	   Ras,	   in	   turn	   giving	   rise	   to	   Erk	  
phosphorylation	  downstream	  of	  RAF/MEK.	  Similarly,	  activation	  of	  PI3K	  downstream	  of	  RTKs	  
causes	   phosphorylation	   of	   PIP2,	   leading	   to	   recruitment	   and	   activation	   of	   Akt	   via	   PDK1.	  
Downstream	  activation	   of	   the	  mTOR	   complex	   1	  mediates	   negative	   feedback	   regulation	   of	  
PI3K	  activity	  via	  phosphorylation	  of	  S6K1.	  PTPs	  exert	  both	  negative	  and	  positive	  regulation.	  
For	   instance	   PTP1B	   dephosphorylates	   the	   insulin	   receptor	   (IR)	   RTK,	   attenuating	   PI3K	  
activation,	  and	  also	  the	  Ras-­‐inhibiting	  scaffold	  complex	  of	  p62Dok/p120RasGAP,	  promoting	  
Ras	  activation.	  There	  is	  considerable	  cross	  talk	  between	  pathways.	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Activation	  of	  ERK	  also	  occurs	  during	  RA-­‐induced	  differentiation	  (Singh	  et	  al.,	  2003),	  
although	  this	   is	  not	  crucial	   (Miloso	  et	  al.,	  2004).	  Lastly,	  Erk	  activation	   is	   involved	   in	  
differentiation	  induced	  by	  Trks	  (Brodeur	  et	  al.,	  2009).	  Thus	  in	  line	  with	  its	  generally	  
diverse	   functions,	   activation	   of	   Erk	   can	   either	   have	   positive	   or	   negative	  
consequences	  on	  NBL	  cell	  survival/differentiation.	  	  
	   Although	  PI3K/Akt	  is	  required	  for	  RA-­‐induced	  differentiation	  (López-­‐Carballo	  
et	   al.,	   2002),	   it	   generally	   contributes	   to	  NBL	   cell	   survival.	   This	  may	  also	  be	   true	  of	  
differentiated	   cells,	   accounting	   for	   their	   survival	   following	   differentiation	   as	   in	   the	  
case	   of	   Trk	   induced-­‐differentiation	   (Brodeur	   et	   al.,	   2009).	   Activation	   of	   Akt	   is	   a	  
negative	   prognostic	  marker	   in	   NBL	   (Opel	   et	   al.,	   2007),	  making	   it	   a	   firm	   target	   for	  
therapeutic	  intervention	  (Brodeur,	  2010;	  Li	  and	  Thiele,	  2007).	  
	   The	   small	  molecule	   Akt	   inhibitor	   perifosine	   reduces	   NBL	   tumour	   growth	   in	  
vitro	  and	  in	  vivo	  by	  p53-­‐independent	  apoptosis	  (Li	  et	  al.,	  2010).	  Similarly	  inhibition	  of	  
PI3K	  synergistically	  augments	  low	  dose	  chemotherapy	  in	  vitro	  by	  altering	  the	  ratio	  of	  
antiapoptotic	  (Bcl-­‐2,	  Bcl-­‐XL,	  Mcl-­‐1)	  and	  pro-­‐apoptotic	  (Bax,	  Bak	  and	  BH3)	  Bcl-­‐2	  family	  
proteins,	   again	   reliant	   on	   p53	   (Bender	   et	   al.,	   2011).	   Inhibition	   of	   PI3K	   with	   the	  
selective	   PI3Kγ	   inhibitor	   AS605240	   causes	   in	   vivo	   growth	   suppression	   in	   tumours	  
characterized	  by	  high	  PI3Kγ	  expression	  (Spitzenberg	  et	  al.,	  2010).	  	  Indeed,	  targeting	  
Akt	  is	   likely	  to	  be	  broadly	  effective	  given	  that	  multiple	  RTKs	  signal	  upstream	  of	  this	  
node,	   thus	   preventing	   circumvention	   of	   therapy	   by	   compensation	   in	   alternative	  
pathways	   (Brodeur,	   2010).	   Activation	   of	   the	   downstream	   PI3K/Akt	   effector	  mTOR	  
occurs	   with	   Akt	   activation	   in	   NBL,	   where	   the	   mTOR	   inhibitor	   rapamycin	   causes	  
apoptosis,	  decreased	  proliferation	  and	  inhibition	  of	  angiogenesis	  in	  vivo,	  particularly	  
in	  MYCN-­‐driven	   tumours	   (Johnsen	   et	   al.,	   2008).	   NBL	   tumour-­‐initiating	   cells	   (TICs),	  
believed	   to	   represent	   a	   cancer	   stem	   cell	   (CSC)	   responsible	   for	   initiating	   tumour	  
formation,	  metastasis	  and	  relapse	  (Hansford	  et	  al.,	  2007),	  are	  selectively	  and	  acutely	  
sensitive	  to	  rapamycin	  (Smith	  et	  al.,	  2010).	  
	  
1.3.4. PI3K/Akt/mTor	  inhibition:	  A	  double	  edged	  sword	  
Thus	  far	  it	  has	  been	  suggested	  that	  inhibition	  of	  the	  PI3K/Akt/mTor	  pathway	  is	  likely	  
to	  form	  an	  effective	  treatment	  strategy	  in	  a	  range	  of	  cancers	  including	  NBL,	  given	  the	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frequency	  of	  activation	  and	  its	  negative	  consequences	  on	  proliferation,	  survival	  and	  
inhibition	   of	   apoptosis.	   However,	   a	   fundamental	   tenet	   of	   cancer	   biology	   is	   a	  
dichotomy	   of	   consequences	   based	   either	   on	   cell	   context	   or	   adaptive	  
strategies/natural	   selection	   in	   cancer	   cell	   populations	   (Greaves,	   2010).	   As	   such	  
targeting	   of	   survival	   pathways	   such	   as	   PI3K/Akt	   may	   have	   adverse	   consequences	  
portending	  to	  treatment	  failure.	  
	   O’Reilly	  et	   al.	  were	   the	   first	   to	  demonstrate	   that	   inhibition	  of	   the	  PI3K/Akt	  
effector	   mTOR	   induces	   the	   expression	   of	   insulin	   receptor	   substrate-­‐I,	   abrogating	  
negative	  feedback	  inhibition	  and	  resulting	  in	  paradoxical	  activation	  of	  Akt	  (O'Reilly	  et	  
al.,	   2006),	   antagonizing	   the	   effects	   of	   rapamycin	   (Zoncu	   et	   al.,	   2011).	   It	   has	   been	  
suggested	  that	  concomitant	   inhibition	  of	  PI3K	  and	  mTOR	  by	  dual	   inhibitors	  such	  as	  
PI-­‐103	  (Fan	  et	  al.,	  2006)	  is	  a	  prerequisite	  for	  more	  effective	  targeting	  of	  this	  pathway	  
(Figure	  1.3.3).	  	  
	  
Figure	   1.3.3.	   Consequences	   of	   mTOR	   inhibition	   due	   to	   relief	   of	   negative	   feedback.	  
Signalling	  downstream	  of	  PI3K	  activates	  Akt	   followed	  by	  mTORC1,	   causing	   S6K1	  activation	  
exerting	   negative	   feedback	   on	   further	   PI3K	   stimulation	   (A).	   Inhibition	   of	   mTORC1	   with	  
rapamycin	   prevents	   activation	   of	   S6K1	   relieving	   negative	   feedback	   of	   PI3K	   (B).	   Catalytic	  
inhibitors	  of	  mTOR	  prevent	  Akt	  activation	  through	  mTORC2,	  but	  leave	  PI3K	  activation	  intact	  
(C).	  Dual	  inhibitors	  of	  PI3K/mTOR	  prevent	  activation	  downstream	  of	  PI3K,	  however	  this	  may	  
exert	  toxicity	  by	  shutting	  down	  an	  entire	  pathway	  crucial	  to	  cell	  survival	  (D).	  	  
	  
However,	   inhibition	   of	   Akt	   itself	   may	   lead	   to	   similar	   effects.	   For	   instance,	  
Chandarlapaty	   et	   al.	   recently	   demonstrated	   attenuation	   of	   negative	   feedback	  
regulation	  due	  to	  Akt	   inhibition	   (Chandarlapaty	  et	  al.,	  2011).	  Specific	  Akt	   inhibitors	  
caused	  both	   the	   induction	   and	  activation	  of	  multiple	  RTKs	   including	  HER3,	   Insulin-­‐
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like	   growth	   factor	   I	   receptor	   (IGF-­‐1R)	   and	   the	   insulin	   receptor,	   primarily	   due	   to	  
mTORC1	   inhibition	   and	   FoxO	   activation	   dependent	   receptor	   expression	   in	   breast	  
cancer	   cells	   driven	   by	   amplification	   of	   HER2,	   with	   combined	   HER3/Akt	   inhibition	  
more	  effective	  than	  either	  treatment	  alone.	  PI3K	  inhibition	  can	  also	  relieve	  negative	  
feedback	  inhibition	  of	  HER	  causing	  activation	  and	  stimulation	  of	  alternative	  signalling	  
effectors	   such	   as	   Erk	   (Serra	   et	   al.,	   2011).	   Here	   Erk	   dependency	   ensued,	   allowing	  
concomitant	   HER2	   or	   MEK	   inhibition	   to	   drastically	   improve	   the	   efficacy	   of	   PI3K	  
inhibition.	  	  	  
	   Another	  way	  in	  which	  cancer	  cells	  may	  circumvent	  PI3K/Akt	  targeted	  therapy	  
is	   by	   the	   induction	   of	   survival	   mechanisms	   such	   as	   autophagy.	   For	   instance	   the	  
inhibitors	  of	  mTOR	  and	  PI3K	  rapamycin	  and	  PI-­‐103	  were	  shown	  to	  potently	   induce	  
macroautophagy	  (autophagy).	  Autophagy	  is	  a	  method	  of	  cell	  survival	  in	  the	  absence	  
of	   adequate	   nutrition,	   or	   under	   other	   stress	   conditions	   (Mizushima	   et	   al.,	   2010).	  
Inhibition	  of	  autophagy	  using	  chloroquine	  synergistically	  enhanced	  apoptosis	  (Fan	  et	  
al.,	  2010).	  	  
	   Lastly,	   Akt	   activation	   itself	   may	   actually	   be	   beneficial	   in	   certain	  
circumstances.	   For	   instance,	   Nogueira	   et	   al.	   showed	   that	   activation	   of	   Akt	   causes	  
ROS	   dependent	   apoptosis	   by	   increasing	   oxygen	   consumption	   and	   inhibiting	   ROS	  
scavengers	   downstream	   of	   FoxO	   (Nogueira	   et	   al.,	   2008).	   Boosting	   Akt	   activation	  
using	  rapamycin	  actually	  enhanced	  cell	  death	  in	  etoposide	  resistant	  cancer	  cells	  via	  
ROS	  production	  and	  ensuing	  apoptosis,	   suggesting	   that	   relieving	  Akt	   inhibition	  can	  
actually	   be	   beneficial	   in	   some	   instances.	   This	   study	   also	   showed	   that	   Akt	   caused	  
premature	  senescence	  in	  normal	  fibroblasts	  (See	  below).	  	  
	  
1.3.5. Oncogene-­‐induced	  senescence	  
2011	   marks	   the	   anniversary	   of	   Hayflick	   and	   Moorhead’s	   seminal	   description	   of	  
cellular	   replicative	   senescence	   (Hayflick	   and	   Moorhead,	   1961),	   whereby	  
untransformed	  cells	  in	  contrast	  to	  cancer	  cells	  exhibit	  a	  finite	  replicative	  potential	  in	  
vitro,	  undergoing	  irreversible	  growth	  arrest	  in	  the	  presence	  of	  mitogenic	  signals	  and	  
sustained	   metabolic	   activity	   characterized	   by	   β-­‐galactosidase	   activity	   at	   acidic	   pH	  
(Dimri	  et	  al.,	  1995).	  Senescent	  cells	  also	  undergo	  telomere	  shortening,	  upregulation	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of	  the	  CDKN2A	   locus	  encoding	  p16INK4A/ADP	  ribosylation	  factor	  (ARF),	  DNA	  damage	  
and	  cytoplasmic	  enlargement/vacuolation	  (Collado	  et	  al.,	  2007).	  	  
	   However,	  less	  than	  15	  years	  ago	  a	  distinct	  phenomenon	  termed	  “premature	  
senescence”	  was	  observed	   following	  overexpression	  of	  proto-­‐oncogenes	   in	  normal	  
cells	  (Serrano	  et	  al.,	  1997).	  Thus	  the	  concept	  of	  oncogene-­‐induced	  senescence	  (OIS)	  
was	   born	   (Braig	   and	   Schmitt,	   2006;	   Collado	   and	   Serrano,	   2010),	   describing	  
premature	   senescence	   attributed	   to	   overexpression	   of	   Ras	   and	   concomitant	  
accumulation	   of	   p53	   and	   p16INK4A.	   Ras	   overexpression	   results	   in	   constitutive	  
activation	  of	  MEK,	  which	  relies	  on	  p53/p16INK4A	  to	  cause	  growth	  arrest	  as	  a	  fail-­‐safe	  
barrier	   to	   sustained	   proliferation	   in	   the	   presence	   of	   mitogenic	   signals	   (Lin	   et	   al.,	  
1998).	   Thus	   OIS	   represents	   a	   tumour-­‐suppressive	   mechanism	   independent	   of	   the	  
telomere	  clock	  (Jones	  et	  al.,	  2000).	  Since	  then	  OIS	  has	  been	  demonstrated	  as	  a	  bona	  
fide	  barrier	   to	   tumorigenesis.	   For	   instance,	  Michaloglou	  et	  al.	   showed	   that	  despite	  
activating	   mutations	   in	   the	   Ras	   effector	   BRAF	   (BRAFV600E),	   human	   nevi	   (benign	  
tumours	  of	  cutaneous	  melanocytes)	  lack	  proliferative	  activity	  for	  up	  to	  several	  years	  
until,	  in	  a	  minority	  of	  cases,	  further	  lesions	  cause	  malignancy.	  Similarly	  mutations	  in	  
KrasG12D	   drive	   premalignant	   lesions	   in	   the	   pancreas,	   lungs	   and	   skin,	   which	   are	  
positive	  for	  senescence	  markers	  (Collado	  and	  Serrano,	  2010).	  Indeed	  loss	  of	  the	  gene	  
encoding	   NF1,	   a	   Ras	   GTPase	   activator,	   occurs	   in	   a	   number	   of	   human	   cancers	  
including	  NBL,	  but	  underlies	  the	  familial	  cancer	  syndrome	  neurofibromatosis	  type	  1,	  
where	   increased	   activity	   of	   Ras	   leads	   to	   neurofibromas	   and	   senescence	   (Courtois-­‐
Cox	  et	  al.,	  2006).	  	  	  
	   The	   PI3K/Akt	   pathway	   can	   trigger	   a	   similar	   OIS.	   For	   instance,	   targeted	  
expression	   of	   Akt1	   to	   the	   prostate	   in	   mice	   results	   in	   prostrate	   intraepithelial	  
neoplasia	   (PIN)	   with	   senescent	   markers	   (Majumder	   et	   al.,	   2008).	   In	   one	   of	   the	  
defining	  studies	  of	  OIS,	  Chen	  et	  al.	  showed	  that	  conditional	  deletion	  of	  both	  alleles	  
of	  PTEN,	  the	  negative	  regulator	  of	  Akt,	  resulted	  in	  p53-­‐mediated	  senescence,	  greatly	  
delaying	   the	   onset	   of	   invasive	   prostate	   cancer	   (Chen	   et	   al.,	   2005).	   However	  
inactivation	  of	  both	  PTEN	  and	  p53	   resulted	   in	  highly	   invasive	  prostate	   cancer	  with	  
short	  latency,	  again	  underlying	  the	  notion	  that	  OIS	  exists	  as	  a	  fail-­‐safe	  mechanism.	  	  
	   The	   exact	   logistics	   of	   OIS	   have	   often	   seemed	   unclear.	   For	   instance,	  
expression	  of	  p16INK4A	  is	  observed	  in	  lymphomas	  in	  which	  senescence	  was	  bypassed,	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and	  its	  expression	  is	  distinct	  to	  that	  of	  senescence-­‐associated	  β-­‐galactosidase	  (SA-­‐β-­‐
gal)	   in	   human	   nevi	   (Braig	   and	   Schmitt,	   2006).	   However	   transgenic	   disruption	   of	  
p16INK4A	   in	   mice	   mediates	   escape	   from	   Ras	   driven	   senescence	   and	   accelerates	  
tumour	  formation	  (Rane	  et	  al.,	  2002).	  Thus	  it	  has	  been	  suggested	  that	  p16INK4A	  may	  
facilitate	   OIS	   whereas	   p53	   is	   required	   to	   maintain	   it	   (Beauséjour	   et	   al.,	   2003).	  
However	  oncogene	  dosage	  may	  also	  be	  crucial,	  as	  expression	  of	  Ras	  at	  normal	  levels	  
fails	   to	   effectively	   stimulate	   downstream	   targets,	   and	   only	   high	   expression	   can	  
surpass	  negative	  feedback	  inhibition	  and	  initiate	  OIS	  (Sarkisian	  et	  al.,	  2007).	  	  
	   A	   number	   of	   studies	   have	   now	   confirmed	   that	   OIS	   can	   be	   exploited	   as	   a	  
treatment	  modality.	  Wu	  et	  al.	  demonstrated	  that	  by	  genetically	  inactivating	  the	  MYC	  
oncogene	  following	  tumour	  onset,	  senescence	  and	  tumour	  regression	  occurs,	  a	  feat	  
that	   was	   blocked	   by	   inactivation	   of	   p53	   and	   p16INK4A.	   This	   demonstrated	   that	  
senescence	   programs	   can	   remain	   latent	   even	   after	   tumour	   onset	   and	   could	   be	  
reactivated	   to	   induce	   regression.	   A	   similarly	   elegant	   transgenic	   mouse	   model	  
developed	  by	  Xue	  et	  al.	  demonstrated	  that	  tumours	  induced	  by	  loss	  of	  p53	  could	  be	  
driven	   into	   senescence	  by	   its	   restoration	   (Xue	  et	   al.,	   2007).	   Indeed	   stabilization	  of	  
p53	  was	  originally	  suggested	  as	  a	  means	  by	  which	  senescence	  could	  be	  engaged	  in	  
pre-­‐existing	   tumours	   (Chen	  et	  al.,	  2005),	  and	  has	  effectively	  been	  demonstrated	   in	  
NBL	   wild-­‐type	   for	   p53	   using	   an	   inhibitor	   of	   the	   negative	   regulator	   of	   p53	  MDM2	  
nutlin-­‐3	   (Van	   Maerken	   et	   al.,	   2006).	   Similarly,	   DNA	   damage	   induced	   by	  
chemotherapy	   has	   been	   shown	   to	   cause	   senescence	   in	   vivo,	   though	   this	   relies	   on	  
correct	   functioning	   of	   p53	   (Schmitt	   et	   al.,	   2002).	   Thus	   OIS	   represents	   both	   an	  
interesting	  phenomenon	  and	  a	  means	  of	  cancer	  cell	  eradication.	  	  
	  
1.3.4. PTEN-­‐loss-­‐induced	  senescence	  
PTEN	  was	  originally	  identified	  as	  the	  elusive	  tumour	  suppressor	  frequently	  deleted	  at	  
10q23	   (Li	   et	   al.,	   1997),	   representing	   one	   of	   the	   most	   frequently	   lost	   tumour	  
suppressors	  in	  many	  cancers	  (Salmena	  et	  al.,	  2008).	  Its	  tumour	  suppressive	  function	  
is	   commonly	   related	   to	   its	   status	   as	   a	   negative	   regulator	   of	   Akt	   signalling.	   PTEN-­‐
deficient	  mice	  form	  tumours	  in	  multiple	  organs	  (Di	  Cristofano	  et	  al.,	  1998).	  However,	  
acute	  loss	  of	  PTEN	  also	  activates	  a	  fail-­‐safe	  senescence	  program	  dependent	  on	  p53	  
(Chen	   et	   al.,	   2005),	   explaining	   why	   complete	   loss	   of	   PTEN	   is	   rarely	   observed	   at	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presentation.	  Perhaps	  the	  key	  to	  understanding	  this	  is	  the	  notion	  that	  specific	  PTEN	  
levels	   are	   crucial	   to	   its	   cell	   biological	   effects	   (Carracedo	  et	   al.,	   2011).	   The	   classical	  
model	  of	  a	  tumour	  suppressor	  involves	  genetic	  loss	  of	  one	  allele	  and	  subsequent	  loss	  
of	   the	   remaining	   allele,	   comprising	   a	   ‘second	   hit’	   (Knudson,	   1971).	   However,	  
haploinsufficiency	  can	  occur	  whereby	  loss	  of	  one	  allele	  is	  sufficient	  to	  abrogate	  wild	  
type	  protein	  function	  (Berger	  and	  Pandolfi,	  2010).	  Indeed,	  monoallelic	  loss	  of	  PTEN	  is	  
sufficient	  to	  trigger	  tumour	  formation	  (Di	  Cristofano	  et	  al.,	  1998).	  PTEN	  is	  however	  
often	   downregulated	   simply	   by	   epigenetic	   silencing	   and	   post-­‐transcriptional	  
regulation	   (Salmena	   et	   al.,	   2008).	   Thus	   PTEN	   protein	   dosage	   does	   not	   always	  
correspond	  to	  0,	  50	  or	  100%	  of	  wild	  type	  levels,	  a	  factor	  that	  is	  crucial	  to	  the	  effects	  
of	  PTEN	  loss.	  	  
	   The	   group	   of	   P.P	   Pandolfi	   elegantly	   demonstrated	   this	   by	   generating	   a	  
‘hypomorphic	  PTEN	  allelic	  series’	  using	  conditional	  transgenic	  mice	  (Carracedo	  et	  al.,	  
2011).	   Here	   PTEN	   heterozygous	  mutants,	   expressing	   50%	   that	   of	   wild	   type	   levels,	  
develop	   prostate	   intraepithelial	   neoplasia	   or	   prostate	   cancer	   in	   situ	   at	   incomplete	  
penetrance,	  while	   PTEN	   ‘hypo’	  mice,	   expressing	   20-­‐30%	   that	   of	  wild	   type	   animals	  
develop	   prostate	   cancer	   lesions	   at	   full	   penetrance	   (Trotman	   et	   al.,	   2003).	   This	  
suggests	   that	   subtle	   decreases	   in	   PTEN	   levels	   drastically	   affect	   tumour	   biology,	  
confirmed	  by	  the	  formation	  of	  mammary	  or	  lung	  tumours	  even	  when	  PTEN	  was	  only	  
reduced	  by	  20%	  (Alimonti	  et	  al.,	  2010a).	  Thus	  PTEN	  is	  defined	  as	  ‘quasi-­‐insufficient’,	  
meaning	   that	   subtle	   reductions	   in	   gene	   dosage	   can	   cause	   tumorigenesis.	  
Importantly,	   similar	   20%	   reductions	   in	   PTEN	   expression	   were	   also	   observed	   in	  
human	  tumours	  (Alimonti	  et	  al.,	  2010a).	  This	  has	  led	  to	  a	  model	  in	  which	  PTEN	  dose,	  
altered	  by	  numerous	  causes,	  can	  exert	  a	  continuum	  of	  effects	  on	  cancer	  cells	  (Figure	  
1.3.4).	  	  
	  
Figure	   1.3.4.	   Causes	   and	   consequences	   of	   PTEN	   loss	   in	  
cancer.	   Transcriptional	   repression,	   and	  
posttranslational/epigenetic	   modification	   cause	  
downregulation	   of	   PTEN	   expression.	   Although	  
downregulation	  represents	  a	  continuum	  of	  severity	  of	  the	  
consequences	   on	   tumour	   growth/survival,	   homozygous	  
loss	   triggers	   a	   fail-­‐safe	   senescence	   response.	   Taken	   from	  
(Salmena	  et	  al.,	  2008).	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These	   findings	   of	   PTEN-­‐dose	   determining	   response	   led	   to	   the	   notion	   that	   the	  
senescence	   response	   induced	   by	   PTEN	   loss	   might	   be	   manipulated	   in	   tumours	  
depending	  on	  PTEN	  status.	  For	  instance	  Alimonti	  et	  al.	  showed	  that	  pharmacological	  
inhibition	  of	  PTEN	  using	  the	  PTEN	   inhibitor	  VO-­‐OH	  pictryhydrate	  (Mak	  et	  al.,	  2010)	  
induced	   senescence	   in	  mouse	   embryonic	   fibroblasts	   (MEFs)	   in	  which	   one	   allele	   of	  
PTEN	   was	   genetically	   deleted	   (Alimonti	   et	   al.,	   2010b).	   Importantly	   this	   response,	  
termed	  PTEN-­‐loss-­‐induced	  senescence	  (PICS)	  depended	  on	  initial	  PTEN	  loss,	  as	  it	  was	  
exhibited	   by	   prostate	   cancer	   cells	   with	   PTEN	   mutations	   but	   not	   wild	   type	   MEFs.	  
Intriguingly	   PICS	  was	   suggested	   to	   be	   independent	   of	   OIS,	   as	   it	   failed	   to	   result	   in	  
hyper	  proliferation	  or	  a	  DNA	  damage	  response,	  but	  was	  potentiated	  by	  stabilization	  
of	   p53.	   Indeed	   PTEN	   status	   also	   determines	   the	   response	   to	   ionizing	   radiation,	  
where	  PTEN-­‐deficient	  cells	  undergo	  ROS	  dependent	  senescence	  and	  PTEN-­‐proficient	  
cells	  undergo	  apoptosis	  (Lee	  et	  al.,	  2011).	  	  
	   These	  results	  are	  complicated	  by	  the	  possibility	  that	  tumour	  suppression	  by	  
PTEN	   is	  due	   in	  part	   to	   its	  nuclear	   localisation,	  where	   it	   regulates	  genomic	  stability,	  
cell	  cycle	  progression,	  differentiation	  and	  gene	  expression.	  These	  are	  independent	  of	  
its	   action	   on	   PIP3	   (Salmena	   et	   al.,	   2008).	   PTEN	   can	   interact	   with	   the	   tumour	  
suppressor	  APC/C,	  promoting	  its	  interaction	  with	  CDH1	  and	  enhancing	  APC/C-­‐CDH1	  
tumour	   suppressive	   activity	   (Song	   et	   al.,	   2011).	   Here	   nuclear	   exclusion,	   but	   not	  
abrogation	   of	   phosphatase	   activity,	   inhibited	   tumour	   suppression.	   Interestingly	  
senescence	  was	   suggested	   to	   result	   from	   loss	   of	   CDH1,	  which	   otherwise	   prevents	  
increases	  in	  p16INK4A.	  Furthermore	  loss	  of	  PTEN	  hyper-­‐sensitized	  cells	  to	  inhibition	  of	  
APC/C-­‐CDH1	   targets	   such	   as	   Aurora	   A,	   the	   activity	   of	   which	   were	   increased	   as	   a	  
compensatory	   mechanism.	   Thus	   taken	   together,	   levels	   of	   PTEN	   are	   likely	   to	  
determine	   aspects	   of	   tumour	   biology,	   suggesting	   tumours	   with	   reduced	   levels	   of	  
PTEN	   could	   paradoxically	   be	   targeted	   by	   PTEN	   inhibition.	   However	   it	   is	   unclear	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1.4. Reversible	   phosphorylation	   and	   the	   protein	   tyrosine-­‐
phosphatase	  gene	  family	  
1.4.1.	  Reversible	  phosphorylation	  and	  the	  PTP	  family	  
Reversible	   phosphorylation	   of	   tyrosine	   residues	   on	   proteins	   is	   arguably	   the	   single	  
most	   important	   regulatory	   process	   of	   intracellular	   signal	   transduction,	   and	   is	  
achieved	  by	   the	   concerted	  action	  of	   PTPs,	  which	   remove	  phosphate	  moieties,	   and	  
protein	  tyrosine	  kinases	  PTKs	  that	  catalyse	  their	  addition	  (Figure	  1.4.1)	  (See	  chapter	  
1.3	   for	   information	   on	   PTKs)	   (Sun	   and	   Tonks,	   1994).	   Rather	   than	   functioning	   as	  
generic	  scavengers	  of	  intracellular	  phosphate,	  PTPs	  exert	  remarkably	  tight	  control	  of	  
signal	  transduction	  in	  a	  positive	  and	  negative	  manner,	  often	  controlling	  the	  rate	  and	  
duration	  of	  response	  where	  PTKs	  control	  its	  amplitude	  (Tonks,	  2006).	  Thus	  although	  
our	  knowledge	  of	  PTPs	  has	  generally	  lagged	  behind	  that	  of	  PTKs,	  recent	  years	  have	  
seen	   much	   research	   on	   their	   diverse	   functions	   culminating	   in	   a	   number	   of	   apt	  
reviews	   discussing	   their	   roles	   in	   signal	   transduction	   (Stoker,	   2005),	   structure	  
(Tabernero	   et	   al.,	   2008),	   regulation	   (Hertog	   et	   al.,	   2008;	  Majeti	   and	  Weiss,	   2001),	  
substrates	   (Tiganis	   and	   Bennett,	   2007),	   function	   in	   neural	   development	   (Ensslen-­‐
Craig	  and	  Brady-­‐Kalnay,	  2004;	  Johnson	  and	  Van	  Vactor,	  2003),	  cell	  adhesion	  (Beltran	  
and	  Bixby,	  2003;	  Sallee	  et	  al.,	  2006),	  and	  disease	  (Hendriks	  et	  al.,	  2008),	  as	  well	  as	  
more	   general	   aspects	   of	   their	   function	   (Alonso	   et	   al.,	   2004;	   Hendriks	   and	   Stoker,	  
2008;	  Tonks,	  2006;	  Tremblay,	  2009).	  	  
	  
	  	  
In	   total	   107	   genes	   encoding	   PTPs	   have	   been	   identified	   in	   the	   human	   genome,	   of	  
which	   38	   show	   specificity	   for	   phosphotyrosine	   (pTyr),	   further	   divided	   into	   17	  
subgroups	   based	   on	   their	   structural	   and	   functional	   diversity	   (Tonks,	   2006)	   (Figure	  
1.4.2).	   Further	   diversity	   is	   generated	   through	   alternative	   promoters/splicing	   and	  
posttranslational	   modifications.	   Although	   identification	   of	   substrates	   has	   proven	  
Figure	   1.4.1.	   Reversible	  
phosphorylation	   of	   proteins.	  
Regulation	   of	   substrate	   function	   by	  
the	   addition	   and	   removal	   of	  
phosphate	   moieties	   (P)	   on	   tyrosine	  
residues	  is	  catalysed	  by	  PTKs	  and	  PTPs	  
respectively.	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difficult	  due	  to	  poor	  specificity	  in	  vitro,	  some	  PTPs	  can	  show	  specificity	  for	  targets	  in	  
vivo	  (Veeriah	  et	  al.,	  2009;	  Zhang	  et	  al.,	  2007).	  Of	  the	  38	  classical	  PTPs,	  21	  comprise	  
receptor	   type	   PTPs	   (RPTPs)	   while	   the	   remaining	   17	   are	   distributed	   within	   the	  
cytoplasm.	   RPTPs,	   capable	   of	   achieving	   ligand-­‐controlled	   dephosphorylation,	   are	  
generally	  characterized	  by	  the	  presence	  of	  immunoglobulin-­‐like/fibronectin	  type	  III-­‐
like	   domains	   making	   up	   their	   extracellular	   domain,	   allowing	   them	   to	   function	   in	  
some	   cases	   as	   cell	   adhesion	   molecules	   (CAMs)	   (Beltran	   and	   Bixby,	   2003).	   Their	  
catalytic	   activity	   generally	   resides	   in	   the	   D1	   membrane-­‐proximal	   intracellular	  
phosphatase	   domain,	   linked	   to	   the	   extracellular	   domain	   via	   a	   transmembrane	  
domain.	   However	   12	   RPTPs	   are	   characterized	   by	   a	   tandem	   repeat	   PTP	   domain	  
arrangement,	  with	   a	  membrane	  distal	  D2	  pseudophosphatase	   domain,	  which	  with	  
the	  exception	  of	  PTPα	  (Buist	  et	  al.,	  1999)	  lacks	  catalytic	  activity.	  The	  remaining	  PTPs	  
make	   up	   the	   dual	   specificity	   phosphatase	   (DSP)	   sub-­‐family,	   capable	   of	   recognizing	  
phosphorylated	   serine	   (pSer)	  and	   threonine	   (pThr)	  as	  well	   as	  pTyr	   residues	   (Pulido	  
and	  van	  Huijsduijnen,	  2008b).	  DSPs	  are	   less	  conserved	   in	  sequence	  to	  one	  another	  
and	  have	  smaller	  catalytic	  domains	  than	  PTPs,	  but	  have	  recently	  emerged	  as	  having	  
a	  similar	  diverse	  range	  of	  functions.	  	  
The	  PTP	  active	  site	  spans	  roughly	  280	  amino	  acid	  residues,	  characterized	  by	  
the	  presence	  of	   a	  highly	   conserved	  HCX5R	  motif	   on	   a	   cysteine	   residue.	  Catalysis	   is	  
carried	   out	   by	   this	   nucleophilic	   cysteine,	   forming	   a	   cysteinyl	   phosphatase	  
intermediate	   while	   undergoing	   a	   concomitant	   nucleophilic	   attack	   by	   the	   sulphur	  
atom	   of	   the	   thiolate	   ion.	   Following	   this	   the	   substrate	   tyrosyl	   leaving	   group	   is	  
protonated	   by	   a	   conserved	   aspartic	   acid	   (Asp)	   residue,	   and	   hydrolysis	   of	   the	  
phosphoenzyme	  intermediate	  is	  mediated	  by	  the	  same	  Asp	  and	  a	  glutamine	  residue,	  
causing	   release	   of	   a	   phosphate	   along	   with	   one	   molecule	   of	   water	   (Figure	   1.4.3).	  
Recently	  a	  secondary	  substrate	  binding	  pocket,	  separated	  from	  the	  catalytic	  site	  by	  a	  
gateway	  region	  was	  proposed	  as	  a	  feature	  dictating	  substrate	  specificity	  (Tremblay,	  
2009).	  This	  second	  site	  may	  be	  crucial	   in	  generating	  specific	   inhibitors	  as	  has	  been	  
demonstrated	  for	  PTP1B	  (Zhang	  and	  Zhang,	  2007).	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Figure	  1.4.2.	  The	  classical	  PTP	   family.	  Tyrosine-­‐specific	  PTPs	  are	   subdivided	   into	   receptor-­‐
like	  and	  cytoplasmic	  groups.	  Although	  all	  PTPs	  harbour	  a	  D1	  phosphatase	  domain,	  diversity	  
manifests	   in	   the	   presence	   of	   various	   other	   extracellular	   domains	   and	   adaptor	   domains.	  
Taken	  from	  (Tonks,	  2006).	  
	  













One	   of	   the	   major	   mechanisms	   of	   PTP	   regulation	   is	   reversible	   oxidation	   of	   the	  
cysteine	  within	  the	  active	  site	  (den	  Hertog	  et	  al.,	  2005;	  Tonks,	  2005;	  Xu	  et	  al.,	  2002).	  
Oxidation	  by	  ROS	  such	  as	  hydrogen	  peroxide	   (H2O2)	   cause	  conformational	   changes	  
Figure	   1.4.3.	   	   Mechanism	   of	   PTP	  
catalysis.	   A	   conserved	   active	   site	  
cysteine	   (Cys)	   binds	   substrate	  
phosphotyrosyl	   forming	   a	  
phosphoenzyme	   intermediate	  
subsequently	   hydrolyzed	   involving	   a	  
conserved	   aspartic	   acid	   (Asp)	   and	  
glutamine	  (Glu)	  releasing	  a	  molecule	  
of	  inorganic	  phosphate	  and	  water.	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and	  stabilize	  an	  inactive	  catalytic	  site	  (Groen,	  2005).	  The	  active	  site	  cysteine	  can	  be	  
converted	   to	   either	   sulphenic	   (SOH),	   sulphinic	   (SO2H)	   or	   sulphonic	   (SO3H)	   acid,	  
depending	   on	   the	   extent	   of	   oxidation.	   Higher	   oxidation	   represents	   an	   irreversible	  
modification	   (Tonks,	   2006),	   and	   is	   prevented	   in	   the	   case	   of	   the	   DSP	   PTEN	   by	   the	  
presence	  of	   a	   second	   cysteine	   residue	   forming	   a	   disulphide	  bridge	  with	   the	   active	  
site	   cysteine.	   	   Oxidation	   likely	   represents	   a	   major	   method	   of	   physiological	   PTP	  
regulation,	  given	  that	  antigen	  receptor	  engagement	  and	  growth	  factors	  can	  generate	  
ROS,	   which	   can	   inhibit	   PTPs	   normally	   attenuating	   downstream	   stimulation	   (den	  
Hertog	  et	  al.,	  2005).	  Inactivation	  by	  oxidation	  is	  also	  likely	  to	  be	  transient	  due	  to	  the	  
presence	   of	   natural	   reducing	   agents	   such	   as	   thioredoxin,	   catalase	   and	   glutathione	  
within	  the	  cell	  (Eruslanov	  and	  Kusmartsev,	  2010).	  It	   is	  unclear	  how	  oxidation	  exerts	  
specificity,	   given	   the	  promiscuous	  nature	  of	  ROS,	  however	   it	   has	  been	   shown	   that	  
PTPs	   are	   subject	   to	   differential	   oxidation	   related	   to	   pH	   changes	   in	   the	   active	   site	  
microenvironment	  and	  also	  orientation	  of	  the	  PTP	  loop	  arginine	  (Groen	  et	  al.,	  2005).	  
In	  addition,	  it	  is	  possible	  that	  RTK-­‐generated	  ROS	  remain	  spatially	  fairly	  localised.	  
Another	  well-­‐characterized	  method	  of	  PTP	   inactivation,	   at	   least	   in	   the	   case	  of	  
RPTPs	  is	  ligand-­‐independent	  dimerization	  (Van	  Der	  Wijk	  et	  al.,	  2005).	  In	  the	  case	  of	  
RPTPα,	   the	   presence	   of	   a	   PTP	   ‘wedge’	   on	   the	   transmembrane	   domain	   allows	   an	  
interaction	  with	  the	  D1	  pocket	  of	  a	  partner	  molecule,	  causing	  steric	  hindrance	  of	  the	  
active	  site	  (Bilwes	  et	  al.,	  1996).	  The	  role	  of	  the	  PTP	  wedge	  domain	  in	  PTP	  inhibition	  
by	   dimerization	   is	   best	   demonstrated	   by	   the	   finding	   that	  mutations	   in	   the	  wedge	  
domain	  of	  CD95	  attenuate	  dimerization	  (Majeti	  et	  al.,	  1998).	  However	  an	  alternative	  
mechanism	   of	   dimerization	   was	   recently	   proposed	   whereby	   the	   presence	   of	   a	  
flexible	   linker	   region	   in	   the	   transmembrane	  domain	  allows	  a	  head-­‐to-­‐toe	  D1	   to	  D2	  
interaction	   of	   neighbouring	   RPTPs	   (Barr	   et	   al.,	   2009).	   Furthermore	   in	   the	   case	   of	  
RPTPs	   that	   function	   as	   CAMS	   such	   as	   PTPσ,	   dimerization	   may	   actually	   facilitate	  
substrate	   binding	  with	   heterophilic	   ligands	   in	   the	   extracellular	   domain	   (Lee	   et	   al.,	  
2007).	  	  
	   One	   of	   the	   ways	   PTPs	   can	   modulate	   intracellular	   signal	   transduction	   is	   by	  
directly	   regulating	   the	   activity	   of	   RTKs	   (Ostman	   and	   Böhmer,	   2001).	   For	   example,	  
ligand-­‐independent	   activation	   of	   RTKs	   occurs	   following	   PTP	   inhibition	   (Jallal	   et	   al.,	  
1992).	   In	   contrast,	   dephosphorylation	   of	   ligand-­‐activated	   RTKs	   occurs	   immediately	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following	  their	  inhibition,	  indicating	  that	  PTPs	  are	  constantly	  on	  hand	  to	  shut	  down	  
RTK	   signalling	   (Sorby	   and	  Ostman,	   1996).	  Many	   PTPs	   also	   negatively	   regulate	   RTK	  
signalling.	   Deletion	   of	   PTP1B	   in	   mice	   results	   in	   prolonged	   insulin-­‐stimulated	  
phosphorylation	  of	  the	  insulin	  receptor	  (Elchebly	  et	  al.,	  1999),	  whereas	  inhibition	  of	  
PTP-­‐LAR	  results	  in	  increased	  stimulation	  of	  multiple	  RTKs	  including	  the	  receptors	  for	  
platelet-­‐derived	  growth	  factor	  (PDGF-­‐R),	  epidermal	  growth	  factor	  (EGFR)	  and	  insulin	  
(IR)	   resulting	   in	   downstream	   MAPK/PI3K	   activation	   (Kulas	   et	   al.,	   1995;	   Suarez	  
Pestana	  et	  al.,	  1999).	  This	  also	  fits	  in	  with	  the	  inactivation	  of	  PTPs	  by	  oxidation,	  since	  
the	  H2O2	  produced	  after	  RTK	  stimulation	  (Rhee	  et	  al.,	  2001)	  is	  likely	  to	  prolong	  RTK	  
signals.	   Some	   PTPs	   also	   facilitate	   RTK	   signal,	   including	   SHP-­‐2,	   which	   mediates	  
mitogen	  activated	  protein	  kinase	  (MAPK)	  signalling	  in	  a	  positive	  manner	  (Araki	  et	  al.,	  
2003).	  PTPs	   such	  as	  PTPα	  also	  directly	  activate	   cytoplasmic	  PTKs	  of	   the	  SRC	   family	  
(Zheng	  et	  al.,	  1992)	  (See	  section	  1.3.2).	  	  
	  
1.4.2. The	  tyrosine	  phosphatome	  in	  human	  cancer:	  Tumour	  suppressors	  
Given	  their	  ability	  to	  negatively	  regulate	  growth	  factor	  receptors,	  the	  PTP	  family	  are	  
intuitive	  candidates	   for	  tumour	  suppressor	  genes.	  However,	  based	  on	  their	  diverse	  
roles	  in	  a	  number	  of	  processes	  including	  differentiation,	  apoptosis,	  cell	  adhesion	  and	  
motility,	  as	  well	  as	  their	  positive	  contribution	  to	  RTK	  signalling	  in	  some	  instances,	  it	  
has	   become	   increasingly	   clear	   that	   this	   view	   is	   simplistic	   and	   instead	   PTPs	   may	  
function	  both	  as	  oncogenes	  and	  tumour	  suppressors	  (Julien	  et	  al.,	  2011;	  Ostman	  et	  
al.,	   2006).	   Unbiased	   RNAi	   screens	   of	   a	   phosphatase/kinase	   library	   in	   HeLa	   cells	  
identified	  32%	  of	  total	  phosphatases	  as	  positively	  regulating	  cell	  survival	  compared	  
with	   only	   11%	   of	   kinases	   (MacKeigan	   et	   al.,	   2005).	   Remarkably,	   only	   5%	   of	   the	  
phosphatome	  were	  survival	  limiting.	  	  
	   Gene	  silencing	   through	  methylation	  of	  CpG	  sites	  at	   the	  5’	  end	  of	  genes	  has	  
been	   observed	   to	   occur	   in	  PTPRG	   (van	  Doorn	   et	   al.,	   2005),	  PTPRD	   (Veeriah	   et	   al.,	  
2009),	  PTPRO	   (Motiwala	  et	   al.,	   2004)	   and	  PTPN13	   (Yeh	  et	   al.,	   2006),	   in	   a	   range	  of	  
cancers	   including	   adenocarcinoma,	   glioblastoma	   and	   squamous	   cell	   carcinoma,	  
demonstrating	  a	  putative	  tumour	  suppressive	  role	  for	  these	  PTPs.	  However	  the	  most	  
comprehensive	  demonstration	  of	  PTP	  tumour	  suppressors	  came	  from	  Wang	  et	  al.,	  in	  
which	  a	  mutational	   analysis	  of	   the	  entire	   gene	   family	  discovered	  83	   tissue-­‐specific	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somatic	  mutations	   in	  PTPRF,	  PTPRG,	  PTPRT,	  PTPN3,	  PTPN13	  and	  PTPN14,	  occurring	  
in	  26%	  of	  colorectal	  cancers	  (Wang	  et	  al.,	  2004).	  Mutations	  in	  PTPRT	  occurred	  most	  
frequently,	  affecting	  17%	  of	  lung	  and	  gastric	  cancers,	  and	  26%	  of	  colorectal	  cancers.	  
Functional	   analysis	   of	   PTPRT	   mutations	   demonstrated	   downregulation	   of	  
phosphatase	   activity	   and	   loss	   of	   growth-­‐suppression	   and	   it	   has	   since	   been	  
demonstrated	  that	  ptprt	  knockout	  mice	  are	  highly	  susceptible	   to	   tumours	   (Zhao	  et	  
al.,	   2010).	   Tumour-­‐derived	  mutations	   in	  PTPRT	   also	   cause	   defective	   cell	   adhesion,	  
possibly	   hinting	   at	   a	   role	   in	   migration/metastasis	   (Yu	   et	   al.,	   2008).	   Korff	   et	   al.	  
detected	  frequent	  frameshift	  mutations	  in	  PTPRA,	  PTPRS,	  PTPN15,	  PTPN13,	  PTPN21	  
and	  PTPN23	  also	  in	  colorectal	  tumours	  (Korff	  et	  al.,	  2008).	  Focal	  deletions	  of	  PTPN2,	  
encoding	   TC-­‐PTP,	   also	   occur	   at	   high	   frequency	   in	   T	   cell	   acute	   lymphoblastic	  
leukaemia,	  contributing	  to	  enhanced	  proliferation	  and	  cytokine	  sensitivity	  (Kleppe	  et	  
al.,	  2010).	  	  
	   One	   of	   the	   most	   broadly	   mutated	   PTP	   genes	   is	   PTPRD,	   encoding	   PTPδ,	  
mutated	   at	   relatively	   high	   frequency	   in	   head	   and	   neck	   squamous	   cell	   carcinoma	  
(13%),	  melanoma	   (12%),	   lung	   cancer	   (9-­‐11%)	   and	   glioblastoma	   (6%)	   (Kohno	   et	   al.,	  
2010;	  Solomon	  et	  al.,	  2008;	  Veeriah	  et	  al.,	  2009).	  A	  number	  of	  mutations	  have	  been	  
detected	  in	  both	  the	  extracellular	  and	  phosphatase	  domains	  of	  PTPRD,	  both	  of	  which	  
generate	  non-­‐functional	  protein	  products	   (Navis	  et	  al.,	   2010;	  Veeriah	  et	  al.,	   2009).	  
Mutations	   in	  PTPRD	   in	   glioblastoma	  were	   also	   found	   to	  occur	   at	   higher	   frequency	  
than	  mutations	   in	  PTEN	   (14%	  versus	  9%),	  despite	   the	   firm	  status	  of	   the	   latter	  as	  a	  
highly	  significant	  tumour	  suppressor	  in	  this	  cancer	  (Solomon	  et	  al.,	  2008).	  	  
	   Another	  hallmark	  of	  a	  tumour	  suppressor	  is	  loss	  of	  heterozygosity	  (LOH).	  This	  
occurs	   in	  PTPRJ	   in	   cancer	   of	   the	   colon	   (49%),	   lung	   (50%)	   and	   breast	   (78%)	   cancer	  
(Ruivenkamp	   et	   al.,	   2002),	   and	   association	   of	   LOH	   with	   disease	   progression	   was	  
demonstrated	   in	   colorectal	   cancer	   (Ruivenkamp	   et	   al.,	   2003).	   Similarly	   missense	  
mutations	   in	   the	   non-­‐catalytic	   domain	   of	   DEP1	   are	   enriched	   in	   brain	   metastases	  
from	  primary	  breast	   tumours,	   suggesting	  a	   role	   in	   tumour	  progression	   (Ding	  et	  al.,	  
2010).	   K1016A	   mutations	   in	   DEP1	   affect	   its	   interaction	   with	   Erk1/2,	   positively	  
affecting	   Ras/Erk	   signalling,	   providing	   an	   appealing	   explanation	   for	   its	   apparent	  
tumour	  suppressive	  role	  (Sacco	  et	  al.,	  2009),	  although	  homozygous	  deletion	  of	  Ptprj	  
in	  mice	  does	  not	  result	  in	  tumours	  (Trapasso	  et	  al.,	  2006).	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   The	  ability	  of	  PTPs	  to	  regulate	  signalling	  downstream	  of	  RTKS	  may	  underpin	  
their	  tumour	  suppressive	  properties.	  For	  instance,	  DEP1	  inhibits	  Ras/MAPK	  signalling	  
and	   limits	   EGFR	   endocytosis	   (Tarcic	   et	   al.,	   2009).	   DEP1	   also	   directly	   targets	  
downstream	  effectors	   such	   as	   Erk1/2,	   further	   inhibiting	   activation	   of	   this	   pathway	  
(Sacco	  et	  al.,	  2009).	  PTPRT	  dephosphorylates	  STAT3	  at	  Y705	  causing	  its	   inactivation	  
following	  cytokine	  stimulation	  by	  soluble	  factors	  such	  as	  interleukin-­‐6	  (Zhang	  et	  al.,	  
2007).	   Here	   STAT3	   activation	   results	   in	   nuclear	   translocation	   and	   transcription	   of	  
target	  genes	  such	  as	   the	  antiapoptotic	  proteins	  BCLXL.	   	  A	  similar	   function	  has	  been	  
noted	   for	   PTPRD,	   which	   also	   dephosphorylates	   STAT3	   at	   Y705,	   a	   process	   that	   is	  
abrogated	  by	  mutations	  in	  both	  the	  extracellular	  and	  phosphatase	  domains	  (Veeriah	  
et	  al.,	  2009).	  	  PTPN13	  negatively	  regulates	  SRC	  activity	  in	  vitro	  by	  dephosphorylation	  
at	  Y416,	  and	  PTPN13	   inhibition	   results	   in	   increased	  proliferation	   (Yeh	  et	  al.,	  2006).	  
Lastly,	   PTPN12	   (encoding	   PTP-­‐PEST)	   was	   recently	   identified	   as	   a	   potent	   negative	  
regulator	  of	  multiple	  RTKs	  including	  EGFR	  and	  HER2	  in	  triple	  negative	  breast	  cancer,	  
being	   subject	   to	  posttranscriptional	   silencing	   leading	   to	   loss	  of	  expression	   in	  up	   to	  
60%	  of	   analysed	   tumour	   samples,	   leading	   to	  malignant	   transformation	   (Sun	   et	   al.,	  
2011).	  
	  
1.4.3.	  	  	  	  	  	  The	  tyrosine	  phosphatome	  in	  human	  cancer:	  Oncogenes	  
As	  well	  as	  deletions,	  mutations	  and	  LOH,	  genomic	  amplification	  of	  genes	  encoding	  
PTPs	   (4/107)	  have	  also	  been	  documented,	   suggesting	  putative	  PTP	  oncogenes.	   For	  
instance,	  Saha	  et	  al.	  found	  that	  PTP4A3	  is	  amplified	  in	  colorectal	  cancer	  resulting	  in	  
encoded	   PRL3	   overexpression	   specifically	   in	  metastatic	   cancer	   (Saha	   et	   al.,	   2001).	  
Overexpression	   of	   PRL-­‐3	   occurs	   primarily	   in	   metastases,	   correlating	   with	   poor	  
prognosis	   in	   liver	   cancer	   (Peng	   et	   al.,	   2004).	   Upregulation	   of	   PRL-­‐3	   promotes	   cell	  
motility	   and	   invasion	   by	   mechanisms	   including	   regulation	   of	   Rho-­‐family	   GTPases	  
(Fiordalisi	   et	   al.,	   2006;	   Zeng	   et	   al.,	   2003),	   where	   monoclonal	   antibody	   targeting	  
inhibits	   metastatic	   spread	   (Guo	   et	   al.,	   2008).	   PTPN1	   is	   also	   subject	   to	   genomic	  
amplification	   in	   epithelial	   cancers	   as	   well	   as	   DUSP26	   (thyroid)	   and	   PTPN7	  
(leukaemia)	  (Julien	  et	  al.,	  2011;	  Yu	  et	  al.,	  2007).	  	  
	   Aside	   form	   the	   large	  number	  of	  potential	   survival-­‐promoting	  PTPs	   found	   in	  
recent	   screens	   (MacKeigan	   et	   al.,	   2005),	   the	   only	   bona	   fide	   oncogene	   currently	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identified	   is	  PTPN11,	  which	   encodes	   SHP2,	   a	   common	   target	   of	   somatic	   activating	  
mutations	   in	   cancers	   (Chan	   et	   al.,	   2008;	   Matozaki	   et	   al.,	   2009).	   Tartaglia	   et	   al.	  
identified	  autosomal	  dominant	  germline	  mutations	  in	  PTPN11	  as	  a	  cause	  of	  Noonan	  
syndrome,	   a	   complex	   disorder	   that	   increases	   susceptibility	   to	   juvenile	  
myelomonocytic	   leukaemia	   (Tartaglia	  et	  al.,	  2003).	  Activating	  mutations	   in	  PTPN11	  
also	  occur	   in	  acute	   lymphoblastic	   leukaemia	  and	  acute	  myeloid	   leukaemia	  (6%	  and	  
5%	   respectively),	   as	   well	   as	   at	   low	   frequency	   in	   solid	   tumours	   (Bentires-­‐Alj	   et	   al.,	  
2004;	  Tartaglia	  et	  al.,	  2004),	  although	   the	  contribution	  of	  SHP2	   to	  a	  wide	   range	  of	  
tumours	   has	   been	   disputed	   (Martinelli	   et	   al.,	   2006).	   SHP2	   is	   also	   involved	   in	   the	  
growth	   and	  migration	   of	   anaplastic	   lymphoma	   cells	   (Voena	   et	   al.,	   2007).	   A	   recent	  
finding	   has	   complicated	   the	   status	   of	   SHP2	   as	   an	   oncogene,	   though,	   in	  
demonstrating	   that	  deletion	  of	   SHP2	   in	  hepatocytes	   caused	   tumours,	   and	  ablation	  
enhanced	  tumour	  progression,	  attenuated	  by	  concomitant	  ablation	  of	  STAT3	  (Bard-­‐
Chapeau	  et	  al.,	  2011).	  
	   SHP2	   dephosphorylates	   sites	   on	   multiple	   RTKs	   that	   negatively	   regulate	  
Ras/MAPK	   signalling,	   providing	   a	   functional	   basis	   for	   SHP2	  mutations	   (Araki	   et	   al.,	  
2003;	   Easton	   et	   al.,	   2006;	   Klinghoffer	   and	   Kazlauskas,	   1995).	   SHP2	   also	   positively	  
regulates	   SRC	   activity	   by	   dephosphorylating	   the	   inhibitory,	   c-­‐terminal	   tyrosine	  
residue,	  again	  promoting	  downstream	  Ras/Erk	  activation	  (Zhang	  et	  al.,	  2004).	  Indeed	  
inhibitors	   of	   SHP2	   have	   recently	   been	   developed	   as	   potential	   therapeutic	   agents	  
(Hellmuth	  et	  al.,	  2008;	  Zhang	  et	  al.,	  2010).	  	  
SRC	  is	  also	  activated	  by	  PTPα,	  leading	  to	  transformation	  of	  fibroblasts	  (Zheng	  
et	   al.,	   2000).	   Given	   the	   PTPRA	   overexpression	   in	   colorectal	   cancer,	   it	   represents	  
another	  potential	  PTP	  oncogene	  (Ardini	  et	  al.,	  2000).	  In	  addition	  to	  SHP2,	  other	  PTPs	  
have	   been	   shown	   to	   act	   cooperatively	   with	   transforming	   lesions.	   Loss	   of	   PTPN1	  
(encoding	   PTP1B)	   either	   through	   genetic	   deletion	   or	   inhibition	   in	   mice	   with	  
constitutively	  active	  Erbb2	  significantly	  increases	  tumour	  latency	  and	  progression	  to	  
metastatic	  cancer,	  while	  overexpression	  induces	  tumour	  formation	  (Bentires-­‐Alj	  and	  
Neel,	  2007;	  Julien	  et	  al.,	  2007).	  This	  is	  consistent	  with	  the	  role	  of	  PTP1B	  as	  a	  positive	  
regulator	  of	  MAPK/Akt	  signalling	   (Haj	  et	  al.,	  2002;	  Tonks	  and	  Muthuswamy,	  2007).	  
More	   recently	   PTP1B	   was	   shown	   to	   drive	   Erbb2-­‐dependent	   breast	   cancer	   by	  
activation	  of	  SRC	  (Arias-­‐Romero	  et	  al.,	  2009).	  Similarly	  loss	  of	  PTPRH	  (encoding	  SAP-­‐
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1)	  inhibits	  the	  formation	  of	  colon	  tumours	  initiated	  by	  loss	  of	  the	  tumour	  suppressor	  
APC,	  explaining	  its	  overexpression	  in	  cancers	  including	  gastric,	  pancreatic	  and	  colon	  
(Sadakata	   et	   al.,	   2009).	   The	  most	   recent	   demonstration	   on	   oncogenic	   cooperation	  
was	  by	  Zhi	  et	  al.,	  who	  showed	  that	  PTPH1,	  which	  is	  overexpressed	  in	  breast	  cancer,	  
stimulated	   cell	   growth	   by	   phosphatase-­‐independent	   stabilization	   of	   the	   vitamin	   D	  
receptor	  (Zhi	  et	  al.,	  2010).	  	  
	  
1.4.4. The	  tyrosine	  phosphatome	  in	  neuroblastoma	  
Although	  research	  into	  the	  contribution	  of	  PTPs	  to	  cancer	  is	  still	  in	  its	  early	  stages,	  a	  
handful	   of	   studies	   have	   already	   described	   roles	   for	   PTPs	   in	   the	   development	   and	  
maintenance	  of	  NBL.	  One	  aberrantly	  expressed	  PTP	  is	  PTPδ,	  encoded	  by	  PTPRD	  (see	  
above).	  De	  Preter	  et	  al.	  found	  that	  PTPRD	  mRNA	  is	  expressed	  at	  lower	  levels	  in	  NBL	  
tumours	   compared	  with	   normal	   fetal	   adrenal	   neuroblasts	   (De	   Preter	   et	   al.,	   2006).	  
Expression	   is	   lowest	   in	   high-­‐stage	  metastatic	   tumours,	   suggesting	   a	   driving	   role	   in	  
tumour	  progression.	  Mapping	  large-­‐scale	  chromosomal	  imbalances	  in	  NBL,	  Stallings	  
et	  al.	  also	  observed	  frequent	  microdeletions	  at	  the	  5’	  untranslated	  region	  (5’UTR)	  of	  
the	  PTPRD	  gene	  (Stallings	  et	  al.,	  2006).	  Homozygous	  deletions	  were	  also	  observed	  in	  
two	  NBL	  cell	  lines,	  SK-­‐N-­‐AS	  and	  Kelly/N206,	  suggesting	  a	  fundamental	  role	  in	  tumour	  
progression.	   The	   same	   group	   further	   characterized	   loss	   of	   PTPRD,	   showing	   that	  
aberrant	  splicing	  causes	  loss	  of	  5’UTR	  exons	  in	  over	  50%	  of	  primary	  tumours	  and	  cell	  
lines,	  mimicking	  microdeletions	  observed	  at	  this	  locus	  (Nair	  et	  al.,	  2008).	  Again	  lower	  
expression	   of	   mRNA	   was	   confirmed	   in	   metastatic	   Mycn	   amplified	   tumours,	  
suggesting	   impairment	   of	   mRNA	   stability	   as	   a	   mechanism	   for	   downregulation	   of	  
PTPRD.	  	  
	   It	  has	  been	  suggested	  that	  rather	  than	  functioning	  to	  suppress	  tumour	  onset,	  
the	  PTPδ	  protein	  may	   instead	   function	  as	  a	   suppressor	  of	  metastasis	   (De	  Preter	  et	  
al.,	   2006;	   Stallings	  et	  al.,	   2006).	   Indeed	  evidence	   for	   this	   comes	   from	   the	   fact	   that	  
PTPδ	  can	  interact	  with	  MIM-­‐B,	  a	  putative	  metastasis	  suppressor	  protein	  capable	  of	  
regulating	  actin	  cytoskeletal	  changes	  downstream	  of	  RTKs	  (Woodings	  et	  al.,	  2003).	  It	  
is	  tempting	  to	  speculate	  that	  an	  ability	  of	  PTPδ	  to	  suppress	  metastatic	  growth	  may	  
derive	   from	   its	   negative	   regulation	   of	   STAT3	   (Veeriah	   et	   al.,	   2009),	   given	   that	  
interleukin-­‐6,	  which	  activates	  downstream	  STAT	  signalling	   is	  specifically	  secreted	   in	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bone	  marrow	  metastases	  where	   it	   triggers	  growth	  and	  survival	  of	  NBL	  cells	   (Ara	  et	  
al.,	  2009).	  However	  functional	  evidence	  for	  this	  hypothesis	  is	  lacking.	  	  
	   A	  second	  RPTP	  detected	  to	  be	  expressed	  at	  low	  levels	  in	  NBL	  by	  De	  Preter	  et	  
al.	  was	  PTPRK,	  encoding	  PTPκ	  (De	  Preter	  et	  al.,	  2006).	  Although	  the	  relevance	  of	  this	  
reduced	  expression	   in	  NBL	   is	  unclear,	  a	  tumour-­‐suppressive	  role	  for	  PTPκ	  has	  been	  
demonstrated	   in	   melanoma	   due	   to	   its	   ability	   to	   negatively	   regulate	   the	  
transcriptional	   activity	   of	   β-­‐catenin	   and	   promote	   the	   formation	   of	   E-­‐cadherin/β-­‐
catenin	   complexes	   at	   adherens	   junctions	   (Novellino	   et	   al.,	   2008).	   Re-­‐expression	   of	  
PTPRK	   in	  cells	  harbouring	  mutations	  reduced	  proliferative	  and	  migrational	  capacity.	  
Indeed	  β-­‐catenin	  has	  been	  hypothesized	  to	  promote	  advanced	  NBL	  disease	  through	  
induction	  of	  MYC	  and	  other	  target	  genes	  crucial	  to	  survival,	  as	  well	  as	  contributing	  to	  
the	  maintenance	  of	  putative	  NBL	  stem	  cells	  (Maris	  et	  al.,	  2007).	  	  
	   In	  line	  with	  its	  general	  status	  as	  a	  PTP	  proto-­‐oncogene,	  activating	  mutations	  
in	  PTPN11	  have	  also	  been	  detected	  at	   low	  frequency	  (3%)	   in	  NBL	  primary	  tumours	  
(Bentires-­‐Alj	  et	  al.,	  2004),	  although	  others	  have	  failed	  to	  detect	  PTPN11	  mutations	  in	  
NBL	  (Martinelli	  et	  al.,	  2006).	  SHP2	  facilitates	  Ras/MAPK	  signalling	  by	  BDNF	  (Easton	  et	  
al.,	  2006),	  which	  may	  contribute	  to	  survival	  signalling	  in	  NBL	  (See	  section	  1.1.6).	  	  
	   Perhaps	   the	  best	  candidate	  PTP	  oncogene	   is	   the	  DSP	  DUSP26.	   	  Shang	  et	  al.	  
elegantly	  demonstrated	  this	  by	  over-­‐expressing	  DUSP26	  in	  NBL	  cells,	  which	  inhibited	  
p53	  activation	  by	  the	  chemotherapeutic	  doxorubicin.	  In	  contrast,	  inhibiting	  DUSP26	  
expression	   activated	  p53	   and	   augmented	  doxorubicin-­‐induced	   apoptosis	   (Shang	   et	  
al.,	   2010).	   Importantly	   DUSP26	   was	   shown	   to	   directly	   dephosphorylate	   p53	   at	  
S20/37	  in	  vitro,	  explaining	  its	  overexpression	  in	  NBL.	  This	  study	  is	  particularly	  useful	  
given	   the	   recent	   development	   of	   the	   novel	   SHP1/2	   inhibitor	   NSC-­‐87877	   showing	  
specificity	   for	   DUSP6	   (Song	   et	   al.,	   2009).	   It	   is	   also	   in	   line	  with	   previous	   reports	   of	  
growth	  promotion	   in	  thyroid	  cancer	  by	  amplification	  of	  the	  gene	  encoding	  DUSP26	  
p38	  MAPK	   inhibition	   (Yu	   et	   al.,	   2007).	   Indeed	   other	   DSPs	   have	   been	   identified	   as	  
contributing	   to	   NBL	   pathogenesis	   in	   genome	   wide	   association	   studies	   (J.Maris,	  
personal	   communication),	   making	   them	   interesting	   targets	   for	   further	   research	  
(Patterson	  et	  al.,	  2009).	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   Thus	   despite	   some	   exciting	   recent	   developments	   concerning	   PTPs	   in	   the	  
search	  for	  NBL	  cancer	  genes,	  a	  more	  extensive	   investigation	   into	  their	  contribution	  
to	  this	  disease	  is	  warranted.	  	  
	  
1.5. The	  development	  of	  phosphatase	  inhibitors	  and	  their	  use	  in	  
cancer	  treatment	  
1.5.1.	  Phosphatase	  inhibitors:	  General	  mechanisms	  and	  problems	  
Due	   to	   their	   ability	   to	   regulate	   intracellular	   signal	   transduction	   in	   a	   number	   of	  
diseases	  including	  cancer,	  targeting	  PTPs	  using	  small	  molecule	  inhibitors	  has	  been	  a	  
topic	   of	   considerable	   interest	   (Bialy	   and	   Waldmann,	   2005;	   Dewang	   et	   al.,	   2005;	  
Ferreira	  et	  al.,	  2006;	  Heneberg,	  2009;	  Jiang	  and	  Zhang,	  2008;	  Umezawa	  et	  al.,	  2003;	  
Vintonyak	   et	   al.,	   2009).	   Much	   of	   this	   work	   has	   centred	   on	   the	   cytoplasmic	  
phosphatase	  PTP1B,	  a	  potent	  negative	  regulator	  of	  insulin	  signalling	  (Elchebly	  et	  al.,	  
1999;	  Seely	  et	  al.,	  1996).	  Driven	  by	  the	  ever-­‐increasing	  prevalence	  of	  type	  2	  diabetes,	  
this	   research	   triggered	   a	   race	   to	   generate	   a	   specific	   inhibitor	   of	   PTP1B,	   expertly	  
reviewed	   elsewhere	   (Taylor,	   2003;	   Zhang	   and	   Zhang,	   2007;	   Zhang	   and	   Lee,	   2003).	  
Current	   issues	  and	  promising	  developments	   in	  the	  generation	  of	  PTP	   inhibitors	  will	  
now	  be	  discussed.	  
	   Strategies	   in	   developing	   PTP	   inhibitors	   have	   been	   based	   on	   the	   unusual	  
active	   site	   of	   PTPs,	  which	   contains	   a	   deep	  pocket	   to	   accommodate	   substrate	   pTyr	  
(9Å	   for	   classical	   PTPs	   versus	   6Å	   for	   DSPs).	   Substrate	   binding	   induces	   a	  
conformational	   change	   bringing	   the	   WPD	   loop	   over	   the	   binding	   pocket	   eliciting	  
further	   stabilizing	   interactions	  crucial	   for	   substrate	  specificity	  and	  catalytic	  activity.	  
Most	   active	   site	   catalytic	   PTP	   inhibitors	   are	   based	   around	   nonhydrolyzable	   pTyr	  
mimetics	   directed	   towards	   the	   P	   loop	   at	   the	   active	   site	   base.	   However,	   the	   high	  
charge	   density	   of	   pTyr	  mimetics	   has	   drastically	   limited	   the	   bioavailability	   of	   these	  
inhibitors,	   as	   well	   as	   problems	   of	   degradation	   by	   proteases.	   The	   most	   notorious	  
issue	  with	  all	  pTyr	  mimetic	  PTP	   inhibitors	   is	  also	  their	   lack	  of	  selectivity	  due	  to	  the	  
highly	  conserved	  PTP	  active	  site.	  However,	  some	  key	  developments	  show	  promise	  in	  
the	  circumvention	  of	  this	  problem.	  (Montalibet	  et	  al.,	  2006;	  Wiesmann	  et	  al.,	  2004).	  
	   Although	  PTP-­‐specific	  inhibitors	  have	  remained	  a	  major	  technical	  challenge,	  a	  
number	  of	  more	  general	   inhibitors,	   including	   those	  derived	   from	  natural	  products,	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have	  shown	  specificity	   for	  PTPs	  and	  have	  been	  widely	  used	   in	  research	   (Heneberg,	  
2009).	   Indeed	   a	   number	   of	   PTP	   inhibitors	   including	   sodium	   stibogluconate,	  
phenylarsine	  oxide,	   alendroate,	   etidronate,	   vanadate,	   gallium	  nitrate,	   suramin	   and	  
aplidin	   have	   been	   approved	   for	   clinical	   testing	   (Heneberg,	   2009).	   Sodium	  
stibogluconate	   for	   example	   is	   currently	   undergoing	   phase	   I-­‐II	   trials	   as	   a	   possible	  
combinatorial	   therapeutic	   with	   interferon	   for	   the	   treatment	   of	   melanoma,	  
lymphoma	  and	  myeloma	   (Julien	  et	  al.,	  2011).	  Furthermore	   inhibitors	  have	   recently	  
been	   characterized	   that	   show	   some	   specificity	   towards	   PTPs	   implicated	   in	  
carcinogenesis	   including	   Shp2	   and	   DUSP26	   (NSC-­‐87877),	   Cdc25	   (NSC-­‐95397)	   and	  
PRLs	  (thienopyridone)	  (Daouti	  et	  al.,	  2008;	  Lazo	  et	  al.,	  2002;	  Song	  et	  al.,	  2009).	  While	  
the	  development	  of	  PTP	  inhibitors	  for	  cancer	  treatment	  clearly	  needs	  to	  go	  hand	  in	  
hand	   with	   an	   increased	   understanding	   of	   the	   role	   PTPs	   play	   in	   oncogenesis,	   it	   is	  
tempting	   to	   speculate	   that	   the	   degree	   of	   PTP	   inhibitors	   available	   could	   be	   highly	  
beneficial	  for	  the	  development	  of	  novel	  treatments.	  	  
	  
1.5.2.	  Vanadium	  compounds	  represent	  a	  major	  class	  of	  PTP	  inhibitors	  
Vanadium-­‐based	   compounds	   are	   generally	   considered	   the	   gold	   standard	  of	  metal-­‐
containing	  phosphate	  mimetic	  PTP	   inhibitors	  and	  a	  number	  of	  derived	  compounds	  
have	  already	  been	  developed	  for	   the	  potential	   treatment	  of	  diabetes	   (Smith	  et	  al.,	  
2008;	  Srivastava	  and	  Mehdi,	  2005;	  Thompson	  et	  al.,	  2009).	  The	  mechanism	  of	  PTP	  
inhibition,	   chemical	   configuration	   and	   pre/clinical	   efficacy	   of	   such	   compounds	  will	  
now	  be	  discussed.	  	  
	   Vanadium	   is	   a	   group	   V	   trace	   metal	   from	   the	   first	   transition	   series,	   and	  
represents	   the	   21st	   most	   common	   metal	   in	   the	   earth’s	   crust.	   It	   is	   exists	   in	   four	  
valency	  states,	  thus	  its	  chemistry	  is	  complex.	  The	  vanadyl	  (VO2+)	  species	  occurs	  at	  a	  
pH	   lower	   than	   3.5,	   however	   the	   predominant	   form	  of	   vanadium	   is	   orthovanadate	  
(VO43-­‐),	   chemically	   similar	   to	   the	   structure	   of	   phosphates	   (PO43-­‐)	   (Figure	   1.5.1).	  
Metavanadate	  (VO3-­‐)	  in	  the	  +5	  oxidation	  state	  commonly	  occurs	  in	  bodily	  fluids	  such	  
as	  plasma,	  where	  it	  enters	  cells	  via	  anion	  transport	  systems	  and	  is	  normally	  reduced	  
by	  endogenous	  glutathione	  to	  vanadyl	  (VO2+)	  in	  the	  +4	  oxidation	  state.	  Vanadium	  (V)	  
compounds	   are	   more	   potent	   PTP	   inhibitors	   compared	   with	   vanadium	   (III)/(IV)	  
compounds	   suggesting	   oxidation	   state	   is	   crucial	   (Thompson	   et	   al.,	   2009).	   Notably	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vanadyl	   was	   actually	   shown	   to	   oppose	   the	   action	   of	   vanadate	   by	   inhibiting	   PTK	  
activation,	  suggesting	  reversible	  oxidation	  as	  a	  physiological	  homeostatic	  mechanism	  
that	  could	  be	  exploited	  for	   instance	  by	  conversion	  using	  hydrogen	  peroxide	  (Elberg	  
et	   al.,	   1994).	   The	   total	   pool	   of	   vanadium	   in	   humans	   has	   been	   estimated	   at	   100-­‐




Figure	  1.5.1.	  PTP	   inhibition	  by	  pTyr	  mimetics.	  Vanadate	   (V)	   (left)	   and	  phosphatase	   (right)	  
exhibit	  remarkable	  structural	  similarity,	   thus	  vanadate	  can	  competitively	   inhibit	  all	  PTPs	  by	  
mimicking	   the	   enzyme-­‐phosphate	   transition	   state	   during	   catalysis.	   Taken	   from	   (Heneberg,	  
2009).	  
	  
Vanadate	   exerts	   competitive,	   non-­‐selective	   inhibition	   of	   PTPs	   due	   to	   its	   structural	  
similarity	   to	   the	   transition	   state	   of	   phosphotyrosyl	   in	   the	   PTP	   active	   site.	   The	  
mechanism	  of	   inhibition	  has	  been	  demonstrated	  by	  crystallographic	  analysis	   (Denu	  
et	   al.,	   1996;	   Pannifer	   et	   al.,	   1998).	   Specifically	   binding	   occurs	   with	   a	   2.5Å	   space	  
between	  the	  conserved	  active	  site	  Cys	  and	  a	  vanadium	  atom,	  indicative	  of	  a	  covalent	  
bond.	   The	   pentavalent,	   trigonal	   bipyramidal	   geometry	   of	   vanadate	   when	   bound	  
highly	  resembles	  that	  of	   transition	  state	  thiol-­‐phosphate.	  Furthermore	  a	  conserved	  
aspartate	  residue	  undergoes	  hydrogen	  bonding	  of	  2.8Å	  to	  the	  oxygen	  of	  vanadium,	  
occupying	   the	   position	   of	   phenolic	   oxygen	   of	   phosphotyrosyl	   and	   water	   during	  
hydrolysis.	   Vanadate	   can	   be	   complexed	   with	   H2O2	   to	   form	   pervanadate,	   which	  
achieves	  more	   potent	   inhibition	   by	   irreversibly	   oxidizing	   the	   catalytic	   Cys	   of	   PTPs.	  
This	  contrasts	  with	  vanadate,	  which	  can	  be	   reversed	  with	  chelating	  agents	   such	  as	  
EDTA	   (Huyer	   et	   al.,	   1997).	   Pervanadate	   more	   effectively	   increases	   cellular	  
phosphotyrosine	  when	  compared	  with	  vanadate	  (Huyer	  et	  al.,	  1997),	  suggesting	  that	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in	  situ	  H2O2	  may	  increase	  the	  potency	  of	  vanadate.	  Peroxovanadium	  compounds	  are	  
however	  much	  more	  toxic	  to	  the	  cell	  and	  can	  cause	  severe	  oxidative	  stress.	  
	   Vanadium	   compounds	   have	   proven	   efficacy	   as	   insulin	   mimetics,	   and	   have	  
been	   used	   in	   preclinical	   and	   clinical	   testing	   for	   both	   type	   1	   and	   type	   2	   diabetes	  
(Smith	  et	  al.,	  2008;	  Srivastava	  and	  Mehdi,	  2005).	  These	  include	  inorganic	  vanadium	  
salts	   such	  as	   sodium	  orthovanadate	   (Na3VO4),	   vanadyl-­‐sulfate	   (VOSO4	  3H2O/4H2O),	  
sodium	   metavanadate	   (NaVO3,	   NaMV),	   and	   vanadyl	   pentaoxide	   (V2O5).	   In	   fact	  
Lyonnet	  et	  al.	  tested	  sodium	  metavandate	  on	  human	  diabetes	  patients	   in	  1899,	  22	  
years	  before	  the	  discovery	  of	  insulin,	  where	  it	  was	  observed	  to	  improve	  symptoms	  in	  
2/3	  patients	  (Srivastava	  and	  Mehdi,	  2005).	  Vanadyl	  sulfate	  has	  been	  clinically	  tested	  
in	   a	   number	   of	   studies,	   but	   encountered	   problems	   due	   to	   toxicity,	   limiting	   the	  
suitable	   dosage	   (Goldfine	   et	   al.,	   2000).	   A	   number	   of	   gastrointestinal	   disturbances	  
have	   been	   reported	   in	   response	   to	   daily	   treatment	   with	   vanadium	   compounds,	  
commonly	   diarrhoea,	   decreased	   fluid	   intake	   and	   weight	   loss	   (Domingo,	   2002),	  
although	  these	  may	  be	  corrected	  by	  adding	  taking	  with	  NaCl,	  adjusting	  to	  pH	  neutral	  
and	  gradually	   increasing	  dosage	   (Srivastava	  and	  Mehdi,	  2005).	  Vanadium	  may	  also	  
accumulate	  in	  bone	  after	  chronic	  treatment,	  causing	  latent	  toxicity	  issues	  (Domingo	  
et	  al.,	  1995).	  
	   During	   the	   early	   1990s,	   a	   strategy	   was	   devised	   to	   complex	   vanadium	  with	  
organic	   ligands	   for	   improved	   bioavailability.	   A	   number	   of	   such	   organovanadium	  
compounds	   have	   since	   been	   tested	   as	   potential	   treatments	   for	   diabetes	   such	   as	  
bis(maltolato)oxovanadium(IV)	   (BMOV),	   vanadyl	   acetylacetone	   and	   bis(6-­‐
methylpicolinato)oxovanadium.	   Crucially	   these	   drugs	   completely	   lack	   the	   toxic	  
effects	  of	  their	   inorganic	  counterparts	  (Thompson	  et	  al.,	  2009).	  Developed	  in	  1992,	  
BMOV,	   a	   complex	   of	   the	   orally	   available	   maltol	   ligand	   with	   vanadium,	   is	   now	  
considered	   the	   benchmark	   of	   such	   compounds,	   however	   its	   ethylmaltol	   analogue	  
bis(ethylmaltolato)oxovanadium(IV)	   (BEOV)	   has	   been	   shown	   to	   be	   similarly	  
potent/orally	   available	   (Figure	   1.5.2).	   These	   compounds	   are	   potent	   activators	   of	  
insulin	  signalling	  and	  enhance	  phosphorylation	  of	  Akt,	  GSK3β	  and	  FOXO1	  (Mehdi	  and	  
Srivastava,	   2005;	   Mehdi	   et	   al.,	   2006;	   Srivastava,	   2009).	   Both	   compounds	   are	   2-­‐3	  
times	   as	   bioavailable	   as	   vanadyl	   sulfate,	   but	   act	   in	   a	   similar	   manner,	   probably	  
achieving	   PTP	   inhibition	   by	   delivering	   unliganded-­‐vanadium	   to	   the	   PTP	   active	   site	  
	   65	  
(Peters	   et	   al.,	   2003).	   Thus	   the	   superior	   effects	   of	   organovanadium	   compounds	   on	  
glucose	   metabolism	   and	   greater	   tolerability	   reported	   are	   likely	   a	   consequence	   of	  
more	   potent	   stimulation	   of	   insulin	   signalling	   (Reul	   et	   al.,	   1999),	   although	   greater	  
absorption	   has	   also	   been	   suggested	   (Thompson	   et	   al.,	   2009).	   In	   July	   of	   2008,	   a	  
phase-­‐IIa	  trial	  was	  released	  demonstrating	  efficacy	  and	  tolerability	  of	  BEOV	  in	  type	  II	  
diabetic	  patients,	  when	  administered	  daily	   for	  28	  days	  at	  a	  20mg	  dosage	   (5.8µmol	  
V).	  This	  represents	  an	  important	  step	  in	  the	  transition	  of	  vanadium	  compounds	  from	  
the	  bench	  to	  the	  bedside,	  as	  well	  as	   facilitating	  their	  use	   in	  drug	  redeployment	  for	  
cancer	  treatment	  (see	  below).	  	  
	  
Figure	   1.5.2.	   Chemical	   structure	   of	   BEOV/BMOV.	   BEOV	   (left)	   and	   BMOV	   (right)	   exhibit	  
structural	   differences	   to	   vanadate	   (Figure	   1.5.1.)	   due	   to	   the	   organic	   ligand	   ethyl	  
maltol/maltol	   scaffolds	   respectively,	   although	   their	   putative	   mechanism	   of	   inhibition	   is	  
identical.	  Taken	  from	  (Thompson	  et	  al.,	  2009;	  Willsky	  et	  al.,	  2001).	  
	  
Of	   further	   note	   is	   the	   recent	   development	   of	   a	   specific	   inhibitor	   of	   PTEN,	   3-­‐
hydroxypicolinate	  vanadium(IV)	  (VO-­‐OH	  Pic),	  by	  complexing	  vanadyl	  with	  the	  organic	  
moiety	   hydroxypicolinic	   acid	   (Rosivatz	   et	   al.,	   2006).	   VO-­‐OH	  Pic	   achieves	   selectivity	  
towards	  PTEN	  due	  to	  its	  wide	  active	  site	  pocket	  (8Å	  deep)	  and	  elliptical	  opening	  (5Å	  
x	  11Å)	  distinguishing	  it	  from	  other	  PTPs,	  inhibiting	  PTEN	  with	  an	  IC50	  of	  35nM.	  VO-­‐
OH	  Pic	   increased	   levels	  of	   cellular	  Ptpins(3,4,5)p3	   and	  caused	   increased	  membrane	  
recruitment/phosphorylation	  of	  Akt	  as	  well	  as	  glucose	  uptake	  in	  adipocytes	  (Rosivatz	  
et	  al.,	  2006).	  Although	  VO-­‐OH	  Pic	  binds	  PTEN	  at	  the	  active	  site,	  its	  inhibitory	  action	  is	  
suggested	  to	  be	  distinct	  from	  vanadate	  delivery	  to	  the	  active	  site	  (Mak	  et	  al.,	  2010).	  
VO-­‐OH	   Pic	   is	   thus	   potentially	   of	   great	   interest,	   as	   it	   represents	   arguably	   the	   first	  
selective	   vanadium	   based	   inhibitor	   of	   a	   PTP,	   based	   on	   enzyme	   structure,	   and	   is	  
selective	  towards	  PTEN,	  a	  protein	  with	  known	  roles	  in	  diabetes	  and	  cancer.	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1.5.3.	  Vanadium	  compounds	  in	  the	  treatment	  of	  cancer	  
The	   ability	   of	   vanadium	   compounds	   to	   exert	   numerous	   effects	   on	   regulatory	  
enzymes	   in	   cells	   has	   made	   them	   an	   interesting	   subject	   for	   anti-­‐carcinogenic	  
research.	   In	   fact	   a	   number	   of	   studies	   have	   already	   documented	   anti-­‐cancerous	  
properties	  of	  vanadium	  compounds	  and	  a	  clear	  ability	  to	  both	  inhibit	  tumorigenesis	  
and	   enhance	   tumour	   regression	   in	   preclinical	   models	   of	   a	   number	   of	   cancers	  
including	  breast,	  liver,	  lung	  and	  colon	  (reviewed	  in	  (Bishayee	  et	  al.,	  2010;	  Evangelou,	  
2002).	  Evidence	  for	  a	  role	  of	  vanadium	  compounds	  as	  therapeutic	  agents	   in	  cancer	  
treatment	  will	  now	  be	  discussed.	  
	   Cytotoxic	   effects	   of	   vanadium	   compounds	   are	   well	   documented.	   For	  
instance,	  the	  metallocene	  dichloride	  compound	  vanodecene	  causes	  p53-­‐dependent	  
acute	  apoptosis	  of	   testicular	   cancer	   cells	   in	  vitro	   (Ghosh	  et	  al.,	  2000).	  Huang	  et	  al.	  
demonstrated	   transactivation	   of	   p53	   as	   a	   result	   of	   ROS	   production	   induced	   by	  
vanadate	   (50-­‐400µM)	   in	   epidermal	   cells	   (Huang	   et	   al.,	   2000a).	  Here	  mitochondrial	  
damage	  and	  apoptosis	  that	  ensued	  was	  blocked	  by	  the	  antioxidant	  reducing	  agent	  n-­‐
acetyl-­‐L-­‐cysteine	   (NAC)	   and	   the	   H2O2	   inhibitor	   catalase	   and	   augmented	   by	  
superoxide	  dismutase/NADPH	  due	  to	  their	  ability	  to	  increase	  intracellular	  ROS.	  This	  
effect	  did	  not	  occur	  in	  p53-­‐/-­‐	  cells,	  which	  is	  of	  relevance	  to	  NBL	  given	  the	  low	  rate	  of	  
p53	  mutations	  in	  this	  cancer.	  Vanadate	  also	  causes	  S-­‐phase	  arrest	  via	  Erk/p38	  MAPK-­‐
induced	   increases	   in	   p21	   only	   in	   p53+/+	   cells	   (Zhang	   et	   al.,	   2002).	   Paradoxically,	  
vanadate	   was	   recently	   shown	   to	   inhibit	   p53-­‐induced	   apoptosis	   via	   transcription-­‐
dependent	   and	   independent	   pathways	   at	   an	   even	   greater	   efficacy	   than	   the	  
established	   pifithrin	   transcriptional	   inhibitors	   (Morita	   et	   al.,	   2010).	   Here	   it	   was	  
argued	   that	   this	   function	   could	   dramatically	   limit	   gastrointestinal/haematopoietic	  
problems	  resulting	  from	  radiation	  treatment.	  	  
	   A	   number	   of	   studies	   have	   focused	   on	   ROS	   as	   a	   mediator	   of	   the	  
antiproliferative	   effects	   of	   vanadium.	   Indeed	   the	   increased	   sensitivity	   of	   insulin	  
resistant	  adipocytes	   to	  vanadate	   treatment	  has	  been	  suggested	  to	  be	  the	  result	  of	  
oxidative	   stress	   preventing	   the	   reduction	   of	   +5	   vanadate	   to	   +4	   vanadyl	   (Lu	   et	   al.,	  
2001),	  of	  interest	  considering	  the	  high	  levels	  of	  oxidative	  stress	  attributed	  to	  cancer	  
cells	   (See	   section	   1.6).	   Gamero	   et	   al.	   demonstrated	   ROS-­‐dependent	   apoptosis	  
induced	  by	  a	  combination	   low-­‐dose	  vanadate	   (5µM)	  and	   interferon-­‐α	  treatment	   in	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multiple	   cancer	   cells	   in	   vitro	   (Gamero	   and	   Larner,	   2001).	   Interestingly	   neither	  
treatment	  alone	  induced	  apoptosis,	  nor	  was	  p53	  necessary	  for	  this	  response.	  In	  lung	  
cancer	   cells	   vanadate-­‐induced	   ROS	   are	   responsible	   for	   Erk/p38	   MAPK	  
phosphorylation	  that	  results	  in	  increased	  p21	  expression	  and	  arrest	  at	  G2/M	  (Zhang	  
et	   al.,	   2003).	   However	   this	   is	   again	   complicated	   by	   the	   recent	   illustration	   of	   ROS	  
independent	   G1/S	   arrest	   resulting	   from	   vanadium	   compounds	   in	   hepatoma	   cells	  
(Wang	   et	   al.,	   2010).	   Here	   it	   was	   suggested	   that	   increased	   ROS	   is	   responsible	   for	  
cytotoxicity	  of	  normal	  cells	  induced	  by	  high	  concentrations	  of	  vanadium	  compounds	  
(400µM),	  a	  negative	  side	  effect	  that	  could	  be	  limited	  by	  concomitant	  treatment	  with	  
NAC.	  	  
	   Chin	  et	  al.	  have	  shown	  that	  vanadate	  can	  actually	  inhibit	  apoptosis	  in	  glioma	  
cells	  (Chin	  et	  al.,	  1999).	  Here	  it	  was	  argued	  that	  dual	  activation	  of	  Erk/p38	  MAPK	  and	  
PI3K/Akt	   resulted	   in	   both	   survival	   and	   apoptotic	   signalling,	   where	   inhibiting	   the	  
latter	  caused	  cell	  death.	  Indeed	  this	  highlights	  the	  cell	  type	  dependency	  and	  role	  of	  
contextual	   signals	   in	   determining	   the	   fate	   of	   tumour	   cells	   treated	   with	   vanadium	  
compounds,	  for	  instance	  activation	  of	  downstream	  effectors	  such	  as	  Erk/Akt	  and	  NF-­‐
kappaB	   may	   result	   in	   either	   survival	   or	   apoptosis.	   Klarund	   et	   al.	   showed	   that	  
vanadate	   can	   even	   cause	   oncogenic	   transformation	   in	   vitro	   by	   increasing	  
intracellular	   pTyr	   (Klarlund,	   1985).	   While	   this	   highlights	   the	   paradoxical	   opposing	  
effects	   of	   vanadium	   and	   demonstrates	   a	   need	   for	   caution	   in	   promoting	   its	   use	   in	  
cancer	  therapy,	  the	  US	  food	  and	  drug	  administration	  (FDA)	  has	  not	  listed	  vanadium	  
as	  a	  known	  carcinogen.	  	  
	   Apart	  from	  directly	  affecting	  proliferation	  and	  apoptosis,	  vanadium	  may	  exert	  
other	   potentially	   anti-­‐cancerous	   effects,	   such	   as	   the	   modulation	   of	   motility	   or	  
invasiveness.	   For	   example	   vanadate	   can	   inhibit	   cell	   adhesion	   and	   cell	   spreading	   in	  
both	   normal	   and	   transformed	   cells	   in	   vitro	   (Edwards	   et	   al.,	   1991).	   More	   recently	  
vanadate	   was	   found	   to	   exert	   inhibition	   of	   matrix	   metalloproteinases	   (MMPs),	  
enzymes	   with	   putative	   roles	   in	   metastasis	   (Chintala	   et	   al.,	   1999).	   Here	   vanadate	  
treatment	   reduced	  actin	  polymerization,	  and	  cell	   spreading	  and	  migration/invasion	  
in	  glioma	  cells,	  providing	  indirect	  evidence	  that	  vanadate	  may	  limit	  invasiveness	  and	  
thus	  metastatic	  spread.	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   A	   role	   of	   vanadium	   in	   stimulating	   neuronal	   differentiation	   has	   also	   been	  
documented.	   Following	   ischemic	   injury,	   treatment	   with	   the	   organovanadium	  
compound	   bis(1-­‐oxy-­‐3-­‐pyridimethiolato)oxovanadium(IV)	   results	   in	   enhanced	  
hippocampal	  neurogenesis	  via	   increasing	  PI3K/Akt	  and	  Erk	   signalling	   (Shioda	  et	  al.,	  
2008;	  Shioda	  et	  al.,	  2007).	  Similarly,	  vanadate	  can	  activate	  TrkA	  signalling	  via	  Akt/Erk	  
stimulation	  and	  mediate	  neurotrophin-­‐independent	  survival	  in	  hippocampal	  neurons	  
(Gerling	   et	   al.,	   2004).	   This	   apparent	   ability	   of	   vanadium	   compounds	   to	   behave	   as	  
neurotrophic	  factor	  mimetics	  suggests	  a	  role	  in	  differentiation	  of	  neural	  cells,	  a	  key	  
determinant	   of	   NBL	   regression	   (Brodeur	   et	   al.,	   2009;	   Nakagawara,	   1998).	   In	   fact	  
Rogers	   et	   al.	   showed	   that	   vanadate	   could	   stimulate	   neurite	   extension,	   a	   cell-­‐
structural	   parameter	   of	   neuritogenesis,	   in	   human	   NBL	   cells	   (Rogers	   et	   al.,	   1994),	  
although	  the	  mechanisms	  behind	   this	  effect	  are	  unclear.	  Similarly	  an	  oxovanadium	  
compound	   causes	   decreased	   proliferation	   and	   reversible	   G2/M	   phase	   cell	   cycle	  
arrest	  in	  both	  NBL	  and	  glioma	  cells	  (Faure	  et	  al.,	  1995).	  This	  suggests	  that	  distinct	  to	  
apoptosis,	  vanadium	  may	  promote	  differentiation	  in	  neuronal	  cancer	  cells.	  	  
	   Clearly,	   definitive	   proof	   of	   the	   anti-­‐cancerous	   effects	   of	   vanadium	  
compounds	   requires	   in	   vivo	   demonstrations	   of	   efficacy	   against	   tumours.	   Indeed	  
numerous	  such	  demonstrations	  exist	  currently;	  dating	  back	  to	  1965	  when	  anticancer	  
effects	   of	   vanadium	   salts	   were	   first	   published	   (Bishayee	   et	   al.,	   2010).	   The	   first	  
controlled	   animal	   study	   into	   the	   chemopreventive	   effects	   of	   vanadyl	   sulfate	   was	  
published	   by	   Thompson	   et	   al.,	   documenting	   a	   decrease	   in	   both	   the	   incidence	   of	  
cancer	   and	   number	   of	   cancers	   per	   rat	   in	   a	   model	   of	   induced	   mammary	  
carcinogenesis	   (Thompson	   et	   al.,	   1984).	   Bishayee	   et	   al.	   similarly	   showed	   that	  
ammonium	   monovanadate	   given	   either	   throughout	   or	   prior	   to	   initiation	   of	   liver	  
tumour	   formation	   in	   rats,	   gave	   significant	   protection	   from	   carcinogenesis	   and	  
increased	  animal	  survival	  (Bishayee	  et	  al.,	  1997).	  Demonstrating	  efficacy	  as	  a	  single	  
agent	   chemotherapeutic	   against	   existing	  murine	   lymphoma	   tumours,	   Sardar	   et	   al.	  
found	   that	   ammonium	   mononium	   monovanadate	   caused	   significant	   tumour	  
regression	   and	   increased	   survival	   when	   supplemented	   daily	   (Sardar	   et	   al.,	   1993).	  
Although	  numerous	  other	  studies	  have	  shown	  similar	  such	  benefits	   in	   liver,	  breast,	  
lung	   and	   colon	   cancer	   as	  well	   as	   tumours	   of	   both	   the	   haematological	   system	   and	  
connective	  tissue	  (Bishayee	  et	  al.,	  2010),	  only	  one	  documented	  study	  has	  examined	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its	   effects	   on	   a	   nervous	   system	   tumour.	   Here	   it	   was	   shown	   that	   the	  
organovanadium(IV)	   compound	   bis(4,7-­‐dimethyl-­‐1,10-­‐phenanthroline)	  
sulfatooxovanadium(IV)	   (metvan)	   displayed	   highly	   significant	   antitumor	   activity	   in	  
mice,	  delaying	  tumour	  progression	  and	  prolonging	  survival	  time	  in	  both	  glioblastoma	  
and	  breast	  cancer	  (Narla	  et	  al.,	  2001).	   	  Remarkably,	  metvan	   induced	  apoptosis	   in	  a	  
range	   of	   different	   tumour	   types	   in	   vitro	   including	   treatment	   resistant	   tumour-­‐
derived	   cells,	   at	   greater	   efficacy	   than	   standard	   chemotherapeutics,	   as	   well	   as	  
inhibiting	  migration/invasion.	  	  
	   In	   sum,	  multiple	   vanadium	   compounds	   exert	   various	   effects	   on	   a	   range	   of	  
processes	   that	   could	   be	   detrimental	   for	   tumour	   maintenance	   and	   progression	  
(Figure	  1.5.3).	  Thus	  in	  light	  of	  this	  mounting	  evidence,	  we	  are	  in	  an	  exciting	  position	  
to	  pursue	  such	  therapies	  given	  the	  extensive	  synthesis	  of	  numerous	  derivatives	  and	  
toxicity	   testing	   in	   both	  mice	   and	  men,	   as	  well	   as	   the	   accompanying	   evidence	   that	  
PTPs	   form	  a	  novel	  group	  of	  enzymes	  worth	   targeting	   in	  numerous	  human	  cancers.	  
However,	   the	  non-­‐PTP	  dependent	  effects	  of	  vanadium	  compounds	  are	  also	  worthy	  
of	  consideration,	  as	  processes	  such	  as	  DNA	  damage	  and	  ROS	  are	  likely	  to	  significant	  
contribute	   to	   cytotoxicity.	   The	   impact	   of	   ROS	   production	   of	   cancer	   cells	   will	   be	  
discussed	  below.	  	  
	  
1.6. Reactive	  oxygen	  species	  as	  mediators	  of	  cellular	  processes	  and	  
tumour	  cell	  survival	  
1.6.1.	  Intracellular	  redox	  regulation	  and	  the	  generation	  of	  reactive	  oxygen	  species	  	  
Cellular	  aerobic	  respiration	  constantly	  generates	  ROS	  including	  the	  superoxide	  anion	  
(O2-­‐),	   singlet	   oxygen	   (1O2),	   hydroxyl	   radicals	   (OH
·∙
),	   peroxides	   (ROOR’),	  
hydroperoxides	  (ROOH),	  and	  hydrogen	  peroxide	  (H2O2)	   (Eruslanov	  and	  Kusmartsev,	  
2010).	  It	  is	  estimated	  that	  1-­‐2%	  of	  electrons	  in	  the	  mitochondrial	  electron	  transport	  
chain	  leak,	  forming	  the	  superoxide	  ion	  O2-­‐.	  The	  enzyme	  superoxide	  dismutase	  (SOD)	  
then	  catalyses	  the	  formation	  of	  H2O2	  from	  O2-­‐,	  which	  can	  react	  with	  Fe2+	  to	  generate	  
damaging	  hydroxyl	  radicals	  via	  Fenton	  reactions.	  Nicotinamide	  adenine	  dinucleotide	  
phosphate	   (NADPH)	   oxidase	   in	   the	   plasma	   membrane,	   xanthine	   oxidase	   in	   the	  
cytosol	  and	  cytochrome	  p450	  in	  the	  endoplasmic	  reticulum	  are	  also	  sources	  of	  free	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radicals.	   Increases	   in	   the	  production	  of	  ROS	   can	   result	   directly	   from	  mitochondrial	  
respiratorial	  chain	  leakage	  or	  indirectly	  from	  attenuation	  of	  the	  antioxidant	  defence	  
system.	   In	   both	   cases	   alteration	   of	   redox	   homeostasis	   results	   in	   oxidative	   stress,	  
causing	   DNA	   damage	   resulting	   in	  mutations,	  modifying/damaging	  macromolecules	  
such	   as	   proteins	   and	   lipids,	   and	   deregulating	   enzymatic-­‐signalling	   cascades	  
(Trachootham	  et	   al.,	   2008).	   Importantly,	   however,	   cellular	   ROS	   also	   have	   a	   role	   in	  
maintaining	   homeostasis,	   functioning	   as	   second	   messengers	   in	   intracellular	   signal	  
transduction	  (Finkel,	  2000;	  Gulati	  et	  al.,	  2001;	  Herrlich	  and	  Bohmer,	  2000).	  	  
	  
	  
Figure	   1.5.3.	   Vanadium	   compounds	   as	   anticancer	   agents.	   Summary	   of	   the	   effects	   of	  
vanadium	   compounds	   detrimental	   to	   cancer	   cells.	   These	   include	   inhibition	   of	   invasion	   via	  
modulation	   of	   adhesion,	   apoptosis	   via	   DNA	   damage/ROS	   production	   and	   reduced	  
proliferation/cell	  cycle	  arrest	  through	  enzymatic	  regulation.	  Taken	  from	  (Evangelou,	  2002).	  	  
	  
	  
Due	  to	  the	  ability	  of	  oxidative	  stress	  to	  cause	  damage	  to	  biological	  macromolecules,	  
cells	   have	   evolved	   extensive	   antioxidant	   defences	   to	   intercept	   and	   thus	   abrogate	  
ROS	   (Eruslanov	  and	  Kusmartsev,	   2010).	   The	  enzymes	  SOD,	   glutathione	  peroxidase,	  
catalase	   and	   thioredoxin	   reductase	   can	   all	   interfere	   with	   ROS	   production	   and	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function	   as	   reducing	   agents.	   For	   instance	   catalase	   catalyses	   the	   reduction	   of	  H2O2	  
into	   a	   molecule	   of	   water	   and	   oxygen.	   One	   of	   the	   most	   important	   defence	  
mechanisms	  against	  H2O2,	  as	  well	  as	  an	   intrinsic	   regulator	  of	   redox	  homeostasis,	   is	  
the	  enzyme	  glutathione	  peroxidase,	  which	  functions	  through	  the	  glutathione	  (GSH)	  
redox	   cycle	   within	   the	   mitochondria	   and	   cytoplasm	   (Filomeni	   et	   al.,	   2002).	   The	  
tripeptide	  GSH	  (γ-­‐Glu-­‐Cys-­‐Gly)	  behaves	  as	  a	  ROS	  scavenger,	  reducing	  free	  radicals	  via	  
electron	  donation.	  Glutathione	  peroxidase	  catalyses	  the	  reduction	  of	  H2O2,	  and	  other	  
peroxidases.	   GSH	   is	   itself	   regulated	   by	   glutathione	   peroxidase,	   converting	   it	   to	   an	  
oxidised	  disulphide	  form	  (GSSG)	  and	  glutathione	  reductase,	  reducing	  it	  back	  to	  GSH.	  
This	   process	   is	   important	   both	   in	   the	   synthesis	   of	   GSH	   and	   its	   role	   in	   acutely	  
managing	   oxidative	   stress,	   increasing	   GSH	   through	   reduction	   of	   GSSG.	   The	   rate-­‐
limiting	   step	   in	   GSH	   synthesis	   is	   catalysed	   by	   the	   enzyme	   L-­‐γ-­‐glutamyl-­‐cysteine	  
synthetase,	  which	  can	  be	  inhibited	  by	  the	  compound	  buthionine	  sulfoximine	  (BSO).	  
In	   sum	   physiological	   levels	   of	   ROS	   are	   affected	   by	   numerous	   stimuli	   and	   thus	   are	  









1.6.2.	  The	  role	  of	  ROS	  in	  cancer:	  A	  double	  edged	  sword	  
Due	  their	  ability	  to	  cause	  DNA	  damage	  and	  increase	  mutations,	  ROS	  are	  considered	  
an	   important	  player	   in	   the	  development	  of	  cancer	   (Halliwell,	  2007).	  However,	   they	  
function	   as	   a	   ‘double-­‐edged	   sword’	   in	   cancer,	   as	   they	   clearly	   have	   the	   converse	  
ability	  to	  reduce	  cell	  survival/proliferation	  and	  enhance	  cytotoxicity	   in	  tumour	  cells	  
Figure	   1.6.1.	   Stimuli/defence	   mechanisms	   regulating	   ROS.	   Numerous	   stimuli	  
contribute	   to	   the	   generation	  of	   ROS	   especially	   in	   human	   cancer	   such	   as	   radiation,	  
chemotherapy	   and	   hypoxia,	   however	   these	   are	   countered	   by	   antioxidant	   defence	  
systems	  including	  glutathione,	  catalase	  and	  SOD	  (Reuter	  et	  al.,	  2010).	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(Engel	  and	  Evens,	  2006).	  The	   reasons	   for	   these	  diametrically	  opposing	   functions	   in	  
cancer	  biology	  will	  now	  briefly	  be	  discussed.	  	  
	   Perhaps	  the	  most	  obvious	  role	  of	  ROS	  in	  triggering	  cancer	  is	  via	  DNA	  damage-­‐
induced	   mutations,	   activating	   oncogenes	   and	   inactivating	   tumour	   suppressors.	   In	  
fact	   the	   increased	   incidences	   in	   cancer	   in	   the	   elderly	   have	   been	   attributed	   to	   a	  
lifetime	  of	  ROS	  attack,	  causing	  accumulating	  mutations	  (Halliwell,	  2007;	  Wellen	  and	  
Thompson,	   2010).	   In	   established	   tumours,	   altered	   cellular	   metabolism	   can	   cause	  
‘nutrient	   stress’	   both	   from	   oncogene	   driven	   increases	   in	   nutrient	  metabolism	   and	  
nutrient	   deprivation	   driven	   by	   hypoxia/inadequate	   vascularisation,	   driving	   ROS	  
production	   in	   the	   tumour	   micro-­‐environment	   (Wellen	   and	   Thompson,	   2010).	   The	  
tumour	  suppressor	  p53	  has	  been	  hypothesized	  to	  play	  a	  role	  in	  invoking	  antioxidant	  
defence	   systems	   and	   p53	   is	   transactivated	   by	   ROS	   (Sablina	   et	   al.,	   2005).	   As	   such,	  
mutations	  in	  p53,	  which	  could	  be	  generated	  by	  ROS	  themselves,	  may	  potentiate	  the	  
ability	  of	  ROS	  to	  promote	  tumorigenesis.	  	  
	   ROS	   can	   also	   inactivate/activate	   enzymes	   crucial	   to	   survival	   and	   apoptosis	  
respectively.	  For	  example,	  increases	  in	  O2-­‐	  can	  increase	  cytoplasmic	  pH	  and	  decrease	  
the	  activation	  of	  caspases,	  allowing	  cell	  survival	  (Akram	  et	  al.,	  2005).	  Similarly	  H2O2	  
inactivates	   the	   tumour	   suppressor	   PTEN	   via	   oxidation	   of	   its	   active	   site	   cysteine,	  
leading	   to	   increases	   in	   levels	  of	  PIP3	  and	  activation	  of	  Akt	  as	  a	  survival	  mechanism	  
(Lee,	  2002).	  PTEN	  is	  however	  regulated	  by	  the	  GSH	  antioxidant	  defence	  system.	  This	  
reduces	  oxidized	  PTEN	  and	  may	  limit	  its	  inactivation	  by	  H2O2	  generated	  from	  growth	  
factor	   signalling	   (Kim	   et	   al.,	   2010).	   Stimulation	   of	   Akt	   itself	   generates	   ROS	   due	   to	  
increased	   oxygen	   consumption	   and	   decreased	   ROS	   scavenger	   expression	  
downstream	  of	  FoxO	  inhibition	  (Nogueira	  et	  al.,	  2008).	  	  
	   Perhaps	  the	  most	  emphatic	  evidence	  for	  the	  role	  of	  ROS	  in	  tumorigenesis	  is	  
the	   finding	   that	   transgenic	   mice	   harbouring	   deletions	   in	   genes	   encoding	   for	  
components	  of	  the	  antioxidant	  defence	  system	  are	  more	  prone	  to	  cancer	  (Neumann	  
et	  al.,	  2003).	  However,	  ROS	  also	  promotes	  growth	  of	  existing	  tumours,	  for	  instance	  
mediating	  anchorage	  independent	  growth	  in	  tumours	  driven	  by	  mutations	  in	  the	  K-­‐
Ras	   oncogene	   (Weinberg	   et	   al.,	   2010).	   In	   sum,	   ROS	   can	   promote	   tumorigenesis	  
through	  multiple	  mechanisms,	   although	   larger	   increases	   in	   ROS	  may	   contribute	   to	  
cell	  death	  (see	  below)	  (Figure	  1.6.2).	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As	   previously	   stated	   ROS	   exhibit	   a	   double-­‐edged	   action	   in	   promoting	  
tumorigenesis/expansion	   while	   also	   stimulating	   tumour	   regression	   depending	   on	  
contextual	   factors	   such	   as	   dynamic	   interactions	   and	   spatial	   localisation	   (Halliwell,	  
2007).	  For	  instance	  transactivation	  of	  p53	  by	  ROS	  due	  to	  DNA	  damage	  can	  trigger	  a	  
senescence	   response,	   with	   p53	   activity	   generating	   further	   ROS,	   representing	   a	  
positive	  feedback	  loop	  (Bensaad	  and	  Vousden,	  2005).	  H2O2	  can	  decrease	  cytoplasmic	  
pH	  and	  cause	  caspase	  activation,	  thus	  inducing	  apoptosis,	  in	  contrast	  to	  its	  opposite	  
effect	  promoting	  survival	  (Hampton	  and	  Orrenius,	  1997).	  Inactivation	  of	  cytochrome	  
oxidases	   may	   also	   decrease	   ATP	   formation	   and	   thus	   tumour	   growth,	   and	  
deactivation	  of	  numerous	  survival	  signalling	  enzymes	  such	  as	  mTOR	  may	  also	  engage	  
apoptosis	   (Chen	   et	   al.,	   2009;	   Chen	   et	   al.,	   2010b).	   As	   well	   as	   the	   aforementioned	  
findings	   that	   genetic	   inactivation	   of	   antioxidant	   defence	   systems	   promotes	  
tumorigenesis,	   the	  most	   important	  antioxidant	  GSH	   is	  actually	  elevated	   in	  therapy-­‐
resistant	  tumour	  cells	  and	  decreased	  in	  cells	  sensitive	  to	  anticancer	  drugs	  (de	  Tudela	  
et	   al.,	   2010).	   Lastly	   ROS	   can	   mediate	   apoptosis	   by	   directly	   activating	   both	   the	  
extrinsic	  and	  intrinsic	  mitochondrial	  death	  pathways	  (Engel	  and	  Evens,	  2006).	  	  
One	   commonly	   noted	   caveat	   is	   the	   suggestion	   that	   in	   vitro	   studies	   may	   be	  
somewhat	  unreliable	  given	   the	  supraphysiological	   levels	  of	  ROS	   in	  cells	   cultured	   in	  
hyperoxic	  conditions	  (5%	  CO2),	  as	  well	  as	   in	  medium	  lacking	  antioxidants	  (Halliwell,	  
2007).	  Thus	  cancer	  cell	  lines	  may	  adapt	  to	  hyperoxia	  and	  thus	  increased	  ROS	  through	  
increased	   production	   and	   subsequent	   reliance	   on	   antioxidant	   defences.	   Although	  
this	   is	   certainly	   worth	   noting,	   numerous	   in	   vivo	   studies	   have	   also	   documented	  
increased	   ROS	   levels	   in	   tumours.	   This	   has	   led	   to	   a	   recurrent	   strategy	   to	   target	  
tumour	  cells	  by	   increasing	  already	  high	   levels	  of	  ROS,	  effectively	   ‘tipping	  cells	  over	  
the	  edge’	  (Huang	  et	  al.,	  2000b).	  One	  potential	  benefit	  of	  this	  strategy	  is	  that	  normal	  
non-­‐neoplastic	   cells	   should	   be	   preferentially	   spared	   given	   their	   lower	   endogenous	  
levels	  of	  ROS,	  provided	  levels	  are	  not	  pushed	  too	  high.	  The	  aforementioned	  study	  by	  
Nogueira	  et	   al.	   elegantly	   demonstrated	   that	   increases	   in	   the	   activity	   of	   Akt,	  while	  
promoting	  survival,	  actually	   render	  cells	  highly	  sensitive	  to	  oxidative	  apoptosis	  due	  
to	   enhanced	   oxygen	   consumption,	   producing	   ROS	   and	   sensitizing	   tumour	   cells	   to	  
death	   through	   inhibition	   of	   the	   GSH	   antioxidant	   system	   (Nogueira	   et	   al.,	   2008).	  
Similarly	   low	  ROS	   levels	  may	  mediate	   resistance	   to	   therapy.	   Putative	   TICs	   or	   CSCs	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where	   shown	   to	   have	   lower	   ROS	   levels	   in	   vivo	   than	   their	   non-­‐tumorigenic	  
counterparts,	   rendering	   them	   insensitive	   to	   radiation	   therapy	   (Diehn	   et	   al.,	   2009).	  
Again	  pharmacological	  depletion	  of	  antioxidants	  decreased	  the	  clonogenicity	  of	  CSCs	  
and	  dramatically	  increased	  sensitivity	  to	  radiation-­‐induced	  cytotoxicity,	  representing	  
an	   effective	  way	   to	   combat	   cells	   that	   often	   circumvent	   standard	   therapies	   due	   to	  
their	  relative	  quiescence	  (Gupta	  et	  al.,	  2009).	  	  
	  
	  
Figure	   1.6.2.	   The	   effects	   of	   ROS	   on	   cancer.	   Increases	   in	   ROS	   production	   may	   promote	  
tumorigenesis,	  which	  could	  be	  further	  augmented	  by	  tumour	  formation	  e.g.	  through	  excess	  
nutrient	  consumption	  of	  oncogene	  activation.	  Pathological	  levels	  of	  ROS	  may	  however	  have	  
the	  converse	  effect,	  stimulating	  cell	  death	  (See	  below).	  Taken	  from	  (Wellen	  and	  Thompson,	  
2010).	  
	  
The	   notion	   that	   ROS	   are	   crucial	   to	   cytotoxicity	   of	   chemotherapy	   has	   been	   around	  
since	  the	  1960s,	  and	  demonstrated	  for	  standard	  front-­‐line	  chemotherapeutics	  such	  
as	  cisplatin	  and	  etoposide	  (Kurosu	  et	  al.,	  2003).	  Many	  studies	  have	  thus	  tested	  the	  
ability	   of	   inhibitors	   of	   antioxidants	   to	   augment	   chemotherapy	   (Engel	   and	   Evens,	  
2006).	   As	   previously	   mentioned,	   the	   GSH	   synthesis	   inhibitor	   BSO	   has	   formed	   a	  
crucial	   part	   of	   these	   studies.	   Twenty	   years	   ago	   BSO	   was	   shown	   to	   cause	  
macrophage-­‐mediated	   cytolysis	   of	   tumour	   cells	   in	   vitro	   (Nathan	   et	   al.,	   1981).	  
Furthermore	   cytotoxicity	   induced	   by	   arsenic	   trioxide,	   itself	   capable	   of	   producing	  
ROS,	   is	   potentiated	   by	   BSO	   in	   treatment-­‐resistant	   multiple	   myeloma	   cells	  
(Gartenhaus	  et	  al.,	  2002).	  BSO	  alone	  can	  activate	  caspase	  8,	  where	  pre-­‐treatment	  of	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tumour	  cells	  sensitized	  to	  arsenic	  trioxide	  induced	  cell	  death	  (Kitamura	  et	  al.,	  2000).	  
Importantly	  BSO	  was	  well	  tolerated	  in	  two	  phase	  I	  clinical	  trials	  in	  humans	  (Engel	  and	  
Evens,	   2006),	   suggesting	   promise	   as	   a	   broadly	   applicable	   anti-­‐cancer	   therapy.	  
However	   in	   addition	   to	   BSO,	   numerous	   antioxidants	   exist	   such	   as	   ascorbic	   acid,	  
imexon	  and	  motexafin	  gadolinium,	  with	  similar	  efficacy	  (Engel	  and	  Evens,	  2006).	  	  
	  
1.6.3.	  BSO-­‐mediated	  sensitization	  to	  chemotherapy	  in	  NBL	  
The	   numerous	   demonstrations	   of	   BSO-­‐induced	   sensitisation	   to	   chemotherapy	   also	  
extend	   to	  NBL,	  where	   ROS	   have	   been	   shown	   to	   play	   a	   causative	   role	   in	   response	  
outcome	   (Marengo	   et	   al.,	   2005).	   Anderson	   et	   al.	   were	   the	   first	   to	   document	  
cytotoxicity	  induced	  by	  BSO	  in	  NBL	  lines,	  demonstrating	  IC90	  ranges	  of	  2.1-­‐1000µM	  in	  
17	   of	   18	   cell	   lines,	   suggested	   to	   be	   lower	   than	   steady	   state	   plasma	   levels	   of	   BSO	  
reported	  in	  adult	  human	  trials	  (Anderson	  et	  al.,	  1999).	  Yang	  et	  al.	  demonstrated	  that	  
BSO	  treatment	  alone-­‐induced	  apoptosis	  in	  NBL	  cells	  cultured	  in	  normoxic	  conditions	  
(20%	  O2)	  but	  not	   in	  hypoxic	  conditions	  (2%	  O2)	  (Yang	  et	  al.,	  2003).	   Importantly	  this	  
may	   reflect	   differences	   in	   ROS	   production	   depending	   on	   the	   tumour	  
microenvironment,	  e.g.	  in	  hypoxic	  conditions	  found	  in	  bone	  marrow,	  which	  underlie	  
treatment	  resistance.	  Tirapazamine,	  a	  bioreductive	  agent	  capable	  of	  generating	  ROS	  
in	  hypoxic	  conditions,	  reversed	  hypoxic	  inhibition	  of	  BSO	  activity,	  causing	  increased	  
ROS	  and	  apoptosis.	  	  
	   The	   protein	   kinase	   C	   (PKC)	   family	   of	   enzymes	   has	   been	   highlighted	   as	   a	  
crucial	   determinant	   of	  NBL	   cells	   to	  ROS	   (Marengo	  et	   al.,	   2005).	  Domenicotti	  et	   al.	  
demonstrated	   that	   decreased	   GSH	   levels	   caused	   by	   BSO	   treatment	   differentially	  
regulated	  PKC	   isoforms,	   causing	   inactivation	  of	   classical	   PKCs	  but	   activation	  of	   the	  
proapoptotic	  PKCδ	  isoform	  (Domenicotti	  et	  al.,	  2000).	  The	  same	  group	  extended	  this	  
work	  to	  NBL	  cells	  in	  vitro,	  showing	  that	  high	  dose	  BSO	  treatment	  of	  a	  Mycn	  amplified	  
NBL	  cell	  line	  caused	  ~50%	  increase	  in	  ROS	  as	  well	  as	  a	  shift	  in	  the	  ratio	  of	  GSH/GSSG	  
accompanied	   by	   increased	   and	   decreased	   activity	   in	   PKCδ	   and	   PKCα	   respectively	  
(Domenicotti	   et	   al.,	   2003a;	   Domenicotti	   et	   al.,	   2003b).	   Importantly	   these	   effects	  
triggered	   apoptosis	   that	   was	   blocked	   by	   the	   PKC	   inhibitor	   rottlerin	   and	   the	  
antioxidant	   vitamin	  C.	  Recently	   a	   causative	   function	   in	  ROS-­‐induced	  apoptosis	  was	  
demonstrated	   for	   PKCδ	   has	   (Marengo	   et	   al.,	   2011).	   Here	   overexpression	   of	   PKCδ	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sensitized	   BSO-­‐resistance	   NBL	   cells	   to	   apoptosis	   by	   increasing	   DNA	   oxidation	   and	  
ROS	  production,	  as	  well	  as	  potentiating	  the	  effect	  of	  BSO	  on	  cells	  already	  sensitive	  to	  
this	  treatment.	  Furthermore	  PKCδ	  overexpression	  also	  increased	  the	  effectiveness	  of	  
the	  standard	  chemotherapeutic	  etoposide,	  confirming	  the	  role	  of	  ROS	  in	  cytotoxicity	  
induced	  by	  front	  line	  agents	  and	  highlighting	  PKCδ	  as	  a	  novel	  target	  to	  augment	  it.	  	  
	   Mycn	  amplification	  status	  plays	  a	  crucial	  role	  in	  determining	  the	  response	  of	  
NBL	  cells	  to	  BSO	  treatment,	  where	  Mycn	  amplified	  cells	  exhibit	  increased	  sensitivity	  
to	  BSO	  treatment	  (Anderson	  et	  al.,	  1999).	  Marengo	  et	  al.	  found	  that	  Mycn-­‐amplified	  
NBL	  cell	  lines	  have	  higher	  basal	  levels	  of	  ROS	  production	  and	  exhibit	  more	  dramatic	  
increases	   following	   BSO	   treatment	   (Marengo	   et	   al.,	   2008).	   This	   was	   suggested	   to	  
result	  from	  higher	  levels	  of	  SOD-­‐1	  in	  Mycn	  amplified	  cells,	  which	  was	  stimulated	  by	  
BSO.	   A	   recent	   finding	   elegantly	   demonstrated	   that	  Mycn	   amplification	   can	   confer	  
resistance	   to	  ROS-­‐induced	  apoptosis	   (de	  Tudela	  et	  al.,	  2010).	  Here	  Mycn	   increased	  
the	  expression	  of	  the	  catalytic	  subunit	  of	  L-­‐γ-­‐glutamate-­‐cysteine	  ligase	  (GCL(cat)),	  a	  
rate	  limiting	  step	  in	  GSH	  synthesis,	  possibly	  explaining	  the	  heightened	  sensitivity	  of	  
Mycn	  amplified	  cells	  to	  BSO	  treatment.	  	  
	   In	  sum	  ROS	  have	  a	  well	  defined	  role	  in	  cytotoxicity	  induced	  by	  chemotherapy	  
and	  intracellular	  ROS	  levels	  may	  underlie	  therapeutic	  resistance	  for	  example	  in	  CSCs	  
or	  Mycn	   amplified	  NBL	   cells.	   Furthermore	   ROS	   are	   crucial	  mediators	   of	   enzymatic	  
signalling	   cascades,	   capable	  of	   acting	  as	   second	  messengers	  as	  well	   as	   inactivating	  
enzymes	  such	  as	  PTPs.	  Thus	  redox	  dependent	  apoptosis	  represents	  a	  very	  interesting	  
and	  largely	  unexplored	  area	  of	  NBL	  tumour	  biology.	  
	  
1.7.	  Project	  aims	  
Thus	  given	  the	  increasing	  evidence	  that	  PTPs	  are	  involved	  in	  fundamental	  aspects	  of	  
tumour	   biology,	   we	   wish	   to	   characterise	   the	   contribution	   played	   by	   this	   enzyme	  
group	   in	  NBL.	  Thus	  the	  specific	  aims	  of	   this	  project	  are	  to	  document	  the	  effects	  of	  
broad	  PTP	   inhibition	  achieved	   through	  vanadium-­‐based	  phosphotyrosine	  mimetics.	  
We	   hypothesise	   that	   by	   controlling	   proliferative	   ability	   and	   cell	   survival,	   the	   PTP	  
family	   might	   harbour	   members	   that	   suppress	   differentiation	   (Chapter	   3)	   and	  
apoptosis	   (Chapter	   4)	   in	   NBL.	   Thus	   PTP-­‐inhibition	   could	   potentially	   enhance	   the	  
effects	  of	  the	  differentiation	  agent	  RA,	  while	  also	  acting	  alone	  in	  a	  cytotoxic	  manner,	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providing	  a	  possible	  targeted	  therapy	  for	  a	  tumour	  still	  lacking	  in	  targets.	  Given	  that	  
broad	   PTP	   inhibition	   is	   likely	   to	   increase	   the	   activity	   of	   intracellular	   signalling	  
cascades	  such	  as	  Ras/RAF/MEK/Erk	  and	  PI3K/Akt,	  we	  hope	  to	  reveal	  undocumented	  
roles	   for	   their	   activation	   in	   NBL	   cell	   death	   and	   differentiation.	   Furthermore	   as	  
vanadium	  compounds	  are	   known	   to	   cause	  ROS	  production,	  we	  aim	   to	  analyse	   the	  
interaction	   between	   oxidative	   stress	   and	   activation	   of	   said	   pathways.	   Lastly	  
candidate	   PTPs	   specifically	   involved	   in	   these	   processes	  will	   be	   identified	   based	   on	  
expression	  profiling	  and	  clustering	  analysis	   (Chapter	  5),	  with	  the	  aim	  of	  stimulating	  
future	  molecular	  genetic	  approaches	  required	  to	  delineate	  the	  function	  of	  individual	  
members	   of	   the	  PTP	   family	   in	  NBL	   cell	   survival/differentiation.	   The	   applicability	   of	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2.1.	  Nucleic	  acid	  methods	  
2.1.1.	  DNA	  purification	  using	  QUIAGEN	  Plasmid	  midi	  kit	  
Purification	  of	  plasmid	  DNA	  was	  performed	  by	  the	  alkaline	  lysis	  method	  as	  described	  
(Birnboim	  and	  Doly,	  1979;	  Ish-­‐Horowicz	  and	  Burke,	  1981)	  using	  a	  QUIAGEN	  plasmid	  
midi	  kit	  (Quiagen	  Inc,	  Valencia,	  CA,	  USA).	  Single	  bacterial	  colonies	  were	  picked	  from	  
ampicillin-­‐resistant	  Luria	  Bertani	  (LB)	  agar	  plates	  and	  grown	  for	  12	  hours	  at	  37°C	  with	  
rigorous	   shaking	   in	   2ml	   LB	   broth	   starter-­‐cultures	   containing	   50µg/ml	   ampicillin.	  
Starter	   cultures	   were	   then	   transferred	   to	   100ml	   of	   LB	   broth	   containing	   50µg/ml	  
ampicillin	  and	  grown	  for	  12-­‐16	  hours	  in	  the	  same	  conditions.	  
	   Bacterial	  cells	  were	  harvested	  by	  centrifugation	  at	  4400	  RPM	  for	  15	  minutes	  
at	  4°C,	  then	  resuspended	  in	  4ml	  of	  resuspension	  buffer	  P1	  (50mM	  Tris-­‐HCl,	  pH	  8.0;	  
10mM	  EDTA;	  100µg/ml	  RNase	  A).	  4ml	  of	  lysis	  buffer	  P2	  (200mM	  NaOH;	  1%	  SDS	  w/v)	  
was	   then	   added	   and	   gently	   mixed	   followed	   by	   5	   minutes	   of	   incubation	   at	   room	  
temperature	  (RT).	  4ml	  of	  neutralization	  buffer	  P3	  (3.0M	  Potassium	  acetate,	  pH	  5.5),	  
pre-­‐chilled	  on	  wet	  ice,	  was	  then	  added,	  mixed	  and	  incubated	  for	  15	  minutes	  on	  ice.	  
Lysates	   were	   centrifuged	   at	   12,000	   RPM	   in	   30ml	   polypropylene	   tubes	   at	   4°C	   to	  
remove	  precipitate.	  	  
	   A	   QUIAGEN-­‐tip	   100	   purification	   column	   was	   equilibrated	   with	   4ml	   of	  
equilibration	  buffer	  QBT	  (750mM	  NaCl,	  50mM	  MOPS,	  pH	  7.0;	  15%	  isopropanol	  (v/v);	  
0.15%	   Triton®	   X-­‐100	   (v/v)),	   and	   the	   supernatant	   from	   the	   bacterial	   lysate	   was	  
allowed	  to	  flow	  through	  the	  column	  by	  gravity	   flow.	  The	  column	  was	  then	  washed	  
twice	   with	   10ml	   of	   wash	   buffer	   QC	   (1.0M	   NaCl;	   50mM	   MOPS,	   pH	   7.0;	   15%	  
isopropanol	   (v/v))	   to	   remove	   contaminants,	   and	   eluted	   into	   a	   30ml	   polypropylene	  
tube	   with	   5ml	   of	   elution	   buffer	   QF	   (1.25M	   NaCl;	   50mM	   Tris-­‐HCl,	   pH	   8.5;	   15%	  
isopropanol	   (v/v)).	   Eluted	   DNA	   was	   then	   precipitated	   by	   the	   addition	   of	   3.5ml	  
isopropanol	  and	  centrifuged	  for	  at	  12,000	  RPM	  for	  30	  minutes	  at	  4°C.	  DNA	  was	  then	  
rinsed	  with	  70%	  ethanol	  and	  centrifuged	  at	  12,000	  RPM	  for	  10	  minutes	  at	  4°C.	  DNA	  
was	  air	  dried	  and	  resuspended	   in	  100µl	  of	  buffer	  TE	  (10mM	  Tris-­‐HCl,	  pH	  8.0;	  1mM	  
EDTA).	  	  
	   General	  plasmid	  DNA	  precipitations	  were	  carried	  out	  by	  mixing	  DNA	  solutions	  
with	  0.7	  volumes	  of	   isopropanol	  and	  centrifuging	  at	  12,000	  RPM	  for	  30	  minutes	  at	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4°C.	   Precipitated	   DNA	   was	   washed	   with	   1ml	   of	   70%	   ethanol	   and	   centrifuged	   at	  
12,000	   RPM	   for	   10	  minutes	   at	   4°C.	   After	   air-­‐drying	   at	   RT	   for	   5	  minutes,	   DNA	  was	  
resuspended	   in	   100µl	   of	   elution	   buffer	   TE	   (10mM	   Tris-­‐Cl,	   pH	   8.0;	   1mM	   EDTA).	   In	  
cases	  where	  the	  presence	  of	  EDTA	  could	  inhibit	  further	  reactions,	  the	  elution	  buffer	  
EB	  (10mM	  Tris-­‐Cl,	  pH	  8.5)	  was	  used.	  
	  
2.1.2.	  Restriction	  digestion	  and	  DNA	  electrophoresis	  
During	   the	   construction	   of	   recombinant	   DNA	   plasmids,	   restriction	   enzymes	   were	  
used	   to	   cut	   double	   stranded	  DNA	  molecules	   at	   restriction	   sites.	   Plasmid	  DNA	  was	  
combined	   with	   restriction	   enzymes	   at	   ~4	   units/µg	   (enzyme:	   DNA)	   along	   with	   an	  
appropriate	  10x	  buffer	  and	  diluted	   in	  75%	  water	  and	   incubated	  at	  37°C	  for	  several	  
hours.	   Following	  digestion	   enzyme	  products	  were	   combined	  with	   5x	   bromophenol	  
blue	   loading	   buffer	   (Bioline	   Ltd,	   London,	   UK)	   allowing	   visualisation	   of	   migration	  
distance	  and	  separated	  by	  agarose	  gel	  electrophoresis	  using	  0.7-­‐1%	  agarose	  gels	   in	  
tris-­‐acetate-­‐EDTA	   (TAE)	   buffer	   containing	   0.0003%	   of	   the	   fluorescent	   DNA	  
intercalating	   agent	   ethidium	   bromide.	   DNA	   size	   was	   visualised	   by	   concurrent	  
electrophoresis	  with	  DNA	  HyperLadder	  1	   (Bioline	  Ltd,	   London,	  UK)	  and	  DNA	  bands	  
recorded	  using	  a	  fluorescent	  transilluminator.	  	  
	  
2.1.3.	  Elution	  of	  DNA	  from	  agarose	  gels	  
Gel	  elution	  was	  performed	  using	  a	  QIAquick	  gel	  extraction	  kit	  (Quiagen	  Inc,	  Valencia,	  
CA,	   USA).	   Differentially	   sized	   DNA	   bands	   were	   separated	   by	   electrophoresis,	   and	  
excised	   using	   a	   scalpel	   under	   a	   fluorescent	   transilluminator.	   Excised	   agarose	   was	  
then	   incubated	  with	  3x	  w/v	  of	   the	   solubilisation	  buffer	  QG	   (Quiagen	   Inc,	  Valencia,	  
CA,	  USA)	   at	   50°C	   for	   10	  minutes.	  DNA	   fragments	  between	  500bp	  and	  400kb	  were	  
precipitated	  by	  adding	  an	  equal	  volume	  of	   isopropanol	  (isopropanol:	  agarose)	  then	  
bound	   to	   a	   QIAquick	   spin	   column	   by	   centrifugation	   at	   12,000	   RPM	   for	   1	   minute.	  
Trace	   agarose	  was	   removed	  by	   centrifugation	   at	   12,000	  RPM	   for	   one	  minute	  with	  
0.5ml	  of	  buffer	  QG,	  and	  any	  remaining	  contaminants	  were	  removed	  by	  an	  additional	  
one	  minute,	  12,000	  RPM	  centrifugation	  step	  with	  0.75	  ml	  of	  the	  PE	  wash	  buffer.	  The	  
QIAquick	  spin	  columns	  were	  transferred	  to	  clean	  1.6	  ml	  microcentrifuge	  tubes	  and	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DNA	  was	  eluted	  by	  adding	  30µl	  of	   the	  elution	  buffer	  EB	   (10mM	  tris-­‐Cl,	  pH	  8.5)	   for	  
one	  minute	  followed	  by	  centrifugation	  at	  12,000	  RPM	  for	  one	  minute.	  	  
	  
2.1.4.	  DNA	  ligation	  
DNA	   ligations	   were	   performed	   as	   described	   (Weiss	   and	   Richardson,	   1967).	  
Specifically	   circular	   plasmid	   DNA	   vectors	   and	   DNA	   fragment	   inserts	  were	   digested	  
with	  restriction	  enzymes	  to	  yield	   linear	  DNA	  molecules	  with	  cohesive	  ends	  capable	  
of	  annealing	  to	  one	  another	  forming	  a	  covalent	  bond.	  Digested	  vector	  DNA	  was	  then	  
treated	   with	   calf	   intestinal	   phosphatase	   (CIP)	   (Roche	   Applied	   Science,	  Mannheim,	  
Germany)	  in	  the	  presence	  of	  10x	  phosphorylation	  buffer	  (0.5M	  Tris-­‐HCl;	  1mM	  EDTA;	  
pH	   8.5)	   for	   two	   hours	   at	   37°C	   in	   order	   to	   prevent	   self-­‐ligation.	   Re-­‐purified	   vector	  
DNA	  was	  then	  ligated	  to	  DNA	  inserts	  using	  an	  equal	  ratio	  of	  DNA	  using	  T4	  DNA	  ligase	  
(Roche	  Applied	  Science,	  Mannheim,	  Germany)	  with	  10x	   ligase	  buffer	   (660mM	  Tris-­‐
HCl;	  50mM	  MgCl2;	  50mM	  DTT;	  10mM	  ATP;	  pH	  7.5)	  overnight	  at	  14°C.	  Vector-­‐insert	  
ligations	   were	   judged	   by	   the	   presence	   of	   increased	   molecular	   weight	   DNA	   as	  
revealed	  by	  agarose	  electrophoresis.	  	  
	  
2.1.5.	  Transformation	  of	  DNA	  
Incorporation	   of	   exogenous	   DNA	   into	   competent	   bacterial	   cells	  was	   performed	   as	  
described	   (Chen	   and	   Dubnau,	   2004).	   Briefly	   ~1ng	   DNA	   dissolved	   in	   3µl	   of	   MilliQ	  
water	  was	  incubated	  in	  the	  presence	  of	  40µl	  of	  either	  the	  Library	  Efficiency®	  DH5α™	  
(Invitrogen,	  Carlsbad,	  CA,	  USA)	  or	  the	  JM109	  	  (Promega,	  Fitchburg,	  WI,	  USA)	  clone	  of	  
the	  bacterial	  cell	  Escherichia	  coli	  for	  45	  minutes	  on	  wet	  ice.	  Bacteria/DNA	  solutions	  
were	   then	   heat-­‐shocked	   by	   incubation	   at	   42°C	   for	   one	   minute	   followed	   by	  
incubation	  on	  wet	  ice	  for	  1	  minute.	  1ml	  of	  LB	  broth	  growth	  medium	  was	  then	  added	  
under	  a	  sterile	  environment	  and	  further	  incubated	  for	  45	  minutes	  at	  37°C.	  100-­‐200µl	  
of	   solution	   was	   then	   transferred	   under	   sterile	   conditions	   to	   a	   10cm	   Petri	   dish	  
containing	  LB	  agar	  with	  50µg/ml	  of	  the	  antibiotic	  ampicillin	  and	  spread	  using	  a	  glass	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2.1.6.	  Detection	  of	  recombinant	  clones	  in	  bacterial	  colonies	  
Following	   transformation	   of	   ligated	  DNA,	   bacterial	   colonies	  were	   screened	   for	   the	  
presence	  of	  supercoiled	  plasmids	  using	  the	  MICROPREP	  method	  (Sekar	  et	  al.,	  1987).	  
Agarose	  gel	  electrophoresis	  (See	  2.1.2)	  was	  performed	  using	  0.8%	  agarose	  dissolved	  
in	  Tris-­‐acetate-­‐EDTA	  (TAE)	  buffer	  (40mM	  Tris-­‐acetate;	  1mM	  EDTA)	  containing	  0.05%	  
SDS.	  	  
	   Bacterial	  colonies	  were	  picked	  from	  agar	  plates	  using	  a	  sterile	  p20	  pipette-­‐tip	  
and	   gently	   vortexed	   into	   6µl	   of	   protoplaster	   buffer	   (30mM	   Tris.Cl,	   pH	   8;	   5mM	  
Na2EDTA;	  50mM	  NaCl;	  20%	  sucrose)	  containing	  50µg/ml	  RNase	  A	  (Sigma-­‐Aldrich,	  St.	  
Louis,	  MO,	  USA)	  and	  50µg/ml	  lysozyme	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  USA)	  After	  10	  
minutes	   of	   incubation,	   5µl	   of	   each	   cell/protoplaster	   buffer	   suspension	  was	   added	  
directly	  to	  agarose	  gel	  wells	  containing	  3µls	  of	  lysis	  solution	  (TAE	  buffer;	  2%	  SDS;	  5%	  
sucrose;	  20%	  bromophenol	  blue).	  Circular/supercoiled	  vector	  DNA	  prepared	   in	   the	  
same	  manner	  was	  used	  as	  a	  negative	  control.	  
	   Samples	  were	  electrophoresed	  in	  TAE	  buffer	  at	  40v	  for	  15	  minutes	  followed	  
by	   100v	   for	   2	   hours,	   stained	   with	   ethidium	   bromide,	   and	   then	   photographed.	  
Recombinant	   clones	  were	   judged	   on	   the	   basis	   of	   an	   increased	   size	   of	   supercoiled	  
DNA	  when	  compared	  with	  vector	  alone.	  	  
	  
2.1.7.	  Polymerase	  chain	  reaction	  (PCR)	  
Polymerase	  chain	   reaction	   (PCR)	  was	  used	   to	  generate	  DNA	   fragments	   for	  plasmid	  
insertion	  as	  previously	  described	  (Saiki	  et	  al.,	  1988).	  Briefly	  37.75µl	  of	  distilled	  water	  
(Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  USA)	  was	  combined	  with	  5µl	  of	  10x	  PfuUltra	  II	  reaction	  
buffer	  (Stratagene,	  La	  Jolla,	  CA,	  USA),	  25mM	  deoxynucleotide	  triphosphates	  (dNTPs),	  
0.025nmol	  of	  two	  oligonucleotide	  primers	  and	  2ng	  of	  plasmid	  DNA.	  Oligonucleotide	  
primers	  were	  diluted	  in	  distilled	  water	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  USA)	  at	  a	  stock	  
concentration	   of	   1nmol/µl.	   Specific	   primer	   information	   can	   be	   found	   in	   table	   2.1.	  
PCR	  was	  run	  using	  a	  PTC-­‐200	  Peltier	  thermal	  cycler	  machine	  (MJ	  Research,	  Waltham,	  
MA,	   USA)	   with	   the	   following	   cycle:	   a)	   95°C	   for	   5	   minutes,	   b)	   85°C	   hold,	   c)	   1U	   of	  
PfuUltra	   II	   Fusion	   HS	   DNA	   polymerase	   (Stratagene,	   La	   Jolla,	   CA,	   USA)	   was	   added	  
along	  with	  1	  drop	  of	  mineral	   oil	   (Sigma-­‐Aldrich,	   St.	   Louis,	  MO,	  USA),	   d)	   95°C	   for	   1	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minute,	   e)	   55°C	   for	   1	   minute,	   f)	   72°C	   for	   one	   to	   four	   minutes;	   repeat	   d-­‐f	   for	   28	  
cycles.	  	  
	  
No	   Oligo	  
name	  






1	   Ptprdfl1	   AACTGGTCTACAAAGATGGGGAGCATGGAC	   68.1	   50%	   9369	  
2	   Ptprdfl1	   TCAAGTTGTCATTTGCTTTCAATCCTCTTTCAATGTG	   63.4	   32.4%	   10378	  
3	   Ptprdfl3	   GGTTTGTTTACTTCCAAGTTGAATGTTCCCAAG	   65.9	   38.2%	   10428	  
4	   FLbg1-­‐1	   GCCGTGTCCCACCAAGATTGTGTATCC	   86	   55.6%	   8131	  
5	   FLbg1-­‐2	   AATGGTCGTATTAAGCAGTTACGATCAGAATCTATTGG	   67.3	   36.8%	   11755	  
6	   HatagF	   CTAGGTATCCCTACGATGTACCCGAGTAGCCTGACTCGAGT	   >75	   54.8%	   12890	  
7	   HatagR	   CTAGACTCGAGTCAGCGAGTCGGGTACATCGTAGGGATAC	   >75	   54.8%	   13099	  
	  
Table	  2.1.	  Summary	  of	  oligonucleotide	  primers	  used	  as	  templates	  for	  PCR	  reactions.	  MW	  =	  
molecular	  weight;	  Tm	  =	  Melting	  temperature	  
	  
2.1.8.	  Extraction	  of	  RNA	  using	  RNeasy	  mini	  kit	  	  
Genomic	  RNA	  was	  purified	  from	  cultured	  cells	  using	  an	  RNeasy	  mini	  kit	  (Quiagen	  Inc,	  
Valencia,	   CA,	  USA).	  One	   to	   three	  million	   cells	  were	   trypsinised	  using	   trypsin-­‐EDTA,	  
and	   rinsed	   in	  PBS	  on	   ice.	  Cells	  were	  centrifuged	  at	  1000	  RPM	  for	  5	  minutes	  at	  RT,	  
resuspended	  in	  350µl	  of	  buffer	  RLT	  containing	  freshly	  added	  1%	  β-­‐mercaptoethanol,	  
then	   homogenized	   by	   passing	   through	   a	   22-­‐gauge	   needle	   fitted	   to	   an	   RNase-­‐free	  
syringe	  5-­‐10	  times.	  	  
	   Following	  homogenization,	  1	   volume	  of	  70%	  ethanol	  was	  added	  and	  mixed	  
by	  pipetting,	  transferred	  to	  an	  RNeasy	  spin	  column	  placed	  in	  a	  2ml	  collection	  tube,	  
and	   centrifuged	   for	   15	   seconds	   at	   12,000	  RPM.	  After	   discarding	   the	   flow-­‐through,	  
700µl	  of	  buffer	  RW1	  was	  added	  to	  the	  column	  and	  re-­‐centrifuged,	  followed	  by	  500µl	  
of	   buffer	   RPE	   and	   further	   centrifugation	   for	   2	   minutes	   at	   12,000	   RPM.	   The	   spin	  
column	  was	   placed	   in	   a	   1.5ml	   collection	   tube,	   and	   30µl	   of	   RNase-­‐free	   water	   was	  
added	   to	   the	   centre	   of	   the	  membrane.	   RNA	  was	   then	   eluted	   by	   centrifugation	   at	  
12,000	  RPM	  for	  1	  minute.	  
	   The	   concentration	   of	   RNA	   was	   then	   determined	   by	   reading	   absorbance	   at	  
260nm	   using	   a	   NanoDrop®	   ND-­‐1000	   spectrophotometer	   (NanoDrop,	   Wilmington,	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DE,	  USA)	  where	  quality	  was	  judged	  by	  the	  260nm:	  280nm	  and	  260nm:	  230nm	  ratios.	  
Additional	   quality	   control	   measures	   were	   undertaken	   by	   the	   bioanalysis	   service	  
provided	  by	  UCL	  genomics	  (UCL,	  London,	  UK).	  	  
	  
2.1.9.	  Generation	  of	  cDNA	  and	  real	  time	  quantitative	  PCR	  analysis	  
All	   reactions	   were	   carried	   out	   by	   Dr.	   Fanny	   Schmidt	   (Merck	   Serono,	   Geneva,	  
Switzerland),	  according	  to	  the	  following	  method.	  1µg	  of	  RNA	  was	  used	  as	  a	  template	  
for	   reverse	   transcription	   using	   the	   qscript	   cDNA	   synthesis	   kit	   (Quanta	   Biosciences	  
Inc,	   Gaithersburg,	   MD,	   USA),	   containing	   a	   master-­‐mixture	   of	   oligo(dT)20,	   reverse	  
transcriptase	   Superscript	   III	   and	   random	   primers	   (Invitrogen,	   Carlsbad,	   CA,	   USA).	  
RNA	  was	  then	  cycled	  for	  1)	  5	  minutes	  at	  25°C,	  2)	  30-­‐minutes	  at	  42°C,	  3)	  5	  minutes	  at	  
85°C	  and	  5)	  10°C	  ad	  infinitum.	  
2.5µl	  of	  cDNA	  diluted	  100	  fold	  was	  then	  added	  to	  a	  mixture	  of	  2.5µl	  of	  pre-­‐
mixed	  primer	  pairs	  and	  5µl	  of	  SYBR	  Green	  PCR	  master	  mix	  (Quantifast,	  Quiagen	  Inc,	  
Valencia,	  CA,	  USA)	  in	  384-­‐well	  plate.	  Each	  reaction	  was	  run	  in	  triplicate	  in	  a	  7900HT	  
Fast	  real-­‐time	  PCR	  system	  (Applied	  Biosystems,	  Carlsbad,	  CA,	  USA)	  with	  the	  cycling	  
protocol	   1)	   2	   minutes	   at	   50°C,	   2)	   10	   minutes	   at	   95°C,	   3)	   1	   minute	   at	   60°C.	  
Dissociation	   curves	   were	   prepared	   following	   each	   qPCR	   run	   to	   determine	   primer	  
specificity.	   Relative	   mRNA	   levels	   were	   determined	   by	   expressing	   as	   a	   percentage	  
expression	   versus	   four	   housekeeping	   genes	   (HKGs).	   Briefly	   cross	   point	   values	   (Ct)	  
obtained	   for	  each	  sample	  were	  normalized	   to	   the	  average	  of	   four	   reference	  genes	  
Actin,	   Canx,	   Psmb3	   and	  Hbms	  using	   the	   equation	   2-­‐ΔCt,	  where	   ΔCt	   =	   Ct	   (sample)	   –	  
Mean	  Ct	  (reference	  genes).	  	  
	  
2.1.10.	  DNA	  Sequencing	  
During	   plasmid	   construction	   gene	   inserts	   were	   verified	   using	   Sanger	   sequencing.	  
Briefly	  high	  quality	  DNA	  was	  purified	  (see	  2.1.1)	  and	  resuspended	  in	  distilled	  H20	  at	  a	  
concentration	   of	   100ng/µl.	   	   Primers	   (see	   table	   2.1)	   were	   diluted	   at	   2-­‐5pmoles/µl.	  
Sequencing	  was	   carried	   out	   through	   the	   DNA	   sequencing	   service	   provided	   by	   the	  
Wolfson	  Institute	  for	  Biomedical	  Research	  (University	  College	  London,	  London,	  UK).	  
Sequences	   were	   visualized	   using	   4Peaks	   software	   (MEKentosj,	   Amsterdam,	   The	  
Netherlands).	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2.1.11.	  Plasmid	  expression	  vectors	  
For	  construction	  of	  plasmids	  expressing	  the	  ptprd	  gene,	  a	  pCH	  vector	  backbone	  was	  
used	   containing	   the	   compound	   CAG	   promoter,	   a	   combination	   of	   the	  
cytomelagovirus	   (CMV)	  early	   enhancer	  element	   and	   the	   chick	  beta-­‐actin	  promoter	  
that	  drives	  high	  gene	  expression	  levels	  (Niwa	  et	  al.,	  1991).	  	  
	   For	   overexpression	   of	   Src,	   the	   pSLX	   vector	   backbone	   containing	   a	   CMV	  
promoter	   was	   used	   expressing	   either	   a	   wild	   type	  murine	   c-­‐Src	   gene,	   or	   a	  mutant	  
version	   in	   which	   the	   inhibitory	   tyrosine	   at	   site	   529	   has	   been	   replaced	   by	  
phenylalanine	  (Y529F)	  causing	  the	  enzyme	  to	  be	  constitutively	  active	  (den	  Hertog	  et	  
al.,	   1994).	   Both	   plasmids	   were	   a	   kind	   gift	   of	   Prof.	   Jeroen	   Den	   Hertog	   (Hubrecht	  
Institute,	  Utrecht,	  The	  Netherlands).	  	  
	   For	  overexpression	  of	  Akt,	   two	  plasmids	  were	  used.	  Firstly	  a	  pCMV5	  vector	  
backbone	  expressing	  a	  HA-­‐tagged	  mutant	  version	  of	  the	  murine	  Akt1	  gene	  under	  the	  
control	  of	  the	  CMV	  promoter,	  in	  which	  the	  lysine	  of	  the	  ATP-­‐binding	  site	  at	  position	  
179	  is	  replaced	  by	  a	  methionine	  (K179M)	  causing	  loss	  of	  kinase	  activity	  was	  used	  as	  a	  
dominant	  negative	  to	  attenuate	  the	  function	  of	  wild-­‐type	  Akt	  (Franke	  et	  al.,	  1995).	  
For	   expression	   of	   a	   constitutively	   active	   form	   of	   the	   Akt	   protein,	   a	   pECE	   vector	  
backbone	   expressing	   containing	   the	   Simian	   vacuolating	   virus	   40	   (SV40)	   promoter	  
was	   used	   to	   express	   the	   murine	   Akt1	   gene	   containing	   a	   14	   amino	   acid	   src	  
myristoylation	  signal	  sequence	  (Cross	  et	  al.,	  1984)	  fused	  to	  the	  N	  terminus	  of	  Akt	  Δ4-­‐
129,	  which	  lacks	  a	  pH	  domain,	  causing	  constitutive	  activation	  of	  Akt	  via	  its	  targeting	  
to	  the	  membrane	  (Kohn	  et	  al.,	  1996).	  	  
	   For	  detection	  of	  autophagy,	  a	  plasmid	  encoding	  enhanced	  green	  fluorescent	  
protein	   (GFP)	   fused	   to	   microtubule-­‐associated	   protein	   1A/1B-­‐light	   chain	   3	   (LC3-­‐I)	  
was	   transfected	   into	   cells	   prior	   to	   drug	   treatment.	   LC3-­‐I	   is	   a	   cytoplasmic	   protein	  
expressed	  in	  a	  diffuse	  manner	  in	  healthy	  cells	  that	  is	  cleaved	  and	  processed	  to	  form	  
LC3-­‐II,	  which	  is	  recruited	  to	  autophagosomal	  membranes	  during	  autophagy	  forming	  
a	  punctate	  distribution	  of	  GFP	   that	   specifically	  marks	  autophagosomes	   (Mizushima	  
et	   al.,	   2010).	   For	   monitoring	   of	   transfection	   efficiency,	   a	   plasmid	   was	   used	   that	  
expresses	  enhanced-­‐GFP	  under	   the	   control	  of	   the	   chick	  beta-­‐actin	  promoter	   (CAβ-­‐
GFP)	  (Niwa	  et	  al.,	  1991).	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2.2.	  Cell	  and	  protein	  methods	  
2.2.1.	  Propidium	  iodide	  staining	  for	  DNA	  content	  
DNA	  content	  was	  used	  to	  assess	  both	  cell-­‐cycle	  distribution	  and	  DNA	  fragmentation	  
indicative	  of	  programmed	  cell	  death	  (PCD)	  as	  described	  (Ormerod,	  2002).	  5x104	  Cells	  
were	  plated	  onto	  35mm	  multiwell	  plates.	  Following	  6	  days	  of	  treatment,	  cells	  were	  
trypsinised	  and	  fixed	   in	  1ml	   ice-­‐cold	  70%	  ethanol	  for	  30	  minutes	  on	   ice.	  Cells	  were	  
rinsed	   twice	   in	   phosphate-­‐citrate	   buffer	   (0.2M	   Na2HPO4/0.1M	   citric	   acid)	   by	  
centrifugation	   at	   2000	   rpm,	   and	   resuspended	   in	   200µl	   propidium	   iodide	   solution	  
(50µg/ml	   in	   PBS;	   Sigma-­‐Aldrich,	   St.	   Louis,	   MO,	   USA)	   and	   50	   µl	   RNaseA	   (Sigma-­‐
Aldrich,	   St.	   Louis,	   MO,	   USA)	   solution	   (100µg/ml	   in	   water).	   Cells	   were	   then	  
transferred	   to	   polypropylene	   FACS	   tubes	   and	   subjected	   to	   flow	   cytometry	   using	   a	  
BDTM	   LSRII	   flow	   cytometer	   system	   (Beckman-­‐Dickson	   Biosciences,	   San	   Diego,	   CA,	  
USA).	  A	  maximum	  of	  10,000	  events	  were	  collected	  per	  sample	  at	  a	  speed	  of	  between	  
100-­‐1000	  events/second	  depending	  on	   the	   total	  number	  of	  cells.	   Light	   scatter	  was	  
used	  to	  determine	  the	  cell	  population	  for	  collection/exclude	  cell	  debris	  based	  on	  size	  
(forward-­‐scatter)	  and	  complexity/shape	  (side	  scatter)	  (figure	  2.1).	  	  
	  
Figure	  2.1.	  Gating	  of	  whole	  cells	  during	  flow	  cytometry.	  Histogram	  based	  on	  forward	  and	  
side	  light	  scatter.	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Data	  was	  analysed	  using	  Flo-­‐jo	  V8	  software	  (Tree	  Star	  Inc,	  Ashland,	  OR,	  USA).	  Single	  
cells	   (singlets)	  were	   judged	  based	  on	  a	  histogram	  plotting	  area	  against	  height,	  and	  
gated	  manually,	   excluding	   cell	   debris	   (figure	   2.2).	   Sub-­‐G1,	   G1,	   S	   and	   G2/M	   phase	  
gates	   were	   applied	   to	   a	   histogram	   of	   DNA	   content	   and	   distribution	   peaks	  
determining	   the	   percentage	   of	   cells	   in	   each	   phase	   of	   the	   cell	   cycle	   were	   judged	  
manually	   (figure	   2.3).	   Sub-­‐G1	   peaks	   were	   removed	   from	   the	   analysis	   when	  
examining	   cell	   cycle	   distribution,	   but	   included	   when	   examining	   cell	   viability	   as	   a	  
marker	   of	   DNA	   fragmentation	   that	   follows	   PCD.	   Independent	   samples,	   two-­‐tailed	  
student’s	   t-­‐tests	   were	   computed	   on	   the	   means	   of	   at	   least	   3	   independent	  
experiments.	  
	  
Figure	  2.2.	  Gating	  of	   single	   cells	  during	   flow	  cytometry.	  Histogram	  based	  on	  area	   (y)	   and	  
height	  (x)	  of	  signal.	  
	  
2.2.2.	  Propagation	  of	  cells	  
Cells	  were	  maintained	  in	  a	  humidified	  incubator	  with	  5%	  CO2.	  Cells	  were	  cultured	  in	  
different	  formulations	  of	  growth	  medium,	  depending	  on	  recommendations	  from	  the	  
cell	   line	   supplier.	   All	   formulations	   of	   medium	   were	   supplemented	   with	   10%	   (v/v)	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heat-­‐inactivated	   fetal-­‐bovine	   serum	   (FBS)	   (PAA,	   Pasching,	   Austria)	   and	   100	   U/ml	  






Figure	   2.3.	   Cell	   cycle	   distribution.	   (A)	   Gating	   of	   cell	   cycle	   distribution	   peaks	   based	   on	  
histogram	  of	  PI	  signal	  area,	  an	  analogue	  of	  cell	  cycle	  phase	  based	  on	  DNA	  content	  (B).	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Dulbecco’s	  modified	   Eagle’s	  Medium	   (DMEM)	   (Gibco,	   Grand	   Island,	   NY,	   USA)	   was	  
used	   for	   the	   culture	   of	   HEK-­‐293T,	  U118,	   Res259	   and	   T98G	   cells.	   Eagle’s	  Minimum	  
Essential	  Medium	  (MEM)	  (Gibco,	  Grand	  Island,	  NY,	  USA)	  was	  supplemented	  with	  the	  
essential	   amino	  acid	  2mM	  L-­‐glutamine	   (Invitrogen,	  Carlsbad,	  CA,	  USA)	  dissolved	   in	  
MilliQ	  distilled	  H20	  (Millipore,	  Billerica,	  MA,	  USA),	  and	  used	  for	  the	  culture	  of	  SK-­‐N-­‐
SH,	   SH-­‐SY5Y	   and	   PC63	   cells.	   Roswell	   Park	  Memorial	   Institute	   (RPMI)	   1640	   (Gibco,	  
Grand	   Island,	   NY,	   USA)	   was	   supplemented	   with	   the	   buffering	   agent	   4-­‐(2-­‐
hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	  acid	  (HEPES)	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  
USA))	  at	  a	  concentration	  of	  25mM	  and	  used	  for	  the	  culture	  of	  SK-­‐N-­‐AS,	  LAN-­‐5,	  SK-­‐N-­‐
DZ,	  SMS-­‐KCN,	  SMS-­‐KCNR,	  IMR-­‐32	  and	  Kelly	  cells.	  An	  additional	  formulation	  of	  RPMI	  
1640	   was	   supplemented	   with	   20%	   (v/v)	   FBS,	   0.000007%	   (v/v)	   β	   mercaptoethanol	  
(Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  USA).	  1%	  non-­‐essential	  amino	  acids	  (Sigma-­‐Aldrich,	  St.	  
Louis,	  MO,	  USA)	  and	  the	  buffering	  agent	  sodium-­‐pyruvate	  (Sigma-­‐Aldrich,	  St.	  Louis,	  
MO,	  USA)	  at	  a	  concentration	  of	  10mM	  and	  used	  for	  the	  culture	  of	  IPhNB1	  cells.	  All	  
medium	  was	  replaced	  every	  3-­‐5	  days.	  
All	   cell	   lines	   were	   grown	   as	   adherent	   monolayers,	   and	   passaged	   at	   sub-­‐
confluency.	   Prior	   to	   Passaging,	   cells	   were	   briefly	   rinsed	   with	   37oC	   phosphate-­‐
buffered	   saline	   (PBS)	   to	   remove	   all	   traces	   of	  medium.	   Cells	  were	   then	   trypsinised	  
using	  37oC	  trypsin-­‐EDTA	  solution	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  USA)	  for	  five	  to	  ten	  
minutes	   in	   a	   humidified	   incubator	   at	   37oC.	   Cells	   were	   then	   resuspended	   in	   37oC	  
medium	   and	   centrifuged	   at	   1000	   RPM	   for	   5	   minutes.	   Medium	   containing	   trypsin	  
solution	  was	  aspirated	  and	  cells	  were	  resuspended	  in	  fresh	  medium	  then	  seeded	  at	  
low	  density	  on	  vented	  tissue	  culture	  flasks	  (TPP,	  Trasadingen,	  Switzerland).	  	  
	  
2.2.3.	  Control	  cell	  line	  information	  
The	  following	  non-­‐NBL	  cell	  lines	  were	  used	  for	  the	  purpose	  of	  either	  optimisation,	  or	  
as	   positive/negative	   controls,	  when	   compared	   to	  NBL	   cell	   lines.	   For	   details	   of	  NBL	  
cell	  line	  properties	  see	  below.	  	  
	  
HEK	  293-­‐T	  
The	  human	  embryonic-­‐kidney	  293T	  (HEK	  293T)	  line	  was	  used	  as	  a	  positive	  control	  for	  
the	   transfection	   of	   foreign	   DNA	   into	   cells.	   The	   HEK-­‐293	   cell	   line	   was	   generated	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through	  the	  exposure	  of	  human	  embryonic-­‐kidney	  cells	  to	  sheared	  fragments	  of	  the	  
human	  adenovirus	   type	  5,	   causing	   transformation	  and	   immortalization	   (Graham	  et	  
al.,	   1977).	   	   The	  HEK-­‐293T	  variant	  was	  generated	   through	   the	  addition	  of	   the	   SV40	  
large	   T	   antigen,	   allowing	   episomal	   replication	   of	   foreign	   plasmids	   containing	   the	  
SV40	  origin	  of	   replication	  and	   thus	  amplification	  of	  gene	  expression	   (Mellon	  et	  al.,	  
1981).	   HEK-­‐293T	   cells	   were	   also	   used	   to	   test	   for	   cytotoxic	   specificity	   of	   chemical	  
compounds	  given	  their	  similarity	  with	  immature	  neuronal	  cells	  (Shaw	  et	  al.,	  2002).	  	  
	  
PC63	  
The	  PC63	  cell	  line	  (provided	  by	  Dr	  John	  Ham,	  ICH,	  London,	  UK)	  is	  a	  sub-­‐clone	  of	  the	  
PC12	   cell	   line,	   which	  was	   originally	   derived	   from	   a	   pheochromocytoma	   of	   the	   rat	  
adrenal	   medulla.	   These	   cells	   differentiate	   into	   post-­‐mitotic	   neurons	   following	  
treatment	  with	  nerve-­‐growth	  factor	  (NGF),	  and	  subsequently	  become	  dependent	  on	  
NGF	   for	   their	   survival	   (Obermeier	   et	   al.,	   1994).	   Thus	   these	   cells	  were	  used	   to	   test	  




The	   T98G	   cell	   line	   was	   derived	   from	   a	   human	  malignant	   glioblastoma-­‐multiforme	  
and	  was	  used	  as	  a	  positive	  control	  for	  the	  suppression	  of	  colony	  formation	  by	  PTPRD	  
(Veeriah	   et	   al.,	   2009).	   T98G	   cells	   were	   also	   used	   to	   test	   for	   cytotoxic	   specificity.	  
Obtained	  from	  Human	  Protection	  Agency,	  UK.	  
	  
COS7	  
COS7	  is	  a	  form	  of	  the	  COS	  cell	  line,	  which	  was	  generated	  through	  immortalization	  of	  
the	   CV-­‐1	   cell	   line	   derived	   from	   kidney	   cells	   of	   the	  monkey	  with	   the	   SV40	   Large	   T	  
antigen	   (Gluzman,	  1981)	  and	  were	  used	   to	   test	   for	  cytotoxic	   specificity.	  Cells	  were	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U118	  MG	  
The	  U118	  MG	  (U118)	  cell	   line	   (provided	  by	  Dr	  Stephen	  Hart,	   ICH,	  London,	  UK)	  was	  




The	   U251	   MG	   (U251)	   cell	   line	   (provided	   by	   Dr.	   Jenni	   Jayalapan,	   Queen	   Mary	  
University	  of	  London,	  London,	  UK)	  was	  derived	  from	  a	  malignant	  glioma	  of	  a	  human	  
adult	  and	  was	  used	  as	  a	  positive	  control	  for	  the	  suppression	  of	  colony	  formation	  by	  
PTPRD	  (Veeriah	  et	  al.,	  2009).	  	  
	  
Mouse	  embryonic	  fibroblasts	  (MEFs)	  
Mouse	  embryonic	   fibroblasts	  were	  obtained	   from	  wild-­‐type	  CD-­‐1	  mouse	   embryos,	  
(provided	  by	  Dr.	  Sandra	  Castro,	   ICH,	  London,	  UK)	  at	  16	  days	  post	  fertilisation	  (dpf).	  
Briefly	   embryos	   were	   dissected	   in	   PBS	   to	   remove	   organs	   and	   skin	   tissue	   was	  
homogenised	  using	  a	  sterile	  razor	  blade.	  Cells	  were	  then	  dissociated	  in	  trypsin-­‐EDTA	  
for	  20	  minutes	  at	  37°C	  and	  centrifuged	  at	  1000	  RPM	  for	  5	  minutes.	  Dissociated	  cells	  
were	   then	   resuspended	   in	   culture	  medium.	  MEFs	   were	   used	   to	   test	   for	   cytotoxic	  
specificity.	  	  
	  
2.2.4.	  Chemical	  treatment	  of	  cells	  
The	   following	   chemicals	   were	   prepared	   and	   applied	   to	   cell	   culture	   medium	   as	  
follows.	  	  
	  
1. Retinoic	   acid	   (C20H2202)	   (Sigma-­‐Aldrich,	   St.	   Louis,	   MO,	   USA)	   was	   diluted	   to	  
10mM	   in	   ethanol	   and	   added	   directly	   to	   cell	   culture	   medium	   at	   a	   final	  
concentration	  of	  5µM.	  	  
2. Sodium	   orthovanadate	   (Na2VO4)	   (Sigma-­‐Aldrich,	   St.	   Louis,	   MO,	   USA)	   was	  
added	  directly	  to	  cell	  culture	  medium	  from	  100mM	  stock	  solution	  at	  a	   final	  
concentration	  of	  5µM.	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3. Bis(maltolato)oxovanadium(IV)	  (BMOV)	  (C12H10O7V)	  (Sigma-­‐Aldrich,	  St.	  Louis,	  
MO,	   USA)	   	  was	   diluted	   to	   10mM	   in	   distilled	   H20	   and	   added	   to	   cell	   culture	  
medium	  at	  a	  final	  concentration	  of	  10µM	  to	  20µM.	  	  
4. VO-­‐OH	   Pic	   trihydrate	   (C12H8N2O7V3H2O)	   (Sigma-­‐Aldrich,	   St.	   Louis,	  MO,	  USA)	  
was	  diluted	   to	  10mM	  in	  DMSO	  and	  added	  to	  cell	   culture	  medium	  at	  a	   final	  
concentration	  of	  0.5-­‐5µM.	  	  
5. Nerve	   growth	   factor	   (NGF)	   (Promega,	   Fitchburg,	   WI,	   USA)	   was	   diluted	   to	  
1mg/ml	   in	  distilled	  H20	  and	  added	  directly	   to	  cell	   culture	  medium	  at	  a	   final	  
concentration	  of	  1µg/ml.	  
6. Propidium	  iodide	  (C27H34I2N4)(Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  USA)	  was	  diluted	  
to	   50mg/ml	   in	   PBS,	   and	   added	   directly	   to	   cell	   culture	   medium	   at	   a	   final	  
concentration	  of	  5µg/ml.	  
7. NSC-­‐87877	   (C19H13N3O7S2)	   (Santa	   Cruz	   Biotechnology,	   Santa	   Cruz,	   CA,	   USA)	  
was	   diluted	   to	   10mM	   in	   distilled	   H20	   and	   added	   directly	   to	   cell	   culture	  
medium	  at	  a	  final	  concentration	  range	  of	  50-­‐100µM.	  
8. Sodium	   etidronate	   (C2H6Na2O7P2)	   (Sigma-­‐Aldrich,	   St.	   Louis,	   MO,	   USA)	   was	  
diluted	  to	  100mM	  in	  distilled	  H2O	  and	  added	  directly	  to	  cell	  culture	  medium	  
at	  a	  final	  concentration	  of	  100µM.	  	  
9. Phenylarsine	  oxide	  (PAO)	  (C6H5AsO)	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  USA)	  was	  
diluted	   to	   10mM	   in	   DMSO	   and	   added	   to	   cell	   culture	   medium	   at	   a	   final	  
concentration	  range	  of	  0.1-­‐0.3µM.	  	  
10. 3-­‐4	  Dephostatin	  (C7H8N2O3)	  (Sigma-­‐Aldrich,	  St.Louis,	  MO,	  USA)	  was	  diluted	  to	  
10mM	  in	  DMSO	  and	  added	  to	  cell	  culture	  medium	  at	  a	  final	  concentration	  of	  
5µM.	  	  
11. U0126	  (C18H16N6S2)	  (Cell	  Signalling	  Technologies	  Inc,	  Danvers,	  MA,	  USA)	  was	  
diluted	   to	   10mM	   in	   DMSO	   and	   added	   to	   cell	   culture	   medium	   at	   a	   final	  
concentration	  range	  of	  1-­‐20µM.	  
12. LY294002	   (C	   19H17NO3)	   (Cell	   Signalling	   Technologies	   Inc,	   Danvers,	  MA,	  USA)	  
was	  diluted	   to	  10mM	  in	  DMSO	  and	  added	  to	  cell	   culture	  medium	  at	  a	   final	  
concentration	  range	  of	  1-­‐20µM.	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13. Rapamycin	  (C51H79NO13)	  (a	  kind	  gift	  of	  Dr.	  Thomas	  Jacques,	  ICH,	  London,	  UK)	  
was	  diluted	  to	  200µM	  in	  DMSO	  and	  added	  to	  cell	  culture	  medium	  at	  a	  final	  
concentration	  range	  of	  100-­‐200nM.	  	  
14. PI-­‐103	   (C19H16N403)	   (Cayman	   Chemical,	   Ann	  Arbor,	  MI,	   USA)	  was	   diluted	   to	  
1mM	   in	   DMSO	   and	   added	   to	   cell	   culture	  medium	   at	   a	   final	   concentration	  
range	  of	  0.5-­‐1µM.	  	  
15. PP2	   (C15H16CIN5)	   (Calbiochem,	   La	   Jolla,	   CA,	   USA)	   was	   diluted	   to	   10mM	   in	  
DMSO	  and	  added	  to	  cell	  culture	  medium	  at	  a	  final	  concentration	  of	  10µM.	  	  
16. PP3	  (C11H9N5)	  (Calbiochem,	  La	  Jolla,	  CA,	  USA)	  was	  diluted	  to	  10mM	  in	  DMSO	  
and	  added	  to	  cell	  culture	  medium	  at	  a	  final	  concentration	  of	  10µM.	  
17. N-­‐Acetyl-­‐L-­‐cysteine	  (NAC)	  (C5H9NO3S)	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  USA)	  was	  
diluted	   to	   1M	   in	   distilled	   H2O	   and	   pH	   adjusted	   to	   pH7.4	   using	   sodium	  
hydroxide	  then	  added	  to	  cell	  culture	  medium	  at	  a	  final	  concentration	  range	  
of	  0.1-­‐2.5mM.	  	  
18. Buthionine	   sulfoximine	   (BSO)	   (C8H18N2O3S)	   (Sigma-­‐Aldrich,	   St.	   Louis,	   MO,	  
USA)	  was	  diluted	  to	  10mM	  in	  distilled	  H2O	  and	  added	  to	  cell	  culture	  medium	  
at	  a	  final	  concentration	  of	  10µM.	  	  
19. Hygromycin	   B	   (C20H37N3O13)	   (PAA,	   Pasching,	   Austria)	   was	   diluted	   to	  
200mg/ml	   in	   distilled	   H2O	   and	   added	   to	   cell	   culture	   medium	   at	   a	   final	  
concentration	  of	  200µg/ml.	  	  
20. G418	   (C20H40N4O10)	   (Sigma-­‐Aldrich,	   St.	   Louis,	   MO,	   USA)	   was	   diluted	   to	  
500mg/ml	   in	   distilled	   H20	   and	   added	   to	   cell	   culture	   medium	   at	   a	   final	  
concentration	  of	  500µg/ml.	  	  
	  
2.2.5.	  Antibodies	  
A	   number	   of	   antibodies	   were	   used	   for	   the	   detection	   of	   antigens	   during	  
immunocytochemistry	  and	  immunoblotting.	  Table	  1	  contains	  a	  summary	  of	  primary	  
antibodies	  and	   table	  2	  contains	  a	   summary	  of	   secondary	  antibodies.	  All	  antibodies	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Antigen/size	   Host	  Species	   Clone	   Clonality	   Supplier	  
HA-­‐Peroxidase	  conjugated	   Rat	   BMG-­‐3F10	   Monoclonal	   Roche	  Applied	  
Science	  
B-­‐Actin	   Mouse	   AC-­‐74	   Monoclonal	   Sigma-­‐Aldrich	  
βIII-­‐Tubulin	   Mouse	   TU-­‐20	   Monoclonal	   Chemicon	  
PTPδ	   Goat	   C-­‐18	   Polyclonal	   Santa	  Cruz	  
Biotechnology	  
HA	   Rabbit	   -­‐	   Polyclonal	   Abcam	  
Trk	   Rabbit	   C-­‐14	   Polyclonal	   Santa	  Cruz	  
Biotechnology	  
Ki67	   Rabbit	   NCL	   Polyclonal	   Novo	  
Castra	  
Stat3	   Mouse	   124H6	   Monoclonal	   Cell	  Signalling	  
Technologies	  
Phospho-­‐Stat3(Tyr705)	   Mouse	   M9C6	   Monoclonal	   Cell	  Signalling	  
Technologies	  
P44/42	  MAPK	  (Erk1/2)	   Rabbit	   -­‐	   Polyclonal	   Cell	  Signalling	  
Technologies	  
p38	  MAPK	   Rabbit	   -­‐	   Polyclonal	   Cell	  Signalling	  
Technologies	  




Rabbit	   -­‐	   Polyclonal	   Cell	  Signalling	  
Technologies	  




Rabbit	   -­‐	   Polyclonal	   Cell	  Signalling	  
Technologies	  




Rabbit	   236B4	   Monoclonal	   Cell	  Signalling	  
Technologies	  




Mouse	   E10	   Monoclonal	   Cell	  Signalling	  
Technologies	  
FAK	   Mouse	   77/FAK	   Monoclonal	   BD	  biosciences	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Phospho-­‐FAK	  (Tyr379	   Mouse	   14/FAK(Y397)	   Monoclonal	   BD	  biosciences	  
PTEN	   Rabbit	   -­‐	   Polyclonal	   Millipore	  
p53	   Rabbit	   Sc-­‐6243	   Polyclonal	   Santa	  Cruz	  
Biotechnology	  
Phosphotyrosine	   Mouse	   4G10	   Polyclonal	   Millipore	  
Table	  2.2.	  List	  of	  primary	  antibodies.	  Antibody	  clone	  is	  stated	  where	  given.	  	  
Santa	   Cruz	   Biotechnology	   (Santa	   Cruz,	   CA,	   USA);	  Millipore	   (Bedford,	  MA,	   USA);	   Beckman-­‐
Dickson	  (BD)	  Biosciences	  (San	  Diego,	  CA,	  USA);	  Cell	  Signalling	  Technologies	  Inc	  (Danvers,	  MA,	  
USA);	   Roche	   Applied	   Science	   (Mannheim,	   Germany);	   Sigma-­‐Aldrich	   (St.Louis,	   MO,	   USA);	  
Chemicon	  (Millipore,	  Bedford,	  MA,	  USA);	  Abcam	  (Cambridge,	  UK);	  Novo	  Castra	  (Newcastle,	  
UK).	  	  
	  
Antigen	   Host	  Species	   Supplier	  
Rabbit	  immunoglobulins/HRP	   Mouse	   Dako	  
Mouse	  immunoglobulins/HRP	   Rabbit	   Dako	  
Goat	  immunoglobulins/HRP	   Rabbit	   Dako	  
Rabbit	  immunoglobulins/biotinylated	   Mouse	   Dako	  
Mouse	  immunoglobulins/biotinylated	   Rabbit	   Dako	  
Goat	  immunoglobulins/biotinylated	   Rabbit	   Dako	  
Rabbit	  Alexa-­‐fluor®	  588	   Goat	   Invitrogen	  
Mouse	  Alexa-­‐fluor®	  477	   Rabbit	   Invitrogen	  
Table	  2.3.	  List	  of	  secondary	  antibodies.	  Used	  for	  the	  detection	  of	  bound	  primary	  antibodies.	  
Dako	  (Carpinteria,	  CA,	  USA);	  Invitrogen	  (Carlsbad,	  CA,	  USA).	  	  
	  
2.2.6.	  Preparation	  of	  coverslips	  for	  cell	  seeding	  
For	   experiments	   involving	   immunocytochemistry	   and	   high	   magnification	   (63x	  
objective)	   microscopy,	   cells	   were	   seeded	   onto	   pretreated/coated	   glass	   coverslips.	  
13mm,	  no.1	   thickness,	  glass	  coverslips	   (VWR	   international,	  West	  Chester,	  PA,	  USA)	  
were	  cleaned	  by	  rinsing	   for	  30	  minutes	   in	  concentrated	  nitric	  acid	   (BDH	   laboratory	  
Supplies,	   Poole,	   UK)	   at	   RT,	   followed	   by	   distilled	   water	   for	   30	  minutes,	   and	   finally	  
absolute	  methanol	   (Fisher	   Scientific,	   Loughborough,	  UK)	   for	   30	  minutes.	   Following	  
this,	  coverslips	  were	  autoclaved	  and	  dried	  over	  night	  in	  a	  conventional	  oven	  at	  75°C.	  	  
	   To	  facilitate	  adherence	  of	  cell	  monolayers,	  sterile	  coverslips	  were	  coated	  with	  
poly-­‐L-­‐lysine	  then	  the	  extracellular	  matrix	  protein	  fibronectin.	  100µl	  of	  0.01%	  (w/v)	  
poly-­‐L-­‐lysine	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  USA)	  diluted	  in	  water	  was	  added	  to	  each	  
13mm	  coverslip	  under	  a	   tissue	  culture	  hood	  and	   left	   to	  coat	   for	  30	  minutes	  at	  RT.	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The	  remaining	  solution	  was	  then	  aspirated	  and	  coverslips	  were	  air	  dried	  for	  a	  further	  
30	  minutes,	  then	  coated	  for	  30	  minutes	  with	  1µg	  fibronectin	  diluted	  in	  MilliQ	  water	  
from	  a	  stock	  solution	  of	  1mg/ml	  fibronectin	  diluted	  in	  0.5M	  NaCl,	  0.05M	  Tris,	  pH	  7.5	  
(Sigma-­‐Aldrich,	   St.	   Louis,	   MO,	   USA).	   Cells	   were	   plated	   directly	   onto	   coverslips	  
following	  coating.	  	  
	  
2.2.7.	  Immunocytochemistry	  
Following	   completion	  of	   the	  experimental	   time	   course,	  medium	  was	   removed	  and	  
cells	   were	   fixed	   either	   directly	   on	   coverslips	   or	   tissue	   culture	   dishes	   using	   a	   4%	  
solution	   of	   the	   protein	   cross-­‐linking	   agent	   paraformaldehyde	   (Fisher	   Scientific,	  
Loughborough,	   UK)	   in	   PBS	   for	   30	  minutes	   at	   RT.	   In	   order	   to	   prevent	   non-­‐specific	  
binding	   of	   antibodies,	   fixed	   cells	   were	   rinsed	   with	   PBS	   and	   pre-­‐blocked	   for	   45	  
minutes	   in	   a	   blocking	   solution	   of	   PBS	   containing	   1%	   bovine	   serum	   albumin	   (BSA)	  
(Sigma-­‐Aldrich,	   St.	   Louis,	   MO,	   USA)	   which	   contains	   immunoglobulins	   capable	   of	  
binding	   to	   epitopes	   on	   proteins,	   and	   permeabilised	   with	   0.05%	   triton-­‐X	   (Sigma-­‐
Aldrich,	   St.	   Louis,	   MO,	   USA).	   Blocking	   solution	   was	   removed	   and	   replaced	   with	  
primary	   antibody	   diluted	   in	   incubation	   buffer	   (PBS;	   3%	  BSA;	   0.05%	   triton)	   for	   one	  
hour.	  Primary	  antibody	  was	  removed	  by	  gentle	  shaking	  for	  3x	  10	  minutes	  with	  wash	  
buffer	  (PBS;	  0.01%	  BSA;	  0.05%	  triton).	  Next,	  secondary	  antibody	  was	  applied,	  diluted	  
in	   incubation	   buffer	   (PBS;	   3%	   BSA;	   0.05%	   triton-­‐X)	   for	   one	   hour,	   followed	   by	   3	  
washes	   with	   wash	   buffer.	   When	   signal	   strength	   of	   the	   primary	   antibody	   was	  
considered	  strong,	  a	  secondary	  antibody	  with	  a	  directly	  conjugated	  fluorophore	  was	  
applied.	   However	   when	   signal	   strength	  was	   considered	  weak,	   a	   biotin-­‐conjugated	  
secondary	   antibody	   was	   used,	   followed	   by	   incubation	   with	   the	   fluorophore	   Cy-­‐5	  
conjugated	   to	   strepdavidin	   (GE	   Healthcare,	   Little	   Chalfont,	   UK),	   diluted	   at	   250x	   in	  
incubation	  buffer	  (PBS;	  1%	  BSA;	  0.05%	  triton-­‐X)	  for	  one	  hour.	  Dishes	  were	  wrapped	  
in	  aluminium	  foil	  to	  avoid	  bleaching	  from	  light	  during	  stages	  involving	  fluorophores.	  
	   Following	   the	   final	   incubation,	   remaining	   solutions	   were	   removed	   by	   3	  
washes	   with	   wash	   buffer,	   then	   coverslips	   (13mm)	   were	   either	   mounted	   on	  
Superfrost®	  Plus	  glass	  slides	   (VWR	  international,	  West	  Chester,	  PA,	  USA),	  or	   if	  cells	  
were	   fixed	   directly	   on	   35mm	   plates,	   the	   base	   of	   the	   plate	   was	   covered	   with	   a	  
coverslip	  (32mm)	  following	  the	  addition	  of	  25µl	  of	  hard-­‐set	  Vector	  shield	  mounting	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solution	   (Vector	   Laboratories,	   Burlingame,	   CA,	   USA)	   containing	   4',6-­‐diamidino-­‐2-­‐
phenylindole	  (DAPI),	  and	  left	  to	  harden	  overnight	  at	  4°C.	  	  
	  
2.2.8.	  Transfection	  of	  DNA	  
Incorporation	   of	   plasmid	   DNA	   into	   cells	   was	   achieved	   using	   various	   methods	   of	  
transfection.	   For	   the	   first	  method,	   transfection	  was	   carried	   out	   using	   the	   cationic	  
polymer	  polyethyleneimine	   (PEI)	   (Sigma-­‐Aldrich,	   St.	   Louis,	  MO,	  USA).	   PEI	   confers	   a	  
positive	  charge	  to	  condensed	  DNA	  molecules	  allowing	  them	  to	  bind	  to	  anionic	  cell-­‐
surface	  residues	  and	  pass	  through	  the	  cell	  membrane	  by	  endocytosis.	  Protonation	  of	  
amine	  groups	  present	  on	  branched	  PEI	  molecules	  then	  causes	  an	  influx	  of	  anions	  and	  
thus	   a	   reduction	   in	   osmotic	   potential	   resulting	   in	   osmotic	   swelling	   and	   vesicle	  
bursting,	  thus	  releasing	  DNA	  polyplexes	  into	  the	  cell	  (Boussif	  et	  al.,	  1995).	  
	   PEI	  was	  prepared	  by	  dilution	  of	  the	  usual	  25	  kDa,	  branched	  form,	  made	  as	  a	  1	  
mg/ml	  stock	  in	  water	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  USA).	  For	  transfection	  of	  one	  35	  
mm	   dish,	   2µg	   total	   DNA	   was	   diluted	   in	   250µl,	   reduced	   serum	   OPTI-­‐MEM	   with	  
GlutaMAXTM	  media	  (OPTI-­‐MEM)	  (Invitrogen,	  Carlsbad,	  CA,	  USA).	  Where	  necessary	  a	  
reporter	  construct	  expressing	  GFP	  was	  added	  at	  10%	  of	  the	  total	  volume	  of	  DNA	  for	  
co-­‐transfection.	   8µg	   PEI	   was	   then	   diluted	   in	   250µl	   OPTI-­‐MEM	   and	   combined	  with	  
DNA	  for	  25	  minutes	  at	  RT.	  This	  was	  then	  added	  drop	  wise	  to	  wells	  containing	  2ml	  of	  
serum-­‐containing	   medium	   and	   incubated	   for	   at	   least	   4	   hours	   at	   37°C,	   before	  
replacing	  with	  normal	  medium.	  	  
	   In	  the	  second	  method,	  lipopolyplex	  formulations	  were	  prepared	  as	  described	  
(Hart	   et	   al.,	   1998).	   Here	   the	   liposome-­‐based	   transfection	   reagent	   Lipofectin	  
(Invitrogen,	  Carlsbad,	  CA,	  USA)	  composed	  of	  a	  1:1	  (w/w)	  formulation	  of	  the	  cationic	  
lipids	  N-­‐[1-­‐2(2,3-­‐dioleyloxy)propyl]-­‐n,n,n-­‐trimethylammonium	  chloride	  (DOTMA)	  and	  
dioleoyl	  phophotidylethanolamine	  (DOPE)	  (Felgner	  et	  al.,	  1987),	  and	  the	  peptide	  (K)	  
16	  GACYGLPHKFCG	   (peptide	  Y)	   (Irvine	  et	  al.,	   2008),	   a	   kind	  gift	  of	  Dr.	   Stephen	  Hart	  
(ICH,	  London,	  UK)	  were	  combined	  to	  generate	  lipopolyplexes.	  	  
	   For	  transfection	  of	  one	  35mm	  dish,	  2µg	  total	  DNA	  was	  diluted	  in	  200µl	  OPTI-­‐
MEM.	  Where	  necessary	  a	  reporter	  construct	  expressing	  enhanced-­‐GFP	  was	  added	  at	  
10%	  of	   the	   total	  volume	  of	  DNA	  for	  co-­‐transfection.	  2µg	  of	  1mg/ml	  Lipofectin	  was	  
then	   combined	   with	   8µg	   of	   peptide	   Y	   (0.1mg/ml	   in	   endotoxin-­‐free	   water)	   and	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diluted	  in	  118µl	  OPTI-­‐MEM,	  giving	  an	  equal	  volume	  of	  DNA:	  Lipid/peptide	  solution.	  
The	   DNA	   solution	   was	   then	   added	   to	   the	   lipid:	   peptide	   complex	   and	   this	   was	  
incubated	  at	  RT	  for	  60	  minutes.	  The	  DNA:	  lipid:	  peptide	  complex	  was	  then	  combined	  
with	   1.6ml	   of	  OPTI-­‐MEM	   to	   create	   a	   total	   volume	  of	   2ml,	  which	  was	   added	  drop-­‐
wise	   to	   the	   well	   and	   incubated	   at	   37°C	   for	   4	   hours	   then	   replaced	   with	   serum-­‐
containing	   medium.	   Transfection	   efficiency	   was	   monitored	   by	   expression	   of	   co-­‐
transfected	  CAβ-­‐GFP	  24	  and	  48	  hours	  post	  transfection.	  	  
	  
2.2.9.	  Optical	  microscopy	  
For	   image	  capture	  of	   live	  cells,	  photographs	  were	   taken	  using	  a	  Zeiss	  Axiovert	  135	  
microscope	   (Zeiss,	  Obercochen,	  Germany)	   fitted	  with	  an	  Exfo	  X-­‐Cite	   series	  120	  UV	  
lamp	   (Exfo,	   Quebec	   City,	   Canada),	   and	   a	   Hamamatsu	   ORCA-­‐ER	   digital	   camera	  
(Hamamatsu,	  Hamamatsu,	  Japan).	  Volocity	  software	  (Improvision,	  Coventry,	  UK)	  was	  
used	   for	   image	   capture.	   Both	   10x	   and	   32x	   objective	   lenses	   were	   used	   to	   obtain	  
images	  at	  100x	  and	  320x	  resolution	  respectively.	  	  
	   For	   image	   capture	   of	   fixed	   cells,	   photographs	   were	   taken	   using	   a	   Zeiss	  
Axiophot	   microscope	   (Zeiss,	   Obercochen,	   Germany)	   fitted	   with	   a	   Leica	   DC500	  
camera	  (Leica,	  Solms,	  Germany)	  and	  a	  Exfo	  X-­‐Cite	  series	  120	  UV	  lamp	  (Exfo,	  Quebec	  
City,	   Canada).	   Leica	   FireCam	   V1.7.1	   (Leica,	   Solms,	   Germany)	   was	   used	   for	   image	  
capture.	   Both	  microscopes	  were	   fitted	  with	   the	  UV	   filter	   cubes	   G	   365,	   exciting	   at	  
365+/-­‐	   10nm	   and	   emitting	   at	   >420nm;	   BP	   450-­‐490,	   exciting	   at	   450-­‐490nm	   and	  
emitting	   at	   515nm;	   and	  BP	  546/12,	   exciting	   at	   546+/-­‐12nm	  and	  emitting	   at	   	   >590.	  
Both	   20x	   and	   63x	   objective	   lenses	   were	   used	   to	   obtain	   images	   at	   200x	   and	   630x	  
resolution	  respectively.	  	  
	  
2.2.10.	   Generation	   of	   whole-­‐cell	   lysates	   and	   determination	   of	   protein	  
concentration	  
Whole	  cell	  lysates	  were	  prepared	  by	  lysing	  cell	  monolayers	  with	  lysis	  buffer	  (50mM	  
Tris-­‐HCl,	  pH	  7.4;	  150mM	  NaCl;	  1%	  Triton	  X-­‐100).	  Degradation	  of	  proteins	  of	  interest	  
was	  prevented	  by	  the	  addition	  of	  50x	  EDTA-­‐free	  proteinase-­‐inhibitor	  cocktail	  (Roche	  
Applied	   Sciences,	   Mannheim,	   Germany).	   Protein	   phosphorylation	   status	   was	  
preserved	   by	   the	   addition	   of	   1mM	   sodium	   orthovanadate,	   10mM	   sodium	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pyrophosphate,	   and	   25mM	   sodium	   fluoride	   	   (Sigma-­‐Aldrich,	   St.	   Louis,	   MO,	   USA).	  
Cells	  were	  lysed	  for	  30	  minutes	  on	  wet	  ice	  in	  order	  to	  inhibit	  enzymatic	  activity	  and	  
thus	  protein	  degradation.	  After	  15	  minutes	  of	  lysis	  monolayers	  were	  detached	  from	  
plates	  using	  a	  24-­‐cm	  cell-­‐scraper	  (TPP,	  Trasadingen,	  Switzerland).	  Lysates	  were	  then	  
centrifuged	  at	  14,000	  RPM	  for	  30	  minutes	  at	  4°C.	  
Lysate	   protein	   concentration	   was	   determined	   with	   the	   Bradford	   Ultra	  
reagent	   (Bio-­‐Rad,	   Hercules,	   CA,	   USA),	   a	   Coomassie-­‐based	   protein	   quantitation	  
reagent	  suitable	  for	  use	  with	  detergent-­‐containing	  lysis	  buffers.	  Briefly	  20µl	  of	  lysate	  
was	   combined	   with	   300µl	   of	   reagent	   in	   a	   96	   well	   tissue	   culture	   plate.	   An	   equal	  
volume	  of	  BSA/lysis	  buffer	  solution	  was	  diluted	  at	  0.5,	  1,	  1.5	  and	  2	  µg/ml	  to	  generate	  
a	  standard	  curve	  of	  protein	  concentrations.	  Absorbance	  was	  read	  at	  590nm	  using	  a	  
Model	  680	  automated	  microplate	  reader	  (Bio-­‐Rad,	  Hercules,	  CA,	  USA).	  	  
	   Protein	  concentration	  was	  determined	  by	  plotting	  a	  line-­‐of-­‐best-­‐fit	  from	  the	  
BSA	  standard	  curve	  values,	  which	  generated	  the	  equation,	  y	  (OD	  value)	  =	  (gradient)	  x	  
+	  y-­‐intercept,	  where	  x	  =	  protein	  concentration.	  This	  equation	  was	   then	  rearranged	  
such	   that	   x	   =	   (y	   –	   y-­‐intercept)/gradient,	   to	   generate	   a	   protein	   concentration	   as	  
determined	   by	   OD	   value.	   A	   sample	   containing	   lysis	   buffer	   only	   was	   used	   as	   a	  
background	  measurement	  and	  subtracted	  from	  each	  sample	  value.	  
	  
2.2.11.	  Immunoblotting	  
Depending	   on	   the	   avidity	   of	   the	   antibody	   and	   the	   abundance	   of	   the	   protein,	  
between	   10-­‐20µg-­‐lysate	   protein	   was	   separated	   by	   sodium	   dodecyl	   sulfate	  
polyacrylamide	  electrophoresis	   (SDS-­‐PAGE)	   as	  described	   (Burnette,	   1981;	   Laemmli,	  
1970;	  Towbin	  et	  al.,	  1979).	  Whole	  cell	   lysates	  were	  solubilised	  by	  heating	  at	  100°C	  
for	  5	  minutes	  with	  loading	  buffer	  (25mM	  Tris-­‐HCl,	  pH	  6.8;	  60%	  glycerol	  (v/v);	  8%	  SDS	  
(w/v);	   0.1%	  bromophenol	   blue	   (w/v))	   containing	   10%	   (v/v)	   freshly	   added	   reducing	  
agent	   β-­‐mercaptoethanol	   (Sigma-­‐Aldrich,	   St.	   Louis,	   MO,	   USA),	   required	   to	   cleave	  
disulphide	  bridges,	  at	  a	  ratio	  of	  3:1	  lysate	  to	  buffer.	  	  
	   Depending	   on	   the	   size	   of	   the	   protein	   of	   interest	   either	   7.5%,	   10%	   or	   12%	  
polyacrylamide	   resolving	   gels	   were	   made	   by	   combining	   varying	   amounts	   of	   30%	  
acrylamide	  and	  distilled	  water.	  Osmolarity	  and	  pH	  were	  maintained	  by	  the	  addition	  
of	   25%	   total	   volume	   resolving	   gel	   buffer	   (1.5M	   tris-­‐base,	   pH	   8.8).	   Resolving	   gels	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contained	   1%	   (w/v)	   of	   the	   anionic	   detergent	   sodium	   dodecyl	   sulfate,	   required	   to	  
disrupt	   non-­‐covalent	   bonds	   and	   thus	   the	   secondary,	   tertiary	   and	   quaternary	  
structure	  of	  proteins,	  causing	  them	  to	  denature	  and	  conferring	  them	  with	  a	  negative	  
charge	   thus	  allowing	   them	  to	  separate	  by	  electrophoresis	  on	   the	  basis	  of	   size.	  The	  
polymerization	  of	  acrylamide	  monomers	  was	  catalyzed	  by	   the	  addition	  of	  0.0075%	  
(v/v)	  final	  volume	  of	  10%	  ammonium	  persulfate	  (APS)	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  
USA)	  diluted	   in	  distilled	  water,	   and	  0.0012%	  Tetramethylethylenediamine	   (TEMED)	  
(Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  USA).	  The	  mixture	  was	  poured	  between	  1mm	  spacer	  
plates	  and	  outer	  plates,	  using	  a	  Bio-­‐Rad	  Mini-­‐PROTEAN	  3	  kit	  	  (Bio-­‐Rad,	  Hercules,	  CA,	  
USA),	   and	   polymerised	   for	   twenty	  minutes	   at	   RT.	   1ml	   of	   Isopropanol	   alcohol	   was	  
added	  after	  pouring	  to	  prevent	  unevenness	  and	  avoid	  air	  contact	  at	  the	  gel	  surface.	  
A	  5%	  polyacrylamide	  stacking	  gel	  was	  made	  by	  combining	  water	  with	  0.132%	  total	  
volume	  of	  30%	  acrylamide,	  in	  addition	  to	  1%	  SDS,	  25%	  stacking-­‐gel	  buffer	  containing	  
0.5M	  tris-­‐base	   (pH	  6.8),	  0.01%	  APS	  and	  0.0012%	  TEMED.	  Stacking	  gel	   solution	  was	  
added	  onto	  the	  polymerised	  resolving	  gel,	  and	  a	  1mm	  comb	  was	  inserted.	  
	   Up	   to	   25µl	   of	   sample	   was	   loaded	   in	   each	   well,	   along	   with	   Precision	   Plus	  
Protein	  standards	  (Bio-­‐Rad,	  Hercules,	  CA,	  USA)	  providing	  a	  protein	  ladder	  of	  known	  
sizes.	   Proteins	   were	   then	   separated	   by	   electrophoresis	   in	   a	   mini-­‐PROTEAN	   3-­‐cell	  
electrophoresis	   tank	   (Bio-­‐Rad,	  Hercules,	   CA,	  USA)	   filled	  with	   running	  buffer	   (water	  
with	   5mM	   tris-­‐base;	   40mM	   glycine;	   1%	   SDS),	   at	   a	   constant	   current	   of	   20	  mA/gel,	  
limited	  to	  200	  V.	  	  	  
	   Following	   electrophoresis,	   separated	   proteins	   were	   transferred	   to	  
Immobilon-­‐P	   0.45µM	   polyvinyldifluoride	   (PVDF)	   membranes	   (Sigma-­‐Aldrich,	   St.	  
Louis,	  MO,	  USA)	   in	   a	   Trans-­‐Blot	   SD	   semi-­‐dry	   electrophoretic	   transfer	   cell	   (Bio-­‐Rad,	  
Hercules,	  CA,	  USA).	  Specifically,	  PVDF	  membranes	  were	  soaked	  in	  absolute	  methanol	  
for	   5	   minutes	   followed	   by	   a	   transfer	   buffer	   (water	   with	   44mM	   tris-­‐base;	   52mM	  
glycine;	  20%	  methanol)	   for	  a	   further	  5	  minutes.	  6	   sheets	  of	  3mm	  chromatography	  
paper	  (Whatman,	  Maidstone,	  USA)	  corresponding	  in	  size	  to	  PVDF	  membranes	  were	  
also	  soaked	  in	  transfer	  buffer	  for	  5	  minutes.	  3	  sheets	  of	  paper	  were	  then	  placed	  on	  
the	  semi-­‐dry	  transfer	  apparatus,	  followed	  by	  the	  PVDF	  membrane,	  followed	  by	  the	  
polyacrylamide	   gel,	   followed	   by	   a	   further	   3	   sheets	   of	   paper.	   Proteins	   were	   then	  
transferred	   at	   a	   constant	   voltage	   of	   18	   V,	   limited	   to	   500	   mA,	   for	   30-­‐60	   minutes	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depending	  on	  the	  number	  of	  gels	  and	  the	  size	  of	  the	  protein	  of	   interest.	  Following	  
transfer,	   PVDF	  membranes	  were	   re-­‐soaked	   in	   absolute	  methanol,	   and	   then	  briefly	  
washed	  with	  distilled	  water.	  
	   Membranes	   were	   blocked	   overnight	   either	   in	   5%	   non-­‐fat	   milk	   powder	  
(Marvel)	   or	   5%	   BSA	   diluted	   in	   tris-­‐based	   saline	   (50mM	   tris-­‐base,	   pH	   7.4;	   150mM	  
NaCl)	  with	   0.1%	   tween-­‐20	   (TBS-­‐T).	  Membranes	  were	   then	   incubated	  with	   primary	  
antibody	  diluted	  in	  blocking	  solution	  for	  1-­‐12	  hours	  depending	  on	  the	  antibody,	  on	  a	  
roller	   at	   RT,	   then	   washed	   3	   times	   in	   TBS-­‐T.	   Secondary	   antibodies	   labelled	   with	  
horseradish	  peroxidase	  (HRP)	  were	  diluted	   in	  TBS-­‐T	  at	  10,000x	  and	  incubated	  for	  1	  
hour	  on	  a	   roller	  at	  RT,	   then	  washed	  3	   times	   in	  TBS-­‐T.	  HRP	  was	  detected	  using	   the	  
electrochemiluminescence	   (ECL)	   Plus	   kit	   (GE	   Healthcare,	   Little	   Chalfont,	   UK)	  
Immediately	   before	   use,	   2ml	   of	   solution	   A	   were	   combined	   with	   50µl	   of	   solution	  
B/blot	   then	   incubated	   for	   5	   minutes.	   Here	   the	   combination	   of	   HRP	   and	   peroxide	  
catalyses	  the	  oxidation	  of	  the	  Lumigen	  PS-­‐3	  acridan	  susbstrate	  generating	  acrinidium	  
ester	   intermediates	   that	   react	   with	   peroxide	   to	   produce	   a	   sustained	   emission	   of	  
430nm	   light	   (Akhavan-­‐Tafti	   et	   al.,	   1994).	   Light	   was	   detected	   by	   autoradiography	  
using	   X-­‐ray	   film	   (Kodak,	   Rochester,	   NY,	   USA)	   that	  was	   developed	   using	   a	   Xograph	  
Compact	  X4	  X-­‐ray	  developer	  (Xograph	  healthcare	  LTD,	  Tetbury,	  UK).	  	  
	  
2.2.12.	  Coomassie	  staining	  of	  protein	  following	  SDS-­‐PAGE	  
In	  cases	  where	  the	  number	  of	  lysed	  cells	  was	  judged	  to	  be	  too	  low	  for	  detection	  by	  
the	   Bradford	   Ultra	   method,	   protein	   levels	   in	   whole-­‐cell	   lysates	   were	   determined	  
using	   Coomassie	   staining.	   Briefly	   a	   duplicate	   SDS-­‐polyacrylamide	   gel	   was	   run	  
alongside	   of	   the	   gel	   that	   was	   subjected	   to	   protein	   transfer,	   then	   stained	   with	  
Coomassie	   stain	   (0.025%	   Brilliant	   Blue;	   40%	   methanol;	   10%	   acetic	   acid)	   for	   30	  
minutes	   with	   gentle	   shaking	   and	   de-­‐stained	   with	   Coomassie-­‐de-­‐stain	   (40%	  
methanol;	  10%	  acetic	  acid)	  overnight.	  Protein	  levels	  were	  judged	  by	  the	  intensity	  of	  
stained	  protein	  bands.	  	  
	  
2.2.13.	  Stripping	  of	  polyvinyl	  diflouride	  (PVDF)	  membranes	  
In	  all	  cases	  were	  more	  than	  two	  proteins	  were	  detected;	  antigens	  were	  stripped	  and	  
membranes	   were	   re-­‐probed	   with	   alternative	   antibodies.	   PVDF	   membranes	   were	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washed	  in	  water	  twice	  for	  10	  minutes	  with	  gentle	  shaking,	  immersed	  in	  0.2M	  NaOH	  
at	  37°C	  for	  20	  minutes,	  then	  shaken	  for	  10	  minutes	  at	  RT.	  NaOH	  was	  then	  removed	  
with	  one	  wash	  of	  TBS-­‐T	  for	  10	  minutes	  and	  membranes	  were	  re-­‐blocked	  in	  blocking	  
solution.	  In	  cases	  where	  high	  protein	  abundance/antibody	  avidity	  prevented	  the	  use	  
of	  NaOH	  as	   a	   stripping	   buffer,	   an	   alternative	   β-­‐mercaptoethanol	   containing	   buffer	  
was	   used.	   Here	   PVDF	   membranes	   were	   incubated	   with	   stripping	   buffer	   (62.5mM	  
tris-­‐HCl,	  pH	  6.8;	  20%	  SDS;	  0.008%	  β-­‐mercaptoethanol)	  at	  50°C	  for	  45	  minutes	  then	  
washed	   once	  with	  water	   for	   1	   hour	  with	   gentle	   shaking	   followed	   by	   TBS-­‐T	   for	   10	  
minutes,	  then	  re-­‐blocked	  in	  blocking	  solution.	  	  
	  
2.2.14.	  Neurite	  outgrowth	  quantification	  
Cells	  were	  seeded	  at	   low	  density	   (5x104)	  one	  day	  prior	   to	  the	  addition	  of	  chemical	  
compounds.	   The	   degree	   of	   neuritogenesis	   was	   determined	   after	   3	   and	   6	   days	   of	  
treatment	  by	  calculating	  the	  average	  neurite	  length	  and	  the	  percentage	  of	  cells	  with	  
neurites,	   using	   Openlab	   V5.5	   software	   (Perkin	   Elmer,	   Waltham,	   MA,	   USA).	  
Specifically	   around	   50	   frames	   were	   photographed	   using	   a	   10x	   objective	   lens,	   and	  
neurites	   were	   measured	   on	   single	   dispersed	   cells	   that	   were	   not	   contacted	   by	  
neighbouring	  cells.	   For	  each	  condition	  at	  each	   time	  point	  around	  200-­‐300	  neurites	  
were	  measured	  from	  at	  least	  10	  separate	  photographs.	  A	  neurite	  was	  defined	  as	  any	  
process	   equal	   to	   or	   greater	   than	   two	   times	   the	   length	   of	   the	   cell	   body,	   and	   was	  
measured	  from	  the	  cell	  body	  to	  the	  tip	  of	  the	  process.	  	  
	  
2.2.15.	  Cell	  viability	  staining	  using	  crystal	  violet	  
To	  analyse	  the	  degree	  of	  cell	  viability	  after	  chemical	  treatment,	  cells	  were	  fixed	  in	  4%	  
paraformaldehyde	  for	  30	  minutes	  then	  rinsed	   in	  PBS.	  Remaining	  cells	  were	  stained	  
using	   the	   protein	   dye	   crystal	   violet	   (hexamethyl	   pararosaniline	   chloride)	   solution	  
(0.1%	  crystal	   violet/10%	  EtOH	   in	  distilled	  water)	   for	  30	  minutes,	   then	   rinsed	   three	  
times	   with	   water	   and	   air	   dried	   overnight.	   Where	   viability	   was	   quantified,	   the	  
remaining	   dye	   was	   solubilised	   using	   20%	   acetic	   acid	   solution	   (500µl/35mm)	   and	  
further	  diluted	  1:3	  in	  water.	  100µl	  of	  the	  solution	  was	  transferred	  to	  a	  96	  well	  plate	  
and	  a	   colorimetric	   reading	  was	  obtained	  at	  495	  nm	  using	  a	  Model	  680	  automated	  
microplate	  reader	  (Bio-­‐Rad,	  Hercules,	  CA,	  USA).	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2.2.16.	  CellTiter	  96	  aqueous	  non-­‐radioactive	  cell	  proliferation	  assay	  
For	  determination	  of	   the	  number	  of	   viable	   cells	   following	   chemical	   treatment,	   the	  
reduction	   of	   the	   tetrazolium	   compound	   3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐5-­‐(3-­‐
carboxymethoxyphenyl)-­‐2-­‐(4-­‐sulfophenyl)-­‐2H-­‐tetrazolium	   (MTS)	   (Promega,	  
Fitchburg,	  WI,	  USA)	  was	  used	  to	  generate	  a	  soluble	  formazan	  product,	  accomplished	  
by	  dehydrogenase	  enzymes	  present	  within	  cells	  and	  thus	  directly	  proportional	  to	  the	  
number	  of	  viable	  cells	  (Goodwin	  et	  al.,	  1995).	  
	   0.002%	   MTS	   reagent	   (diluted	   in	   PBS,	   pH6.5)	   was	   combined	   with	   0.092%	  
phenazine	  methosulfate	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  USA)	  (diluted	  in	  PBS)	  at	  20:1	  
immediately	   before	   use	   and	   diluted	   in	   cell	   culture	   medium	   at	   10%	   of	   the	   total	  
volume,	  then	  added	  to	  cell	  culture	  plates	  and	  incubated	  for	  4	  hours	  at	  37°C.	  100µl	  of	  
the	   culture	   medium	   containing	   soluble	   formazan	   product	   was	   then	   removed	   and	  
transferred	  to	  a	  96	  well	  plate.	  The	  absorbance	  of	  formazan	  was	  read	  at	  495	  nm	  using	  
a	  Model	  680	  automated	  microplate	  reader	  (Bio-­‐Rad,	  Hercules,	  CA,	  USA).	  	  
	  
2.2.17.	  Detection	  of	  cell	  senescence	  
For	   detection	   of	   senescent	   cells	   the	   senescence-­‐associated-­‐β-­‐galactosidase	   assay	  
was	   used,	  which	   detects	   senescent	   cells	   at	   an	   acidic	   pH	   (Dimri	   et	   al.,	   1995).	   Cells	  
were	  fixed	  in	  4%	  paraformaldehyde	  for	  30	  minutes	  then	  rinsed	  with	  PBS.	  A	  staining	  
solution	  was	   combined	   immediately	   before	   incubation	   containing	   5mM	  potassium	  
ferrocyanide;	   5mM	   potassium	   ferricyanide;	   2mM	   magnesium	   chloride;	   150mM	  
sodium	  chloride;	  30mM	  citric	  acid/phosphate	  buffer	  (0.1M	  citric	  acid;	  0.2M	  sodium	  
phosphate	  dibasic;	   pH	  6)	   and	  1mg/ml	  Xgal	   solution	   (20mg/ml	  5-­‐bromo-­‐4-­‐chloro-­‐3-­‐
indoly-­‐	  β-­‐D-­‐galactopyranoside	  diluted	  in	  dimethyl	  formamide).	  Approximately	  1ml	  of	  
solution	  was	  added	  to	  each	  35mm	  well	  and	  cells	  were	  incubated	  overnight	  at	  37°C.	  
Staining	  solution	  was	  then	  removed	  and	  wells	  were	  washed	  with	  water.	  
	  
2.2.18.	  Detection	  of	  reactive	  oxygen	  species	  using	  2’,7’-­‐di-­‐chlorodihydrofluorescein	  
diacetate	  
Cellular	   generated	   reactive	   oxygen	   species	   (ROS)	  were	   detected	   via	   an	   increase	   in	  
fluorescence	   that	   occurs	   following	   the	   conversion	   of	   the	   cell-­‐permeable,	   non-­‐
fluorescent	   dye	   2’,7’-­‐di-­‐chlorodihydrofluorescein	   diacetate	   (DCFDA)	   to	   2’,7’-­‐Di-­‐
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chlorofluorescein	  (DCF)	  	  after	  esterase-­‐mediated	  cleavage,	  cellular	  accumulation	  and	  
oxidation	   by	   ROS,	   as	   described	   (Eruslanov	   and	   Kusmartsev,	   2010).	   Briefly	   DCFDA	  
(Invitrogen,	  Carlsbad,	  CA,	  USA)	  was	  dissolved	   in	  dimethyl	  sulfoxide	  (DMSO)	  (Sigma-­‐
Aldrich,	   St.	   Louis,	   MO,	   USA)	   at	   a	   concentration	   of	   5mM	   and	   added	   to	   Hank’s	  
balanced	  salt	  solution	  (HBSS)	  (Gibco,	  Grand	  Island,	  NY,	  USA)	  pre-­‐warmed	  to	  37°C	  at	  a	  
final	  concentration	  of	  5µM.	  The	  solution	  was	  kept	  in	  a	  light-­‐resistant	  tube.	  Cells	  were	  
then	   washed	   in	   HBSS	   and	   DCFDA	   was	   added	   to	   each	   well	   (2ml/35mm)	   then	   in	   a	  
humidified	   37°C	   incubator	   for	   10	  minutes	   under	   aluminium	   foil.	   DCFDA	  was	   then	  
aspirated	  and	  cells	  were	  rinsed	  once	  with	  HBSS.	  Fresh	  HBSS	  was	  then	  added	  to	  each	  
well,	   with	   cells	   being	   kept	   in	   the	   dark	   as	   much	   as	   possible,	   and	   cells	   were	  
photographed	   using	   a	  microscope	   and	   a	   fluorescence	   filter	  microscope	   excited	   at	  
485nm.	   Intensity	   of	   fluorescence	   was	   quantified	   using	   Volocity	   software	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3.1.	  Introduction	  
Conventional	   treatment	   of	   cancer	   involves	   the	   selective	   induction	   of	   cell	   death	   in	  
tumour	  cells	  through	  single	  or	  combined	  cytotoxic	  agents	  that	  induce	  DNA-­‐damage,	  
thus	  targeting	  dividing	  cells.	  Although	  this	  largely	  forms	  the	  basis	  of	  modern	  cancer	  
therapy,	   it	   is	   widely	   acknowledged	   that	   most	   cytotoxics	   exhibit	   considerable	   side	  
effects	   related	   to	   targeting	   of	   normal	   organs	   such	   as	   the	   bone	   marrow	   or	  
gastrointestinal	   tract	   that	   harbour	   large	   populations	   of	   dividing	   cells.	   However	   an	  
alternative	   approach	   to	   chemotherapy	   involves	   the	   induction	   of	   differentiation,	  
forcing	   proliferative,	   pluripotent	   tumour	   cells	   down	   their	   respective	   lineages	   into	  
mature,	   mitotically	   arrested	   cells,	   preventing	   tumour	   progression	   and	   potentially	  
circumventing	   toxic	   side	   effects	   involved	   in	   standard	   chemotherapy	   (Reynolds,	  
1991).	  Perhaps	  the	  best-­‐characterised	  example	  of	  such	  differentiation	  therapy	  is	  the	  
clinical	   use	  of	   all-­‐trans	   retinoic	   acid	   (RA),	  which	   shows	   remarkable	  efficacy	   against	  
acute-­‐promyelocytic	  leukaemia,	  demonstrated	  by	  a	  cure	  rate	  of	  ~90%	  (Huang	  et	  al.,	  
1988).	  Although	  this	  task	  may	  be	  more	  complicated	  in	  cancers	  of	  polygenic	  origins,	  
the	  induction	  of	  differentiation	  still	  represents	  a	  powerful	  tool	  in	  cancer	  treatment.	  
	   NBL	   has	   one	   of	   the	   highest	   rates	   of	   spontaneous	   regression	   of	   any	   human	  
cancer,	  whereby	   the	   tumour	   resolves	  with	  minimal	   therapy,	   occurring	   in	   5-­‐10%	  of	  
clinical	  cases	  but	  probably	  occurring	  at	  even	  higher	  rates	   in	  cases	  of	  asymptomatic	  
NBL.	   Spontaneous	   regression	  often	   results	   from	  differentiation	  whereby	   immature	  
proliferative	  neuroblasts	  differentiate	   in	  situ	   into	  mature	  ganglion	  cells	  forming	  the	  
benign	   tumour	   ganglioneuroma.	   Although	   the	   molecular	   basis	   of	   spontaneous	  
regression	  is	  unclear,	  it	  likely	  involves	  influences	  from	  pathways	  normally	  governing	  
neuronal	   development	   e.g.	   neurotrophic	   factors	   (Nakagawara,	   1998).	   In	   fact,	   the	  
original	   description	   of	   spontaneous	   regression	   of	   NBL	   by	   Cushing	   and	  Wolbach	   in	  
1927	  hinted	  to	  this	  hypothesis	  prior	  to	  the	  discovery	  of	  neurotrophins,	  stating	  “one	  
is	  forced	  to	  conclude	  that	  the	  cells	  of	  this	  tumour	  as	  a	  whole	  have	  responded	  to	  the	  
influences	   or	   factors	   governing	   the	   normal	   differentiation	   of	   the	   nervous	   system”	  
(Cushing	   and	   Wolbach,	   1927).	   Thus	   the	   discovery	   that	   NBL	   could	   spontaneously	  
differentiate	   into	   a	   benign	   tumour	   led	   to	   the	   idea	   that	   differentiation	   induction	  
could	  represent	  a	  clinically	  effective	  tool	  in	  NBL	  treatment.	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RA	  represents	  a	  gold	  standard	  differentiation-­‐inducing	  agent.	  However,	  due	  
to	   issues	   of	   resistance,	   toxicity	   and	   relapse,	   research	   has	   often	   centred	   around	  
improving	   retinoid	   therapy	   through	   the	   use	   of	   additional	   differentiation	   agents,	  
which	  potentially	   impinge	  on	  both	  common	  and	  distinct	  pathways	   (Chevrier	  et	  al.,	  
2008;	   Encinas	   et	   al.,	   2000a;	   Lucarelli	   et	   al.,	   1995;	   Sidell	   et	   al.,	   1995).	   Of	   potential	  
interest	  here	   is	   that	   the	  PTP	   inhibitor	   sodium	  orthovanadate	   (VA),	  was	   shown	   like	  
RA,	   to	   induce	   morphological	   differentiation	   in	   NBL	   in	   vitro	   (Rogers	   et	   al.,	   1994).	  	  
Although	  the	  molecular	  details	  of	  this	  effect	  are	  unclear,	  VA	  represents	  a	  potentially	  
novel	  agent	  in	  combination	  differentiation	  therapy.	  	  
	   Pro-­‐senescence	   therapy	   is	   a	   distinct	   but	   related	   concept	   centring	   on	   the	  
activation	  of	  senescence	  programs	  that	   lay	  dormant	   in	  tumour	  cells	  to	  prevent	  cell	  
replication	  and	  thus	  tumour	  progression	  (Nardella	  et	  al.,	  2011).	  It	  is	  likely	  that	  as	  well	  
as	   inducing	  apoptosis,	   conventional	   cytotoxic	   therapy	   induces	  a	   significant	  amount	  
of	   senescence	   that	   contributes	   to	   its	   efficacy,	   although	   this	   is	   difficult	   to	   prove	   in	  
human	  patients.	  However,	  as	  well	  as	  a	  side	  effect	  of	  therapy,	  a	  senescence	  response	  
could	   potentially	   be	   targeted	   pharmacologically.	   One	   such	   example	   of	   this	   is	   the	  
inhibition	  of	  the	  dual-­‐specificity	  PTP	  PTEN,	  whereby	  acute	  loss	  of	  PTEN	  through	  small	  
molecule	   inhibition	   following	   its	   monoallelic	   loss	   results	   in	   a	   p53-­‐dependent	  
senescence	   response	   (Alimonti	   et	   al.,	   2010b).	   Thus	   targeting	   other	   PTPs	   may	  
potentially	   have	   similar	   effects	   due	   to	   loss	   of	   negative	   feedback	   regulation	   of	  
oncogenic	  pathways	  such	  as	  PI3K/Akt	  or	  Ras/RAF/MEK/Erk.	  
Indeed	  pro-­‐senescence	  therapy	  has	  been	  considered	  in	  the	  treatment	  of	  NBL,	  
due	   to	   the	   rareness	   of	   p53	   mutations	   at	   presentation,	   and	   the	   fact	   that	   both	  
oncogene-­‐induced	  senescence	  and	  PTEN-­‐loss-­‐induced	  senescence	  generally	  require	  
p53	  induction.	  One	  such	  therapeutic	  strategy	  is	  the	  stabilization	  of	  p53	  using	  nutlin-­‐
3,	  a	  small	  molecule	  that	  antagonizes	  the	  p53	   inhibitor	  MDM2	  (Van	  Maerken	  et	  al.,	  
2011;	  Van	  Maerken	  et	   al.,	   2006).	  Nutlin-­‐3	   has	   been	   shown	   to	  be	   effective	   in	   vitro	  
against	  NBL	  cells	  due	  to	   its	  potent	  ability	   to	   induce	  senescence,	  and	   is	  currently	   in	  
phase	   1	   clinical	   trials	   in	   other	   cancers.	   Similarly	   RA	   has	   been	   shown	   to	   cause	  
senescence	   in	   NBL	   cells	   of	   specific	   lineages	   based	   on	   their	   molecular	   profile	  
(Wainwright	   et	   al.,	   2001),	   although	   it	   is	   currently	   unclear	   whether	   senescence	  
represents	  a	  significant	  component	  of	  the	  clinical	  response	  to	  RA.	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   Thus	  based	  on	   this	   evidence	  we	   sought	   to	   examine	  whether	   PTP	   inhibition	  
can	   cause	   differentiation	   and/or	   senescence	   in	   NBL	   cells,	   hypothesising	   that	   such	  
effects	  may	  result	  from	  the	  activation	  of	  tyrosine-­‐kinase	  driven	  pathways	  controlling	  
such	  responses.	  We	  also	  tested	  whether	  PTP	  inhibition	  would	  augment	  the	  effects	  of	  
RA,	   potentially	   through	  activation	  of	   similar	   pathways,	   leading	   to	   a	  more	  effective	  
differentiation	  or	  senescence	  response.	  	  
	  
3.2.	  Experimental	  procedures	  
3.2.1.	  Neuroblastoma	  cell	  lines	  
A	   large	  number	  of	  NBL	  cell	   lines	  have	  been	   isolated	   from	  explanted	   tumour	   tissue	  
and	  propagated	   in	  vitro	  for	  the	  characterisation	  of	  cell	  behaviour	  and	  propensity	  to	  
differentiate	   from	   immature	   neuroblasts	   to	   mature	   sympathetic	   neurons.	   Of	   the	  
hundred	  or	  so	  NBL	  cell	   lines	  established	  to	  date,	  many	  have	  been	  characterised	  for	  
biological	   characteristics	   such	   as	   Mycn	   status,	   chromosomal	   aberrations	   and	   the	  
expression	   of	   enzymes	   involved	   in	   the	   synthesis	   of	   catecholamines	   (Thiele,	   2006).	  
Generally	   speaking	   all	   NBL	   cell	   lines	   are	   derived	   from	   aggressive	   high	   stage	   (3-­‐4)	  
tumours,	   however	   a	   number	   of	   distinctions	   have	   been	   made	   due	   to	   phenotypic	  
variation	  between	  cell	  lines,	  reflecting	  tumour	  heterogeneity.	  
The	  most	  common	  factor	  in	  distinguishing	  NBL	  cell	  lines	  is	  the	  cell	  phenotype,	  
where	   three	   variants	   have	   been	   described,	   namely	   neuroblastic	   or	   N-­‐type,	  
Schwannian/substrate-­‐adherent	   or	   S-­‐type	   and	   intermediate	   or	   I-­‐type.	   These	  
categories	   reflect	   phenotypic	   properties,	  where	  N-­‐type	   cell	   lines	   are	   composed	   of	  
small	  neuroblasts	   that	  harbour	  neuritic	  processes,	   capable	  of	  undergoing	  neuronal	  
differentiation	  in	  response	  to	  chemicals	  such	  as	  retinoic	  acid.	  In	  contrast	  S-­‐type	  cell	  
lines	   are	   composed	   of	   flattened	   fibroblastic/epithelioid	   cells	   which	   lack	   processes	  
and	   are	   precursors	   to	   the	   non-­‐neuronal	   lineages	   of	   the	   neural	   crest	   i.e.	   Schwann	  
cells/smooth	   muscle	   cells/melanocytes	   (Ross	   and	   Spengler,	   2007).	   I	   type	   cells	  
represent	   an	   intermediate	   between	   the	   two,	   although	   obviously	   a	   number	   of	   cell	  
lines	   contain	  mixed	   populations	   of	   the	   three	   cell	   types.	   Perhaps	   one	   of	   the	  most	  
interesting	   factors	   distinguishing	   NBL	   cell	   type	   is	   their	   relative	   differences	   in	  
malignancy,	  whereby	   I	   type	   cells	   have	  a	  3-­‐4	   fold	  higher	   ability	   to	   form	   tumours	   in	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xenografts	  models	   in	  contrast	  to	  N	  type	  cells,	  which	  are	   less	  malignant,	  and	  S	  type	  
cells	  which	  do	  not	   spontaneously	   form	   tumours	   at	   all	   (Ross	   et	   al.,	   2003;	   Ross	   and	  
Spengler,	   2007;	   Walton	   et	   al.,	   2004).	   As	   such	   I	   type	   cells	   have	   been	   deemed	   a	  
putative	  NBL	  cancer	  stem	  cell.	  	  
	   We	  sought	   to	   test	  a	  number	  of	  phenotypically	  and	  molecularly	  distinct	  NBL	  
cell	  lines,	  in	  order	  to	  reflect	  the	  heterogeneity	  of	  NBL	  tumours	  in	  terms	  of	  efficacy	  of	  
therapeutics.	  These	  cell	  lines	  harboured	  differences	  in	  cytogenetics,	  origin	  and	  Mycn	  
amplification	  status	  (Table	  3.1).	  As	  described,	  NBL	  cell	  lines	  (Figure	  3.1)	  were	  chosen	  
to	   represent	  a	   range	  of	  phenotypic	   categories	   including	  N	   type	   (SH-­‐SY5Y,	   SK-­‐N-­‐SH,	  
LAN5	  and	  SMS-­‐KCNR),	  S	  type	  (SMS-­‐KCN,	  SK-­‐N-­‐AS,	  Kelly),	  and	  I	  type	  (IMR32,	  SK-­‐N-­‐DZ,	  
SK-­‐N-­‐BE(2).	   Note	   that	   these	   are	   not	   formal	   classifications	   and	   reflect	   the	   authors	  
judgement	  based	  on	  morphology,	   as	   such	   these	  may	  vary	  depending	  on	   the	   study	  
(See	  (Thiele,	  2006)	  for	  further	  discussion).	  	  SH-­‐SY5Y	  cells	  were	  also	  originally	  derived	  
from	   SK-­‐N-­‐SH	   cells,	   representing	   a	   neuronal	   type	   subclone	   (Biedler	   et	   al.,	   1978).	  
Lastly	   the	  present	   study	  made	  use	  of	  a	   recently	  generated	  cell	   line	  derived	   from	  a	  
treatment-­‐resistant	   tumour	  of	   a	  patient	   at	  Great	  Ormond	  Street	  Hospital,	   IPhNB1,	  
generously	  provided	  by	   Izabella	   Piotrowska	   and	  Arturo	   Sala	   (UCL	   Institute	  of	   Child	  
Health,	  London,	  UK)	  	  (Figure	  3.2).	  	  
SH-­‐SY5Y	  and	  SK-­‐N-­‐SH	  were	  maintained	   in	  minimum	  essential	  medium	  Eagle	  
(MEME)	  supplemented	  with	  10%	  FBS,	  1%	  Pen	  Strep	  and	  2mM	  L-­‐glutamine.	  All	  other	  
cell	   lines	   were	   maintained	   in	   Roswell	   Park	   Memorial	   Institute	   (RPMI	   1640)	  
supplemented	  with	  10%	  FBS,	  1%	  Pen	  Strep	  and	  25mM	  Hepes	  (pH	  7.4).	  	  
	  
3.3.	  Results	  
3.3.1.	   Vanadate	   augments	   retinoic	   acid-­‐induced	   neuritogenesis	   and	   upregulation	  
of	  neuronal	  differentiation	  markers	  
Vanadate	  (VA)	  has	  been	  shown	  to	  induce	  neurite	  elongation	  in	  SH-­‐SY5Y	  human	  NBL	  
and	  neuritogenesis	  in	  PC-­‐12	  pheochromocytoma	  cells	  (Rogers	  et	  al.,	  1994).	  Thus	  we	  
sought	  to	  extend	  these	  findings	  by	  testing	  the	  efficacy	  of	  VA	  on	  a	  range	  of	  NBL	  cell	  
lines	  exhibiting	  varying	  phenotypic	  characteristics	  and	  genetic	  backgrounds.	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IMR32	   I	   Y	   Y	   Y	   Y	   None	  
SK-­‐N-­‐SH	   N/S	  
	  
N	   N	   Y	   Y	   CT/RT	  
SH-­‐SY5Y	   N/S	   N	   N	   N	   Y	   CT/RT	  
LAN5	   N	   Y	   Y	   N	   Y	   Unk.	  
SK-­‐N-­‐DZ	   I	   Y	   N	   Y	   Y	   Unk.	  
SK-­‐N-­‐BE(2)	   I	   Y	   Y	   Y	   Y	   CT	  
SMS-­‐KCN	   S	   Y	   Y	   N	   Y	   None	  
SMS-­‐KCNR	   N	   Y	   Y	   Y	   Y	   CT	  
SK-­‐N-­‐AS	   S	   N	   Y	   Y	   Y	   CT/RT	  
Kelly(N206)	   S	   Y	   Y	   Y	   Y	   Unk.	  
	  
Table	   3.1.	   Neuroblastoma	   cell	   lines	   information.	   Table	   shows	   the	   status	   of	   common	  
cytogenetic	  abnormalities	  (1p/11q	  deletion,	  17q	  gain)	  as	  well	  as	  Mycn	  amplification	  status,	  
phenotypic	   classification	   and	   known	   treatments	   of	   primary	   tumours	   from	  which	   cell	   lines	  
were	   derived.	  N	   =	  Neuronal;	   S	   =	   Schwannian;	   I	   =	   Intermediate.	   CT	   =	   Chemotherapy;	   RT	   =	  
Radiotherapy;	  Unk.	  =	  Unknown.	  	  
	  
Figure	  3.1.	  Neuroblastoma	  cell	  line	  phenotype.	  Examples	  of	  untreated	  NBL	  cell	  lines.	  Scale	  
bar	  =	  10	  microns.	  Arrows	   refer	   to	  neuroblasts;	  arrowheads	   refer	   to	  S	   type	  cells.	  Note	   that	  
some	  cell	  lines,	  e.g.	  SK-­‐N-­‐SH	  contain	  a	  mixed	  population	  of	  N	  and	  S	  type,	  whereas	  some	  cell	  
lines	  contain	  I	  type	  cells	  with	  less	  obvious	  distinguishing	  features.	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Figure	  3.2.	  Primary	  tumour	  derived	  cell	   line.	  The	  cell	   line	  IPhNB1	  was	  recently	  established	  
by	   Izabella	   Piotrowska	   and	   Arturo	   Sala,	   from	   a	   primary	   tumour	   specimen	   taken	   from	   a	  
treatment-­‐resistant	  NBL.	  Note	  the	  presence	  of	  S	  and	  N	  type	  cells.	  
	  
Furthermore	  we	   hypothesized	   that	   the	  VA-­‐induced	   neurite	   extension	   documented	  
by	   (Rogers	   et	   al.,	   1994)	   might	   cause	   additive	   gains	   in	   retinoic-­‐acid	   induced	  
neuritogenesis,	  given	  that	  other	  differentiation	  agents	  have	  been	  shown	  to	  augment	  
the	  effects	  of	  retinoic	  acid,	  including	  vandetanib,	  an	  inhibitor	  of	  vascular	  endothelial	  
growth	   factor	   receptor,	   epidermal	   growth	   factor	   receptor	   and	   rearranged	   during	  
transfection	   tyrosine	   kinase	   (RET)	   (Zage	   et	   al.,	   2010b),	   phenylacetate	   (Sidell	   et	   al.,	  
1995)	  and	  vasoactive-­‐intestinal	  peptide	  (Chevrier	  et	  al.,	  2008).	  
	   Initial	   serial	   dosage	   testing	   suggested	   that	   VA	   had	   potentially	   non-­‐specific	  
toxic	   effects	   beyond	   10-­‐20µM,	   preventing	   phenotypic	   analysis	   (data	   not	   shown).	  
Thus	  NBL	  cells	  were	   treated	  with	  5µM	  VA	  over	  a	  6-­‐day	  period	   (see	  Chapter	  2).	  VA	  
induced	   significant	   neurite	   extension	   in	   LAN-­‐5,	   SH-­‐SY5Y	   and	   SK-­‐N-­‐SH	   cells	   (Figure	  
3.3,	   D,	   E,	   F).	   Notably	   these	   cells	   are	   primarily	   neuroblastic	   in	   morphology,	   and	  
harbour	   small,	   neuritic	   processes	   endogenously,	   which	   were	   found	   to	   extend	  
following	  VA	  treatment.	  We	  further	  tested	  the	  cell	  lines	  SMS-­‐KCNR,	  SMS-­‐KCN,	  SK-­‐N-­‐
BE(2),	   SK-­‐N-­‐AS,	   Kelly,	   IMR-­‐32	   and	   SK-­‐N-­‐DZ	   and	   found	   that	   VA	   was	   unable	   to	  
stimulate	  neurite	  extension	  (data	  not	  shown),	  although	  with	  the	  exception	  of	  SMS-­‐
KCN	  and	  SMS-­‐KCN-­‐R	   these	   cell	   lines	  do	  not	  undergo	  differentiation	   in	   response	   to	  
RA,	  suggesting	  they	  may	  be	  from	  a	  less	  mature	  progeny.	  	  
As	   RA	   also	   stimulated	   neurite	   extension	   in	   LAN-­‐5,	   SH-­‐SY5Y	   and	   SK-­‐N-­‐SH	  
(Figure	   3.3	   G,	   H,	   I),	   we	   sought	   to	   examine	   whether	   a	   combination	   of	   VA	   and	   RA	  
treatment	   (VA/RA	   hereafter)	   induced	   greater	   phenotypic	   differentiation.	   VA/RA	  
treatment	  led	  to	  a	  more	  highly	  differentiated	  phenotype	  in	  all	  cell	  lines	  (Figure	  3.3,	  J,	  
K,	   I).	   This	  was	  particularly	   evident	   in	   both	   LAN-­‐5	   cells,	  which	   exhibited	   longer	   and	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denser	  axonal-­‐like	  neurites,	  and	  SK-­‐N-­‐SH,	  which	  exhibited	  an	  almost	  entirely	  uniform	  
population	   of	   differentiated	   neuronal-­‐type	   cells	   rather	   than	   mixed	   clones	   of	  
epithelioid/neuronal	  cells	  caused	  by	  RA	  treatment	  alone.	  
We	   quantified	   both	   the	   average	   length	   of	   neurite	   per	   cell	   across	   the	  
population	  of	   cells	   and	   the	  percentage	  of	   cells	  with	  extended	  neurites	   (defined	  as	  
any	  neuritic	  process	  twice	  the	  length	  of	  the	  cell	  body),	  revealing	  that	  six	  days	  of	  VA	  
treatment	  was	   sufficient	   to	   induce	   significant	   gains	   in	  both	  average	  neurite	   length	  
and	   the	   percentage	   of	   cells	   with	   neurites	   compared	   with	   untreated	   control	   cells	  
(Figure	  3.4,	  light	  grey	  bars),	  fully	  comparable	  to	  that	  induced	  by	  RA	  (Figure	  3.4,	  dark	  
grey	   bars).	   However	   combination	   VA/RA	   treatment	   significantly	   increased	   both	   of	  
these	  parameters	  when	  compared	  to	  single-­‐agent	  treatment	  (Figure	  3.4,	  black	  bars).	  
A	   noteworthy	   finding	   is	   that	   VA/RA	   treatment	   caused	   a	   near	   homogenous	  
population	  (70-­‐80%)	  of	  neurite-­‐extended	  cells,	  compared	  to	  RA	  alone	  (50%).	  	  
We	  next	  sought	  to	  see	  whether	  these	  cell-­‐structural	  effects	  of	  VA	  and	  VA/RA	  
were	  mimicked	  by	   changes	   in	  expression	   levels	  of	  neuronal	  proteins.	  A	  number	  of	  
proteins	   have	   been	   shown	   to	   be	   either	   involved	   in,	   or	   a	   consequence	   of,	   retinoic	  
acid-­‐induced	  neuronal	  differentiation.	  We	  chose	  to	  examine	  the	  neuron	  specific	  βIII	  
tubulin,	   a	   cytoskeletal	   protein	   involved	   in	   microtubule	   structure,	   and	   the	  
tropomyosin-­‐related	  kinase	  (Trk)	  family,	  both	  of	  which	  increase	  in	  expression	  levels	  
following	  neuronal	  differentiation	  (Eggert	  et	  al.,	  2000).	  
Both	  SH-­‐SY5Y	  and	   LAN-­‐5	   cells	   responded	   to	  VA/RA	   treatment	  by	   increasing	  
the	   expression	   of	   Trk	   significantly	   beyond	   that	   induced	   by	   RA	   alone	   (Figure	   3.5).	  
Similarly	   VA	   treatment	   caused	   an	   increase	   in	   the	   levels	   of	   βIII	   tubulin,	   which	  was	  
further	   increased	   by	   VA/RA	   treatment	   in	   SH-­‐SY5Y	   cells,	   although	   this	   protein	   was	  
expressed	   at	   relatively	   high	   levels	   endogenously	   in	   both	   SK-­‐N-­‐SH	   and	   LAN-­‐5,	  
suggesting	  that	  it	  may	  mark	  immature	  cells	  of	  a	  neuronal	  lineage.	  
In	  sum,	  while	  both	  VA	  and	  RA	  are	  capable	  of	  effectively	  stimulating	  both	  cell	  
structural	  and	  biochemical	  differentiation	  as	  single	  agents,	  both	  of	  these	  parameters	  
are	  significantly	  enhanced	  with	  a	  combination	  of	  VA/RA	  treatment.	  	  
	  
3.3.2.	  Vanadate	  has	  only	  modest	  effects	  on	  the	  distribution	  of	  cells	  within	  the	  cell	  
cycle,	  and	  does	  not	  enhance	  retinoic	  acid-­‐induced	  growth	  arrest	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We	   next	   sought	   to	   examine	   whether	   the	   effects	   of	   VA	   on	   cell-­‐structural	   and	  
biochemical	  differentiation	  altered	  the	  proliferative	  capacity	  of	  NBL	  cells.	  Vanadium	  
compounds	   have	   been	   shown	   to	   cause	   cell	   cycle	   arrest	   at	   both	   the	  G1	   and	  G2/M	  
phase	  in	  lung	  and	  kidney	  cancer	  cells,	  through	  stimulation	  of	  ROS	  and	  activation	  of	  
Erk	   (Wang	   et	   al.,	   2010;	   Zhang	   et	   al.,	   2003).	   Similarly	   peroxovanadium-­‐based	  
inhibitors,	  which	  irreversibly	  inhibit	  PTPs	  through	  oxidation	  of	  the	  active	  site	  cysteine	  
residue,	  have	  been	  shown	  to	  decrease	  proliferation	  resulting	  in	  accumulation	  in	  the	  
G2/M	  phase	   of	   the	   cell	   cycle	   in	  NB-­‐12	  NBL	   cells	   (Faure	   et	   al.,	   1995).	   RA	   has	   been	  
shown	   to	   decrease	   proliferation,	   resulting	   in	   cell-­‐cycle	   arrest	   primarily	   at	   the	   G1	  
stage	   (For	  a	  review	  see	   (Melino	  et	  al.,	  1997)).	  Thus	  we	  predicted	  VA/RA	  treatment	  
would	  enhance	  growth	  arrest	  induced	  by	  both	  compounds	  	  
We	   first	   conducted	   cell-­‐cycle	   profile	   analysis	   using	   flow	   cytometry.	   RA	  was	  
observed	   to	   increase	   the	   proportion	   of	   cells	   in	   G1	   phase	   (SH-­‐SY5Y,	   LAN-­‐5)	  
accompanied	  by	  decreases	   in	   the	  number	  of	  G2/M	  phase	   cells	   (SH-­‐SY5Y,	   SK-­‐N-­‐SH)	  
and	   S	   phase	   cells	   (LAN-­‐5)	   (Figure	   3.6).	   Although	   VA	   did	   significantly	   increase	   the	  
proportion	  of	  cells	   in	  G2/M	  phase	   (SH-­‐SY5Y,	  SK-­‐N-­‐SH),	   this	   increase	  was	  modest	   in	  
comparison	   to	   that	   induced	   by	   RA	   and	   was	   unlikely	   to	   be	   the	   result	   of	   cell-­‐cycle	  
arrest.	   This	   apparent	   discrepancy	   between	   vanadate/peroxovanadium	   based	   PTP	  
inhibitors	   inducing	   G1	   or	   G2/M	   cell-­‐cycle	   arrest	   (Faure	   et	   al.,	   1995;	   Wang	   et	   al.,	  
2010;	  Zhang	  et	  al.,	  2003)	  probably	  reflects	  the	  low	  dosage	  of	  VA	  used	  in	  the	  present	  
study	   and	   the	   fact	   that	   peroxovanadium	   compounds	   cause	   irreversible	   PTP	  
inhibition.	  
	   Unlike	   the	   effects	   of	   VA/RA	   on	   neuritogenesis	   and	   biochemical	  
differentiation,	   combination	   treatment	   did	   not	   enhance	   the	   effects	   of	   RA	   alone.	  
Conversely	  we	  observed	  a	  significant	  reduction	  in	  the	  G1	  increase	  (SH-­‐SY5Y,	  LAN-­‐5)	  
G2/M	  decrease	  (SK-­‐N-­‐SH,	  SH-­‐SY5Y)	  and	  S	  phase	  decrease	  (SH-­‐SY5Y)	  that	  was	  induced	  
by	   RA	   following	   combination	   VA/RA	   treatment	   (Figure	   3.6,	   black	   bars	   versus	   dark	  
grey	   bars).	   This	   suggests	   that	   both	   compounds	   exert	   their	   effects	   on	   cell-­‐cycle	  
progression	   through	   distinct	   targets,	   which	   when	   combined	   may	   result	   in	  
competition,	   thus	  shifting	   the	  proportions	  of	  each	  cell	   cycle	  phase,	   i.e.	  VA	   induced	  
G2/M	  increases	  partially	  attenuate	  RA	  induced	  G2/M	  decreases.	  However	  this	  would	  
not	  necessarily	  result	  in	  increased	  proliferation	  if	  each	  compound	  caused	  stalling	  in	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different	   cell-­‐cycle	   phases,	   and	   may	   actually	   result	   in	   additive	   gains	   in	   cell-­‐cycle	  
blockade.	  	  	  	  	  	  	  	  	  	  
	  
Figure	  3.3.	  Vanadate	  treatment	  causes	  neurite	  outgrowth.	  Cells	  treated	  for	  6	  days	  with	  VA	  
(5µM)	  and	  RA	  (5µM),	  alone	  or	  in	  combination.	  Both	  treatments	  induced	  neurite	  outgrowth	  
(white	   arrows	   –	   D-­‐F	   and	   G-­‐I	   respectively),	   while	   VA	   enhanced	   phenotypic	   differentiation	  
induced	   by	   retinoic	   acid	   (J-­‐L).	   SK-­‐N-­‐SH	   cells	   also	   exhibted	   a	   flattened	   S-­‐type	   morphology	  
following	  RA	  treatment	  (arrowheads)	  Scale	  bar	  –	  10	  microns.	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Figure	   3.4.	   Quantification	   of	   neuritogenesis.	   Vanadate	   treatment	   significantly	   increases	  
both	  neurite	   length	  and	  the	  percentage	  of	  neurite-­‐bearing	  cells,	  and	  significantly	  enhances	  
the	   effects	   of	   retinoic	   acid	   alone.	   Graphs	   show	   means	   and	   SEM.	   Statistical	   comparisons	  
show	   two-­‐tailed,	   independent	   samples	   student’s	   t-­‐tests,	  where	   *	   =	   P<0.05;	   **	   =	   P<0.005,	  
***=P<0.001.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  3.5.	  The	  effects	  of	  VA/RA	  on	  the	  expression	  of	  neural	  differentiation	  markers.	  Cells	  
were	  treated	   for	  6	  days	  with	  VA	  (5µM)	  and	  RA	  (5µM)	  either	  separately	  or	   in	  combination.	  
Total	  Trk	  levels	  (pan-­‐Trk)	  and	  βIII	  tubulin	  levels	  are	  shown	  by	  immunoblotting.	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Given	  that	  the	  influence	  of	  VA	  and	  RA	  on	  distinct	  phases	  of	  the	  cell	  cycle	  could	  still	  
result	  in	  increases	  in	  growth	  arrest,	  we	  sought	  to	  see	  whether	  VA/RA	  led	  to	  terminal	  
differentiation	   and	   cell	   cycle	   exit,	   by	   immunostaining	   for	   the	   proliferation	  marker	  
Ki67,	  an	  antigen	  of	  unknown	  function	  that	  is	  expressed	  in	  all	  stages	  of	  the	  cell-­‐cycle	  
but	  absent	  in	  G0	  cells	  (Endl	  and	  Gerdes,	  2000).	  	  
As	  expected	  RA	  treatment	  induced	  significant	  decreases	  in	  the	  percentage	  of	  
Ki67	   positive	   cells,	   indicative	   of	   cell-­‐cycle	   exit	   (Figure	   3.7).	   However	   VA/RA	  
treatment	  did	  not	  significantly	  decrease	  the	  number	  of	  Ki67	  positive	  cells	  beyond	  RA	  
treatment	  alone,	  although	  we	  did	  observe	  a	  small	  non-­‐significant	  decrease	  in	  SK-­‐N-­‐
SH	  cells	  (Figure	  3.7,	  B).	  Similarly	  VA	  alone	  did	  not	  alter	  the	  number	  of	  Ki67	  positive	  
cells.	  Thus	  based	  on	  these	  data	   it	   is	  unlikely	  that	  VA	  exerts	  any	  major	   influence	  on	  
the	   cell	   cycle	   and	   the	  proliferative	   capacity	   of	  NBL	   cells	   over	   6	   days	   of	   treatment,	  
despite	  causing	  cell-­‐structural	  differentiation.	  	  Viewed	  from	  a	  different	  perspective,	  
if	  VA	  is	  exerting	  its	  effects	  primarily	  through	  inhibition	  of	  PTPs,	  one	  might	  expect	  an	  
increase	   in	  cell	  proliferation,	  given	   that	  PTPs	  often	  counter	   the	  growth-­‐stimulatory	  
effects	   of	   PTKs	   in	   cancer	   cells	   (See	   Chapter	   1),	   however	   VA	   did	   not	   stimulate	  
proliferation	  when	  used	  as	  a	  single	  agent	  and	  did	  not	  counter	  RA.	  	  
In	  sum,	  6	  days	  VA	  treatment	  does	  not	  result	   in	  terminal	  differentiation,	  and	  
thus	  cell-­‐structural	  changes	  resulting	  in	  neurite	  extension	  are	  more	  likely	  the	  result	  
of	  further	  neuronal	  specification	  that	  does	  not	  culminate	  in	  terminal	  differentiation	  
and	   mitotic	   arrest.	   Similarly	   VA	   does	   not	   augment	   the	   growth-­‐suppressing	  
capabilities	  of	  RA,	  however	  it	  also	  does	  not	  attenuate	  RA-­‐induced	  cell	  cycle	  exit.	  	  
	  
3.3.3.	   Effects	   of	   an	   organometallic	   vanadium	   derivative	   bis(maltolato)-­‐
oxovanadium	   IV	   (BMOV)	   and	   non-­‐vanadium	   based	   PTP	   inhibitors	   on	  
neuritogenesis	  	  
Vanadium	   has	   been	   documented	   to	   influence	   several	   enzyme	   groups	   other	   than	  
PTPs	   including	   ATPases,	   peroxidases,	   ribonucleases,	   PTKs	   and	   oxidoreductases,	   as	  
well	   as	   stimulating	   changes	   in	   gene	   expression	   and	   altering	   cellular	   redox	   state	  
(Evangelou,	   2002;	   Mukherjee	   et	   al.,	   2004).	   Thus	   we	   sought	   to	   confirm	   that	   the	  
effects	   of	   VA	   on	   neuritogenesis	   where	   primarily	   due	   to	   the	   inhibition	   of	   PTPs	   by	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examining	   the	   effects	   of	   the	   established	   PTP	   inhibitors	   sodium	   etidronate	   (EHDH)	  
and	  phenylarsine	  oxide	  (PAO)	  on	  the	  morphology	  of	  NBL	  cells.	  	  	  
	   In	   contrast	   to	   VA,	   neither	   PAO	   nor	   EHDH	   caused	   neurite	   extension	   in	   the	  
tested	  NBL	  cell	  lines.	  Specifically	  PAO	  caused	  cytotoxicity	  at	  comparatively	  low	  doses	  
(100-­‐300nM),	   whereas	   cells	   were	   unresponsive	   to	   comparatively	   high	   doses	  
(200µM)	  of	  EHDH	   (data	  not	   shown).	  We	  next	   sought	   to	  see	  whether	   the	   failure	  of	  
PAO	  or	   EHDH	   to	   stimulate	  neurite	   extension	  was	  due	   to	  weak	   affinity	   for	   PTPs	  by	  
examining	   changes	   in	   total	   cellular	   phosphotyrosine	   (pTyr)	   levels	   following	   short-­‐
term	  treatment.	  However	  we	  did	  not	  observe	  any	  consistent,	  gross	  changes	  in	  pTyr	  
following	  treatment	  with	  any	  PTP	  inhibitor,	   including	  VA,	  at	  the	  doses	  used	  (Figure	  
3.8).	  	  
We	  next	  sought	  to	  examine	  whether	  the	  neuritogenesis	  stimulating	  ability	  of	  
VA	   was	   specific	   to	   vanadium	   compounds	   rather	   than	   a	   general	   property	   of	   PTP	  
inhibition.	   	   Thus	   we	   tested	   the	   organometallic	   vanadium	   derivative	  
bis(maltolato)oxovanadium	   IV	   (BMOV),	   a	   reversible,	   competitive	   phosphatase	  
inhibitor	  with	  a	  similar	  ability	  of	  VA	  to	  deliver	  uncomplexed	  vanadium	  (VO4)	  to	  the	  
active	  site	  of	  PTPs	  (Peters	  et	  al.,	  2003).	  BMOV	  was	  found	  to	  cause	  neurite-­‐extension	  
to	   a	   similar	   degree	   to	   VA	   (Figure	   3.9).	   	   The	   neuritogenesis	   exhibited	   by	   BMOV-­‐
treated	  NBL	   cells	  was	   highly	   reminiscent	   of	   VA	   treated	   cells,	  with	   aggregating	   cell	  
bodies	   extending	   elongated	   neurites	   rather	   than	   forming	   dispersed	   neuronal	  
networks.	  Although	  a	  10µM	  dose	  of	  BMOV	  was	  required	  to	  achieve	  a	  similar	  degree	  
of	   neuritogenesis,	   we	   did	   not	   note	   non-­‐specific	   cytotoxicity	   at	   this	   or	   a	   two-­‐fold	  




















Figure	  3.6.	  The	  effects	  of	  VA/RA	  on	  cell-­‐cycle	  distribution.	  Cells	  were	  treated	  for	  6	  days	  
with	  VA	   (5µM)	  and	  RA	   (5µM)	  both	  alone	  and	   in	   combination,	   then	  processed	   for	   flow	  
cytometry	  using	  propidium	  iodide.	  The	  proportions	  of	  the	  cells	  in	  each	  stage	  of	  the	  cell	  
cycle	   are	   shown	   in	   representative	   cell-­‐cycle	   distribution	   histograms	   (A)	   and	  means	   of	  
data	   taken	   from	   6	   experiments	   (B).	   Graphs	   show	   means	   and	   SEM.	   Statistical	  
comparisons	  show	  two-­‐tailed,	  independent	  samples	  student’s	  t-­‐tests,	  where	  *	  =	  P<0.05;	  
**	  =	  P<0.005,	  ***=P<0.001.	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Figure	  3.7.	  VA	  does	  not	  cause	  cell-­‐cycle	  arrest.	  Cells	  were	  treated	  for	  6	  days	  with	  VA	  (5µM)	  
and	  RA	  (5µM)	  both	  alone	  and	  in	  combination.	  Representative	  images	  (A)	  and	  histograms	  (B)	  
showing	  the	  proportion	  of	  Ki67	  positive	  cells,	  which	  is	  decreased	  by	  RA	  but	  not	  VA.	  Scale	  bar	  
=	   10	   microns.	   Graphs	   show	   means	   and	   SEM.	   Statistical	   comparisons	   show	   two-­‐tailed,	  
independent	  samples	  student’s	  t-­‐tests,	  where	  *	  =	  P<0.05;	  **	  =	  P<0.005,	  ***=P<0.001.	  	  
	  
	  
Figure	  3.8.	  Phosphotyrosine	  levels	  after	  PTP	  inhibition.	  2	  hour	  treatment	  of	  LAN5	  NBL	  cells	  
with	   (5µM)	   VA	   or	   RA	   does	   not	   alter	   intracellular	   levels	   of	   pTyr,	   nor	   do	   the	   alternative	  
phosphatase	  inhibitors	  3-­‐4	  dephostatin	  (5µM),	  PAO	  (200nm)	  and	  EHDH	  (200µM).	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We	   next	   tested	   whether	   low-­‐dose	   BMOV	   treatment	   stimulated	   gross	   changes	   in	  
cellular	  pTyr	  levels,	  indicative	  of	  widespread	  PTP	  inhibition.	  	  Immunoblotting	  for	  pTyr	  
revealed	   a	   lack	  of	   gross	   changes	   in	   pTyr	   levels	   induced	  by	  BMOV	   treatment	  up	   to	  
100µM,	  similar	  to	  the	  effects	  of	  VA	  (Figure	  3.10).	  This	  is	  in	  accordance	  with	  previous	  
findings	   suggesting	   that	   neither	   VA	   nor	   BMOV	   stimulate	   pTyr	   accumulation	  
compared	   to	   the	   peroxovanadium	   compound	   sodium	   oxodiperoxo(1,10-­‐
phenanthroline)vanadate(V)	   (pV(phen)),	   an	   irreversible	   inhibitor	   of	   PTPs	   (Krejsa	   et	  
al.,	   1997).	   This	   suggests	   that	   rather	   than	   non-­‐specifically	   inhibiting	   the	   entire	   PTP	  
family	   with	   similar	   efficacy,	   both	   VA	   and	   BMOV	   may	   exert	   their	   actions	   through	  
more	  selective	  inhibition	  of	  a	  smaller	  range	  of	  enzymes,	  thus	  leading	  to	  only	  minor	  
changes	  in	  pTyr	  levels.	  Alternatively	  VA	  and	  BMOV	  induced	  neurite-­‐extension	  could	  
be	  achieved	  independently	  of	  PTPs,	  given	  that	  vanadium	  compounds	  exert	  effects	  on	  
a	   number	   of	   enzyme	   groups,	   as	   well	   as	   stimulating	   the	   production	   of	   ROS	   (see	  
section).	   	   In	   line	  with	   this	   Kresja	  et	   al.	   suggest	   that	   pV(phen)	   induced	   intracellular	  
pTyr	   accumulation	   is	   primarily	   the	   result	   of	   ROS	   stimulation	   rather	   than	   PTP	  
inhibition	  alone	  (Krejsa	  et	  al.,	  1997).	  
In	  sum,	  the	  effects	  of	  VA	  on	  neuritogenesis	  are	  not	  shared	  by	  non-­‐vanadium	  
based	   PTP	   inhibitors,	   but	   are	   mimicked	   by	   the	   vanadium	   derivative	   BMOV.	  
Furthermore	  neither	  BMOV	  nor	  VA	   causes	  detectable	   changes	   in	   total	   pTyr	   levels,	  
suggesting	  that	  their	  effects	  may	  be	  the	  result	  of	  either	  more	  selective	  PTP	  inhibition	  
or	  non-­‐PTP	  related	  consequences	  of	  vanadium	  treatment.	  However	  analysis	  of	  signal	  
transduction	   following	   BMOV	   and	   VA	   treatment	   suggests	   that	   PTP	   inhibition	   is	   a	  
likely	   candidate	   in	  mediating	   the	   phenotypic	   effects	   of	   vanadium	   compounds	   (see	  
below).	  
	  
	   122	  
	  
Figure	  3.9.	  Bis(maltolato)oxovanadium	  IV	  (BMOV)	  induces	  neurite-­‐extension.	  Cells	  treated	  
for	  6	  days	  with	  VA	  (5µM)	  or	  BMOV	  (10µM)	  both	  exhibit	  neurite	  outgrowth	  (white	  arrows)	  to	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Figure	   3.10.	  Phosphotyrosine	   levels	   following	   treatment	  with	   BMOV	   and	   VA.	   LAN5	   cells	  
treated	   for	   2	   hours	   with	   BMOV	   and	   VA	   at	   varying	   doses.	   Neither	   compound	   causes	  
detectable	   alterations	   in	   cellular	   pTyr	   levels	   at	   dosages	   capable	   of	   stimulating	   phenotypic	  
effects.	  PC	  =	  positive	  control	  of	  5	  minute	  treatment	  with	  1mM	  pervanadate.	  	  
	  
3.3.4.	  Vanadium	  compounds	  and	  retinoic	  acid	  synergistically	  activate	  both	  Erk1/2	  
and	  Akt,	  which	  is	  sustained	  throughout	  differentiation	  and	  is	  independent	  of	  ROS	  
production	  
Although	   neither	   BMOV	   nor	   VA	   treatment	   led	   to	   an	   obvious	   accumulation	   of	  
intracellular	   pTyr,	   we	   hypothesized	   that	   both	   compounds	   may	   be	   exerting	   more	  
selective	  alterations	  in	  phosphotyrosine	  signalling	  within	  a	  limited	  set	  of	  intracellular	  
signalling	   cascades.	   We	   also	   predicted	   that	   activation	   of	   signalling	   nodes	   might	  
underlie	   the	   enhancement	   of	   RA-­‐induced	   neuritogenesis	   with	   combination	   VA/RA	  
treatment,	  given	  that	  a	  number	  of	  major	  signalling	  pathways	  have	  been	  implicated	  
in	  RA-­‐induced	  differentiation	  (Niles,	  2004).	  	  
We	   initially	   focused	   on	   the	   Ras/RAF/MEK/Erk	   and	   the	   PI3K/Akt	   pathways,	  
owing	  to	  their	  importance	  in	  a	  number	  of	  cellular	  processes	  including	  differentiation,	  
proliferation	  and	  programmed-­‐cell	  death	  (see	  Chapter	  1).	  	  Immunoblotting	  revealed	  
that	  both	  RA	  and	  VA	  activated	  Erk1/2	  (Erk	  hereafter)	  and	  Akt,	  the	  effectors	  of	  both	  
of	   these	  pathways	   respectively,	   to	   a	   similar	  degree	   in	   two	  NBL	   cell	   lines	   (SK-­‐N-­‐SH,	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LAN-­‐5)	   that	   respond	   to	   both	   treatments	   with	   neuritogenesis	   (Figure	   3.11,	   A).	  
However,	  more	  surprisingly	  combination	  VA/RA	  and	  BMOV/RA	  treatment	  induced	  a	  
clearly	   synergistic	   augmentation	   of	   this	   response,	   causing	   hyperactivation	   of	   both	  
pathways.	   Importantly	   this	  effect	  was	  not	  exhibited	   in	   two	  NBL	  cell	   lines	   (SK-­‐N-­‐AS,	  
SK-­‐N-­‐DZ)	   that	   did	   not	   undergo	   neuritogenesis	   following	   treatment	   with	   either	  
compound	   (Figure	   3.11,	   C),	   but	   it	   did	   occur	   in	   two	  NBL	   cell	   lines	   that	   respond	   to	  
vanadium	   compounds	   by	   undergoing	   cell	   death	   and	   to	   RA	   by	   undergoing	   growth-­‐
suppression	   (Figure	   3.11,	   B)	   (See	   Chapter	   5),	   suggesting	   that	   this	   was	   not	   a	   non-­‐
specific	  consequence	  of	  vanadium	  compound	  treatment.	  	  
	   We	  also	  examined	  the	  expression	  levels	  of	  the	  prognostic	  marker	  Mycn	  (see	  
Chapter	   1),	   which	   have	   been	   documented	   to	   decrease	   following	   RA	   treatment	  
(Thiele	   et	   al.,	   1985)	   and	   increase	   following	   PI3K	   stimulation	   (Chesler	   et	   al.,	   2006).	  
Although	  VA	  and	  BMOV	  alone	  caused	  a	  slight	  upregulation	  of	  Mycn	  (SK-­‐N-­‐DZ,	  LAN5),	  
neither	   compound	   affected	   the	   ability	   of	   RA	   to	   decrease	   expression	   levels	   (Figure	  
3.11),	  despite	  hyperactivation	  of	  Akt	  suggestive	  of	  PI3K	  stimulation.	  	  
The	   functional	   consequences	   of	   intracellular	   signalling	   cascades	   are	   highly	  
dependent	   on	   the	   duration	   of	   activation.	   For	   instance,	   Erk	   activation	   has	   been	  
shown	   to	   exert	   contrasting	   effects	   of	   proliferation	   and	   differentiation	   following	  
either	  transient	  or	  sustained	  stimulation	  respectively,	  in	  PC12	  cells	  (Marshall,	  1995).	  
This	  has	  been	  suggested	  to	  be	  a	  consequence	  of	  differential	   interaction	  of	  effector	  
proteins	   (von	   Kriegsheim	   et	   al.,	   2009).	   Thus	   we	   sought	   to	   characterize	   the	   time-­‐
course	  of	  Erk/Akt	  stimulation	  induced	  by	  vanadium	  compounds	  and	  retinoic	  acid	  in	  
combination,	  primarily	   focusing	  on	  BMOV.	  Activation	  of	  both	  Erk	  and	  Akt	   failed	   to	  
occur	   following	   short-­‐term	   treatment	   with	   BMOV/RA	   (Figure	   3.12,	   A).	   In	   fact	  
stimulation	   only	   became	   apparent	   between	   2.5-­‐10	   hours,	   sharply	   peaking	   at	   the	  
latter,	   despite	   the	   effects	   of	   PTP	   inhibitors	   often	   occurring	   following	   as	   little	   as	   5	  
minutes	  of	  treatment	  (Mak	  et	  al.,	  2010).	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Figure	   3.11.	   Hyperactivation	   of	   Akt	   and	   Erk	   following	   VA/RA	   and	   BMOV/RA	   treatment.	  
Cells	  were	  treated	  for	  24	  hours	  with	  VA	  (5µM),	  BMOV	  (10µM)	  and	  RA	  (5µM).	  Both	  cell	  lines	  
that	   respond	   to	   vanadium	   compounds	   and/or	   RA	   by	   undergoing	   neuritogenesis	   (A)	   and	  
vanadium	  compounds	  alone	  by	  undergoing	  cell	  death	  (B)	  respond	  to	  combination	  VA/RA	  or	  
BMOV/RA	   treatment	   by	   hyperactivation	   of	   Akt	   and	   Erk	   while	   cell	   lines	   which	   are	  
phenotypically	  unresponsive	  to	  treatment	  (C)	  do	  not.	  Vanadium	  compounds	  do	  not	  reduce	  
the	   expression	   of	   Mycn	   but	   do	   not	   interfere	   with	   its	   downregulation	   by	   RA	   in	   Mycn	  
amplified	  cell	  lines	  (LAN-­‐5,	  KCNR,	  Kelly,	  SK-­‐N-­‐DZ).	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Given	  that	   long-­‐term	  stimulation	  is	  associated	  with	  cellular	  differentiation,	  we	  next	  
sought	   to	   examine	   whether	   the	   latent	   activation	   of	   Akt/Erk	   was	   sustained	   or	  
whether	  this	  activation	  was	  a	   transient	  event.	  Following	  BMOV/RA	  treatment	  both	  
Akt	   and	  Erk	   remained	  activated	  at	   a	   steady	   state	   for	  72	  hours	   following	   the	   initial	  
activation	   at	   10	   hours	   (Figure	   3.12,	   B).	   Again	   SK-­‐N-­‐SH	   cells	   exhibited	   maximal	  
stimulation	   after	   12	   hours	   that	   remained	   constant,	   while	   LAN-­‐5	   cells	   were	   only	  
partially	  activated	  after	  12	  hours	  requiring	  48	  hours	  to	  achieve	  full	  stimulation.	  	  
	   Given	  that	  the	  morphological	  effects	  of	  retinoic	  acid	   induced	  differentiation	  
generally	   manifest	   after	   48-­‐72	   hours	   treatment,	   we	   wished	   to	   examine	   whether	  
activation	   of	   Akt/Erk	   by	   BMOV/RA	   treatment	   occurred	   prior	   to	   the	   onset	   of	  
morphological	   differentiation	   before	   returning	   to	   basal	   levels	   following	  
differentiation.	   However	   after	   6	   days	   of	   treatment	   NBL	   cells	   still	   exhibited	  
hyperactivation	   of	   both	   Akt	   and	   Erk,	   remaining	   comparable	   to	   that	   seen	   after	  
shorter	   treatment	   periods	   (Figure	   3.12,	   C).	   As	   before	   SK-­‐N-­‐SH	   cells	   remained	   fully	  
activated	   from	  3-­‐6	  days	  with	   the	   intensity	  of	   signalling	  still	   rising	  between	  3	  and	  6	  
days	  of	  treatment,	  while	  LAN-­‐5	  cells	  exhibited	  a	  similar	  profile	  but	  to	  a	  lesser	  degree	  
of	  stimulation.	  	  
Activation	   of	   protein-­‐kinases	   following	   PTK	   receptor	   stimulation	   is	   a	   likely	  
consequence	  of	  PTP	  inhibition,	  given	  that	  the	  latter	  exert	  negative	  regulation	  of	  PTK	  
driven	   signalling	   cascades	   (Ostman	   and	  Böhmer,	   2001).	   	   However	  we	  obtained	  no	  
formal	   proof	   that	   the	   effects	   of	   vanadium	   compounds	   are	   solely	   due	   to	   PTP	  
inhibition	   (See	   section	   4.3.3).	   Thus	   we	   sought	   to	   rule	   out	   the	   possibility	   that	  
stimulation	   of	   Akt	   and	   Erk	   was	   the	   result	   of	   auxiliary	   consequences	   of	   BMOV	  
treatment	   i.e.	   the	   production	   of	   ROS,	   which	   are	   frequently	   induced	   by	   vanadium	  
compounds	   (Wang	   et	   al.,	   2010;	   Wu	   et	   al.,	   2009)	   leading	   to	   the	   activation	   of	  
intracellular	  signalling	  cascades.	  Thus	  we	  examined	  Akt	  and	  Erk	  stimulation	  following	  
treatment	   with	   the	   reducing	   agent	   NAC	   in	   order	   to	   reduce	   free	   radicals.	   NAC	  
however	   caused	  no	  discernible	   reduction	   in	   the	   stimulation	  of	  either	  Akt	  or	   Erk	   in	  
both	  SK-­‐N-­‐SH	  and	  LAN-­‐5	  cells	  (Figure	  3.12,	  D).	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Figure	   3.12.	   Timecourse	   and	   ROS-­‐independence	   of	   Akt	   and	   Erk	   hyperactivation.	   (A)	  
Activation	  of	  both	  Akt	  and	  Erk	  occurs	  following	  treatment	  of	  NBL	  cells	  with	  a	  combination	  of	  
BMOV	  (10µM)	  and	  RA	  (5µM)	  after	  2.5	  hours	  but	  sharply	  peaks	  after	  10	  hours.	   (B)	  Akt	  and	  
Erk	  remain	  highly	  activated	  following	  activation	  onset	  up	  to	  72	  hours	  after	  stimulation	  with	  
BMOV/RA.	   (C)	   Activation	  of	  Akt	   and	  Erk	   is	   fully	   sustained	   throughout	  6	  days	  of	  BMOV/RA	  
treatment.	   (D)	   Cells	   were	   pretreated	   with	   the	   reducing	   agent	   NAC	   (2mM)	   for	   2	   hours,	  
followed	   by	   24	   hour	   treatment	   with	   BMOV/RA,	   revealing	   Akt	   and	   Erk	   activation	   is	  
independent	  of	  ROS	  production.	  	  
	  
In	   sum,	   it	   has	   been	   shown	   that	   while	   RA	   and	   both	   of	   the	   vanadium	   compounds	  
BMOV	   and	   VA	   independently	   cause	   activation	   of	   both	   Akt	   and	   Erk,	   the	   level	   of	  
activation	   seen	   following	   combination	   treatment	   is	   suggestive	   of	   synergistic	  
hyperactivation,	   which	   occurs	   only	   in	   NBL	   lines	   that	   respond	   phenotypically	   to	  
vanadium	  compounds.	  Furthermore,	  rather	  than	  being	  an	  acute,	  transient	  effect	  of	  
treatment,	   the	   activation	   kinetics	   of	   these	   enzymes	   occur	   several	   hours	   following	  
treatment	   and	   are	   sustained	   throughout	   6	   days	   of	   treatment,	   over	   which	   time	  
morphological	  differentiation	  occurs.	  Finally	  activation	  of	  both	  of	   these	  enzymes	   is	  
not	  a	  consequence	  of	  ROS	  production,	  suggestive	  of	  PTP	  inhibition	  being	  responsible	  
instead.	  	  
	  
3.3.5.	   The	   functional	   consequences	   of	   Akt	   and	   Erk	   activation	   by	   BMOV/RA	  
treatment	  on	  cellular	  differentiation	  and	  cell	  survival	  
As	   previously	   discussed,	   activation	   of	   both	   Akt	   and	   Erk	   can	   result	   in	   diverse	  
outcomes	   ranging	   from	   altered	   proliferative	   ability,	   enhanced	   cell	   survival,	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differentiation	   or	   PCD,	   often	   depending	   on	   the	   time-­‐course	   of	   stimulation	   (see	  
Chapter	  1).	  RA-­‐induced	  differentiation	  of	  SH-­‐SY5Y	  NBL	  cells	  has	  been	  suggested	  to	  be	  
both	   independent	   of	   Erk	   (Miloso	   et	   al.,	   2004)	   and	   dependent	   on	   PI3K	   signalling	  
(López-­‐Carballo	   et	   al.,	   2002),	   although	   the	   role	   of	   different	   signalling	   pathways	   is	  
clouded	   due	   to	   conflicting	   evidence	   of	   involvement	   of	   any	   one	   pathway	   (Clagett-­‐
Dame	  et	  al.,	  2006).	  Inhibition	  of	  PTPs	  using	  the	  omega-­‐3	  fatty	  acid	  docosahexaenoic	  
acid	  has	  also	  been	  shown	  to	  rely	  on	  Erk	  activation	  for	  neurite	  extension	  in	  the	  same	  
cell	   type	   (Wu	   et	   al.,	   2009).	   Thus	  we	   hypothesized	   that	   the	   hyperactivation	   of	   Erk	  
and/or	   Akt	   exhibited	   by	   BMOV/RA-­‐treated	   cells	   that	   precedes	   neuronal	  
differentiation	   and	   remains	   following	   it,	   could	   be	   functionally	   responsible	   for	  
augmentation	   of	   retinoic	   acid	   induced-­‐morphological	   differentiation	   and	  
upregulation	   of	   neuronal	   markers	   following	   combined	   vanadium	   compound	  
treatment	  (See	  4.3.1).	  	  
In	   order	   to	   test	   this	   possibility,	   we	   used	   inhibitors	   of	   both	  MEK	   and	   PI3K,	  
enzymes	   upstream	   of	   Erk	   and	   Akt	   respectively	   and	   examined	   morphological	  
differentiation	   following	   treatment	   with	   BMOV,	   RA	   and	   BMOV/RA	   for	   6	   days.	  
Inhibition	   of	   MEK	   (and	   hence	   Erk)	   with	   U0126	   effectively	   blocked	   BMOV-­‐induced	  
neurite	   extension	   in	   SK-­‐N-­‐SH,	   LAN-­‐5	   and	   SH-­‐SY5Y	   cells	   (Figure	   3.13,	   A,	   B,	   C	  
respectively),	  which	  was	  unaffected	  by	  inhibition	  of	  PI3K/Akt	  with	  LY294002	  except	  
in	   the	   case	   of	   SH-­‐SY5Y	   cells.	   	   In	   contrast,	   RA-­‐induced	   neurite	   outgrowth	   was	  
unaffected	  by	  MEK/Erk	  inhibition,	  but	  was	  abrogated	  in	  both	  SK-­‐N-­‐SH	  and	  SH-­‐SY5Y,	  
but	   not	   LAN-­‐5	   cells,	   by	   inhibition	   of	   PI3K/Akt	  with	   LY294002.	   BMOV/RA-­‐mediated	  
neurite	  outgrowth	  was	  only	  partially	  attenuated	  by	  PI3K/Akt	  inhibition	  (SK-­‐N-­‐SH)	  and	  
both	  MEK/Erk	  and	  PI3K/Akt	  inhibition	  (SH-­‐SY5Y)	  though	  this	  did	  not	  extend	  to	  LAN-­‐5	  
cells.	  	  
	   These	  results	  are	  difficult	  to	  interpret	  given	  that	  the	  toxicity	  associated	  with	  
the	   first	   generation	   MEK	   (U0126)	   and	   PI3K	   (LY294002)	   inhibitors	   respectively	   at	  
doses	   that	   achieve	   effective	   enzyme	   inhibition	   precluded	   quantitative	   analysis	   of	  
neurite	   length/percentage	  of	  neuritogenesis	  and	   immunoblotting	   to	  determine	   the	  
expression	  of	  differentiation	  markers.	  However,	   taken	   together	   this	  again	   suggests	  
that	   the	   abilities	   of	   both	  BMOV	  and	  RA	   to	  promote	  neurite	   extension	   are	   at	   least	  
partly	   independent	   of	   each	   other,	   and	   mediated	   by	   Erk+Akt	   and	   Akt	   activation,	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respectively.	   In	   the	   case	   of	   combined	   BMOV/RA	   treatment,	   which	   causes	  
hyperactivation	   of	   both	   pathways,	   there	   may	   be	   a	   very	   strong	   neurite-­‐extension	  
signal,	  giving	  rise	  to	  redundancy	  between	  the	  two	  pathways	  manifesting	  in	  neurite-­‐
extension	  that	  is	  affected	  to	  a	  lesser	  degree	  by	  either	  MEK/Erk	  inhibition	  or	  PI3K/Akt	  
inhibition	   alone.	   This	   again	   could	   support	   distinct	   but	   overlapping	   signalling	  
networks	  affected	  by	  BMOV	  and	  RA.	  Alternatively	  both	  U0126/LY294002	  may	  simply	  
be	  achieving	  less	  effective	  inhibition	  of	  cells	  treated	  with	  BMOV/RA	  in	  combination	  
compared	  with	   those	   treated	   separately	   due	   to	   higher	   activation	   levels.	   	   In	   either	  
case	  these	  data	  argues	  against	  a	  functional	  role	  for	  hyperactivation	  of	  Akt	  and	  Erk	  in	  
neurite-­‐extension,	   given	   that	   the	   morphological	   difference	   observed	   between	   RA	  
treated	   cells	   versus	   BMOV/RA	   treated	   cells	   is	   relatively	   minor	   compared	   to	   the	  
difference	  in	  activation	  state.	  	  
Given	   that	   hyperactivation	   of	   Akt	   and	   Erk	   caused	   by	   BMOV/RA	   treatment	  
does	   not	   seem	   to	   result	   in	   comparable	   increases	   in	   neuritogenesis,	   we	   instead	  
hypothesized	   that	   it	   may	   enhance	   cell-­‐survival	   of	   morphologically	   differentiated	  
cells.	  Thus	  we	  analysed	  cell	  viability	   following	  6	  days	  of	   treatment	  with	  BMOV	  and	  
RA	  both	  separately	  and	  in	  combination	  with	  inhibitors	  of	  MEK	  and	  PI3K.	  As	  expected	  
we	   observed	   a	   decrease	   in	   cell	   numbers	   following	   treatment	  with	   BMOV,	   RA	   and	  
BMOV/RA	   following	   6	   days	   treatment	   (Figure	   3.14)	   presumably	   due	   to	   decreased	  
proliferative	   rates	   (SK-­‐N-­‐SH)	   and	   decreased	   cell	   viability	   for	   BMOV	   (LAN-­‐5).	   RA	  
treatment	  was	  highly	  effective	  at	  reducing	  cell	  numbers,	  while	  BMOV/RA	  modestly	  
but	   not	   significantly	   reduced	   this	   effect	   in	   SK-­‐N-­‐SH	   cells,	   suggesting	   that	   while	  
morphological	   differentiation	   occurred	   in	   SK-­‐N-­‐SH	   following	   BMOV/RA	   treatment,	  
cell	  division/survival	  was	  not	  suppressed	   to	  quite	   the	  same	   level	  as	  with	  RA	  alone.	  
However	  both	  U0126	  and	  LY294002	  reduced	  this	  effect	  in	  SK-­‐N-­‐SH	  cells,	  suggesting	  
that	   the	  hyperactivation	  of	  Akt/Erk	   seen	   in	  BMOV/RA	   treated	   cells	   compared	  with	  
RA	  alone	  results	  in	  a	  small	  increase	  in	  cell-­‐survival/proliferation,	  that	  is	  abrogated	  by	  














Figure	   3.13.	   Effects	   of	  MEK/PI3K	   inhibition	   on	  morphological	   differentiation	   induced	  
by	  BMOV/RA.	  Cells	  were	  treated	  with	  BMOV	  (10µM)	  and	  RA	  (5µM)	  both	  alone	  and	   in	  
combination,	  with	  and	  without	  the	  MEK	  inhibitor	  U0126	  (20µM)	  and	  the	  PI3K	  inhibitor	  
LY294002	   (20µM)	   for	   6	   days.	   U0126	   partially	   abrogated	   BMOV	   induced	   neurite	  
outgrowth	   (white	  arrows)	   instead	  causing	  cells	   to	  exhibit	   small,	  neuroblastic	  processes	  
(arrow	  heads),	  while	  a	  similar	  effect	  was	  observed	  with	  RA	  treatment	  by	  LY294002.	  Scale	  
bar	  =	  10	  microns.	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Figure	  3.14.	  Effects	  of	  MEK/PI3K	   inhibition	  on	  growth	  arrest	   induced	  by	  BMOV/RA.	  Cells	  
were	   treated	  with	  BMOV	   (10µM)	  and	  RA	   (5µM)	  alone	  and	   in	   combination	  as	  well	   as	  with	  
and	  without	  the	  MEK	  inhibitor	  U0126	  (20µM)	  and	  the	  PI3K	  inhibitor	  LY294002	  (20µM)	  for	  6	  
days.	  Neither	  U0126	  nor	   LY294002	   significantly	  abrogated	  RA/BMOV-­‐induced	  decreases	   in	  
the	   percentage	   of	   viable	   cells	   as	   assayed	   by	   crystal	   violet	   staining.	   Means	   and	   standard	  
deviation	  from	  3	  independent	  experiments.	  
	  
In	   sum,	   inhibiting	   BMOV-­‐induced	   activation	   of	   Erk	   and	   to	   a	   lesser	   extent	   Akt,	  
inhibited	  neurite	  extension	  while	  inhibiting	  RA	  induced	  activation	  of	  Akt	  not	  Erk	  had	  
the	  same	  effect,	  suggesting	  that	  neurite-­‐extension	  is	  mediated	  by	  distinct	  signalling	  
pathways	   in	   the	   case	   of	   BMOV	  and	  RA,	  which	   cause	   additive	   effects.	   Inhibition	   of	  
both	  Akt	  and	  Erk	  in	  the	  case	  of	  combined	  BMOV/RA	  treated	  cells	  was	  less	  effective	  
at	   abrogating	   neurite	   extension,	   however	   this	   may	   suggest	   redundancy	   between	  
these	  two	  pathways.	  BMOV/RA	  treatment	  also	  resulted	  in	  a	  modest	  increase	  in	  the	  
number	   of	   viable	   cells	   in	   SKNSH	   compared	   with	   RA	   treatment	   alone,	   which	   was	  
attenuated	   by	   inhibition	   of	   Akt	   and	   Erk,	   suggesting	   that	   hyperactivation	   could	  
enhance	  cell-­‐survival	  following	  differentiation	  although	  this	  effect	  was	  limited	  to	  SK-­‐
N-­‐SH	  cells	  only.	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3.3.6.	   BMOV	   sustains	   retinoic	   acid-­‐induced	   differentiation	   in	   the	   absence	   of	  
ongoing	  treatment,	  causing	  senescence	  	  
Oncogene-­‐induced	  senescence	  (OIS)	   is	  a	  form	  of	  replicative	  senescence	  that	  occurs	  
following	  the	  activation	  of	  proto-­‐oncogenes	  as	  a	  fail-­‐safe	  mechanism	  against	  tumour	  
formation	  (Braig	  and	  Schmitt,	  2006;	  Collado	  and	  Serrano,	  2010).	  OIS	  has	  been	  shown	  
to	  result	  from	  constitutive	  activation	  of	  both	  Ras/MAPK	  (Lin	  et	  al.,	  1998;	  Michaloglou	  
et	  al.,	  2005;	  Serrano	  et	  al.,	  1997;	  Wajapeyee	  et	  al.,	  2008)	  and	  PI3K/Akt	  (Chen	  et	  al.,	  
2005;	   Nogueira	   et	   al.,	   2008)	   signalling,	   and	   generally	   occurs	   via	   a	   DNA	   damage	  
response	   invoking	  p53	   and/or	   cell	   cycle	   inhibitors	   such	   as	  p164INK4A	   (Beauséjour	   et	  
al.,	   2003;	   Schmitt	   et	   al.,	   2002).	   The	   activation	   of	   OIS	   has	   been	   shown	   to	   directly	  
result	   in	   tumour	  regression	  and	  thus	  could	  be	  viewed	  as	  a	  novel	  means	  of	   tumour	  
targeting,	  especially	  due	  to	  the	  lack	  of	  obvious	  side	  effects	  (Wu	  et	  al.,	  2007;	  Xue	  et	  
al.,	  2007).	  	  
	   Several	   lines	   of	   evidence	   link	   the	   novel	   NBL	   combination	   therapy	   of	  
BMOV/RA	   treatment	   with	   OIS.	   First,	   hyperactivation	   of	   proto-­‐oncogene	   signalling	  
pathways	   has	   been	   demonstrated	   to	   be	   crucial	   for	   OIS	   induction	   (Sarkisian	   et	   al.,	  
2007).	  This	  is	  applicable	  to	  the	  current	  study	  given	  the	  dramatic	  increases	  in	  both	  Akt	  
and	  Erk	  activation	  following	  BMOV/RA	  treatment.	  Second,	  the	  effects	  of	  BMOV	  are	  
thought	   to	  occur	  primarily	   via	  PTP	   inhibition,	  which	   could	   clearly	  either	  directly	  or	  
indirectly	   activate	   targets	   of	   OIS	   via	   upstream	   RTK	   signalling.	   This	   has	   been	  
demonstrated	   for	   instance	   by	   inhibition	   of	   the	   dual-­‐specificity	   PTP	   PTEN,	   which	  
increases	  the	  levels	  of	  activated	  Akt,	  resulting	  in	  senescence	  (Alimonti	  et	  al.,	  2010b).	  
Furthermore	  RA	  has	  actually	  been	  demonstrated	  to	  activate	  replicative	  senescence	  
in	  an	  schwannian-­‐type	  subclone	  of	   the	  NBL	   line	  SK-­‐N-­‐SH	   (Wainwright	  et	  al.,	  2001).	  
Last,	   the	  wild-­‐type	  p53	  status	  of	  a	  number	  of	  NBL	  cell	   lines	  has	  been	  suggested	  to	  
prime	  them	  for	  the	  induction	  of	  senescence	  for	  instance	  by	  stabilization	  of	  p53	  (Van	  
Maerken	  et	  al.,	  2006).	  
Although	   we	   did	   not	   observe	   changes	   in	   the	   level	   of	   cell-­‐cycle	  
exit/proliferative	   index	  following	  short-­‐term	  (6	  day)	  treatment	  with	  BMOV/RA	  (See	  
4.3.3-­‐4),	   we	   sought	   to	   examine	   whether	   longer-­‐term	   treatment	   with	   these	  
compounds	   enhanced	   growth	   arrest	   further	   than	   RA	   alone.	   Further	   more	   we	  
obtained	  evidence	  that	  hyperactivation	  of	  Akt	  and	  Erk	  was	  still	  increasing	  following	  6	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days	  of	  treatment,	  which	  could	  drive	  cells	  into	  senescence.	  To	  test	  this,	  we	  reasoned	  
that	   if	   BMOV/RA	   induced	   replicative	   senescence	   then	   this	   should	   ensue	   during	  
treatment	  but	  crucially	  remain	  after	  treatment	  withdrawal.	  Thus	  cells	  were	  treated	  
with	  both	  RA	  and	  RA/BMOV	  for	  a	  period	  of	  12	  days,	   followed	  by	  a	   ‘rescue’	  period	  
during	   which	   treatment	   was	   removed	   and	   replaced	   with	   normal	   culture	  medium.	  
Remarkably	   in	   SK-­‐N-­‐SH	   and	   LAN-­‐5	   this	   resulted	   in	   cells	   that	   remained	   highly	  
differentiated,	  as	  judged	  by	  elongated	  processes	  and	  condensed	  cell	  bodies,	  only	  in	  
cells	   treated	   with	   BMOV/RA	   (Figure	   3.15).	   While	   undergoing	   similar	   initial	  
morphological	  differentiation,	   cells	   treated	  with	  RA	   (only)	  were	  observed	   to	   revert	  
back	  to	  a	  proliferative	  neuroblastic	  phenotype	  resembling	  untreated	  cells.	   	  Notably	  
BMOV/RA	   treatment	   often	   resulted	   in	   the	   formation	   of	   pseudo-­‐ganglia,	   i.e.	  
aggregates	   of	   differentiated	   cell	   bodies	   projecting	  processes	   outwards	   reminiscent	  
of	   the	  phenotype	  of	  dorsal-­‐root	  ganglia	   in	  vitro.	  Although	   this	  has	  previously	  been	  
reported	   for	   RA	   treatment,	   these	   structures	   remained	   in	   the	   absence	   of	   any	  
treatment	  in	  the	  BMOV/RA	  condition.	  	  
Given	   the	  apparent	  growth	  arrest	  of	  BMOV/RA	  rescued	  cells,	  we	  wished	   to	  
examine	  whether	  these	  cells	  had	  undergone	  replicative	  senescence.	  To	  test	  this	  we	  
assessed	   levels	   of	   senescence-­‐associated	   β-­‐galactosidase	   (SA-­‐β-­‐Gal),	   following	   the	  
same	   treatment-­‐rescue	   procedure.	   SA-­‐β-­‐Gal	   has	   been	   shown	   to	   specifically	   label	  
senescent	   cells	   at	   an	   acidic	   pH	   (pH	   6.0)	   due	   to	   the	   accumulation	   of	   lysosomal	   β-­‐
galactosidase	  in	  senescent	  cells	  (Dimri	  et	  al.,	  1995).	  Indeed	  treatment	  of	  two	  NBL	  cell	  
lines	   (SK-­‐N-­‐SH,	   SH-­‐SY5Y)	  with	  BMOV/RA	   (12	  days	   followed	  by	  20	  days	  withdrawal)	  
produced	   clear	   evidence	   of	   SA-­‐β-­‐Gal	   activity	   and	   at	   a	   much	   higher	   rate	   than	   RA	  
treatment	   (Figure	   3.16).	   Furthermore	   we	   observed	   intense	   SA-­‐β-­‐Gal	   staining	   in	  
pseudo	   ganglia,	   the	   remnants	   of	  which	   remained	   in	   RA	   treated	   cultures,	   although	  
this	  may	  be	  due	  to	  confluence-­‐induced	  quiescence	  due	  to	  high	  cell	  density	  in	  these	  
structures,	  which	  has	  been	   suggested	   to	  occur	   in	   fibroblasts	   resulting	   in	   increased	  
SA-­‐β-­‐Gal	  activity	  (Yang	  and	  Hu,	  2005).	  Staining	  of	  BMOV/RA-­‐treated	  cells	  commonly	  
occurred	  in	  cells	  with	  a	  highly	  flattened,	  enlarged	  and	  vacuolated	  cytoplasm,	  also	  a	  
common	   morphological	   marker	   of	   senescence	   (Collado	   and	   Serrano,	   2010).	  
Interestingly	   although	   an	   apparent	   growth	   arrest	   also	   occurred	   in	   LAN5	   cells,	   we	  
failed	  to	  detect	  SA-­‐β-­‐Gal	  labelling	  even	  in	  LAN5	  pseudo	  ganglia	  (data	  not	  shown).	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Figure	   3.15.	   	   Prevention	   of	   relapse	   from	  morphological	   differentiation/growth	   arrest	   by	  
BMOV/RA.	  Cells	  were	   treated	   for	  12	  days	  with	  either	  RA	   (5µM)	  or	  BMOV	  (10µM)	  with	  RA	  
(Day	  0	  of	  removal),	  then	  cultured	  in	  the	  absence	  of	  treatment	  for	  a	  further	  twenty	  days	  (Day	  
20	   of	   removal).	   Cells	   treated	  with	   RA	   alone	   reverted	   to	   rapidly	   dividing	   neuroblastic	   cells	  
lacking	   elongated	   neurites,	   while	   cells	   treated	   with	   BMOV/RA	   remained	   highly	  
differentiated,	  forming	  networks	  of	  processes	  and	  pseudo-­‐ganglia.	  Scale	  bar	  =	  10	  microns.	  	  	  
	  
Lastly	  we	  sought	  to	  characterise	  the	  timing	  of	  senescence	  induction	  in	  SH-­‐SY5Y	  cells.	  
OIS	   has	   been	   shown	   to	   result	   from	   acute	   activation	   of	   proto-­‐oncogenes	   in	   a	  
relatively	  fast	  manner	  (3-­‐6	  days),	  however	  we	  previously	  failed	  to	  detect	  enhanced	  
growth	  arrest	  in	  BMOV/RA	  treated	  cells	  during	  this	  time	  period,	  suggestive	  of	  a	  lack	  
of	   terminal	   differentiation.	   In	   concordance	  with	   this,	   SA-­‐β-­‐Gal	   activity	   was	   absent	  
from	   both	   RA	   and	   RA/BMOV	   treated	   cells	   after	   3	   and	   6-­‐day	   constant	   treatment	  
periods	   (Figure	   3.17),	   despite	  morphological	   differentiation.	   However,	   following	   9	  
days	   of	   treatment	   both	   RA	   and	   RA/BMOV	   caused	   a	   marked	   increase	   in	   SA-­‐β-­‐Gal	  
labelled	  cells,	  which	   further	   increased	  after	  14	  days	  of	   treatment.	   It	   is	  noteworthy	  
that	  the	  proportion	  of	  SA-­‐β-­‐Gal	  labelled	  cells	  following	  BMOV/RA	  treatment	  roughly	  
corresponded	  with	  that	  following	  RA	  treatment	  alone,	  suggesting	  an	  initial	  response	  
followed	  by	  reversion	  in	  the	  absence	  of	  treatment	  after	  RA	  treatment	  alone.	  This	  is	  
perhaps	   in	   conflict	   with	   the	   notion	   of	   replicative	   senescence,	   which	   should	   be	  
characterized	   by	   irreversible	   growth	   arrest.	   This	   raises	   the	   caveat	   that	   RA	   and	  
perhaps	  BMOV/RA	  treatment	  might	  instead	  induce	  quiescence	  rather	  than	  bona	  fide	  
senescence,	  although	  SA-­‐β-­‐Gal	  has	  been	  suggested	  to	  distinguish	  quiescent	  and	  pre-­‐
senescent	  cells	  from	  senescence	  (Dimri	  et	  al.,	  1995).	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Figure	  3.16.	  β-­‐Gal	   staining	   for	   replicative	  senescence.	  Cells	  were	   treated	   for	  12	  days	  with	  
either	  RA	  (5µM)	  or	  BMOV	  (10µM)	  with	  RA	  then	  cultured	  in	  the	  absence	  of	  treatment	  for	  a	  
further	  14	  days.	  Cells	  were	  then	   fixed	  and	  stained	   for	  β-­‐Gal	  activity.	   (A)	  RA/BMOV	  treated	  
cells	  exhibited	  morphological	  evidence	  of	  senescence	  as	  well	  as	  increases	  in	  the	  number	  of	  
β-­‐Gal	   positive	   cells.	   (B)	   5x	   objective	  magnification	   showing	   the	   presence	   of	   colonies	   of	   β-­‐
Galactosidase	  positive	  cells	  following	  treatment	  with	  BMOV/RA	  (arrowheads).	  RA	  alone	  did	  
cause	   the	   formation	  of	  pseudo-­‐ganglia	   that	  often	  stained	  positive	   (arrows).	   Scale	  bar	  =	  10	  
microns.	  (C)	  Histogram	  revealing	  mean	  and	  SEM	  for	  the	  number	  of	  β-­‐Gal	  positive	  cells	  (N=2).	  	  
	  
Thus	   in	   sum,	   BMOV/RA	   treatment	   induces	   a	   latent	   differentiation/growth	   arrest	  
which	   remains	   in	   the	  absence	  of	  on	  going	   treatment,	  which	   is	  not	  matched	  by	  RA	  
treatment	   alone,	   the	   removal	   of	   which	   allows	   a	   reversion	   back	   to	   a	   proliferative	  
neuroblastic	   state.	   Importantly,	   the	   presence	   of	   senescent	   cells	   was	   confirmed	  
during	   refractory	   periods,	   suggesting	   that	   BMOV/RA	   activates	   a	   senescence	  
response	   that	  once	  engaged,	   remains	   following	   treatment	   removal.	   This	  may	  have	  
crucial	   benefits	   for	   RA-­‐therapy,	   given	   the	   high	   levels	   of	   relapse	   due	   to	   minimal-­‐
residual	  disease.	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3.3.7.	  	   The	  effects	  of	  BMOV/RA	  appear	  independent	  of	  PTEN	  
In	  contrast	  to	  the	  majority	  of	  human	  neoplasms,	  mutations	  in	  PTEN	  have	  been	  rarely	  
documented	   in	  NBL,	   and	  have	  been	   suggested	   to	  occur	   in	   only	   a	   small	   fraction	  of	  
tumours	   (Muñoz	  et	   al.,	   2004),	   although	  downregulation	   through	  mechanisms	   such	  
as	  promoter	  hypermethylation	  may	  account	   for	   reduced	  expression	   independently	  
of	  mutations	   (Lázcoz	  et	  al.,	  2007).	  Consequently	   little	   research	  has	  been	  done	   into	  
the	   function	   of	   PTEN	   in	   NBL,	   despite	   recent	   advances	   in	   the	   characterisation	   of	  
PI3K/Akt	   activation	   in	   a	   large	   proportion	   of	   NBL	   cases,	   accounting	   for	   cell	  
survival/proliferation	   and	   tumour	   progression	   (Bender	   et	   al.,	   2011;	   Li	   et	   al.,	   2010;	  
Opel	   et	   al.,	   2007).	  With	  Akt	   now	   considered	   a	  major	   drug	   target	   in	  NBL	   (Brodeur,	  
2010),	  it	  is	  surprising	  that	  so	  little	  is	  known	  about	  the	  status	  of	  the	  primary	  negative	  
regulator	  of	  its	  activity.	  	  
	   We	   previously	   demonstrated	   that	   BMOV	   induces	   potent	   activation	   of	   Akt	  
especially	   when	   combined	  with	   RA	   treatment,	   as	   well	   as	   causing	   cell	   senescence.	  
This	  makes	  PTEN	  an	  interesting	  candidate	  as	  a	  determinant	  of	  the	  effects	  of	  BMOV.	  
Thus	  we	   sought	   to	   examine	  whether	   PTEN	   inhibition	  mimics	   the	   effects	   of	   BMOV	  
treatment	  in	  NBL	  cells.	  As	  previously	  mentioned,	  VO-­‐OH	  Pic	  is	  a	  recently	  developed	  
small-­‐molecule	   compound	   that	   has	   been	   shown	   to	   achieve	   effective	   and	   selective	  
inhibition	  due	   to	   its	   ability	   to	   specifically	  bind	   to	   the	  PTEN	  active	   site	  based	  on	   its	  
wide	  cleft	  in	  comparison	  to	  other	  PTPs,	  inhibiting	  PTEN	  at	  nanomolar	  concentrations	  
(IC50	   =	   35nM)	   (Rosivatz	   et	   al.,	   2006).	   VO-­‐OH	   Pic	   has	   also	   been	   shown	   to	   act	  
maximally	  on	  PTEN	  in	  live	  cells	  at	  500nM	  (Mak	  et	  al.,	  2010).	  
We	  first	  sought	  to	  determine	  the	  effects	  of	  VO-­‐OH	  Pic	  on	  Akt	  stimulation,	  in	  
comparison	  with	  BMOV,	  to	  examine	  whether	  VO-­‐OH	  PIC	  could	  achieve	  Akt	  activation	  
at	   500nM.	   This	   assay	  was	   done	   in	   KCNR	   and	   Kelly	   cells	   due	   to	   their	   intermediate	  
levels	   of	   PTEN	   protein	   expression	   (see	   figure	   3.20)	   and	   the	   high	   levels	   of	   Akt	  
stimulation	  we	  observed	  with	  BMOV	   treatment	   (see	   figure	  3.11).	  However	  neither	  
compound	  was	   observed	   to	   activate	   Akt	   at	   doses	   below	   5µM	   (Figure	   3.18,	   A).	   At	  
concentrations	  ≥	  5µM,	  VO-­‐OH	  Pic	  did	  appear	  more	  effective	  at	  inducing	  Akt	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Figure	  3.17.	  Timecourse	  of	  senescence.	  Cells	  were	  treated	  for	  3,	  6	  or	  9	  days	  with	  RA	  (5µM)	  
or	   BMOV	   (10µM)/RA	   and	   analysed	   for	   SA-­‐β-­‐Gal	   activity.	   Although	   all	   treatments	   induced	  
morphological	   differentiation	   (B),	   SA-­‐β-­‐Gal	   activity	   was	   only	   observed	   after	   9	   days	   of	  
treatment	  in	  both	  RA	  and	  RA/BMOV	  treated	  cells	  (B).	  	  
	  
activation	  than	  BMOV,	  achieving	  similar	   levels	  at	  5µM	  when	  compared	  with	  BMOV	  
at	   10µM	   (Figure	   3.18,	   A).	   This	   is	   however	   difficult	   to	   interpret	   for	   a	   number	   of	  
reasons.	   Firstly	   VO-­‐OH	   Pic	   has	   been	   suggested	   to	   cause	   Akt	   phosphorylation	   at	  
40nM,	  achieving	  saturation	  at	  75nM	  (Rosivatz	  et	  al.,	  2006),	  however	  both	   levels	  of	  
activation	  induced	  in	  the	  present	  study	  by	  higher	  doses	  of	  BMOV	  and	  VO-­‐OH	  Pic	  far	  
exceeds	   the	   level	   of	   activation	   documented	   by	   Rosivatz	   et	   al.,	   which	   is	   barely	  
detectable.	   Similarly	   it	   was	   suggested	   that	   VO-­‐OH	   Pic	   failed	   to	   affect	   tyrosine-­‐
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phosphorylation	  at	  10µM,	  and	  that	  IC50	  ranges	  for	  other	  PTPs	  far	  exceeded	  that	  of	  
PTEN,	   suggesting	   good	   specificity	   for	   PTEN.	   It	   is	   difficult	   to	   explain	   a	   lack	   of	  
stimulation	  at	  doses	  below	  5µM	  without	  invoking	  non-­‐specific	  PTP	  stimulation.	  This	  
is	  especially	  pertinent	  given	  that	  other	  PTPs	  have	  been	  shown	  to	  negatively	  control	  
Akt	  that	  would	  be	  targeted	  by	  BMOV,	  and	  both	  inhibitors	  showed	  the	  same	  level	  of	  
Akt	   stimulation	   (albeit	   at	   a	   2	   fold	   higher	   dose)	   (Omerovic	   et	   al.,	   2010).	   However	  
these	   caveats	   aside,	   VO-­‐OH	   Pic	   was	   used	   at	   a	   dosage	   shown	   to	   activate	   Akt	  
signalling.	  
	   We	  next	  sought	  to	  determine	  whether	  VO-­‐OH	  Pic	  mimicked	  the	  effects	  of	  VA	  
and	  BMOV	  in	  synergistically	  activating	  both	  Akt	  and	  Erk	  when	  used	   in	  combination	  
with	  RA.	  Remarkably	  VO-­‐OH	  Pic	  at	  5µM	  displayed	  the	  exact	  same	  profile	  as	  BMOV	  
inducing	   activation	   of	   Akt	   and	   Erk	   when	   used	   alone,	   but	   also	   synergistically	  
enhanced	   RA	   driven	   activation	   of	   both	   of	   these	   enzymes	   (Figure	   3.18,	   B).	   Here	  
activation	   was	   clearly	   synergistic,	   vastly	   exceeding	   that	   seen	   by	   either	   treatment	  
alone	   in	   two	   cell	   lines	   (KCNR/Kelly).	   Interestingly	   Erk	   was	   activated	   to	   a	   similar	  
extent	  as	  Akt,	  despite	  an	  overwhelming	  amount	  of	  evidence	  suggesting	  the	  latter	  to	  
be	  the	  main	  target	  of	  PTEN.	  This	  perhaps	  suggests	  as	  previously	  noted	  that	  VO-­‐OH	  
Pic	  may	   be	   acting	   non-­‐specifically	   at	   this	   dosage,	   although	   others	   have	   suggested	  
Ras/MAPK	  may	  be	  affected	  by	  PTEN	  (Gu	  et	  al.,	  1998).	  Thus	  VO-­‐OH	  Pic	  clearly	  causes	  
similar	   consequences	   to	   BMOV	  with	   regards	   to	   signal	   transduction,	   activating	   Akt	  
and	   Erk	   alone	   as	   well	   as	   synergising	   with	   RA,	   albeit	   at	   ten	   fold	   higher	   doses	  
compared	  with	  those	  published	  previously.	  	  
Given	  the	  similarity	  between	  biochemical	  effects	  of	  VO-­‐OH	  Pic	  and	  BMOV,	  we	  
next	   sought	   to	   examine	   whether	   both	   of	   these	   compounds	   could	   induce	   neurite	  
outgrowth,	  as	  has	  previously	  been	  shown	  for	  BMOV	  and	  VA.	  Indeed	  longer-­‐term	  (6	  
day)	  treatment	  with	  VO-­‐OH	  Pic	  caused	  neurite	  extension	  in	  both	  SH-­‐SY5Y	  and	  SK-­‐N-­‐
SH	  cells,	  to	  a	  similar	  degree	  as	  BMOV,	  at	  a	  2	  fold	  lower	  dosage	  (Figure	  3.19).	  Again	  it	  
should	  be	  stated	  that	  VO-­‐OH	  Pic	   failed	  to	   induce	  neuritogenesis	  below	  micromolar	  
dosages,	   raising	   the	   recurring	   issue	   of	   specificity.	   However	   this	   provides	   some	  
evidence	   that	  PTEN	  may	  be	  one	   target	  of	  BMOV,	   responsible	   for	  both	  biochemical	  
alterations	  in	  signal	  transduction,	  as	  well	  as	  cell-­‐structural	  changes	  in	  differentiation.	  
Interestingly	   this	   is	   not	   the	   first	   demonstration	   that	   PTEN	   inhibition	   can	   facilitate	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neurite	   outgrowth	   (Christie	   et	   al.,	   2010),	   and	   the	   activation	   for	   Erk/Akt	   that	   may	  
occur	  following	  this	  inhibition	  could	  be	  a	  primary	  determinant	  of	  this	  response.	  
The	   former	   studies	   with	   VO-­‐OH	   Pic	   provide	   some	   evidence	   for	   the	  
involvement	  of	  PTEN	   in	  the	  response	  of	  NBL	  cells	   to	  BMOV.	  However	  the	   fact	   that	  
VO-­‐OH	  Pic	  only	  resulted	   in	  phenotypic	  and	  biochemical	  effects	  at	  a	  ten	  fold	  higher	  
dosage	   than	   that	   at	   which	   PTEN	   was	   said	   to	   be	   saturated	   (Rosivatz	   et	   al.,	   2006),	  
raises	  serious	  concerns	  that	  these	  effects	  are	  instead	  the	  result	  of	  vanadium	  delivery	  
to	  a	  wider	  range	  of	  PTPs.	  This	  discrepancy	  could	  potentially	  be	  answered	  by	  asking	  
the	   question	   of	   whether	   PTEN	   status	   is	   the	   primary	   explanation	   for	   variability	  
between	  the	  responses	  of	  individual	  NBL	  cell	  lines	  to	  BMOV	  treatment.	  For	  instance,	  
it	   has	   been	   argued	   that	   PTEN	   status	   confers	   susceptibility	   to	   PTEN-­‐loss	   induced	  
senescence	   following	   PTEN	   inhibition	   using	   VO-­‐OH	   Pic	   (Alimonti	   et	   al.,	   2010a;	  
Alimonti	  et	  al.,	  2010b;	  Carracedo	  et	  al.,	  2011).	  This	  begs	  the	  question	  of	  whether	  low	  
levels	  of	  endogenous	  PTEN	  account	  for	  BMOV-­‐induced	  senescence,	  due	  to	  acute	  loss	  
of	   PTEN	   and	   induction	   of	   a	   fail-­‐safe	   senescence	   response.	   Importantly	   this	  
hypothesis	   would	   predict	   high	   levels	   of	   PTEN	   in	   BMOV-­‐unresponsive	   cells	   (SK-­‐N-­‐
AS/SK-­‐N-­‐DZ)	   preventing	   the	   activation	   of	   PI3K/Akt	   signalling	   following	   BMOV/RA	  
treatment.	   Conversely	   through	   previously	   unspecified	   mechanisms	   such	   as	  
transcriptional	   downregulation,	   post-­‐translational	   modification	   or	   epigenetic	  
regulation,	   BMOV-­‐responsive	   cells	   capable	   of	   undergoing	   senescence	   would	   have	  
low	   endogenous	   levels	   of	   PTEN,	   and	   thus	   less	   subject	   to	   dampening	   of	   PI3K/Akt	  
signalling	   following	   stimulation	   by	   BMOV/RA,	   allowing	   a	   putative	   threshold	   to	   be	  
surpassed	   where	   senescence	   would	   ensue	   (Figure	   3.19).	   This	   is	   a	   tempting	  
explanation	   for	   the	   low	   levels	   of	   activated	   Akt	   in	   BMOV-­‐unresponsive	   cells	   (See	  
figure	  3.11).	  	  
Thus	  we	  conducted	  qPCR	  analysis	  of	  NBL	  cell	   lines	   in	  comparison	  with	  each	  
other	   as	  well	   as	   non-­‐neoplastic	   nervous	   system	   control	   tissue	   to	   examine	   relative	  
levels	  of	  PTEN	  mRNA.	  These	  qPCR	  data	  are	  extracted	  from	  a	  larger	  dataset	  discussed	  
in	  chapter	  6.	  First,	  PTEN	  expression	  was	  vastly	  reduced	  in	  all	  NBL	  lines	  in	  comparison	  
with	   non-­‐neoplastic	   neural	   tissue	   (Figure	   3.20,	   A).	   This	   is	   significant	   given	   the	  
previously	  reported	  evidence	  for	  a	   lack	  of	  tumour-­‐suppressive	  function	  for	  PTEN	  in	  
NBL	  (Muñoz	  et	  al.,	  2004),	  as	  PTEN	  expression	  was	  fairly	  similar	  to	  that	  observed	   in	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the	  putatively	  PTEN-­‐deficient	  glioma	  cell	  line	  U118.	  However,	  we	  failed	  to	  observe	  a	  
correlation	   between	   the	   levels	   of	   PTEN	   and	   responsiveness	   to	   BMOV	   in	  NBL	   cells.	  
PTEN	   expression	   was	   highest	   in	   BMOV-­‐unresponsive	   SK-­‐N-­‐AS	   cells	   followed	   by	  
IPhNB1,	  IMR32	  and	  Kelly,	  all	  of	  which	  failed	  to	  undergo	  senescence,	  however	  other	  
cell	   lines	   which	   had	   lower	   levels	   of	   PTEN	   were	   mixed	   in	   their	   responsiveness	   to	  
BMOV/RA,	   with	   two	   undergoing	   senescence	   (SH-­‐SY5Y,	   SK-­‐N-­‐SH),	   two	   responding	  
with	  Akt	  activation	  and	  undergoing	  differentiation,	  but	  failing	  to	  undergo	  senescence	  
(LAN-­‐5,	  KCNR)	  and	  two	  failing	  to	  respond	  to	  BMOV	  at	  all	  (SK-­‐N-­‐BE(2),	  SK-­‐N-­‐DZ).	  	  
	  
Figure	  3.18.	  The	  biochemical	  effects	  of	  VO-­‐OH	  Pic.	  Cells	  treated	  for	  24	  hours	  with	  increasing	  
doses	  of	  BMOV	  and	  VO-­‐OH	  Pic.	  The	  effects	  of	  the	  PTEN	  inhibitor	  VO-­‐OH	  Pic	  are	  shown	  both	  
alone	  on	  the	  PTEN	  effector	  Akt	  in	  KCNR	  cells	  and	  in	  combination	  with	  retinoic	  acid	  (RA)	  on	  
both	  Akt	  and	  Erk.	  VO-­‐OH	  Pic	  treatment	  caused	  Akt	  phosphorylation	  at	  Ser473	  as	  expected	  to	  
a	  similar	  degree	  as	  BMOV	  in	  KCNR	  cells,	  but	  only	  at	  5µM	  and	  above	  (A).	  VO-­‐OH	  Pic	   (5µM)	  
synergistically	  activated	  both	  Erk	  and	  Akt	  in	  combination	  with	  RA	  (5µM)	  in	  a	  similar	  fashion	  
to	   BMOV	   (10µM)	   in	   both	   KCNR	   and	   Kelly	   cells	   (B),	   however	   this	   hyperactivation	  was	   less	  
apparent	  at	  500nM	  in	  SK-­‐N-­‐SH	  cells	  (C).	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Figure.	   3.19.	   A	   hypothesis	   concerning	   relative	   PTEN	   expression	   and	   functional	  
consequences	   of	   BMOV/RA	   treatment.	   This	  model	   predicts	   that	   BMOV-­‐unresponsive	   cell	  
lines	   such	   as	   SK-­‐N-­‐AS/SK-­‐N-­‐DZ	   harbour	   relatively	   high	   levels	   of	   PTEN	   protein,	   causing	  
ineffective	   inhibition	   by	   BMOV	   (thin	   line),	   effective	   Akt	   inhibition	   (thick	   line)	   and	  
consequently	   ineffective	   stimulation	   of	   Akt	   by	   BMOV/RA	   (thin	   line).	   In	   contrast,	   BMOV	  
responsive	   lines	   (SK-­‐N-­‐SH,	   SH-­‐SY5Y)	   harbour	   relatively	   lower	   levels	   of	   PTEN,	   which	   is	  
effectively	  inhibited	  by	  BMOV	  (thick	  line)	  preventing	  Akt	  inhibition	  (thin	  line)	  and	  achieving	  
high	  overall	  stimulation	  of	  Akt	  from	  BMOV/RA	  (thick	  line).	  	  
	  
However	   as	   previously	   stated,	   BMOV/RA-­‐induced	   senescence	   is	   unlikely	   to	   result	  
simply	   from	   activation	   of	   Akt	   alone,	   as	   this	   occurred	   in	   Kelly	   cells	   which	   failed	   to	  
undergo	  senescence	  in	  response	  to	  RA	  (data	  not	  shown).	  Instead	  this	  response	  may	  
require	  a	  particular	   transcriptional	  program	   induced	  by	  RA	  along	  with	  concomitant	  
Akt	  hyperactivation	  caused	  by	  combined	  BMOV/RA.	  Furthermore	  these	  data	  reflect	  
PTEN	  at	   the	  mRNA	  expression	   level	  only,	  which	  often	   fails	   to	   completely	   correlate	  
with	  protein	   level.	   Indeed	  T98G	  and	  U118	  glioma	  cells	  were	  shown	  to	  have	  similar	  
levels	   of	   PTEN,	   despite	   being	   classified	   as	   PTEN	   deficient	   and	   PTEN	   proficient	  
respectively.	  We	  therefore	  sought	  to	  confirm	  these	  data	  by	  examining	  protein	  level	  
of	   PTEN	   via	   immunoblotting.	   Indeed	   PTEN	   protein	   expression	   did	   fail	   to	   correlate	  
with	  mRNA	  expression	   (Figure	  3.20,	  B).	  However	  we	  still	   failed	   to	  observe	  cell-­‐line	  
specific	   PTEN	   levels	   in	   fitting	  with	   the	   former	   prediction.	   Here	   SK-­‐N-­‐SH	   and	   KCNR	  
cells	   had	   the	   highest	   levels	   of	   PTEN,	   despite	   both	   undergoing	   BMOV/RA-­‐induced	  
senescence/differentiation,	   respectively.	   Similarly	   SH-­‐SY5Y	   cells	   that	   responded	   to	  
BMOV/RA	   had	   much	   lower	   relative	   PTEN	   expression.	   Lastly	   SK-­‐N-­‐AS	   and	   SK-­‐N-­‐DZ	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cells	  that	  failed	  to	  respond	  to	  either	  BMOV	  alone	  or	  BMOV/RA	  either	  phenotypically	  
or	   by	   activating	   Akt	   had	   similarly	   low	   levels	   of	   PTEN	   protein.	   Thus	   PTEN	   protein	  
expression	   failed	   to	   conform	   to	   the	   model	   of	   PTEN	   status	   as	   an	   indicator	   of	  
BMOV/RA	   responsiveness.	   We	   next	   examined	   endogenous	   activation	   of	   Akt,	   to	  
determine	  whether	  differences	  in	  PTEN	  protein	  expression	  manifested	  in	  alterations	  
in	  basal	  signal	  strength.	  However	  again	  PTEN	  expression	  failed	  to	  correlate	  with	  Akt	  
activation,	  the	  basal	   levels	  of	  which	  were	  broadly	  comparable	  across	  all	  tested	  NBL	  
lines	  (Figure	  3.20,	  B).	  	  
	  
Figure.	   3.20.	   Expression	   of	   PTEN	   in	   NBL	   cell	   lines.	   (A)	   qPCR	   showing	   expression	   of	   PTEN	  
relative	   to	   4	  HKGs	   in	   both	   control	   non-­‐neoplastic	   nervous	   system	   tissue,	   glioma	   and	  NBL.	  
Although	   PTEN	   expression	   in	   NBL	   is	   lower	   than	   control	   tissue	   and	   comparable	   to	   that	   of	  
PTEN-­‐deficient	   glioma	   cells	   (U118)	   suggestive	   of	   a	   tumour	   suppressive	   function,	   levels	   do	  
not	   correlate	   well	   with	   responsiveness	   to	   BMOV	   e.g.	   compare	   SK-­‐N-­‐DZ	  with	   SH-­‐SY5Y.	   (B)	  
Immunoblot	  showing	  endogenous	  protein	  expression	  of	  PTEN	  as	  well	  as	  phosphorylated	  Akt.	  
Protein	   expression	   fails	   to	   correlate	   with	   mRNA	   expression	   (compare	   A	   versus	   B),	   but	  
confirms	   a	   lack	   of	   correlation	   between	   BMOV	   responsiveness	   and	   PTEN	   expression	   (e.g.	  
compare	  SK-­‐N-­‐SH	  with	  SK-­‐N-­‐DZ).	  Note	  that	  basal	  Akt	  phosphorylation	  also	  fails	  to	  correlate	  
with	  PTEN	  expression.	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Lastly	  we	   tested	   the	   efficacy	   of	   VO-­‐OH	  Pic	   at	   inducing	   senescence	   in	   combination	  
with	  RA	  treatment,	  using	  a	  500nM	  dosage	  given	  that	  PICS	  occurs	  without	  RA	  at	  this	  
dosage	  (Alimonti	  et	  al.,	  2010b).	  However	  cells	  treated	  for	  14	  days	  with	  VO-­‐OH	  Pic/RA	  
were	  phenotypically	  indistinguishable	  from	  cells	  treated	  with	  RA	  alone	  after	  a	  14	  day	  
treatment	   removal	   period,	   exhibiting	   a	   similar	   low	   frequency	   of	   SA-­‐β-­‐Gal	   positive	  
cells	  and	  a	  lack	  of	  morphological	  evidence	  of	  senescence	  (Figure	  3.21).	  	  
	  
Figure	  3.21.	  VO-­‐OH	  Pic	  does	  not	  augment	  RA-­‐induced	  senescence.	  Cells	  treated	  for	  14	  days	  
with	   RA	   (5µM)	   with	   and	   without	   VO-­‐OH	   Pic	   (500nM)	   followed	   by	   14	   days	   of	   culture	   in	  
treatment-­‐free	   medium	   and	   stained	   for	   β-­‐gal	   activity	   indicative	   of	   senescence.	   Both	   cell	  
types	  are	  indistinguishable	  both	  in	  morphology	  and	  frequency	  of	  SA-­‐β-­‐Gal	  staining.	  	  
	  
In	   sum,	   the	   PTEN	   inhibitor	   VO-­‐OH	   Pic	   induces	   similar	   effects	   to	   BMOV,	   including	  
increases	   in	   Akt	   activation,	   synergistic	   hyperactivation	   of	   Akt/Erk	   in	   combination	  
with	  RA,	  and	  phenotypic	  neurite	  outgrowth.	  However	  the	  substantial	  caveat	  arguing	  
against	   these	   responses	  stemming	  solely	   from	  PTEN	   inhibition	   is	   that	   these	  effects	  
required	  a	  ten	  fold	  higher	  dose	  of	  VO-­‐OH	  Pic	  than	  commonly	  used,	  while	  VO-­‐OH	  Pic	  
used	  at	  a	  dosage	  sufficient	  to	  cause	  senescence	  in	  prostate	  cancer	  cells	  (Alimonti	  et	  
al.,	  2010b)	  did	  not	  mimic	  BMOV/RA	  induced	  senescence	  in	  NBL	  cells.	  Although	  it	  has	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been	  argued	  that	  VO-­‐OH	  Pic	  should	  retain	  its	  specificity	  for	  PTEN	  at	  higher	  doses,	  it	  
cannot	  be	  ruled	  out	  that	  this	  compound	  is	  simply	  delivering	  uncomplexed	  vanadium	  
generically	   to	  multiple	   PTPs	   when	   used	   at	   higher	   doses.	   Its	   activation	   of	   Erk	  may	  
argue	  for	  this.	  Furthermore	  although	  differences	  in	  the	  status	  of	  PTEN	  between	  cell	  
lines	   is	  a	  convenient	  hypothesis	   to	  explain	   responsiveness	   to	  BMOV	  at	   the	   level	  of	  
Akt/Erk	   activation,	   neurite	   outgrowth	   and	   BMOV/RA-­‐induced	   senescence,	   both	  
mRNA	  and	  protein	  levels	  failed	  to	  correlate	  with	  BMOV	  phenotypic	  behaviour	  across	  
most	  NBL	  cell	  lines.	  Similarly	  while	  low	  levels	  of	  PTEN	  argue	  for	  a	  tumour	  suppressive	  
function	   in	   NBL,	   PTEN	   protein	   expression	   failed	   to	   correlate	   with	   Akt	   activation,	  
suggesting	  other	  mechanisms	  may	  predominate	  in	  driving	  PI3K/Akt	  signalling	  in	  this	  
tumour	  type,	  although	  alternatively	  PTEN	  may	  be	  non-­‐functional	   in	  some	  instances	  
where	  high	  expression	  is	  accompanied	  with	  high	  Akt	  activation.	  	  
	  
3.3.8.	  BMOV/RA-­‐induced	  senescence	  is	  independent	  of	  p53/p16INK4A	  	  
Oncogene	  induced	  senescence	  (OIS)	  typically	  involves	  the	  initiation	  of	  a	  DNA	  damage	  
response	  centring	  on	  the	  activation	  of	  the	  tumour	  suppressors	  p53	  and	  p16INK4A	  (Lin	  
et	   al.,	   1998;	   Schmitt	   et	   al.,	   2002;	   Serrano	   et	   al.,	   1997).	   Thus	   these	   genes	   are	  
frequently	   mutated	   in	   numerous	   human	   cancers,	   however	   when	   functional	   the	  
induction	  of	  OIS	   is	   accompanied	  by	   the	   accumulation	  of	   both	   p53/p16INK4A,	  where	  
loss	   of	   function	   of	   either	   gene	   abrogates	   this	   effect	   (Beauséjour	   et	   al.,	   2003).	  
Similarly	  PTEN-­‐loss-­‐induced	  senescence	   (PICS)	   is	  accompanied	  by	   the	  accumulation	  
of	  p53	  expression,	  and	  functional	  p53	  is	  a	  prerequisite	  for	  this	  response	  (Alimonti	  et	  
al.,	  2010b;	  Chen	  et	  al.,	  2005).	  	  
	   Intriguingly,	   p53	   mutations	   are	   rarely	   observed	   at	   presentation	   in	   NBL.	  
However	  fail-­‐safe	  barriers	  to	  tumorigenesis	  exerted	  by	  p53	  are	  often	  circumvented	  
by	  other	  means	  such	  as	  the	  p53	  inhibitor	  MDM2	  (Van	  Maerken	  et	  al.,	  2009).	  This	  has	  
led	   to	   the	   approach	   of	   inhibition	   of	  MDM2	  using	   the	   small-­‐molecule	   nutlin-­‐3	   as	   a	  
means	   of	   p53	   stabilization,	  which	   has	   been	   shown	   to	   induce	   senescence	   (SK-­‐N-­‐SH	  
cells)	   and	   differentiation	   (NGP,	   GLB-­‐GA	   cells)	   in	   vitro	   (Van	  Maerken	   et	   al.,	   2006).	  
However	   this	   is	   complicated	   by	   the	   finding	   that	   downstream	   effectors	   of	   p53	   are	  
generally	   intact	   in	   NBL,	   raising	   the	   question	   of	   whether	   senescence	   might	   be	  
activated	   without	   the	   need	   for	   p53	   reactivation	   (Van	  Maerken	   et	   al.,	   2011).	   This	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point	   is	   further	   emphasised	   by	   the	   fact	   that	   mutations	   in	   the	   CDKN2A	   locus	   are	  
rarely	   observed	   in	   both	   primary	   NBL	   and	   cell	   lines,	   suggesting	   that	   p16INK4A	   is	  
potentially	   functional	   (Beltinger	  et	  al.,	   1995).	   	   It	   is	   also	  noteworthy	   that	  while	  RAS	  
proto-­‐oncogenes	  are	   frequently	   targeted	  by	  activating	  mutations	   in	  human	  cancer,	  
at	   least	   the	   HRAS	   member	   of	   this	   family	   is	   actually	   expressed	   at	   high	   levels	   in	  
favourable	   tumours,	   where	   it	   has	   been	   suggested	   to	   potentially	   contribute	   to	  
regression	   (Kitanaka	  et	  al.,	  2002).	  The	  Possibility	  of	  an	   intact	  Ras,	  p16INK4A	  and	  p53	  
raises	  the	  question	  of	  whether	  senescence	  is	  a	  feature	  of	  NBL	  tumours	  at	  baseline	  or	  
following	  chemotherapy,	  and	  if	  not	  how	  might	  NBL	  tumours	  attenuate	  OIS.	  
	   It	   has	   been	   shown	   that	   accumulation	   of	   p16INK4A	   contributes	   to	   replicative	  
senescence	   caused	  by	  RA	   in	   a	   schwannian	   type	   sub-­‐clone	  of	   the	  NBL	   line	   SK-­‐N-­‐SH	  
(Wainwright	  et	  al.,	  2001),	  where	   it	  was	  suggested	  that	  neuronal-­‐type	  SK-­‐N-­‐SH	  cells	  
preferentially	  undergo	  differentiation	  in	  contrast	  to	  senescence	  due	  to	  an	  absence	  of	  
p16INK4A.	   The	   finding	   that	   SH-­‐SY5Y/SK-­‐N-­‐SH/KCNR	   cells	   are	   capable	   of	   undergoing	  
senescence	  as	  shown	  by	  positive	  staining	  for	  SA-­‐β-­‐Gal	  and	  evidence	  of	  growth	  arrest	  
begs	  the	  question	  of	  whether	  BMOV/RA	  treatment	  causes	  the	  accumulation	  of	  p53	  
and/or	  p16INK4A,	  and	  whether	  these	  proteins	  are	  required	  for	  a	  senescence	  response.	  
Thus	  we	  sought	  to	  examine	  p53/p16INK4A	  levels	  following	  BMOV/RA	  treatment.	  	  
	   We	  conducted	   immunoblotting	   for	  both	  p53	  and	  p16INK4A	   following	  14	  days	  
of	  continuous	  treatment	  with	  BMOV/RA	   in	  two	  cell	   lines	  that	  are	  SA-­‐β-­‐Gal	  positive	  
following	  such	  a	  treatment	  course	  (SH-­‐SY5Y	  and	  SK-­‐N-­‐SH).	  However	  neither	  cell	  line	  
exhibited	   evidence	   of	   p53	   or	   p16INK4A	   induction/accumulation	   in	   either	   treatment	  
condition	   (BMOV/RA	   separately	   and	   in	   combination)	   (Figure	   3.22).	   This	   finding	   is	  
difficult	   to	   explain,	   given	   that	   both	   cell	   lines	   have	   a	  wild-­‐type	   p53	   gene,	   and	   that	  
p16INK4A	   induction	  has	  been	  shown	  to	  occur	  following	  RA	  treatment	  (Wainwright	  et	  
al.,	   2001).	   It	   is	   entirely	   possible	   that	   detection	   of	   both	   proteins	   was	   not	   possible	  
owing	   to	   limitations	   of	   the	   used	   antibodies,	   given	   that	   both	   p53	   and	   p16INK4A	   are	  
often	  expressed	  at	  very	   low	   levels,	  and	   that	   the	  chosen	  positive	  controls	  were	  not	  
thoroughly	   matched.	   However	   this	   also	   raises	   the	   possibility	   that	   BMOV/RA	  
treatment	  induces	  cell	  senescence	  that	  is	  independent	  of	  either	  protein.	  This	  may	  be	  
potentially	  useful	  given	  that	  at	  there	  is	  evidence	  at	  least	  for	  p53,	  that	  mutations	  may	  
occur	   following	  chemotherapy,	   leading	  to	  therapeutic	  resistance	  (Carr-­‐Wilkinson	  et	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al.,	   2010).	   This	   also	   suggests	   that	   BMOV/RA-­‐induced	   senescence	   is	   distinct	   from	  
PICS,	  which	  requires	  the	  induction	  of	  p53	  (Alimonti	  et	  al.,	  2010b).	  	  
	  
Figure	   3.22.	   Absence	   of	   p53/p16INK4A	   accumulation	   following	   long-­‐term	   BMOV/RA	  
treatment.	   Immunoblotting	   for	   p53/p16INK4A	   reveals	   an	   absence	   of	   protein	   expression	  
following	   treatment	   for	  14	  days	  with	  RA	   (5µM)	  and	  BMOV	   (10µM)	  both	   separately	  and	   in	  
combination.	   PC	   represents	   positive	   control	   of	   Kelly	   cells	   (p53)	   and	   murine	   brain	   tissue	  
(p16INK4A).	  However	   it	   should	  be	  noted	  that	  detection	  of	  p16INK4A	  might	  be	  more	  difficult	   in	  
human	   tissue	   compared	   with	   mouse,	   thus	   making	   human	   brain	   a	   more	   suitable	   positive	  
control.	  	  
	  
3.3.9.	  BMOV/RA-­‐induced	  senescence	  is	  dependent	  on	  Akt	  and	  Erk	  
We	  hypothesized	  that	  the	  hyperactivation	  of	  both	  Erk	  and	  Akt	  caused	  by	  BMOV/RA	  
treatment	  might	  be	  responsible	  for	  senescence,	  given	  that	  OIS	  frequently	  occurs	  in	  a	  
dose	   dependent	   manner	   (Sarkisian	   et	   al.,	   2007),	   following	   stimulation	   of	   both	   of	  
these	  oncogenic	  signalling	  nodes.	  Thus	  we	  treated	  cells	  with	  BMOV/RA	  for	  14	  days	  
followed	  by	  a	  14-­‐21	  day	  treatment-­‐removal	  period	  in	  the	  presence	  of	  absence	  of	  the	  
PI3K	   inhibitor	   PI103	   or	   the	   MEK	   inhibitor	   U0126.	   In	   both	   SK-­‐N-­‐SH	   and	   SH-­‐SY5Y,	  
inhibition	  of	  both	  Akt	  and	  Erk	  caused	  a	  substantial	   reduction	   in	  BMOV/RA-­‐induced	  
SA-­‐β-­‐Gal	   staining	   following	   treatment	   removal	   (Figure	   3.23),	   (although	   there	   was	  
little	   evidence	   of	  morphological	   differences	   between	   treatment	   conditions	   (Figure	  
3.24),	   suggesting	   a	   causal	   role	   for	   enzymes	   in	   this	   senescence	   response.	   Although	  
SA-­‐β-­‐Gal	   activity	   was	   noted	   following	   treatment	   with	   10µM	   BMOV,	   we	   observed	  
more	  variability	  in	  this	  response	  during	  these	  experiments,	  and	  thus	  chose	  to	  use	  a	  
two	   fold	   higher	   dosage.	   This	   may	   reflect	   phenotypic	   drift,	   or	   selective	   pressure	  
affecting	  levels	  of	  Akt	  and	  Erk	  activity,	  although	  this	  is	  unknown.	  Similarly	  U0126	  was	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used	   at	   a	   two	   fold	   lower	   dosage	   compared	   with	   section	   3.3.5,	   given	   that	   we	  





Figure	  3.23.	  BMOV/RA	  induced	  senescence	  is	  Erk	  and	  Akt-­‐dependent.	  Cells	  treated	  for	  14	  
days	  with	  RA	  (5µM)	  and	  BMOV	  (20µM)/RA	  in	  the	  presence	  or	  absence	  of	  the	  MEK	  inhibitor	  
U0126	  (10µM)	  or	  the	  PI3K	  inhibitor	  PI103	  (500nM)	  followed	  by	  a	  14	  (SK-­‐N-­‐SH)	  or	  a	  21	  (SH-­‐
SY5Y)	   day	   treatment-­‐removal	   period	   and	   stained	   for	   SA-­‐β-­‐Gal	   activity.	   (A)	   Both	   PI103	   and	  
U0126	   cause	   reductions	   in	   the	   number	   of	   SA-­‐β-­‐Gal	   positive	   cells	   (arrows)	   and	   sharp	  
increases	  in	  the	  number	  of	  strongly	  negative	  cells	  (arrowheads).	  (B)	  Means	  and	  SEMs	  of	  the	  
proportion	  of	  SA-­‐β-­‐Gal	  positive	  cells	  (N=3).	  (C)	  Immunoblot	  showing	  affect	  of	  both	  inhibitors	  
on	  BMOV/RA	  induced	  Akt	  and	  Erk	  activation	  following	  1	  day	  of	  treatment.	  A	  =	  40x	  objective	  


















Figure	   3.24.	   Compound	   PI103/U0126	   treatment	   does	   not	   alter	   cellular	  
morphology.	  Cells	  treated	  for	  14	  days	  (Day	  0)	  followed	  by	  7	  and	  14	  days	  of	  culture	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3.4.	  Discussion	  
PTPs	   frequently	   function	   as	   negative	   regulators	   of	   RTK-­‐driven	   signalling	   pathways	  
that,	   when	   activated,	   can	   drive	   cancer	   cells	   to	   differentiate/undergo	   senescence	  
(Alimonti	  et	  al.,	  2010b;	  Lin	  et	  al.,	  1998;	  Nogueira	  et	  al.,	  2008).	  We	  sought	  to	  test	  the	  
hypothesis	   that	   broad	   inhibition	   of	   PTPs	   achieved	   with	   vanadium	   compounds,	  
principally	   BMOV,	   would	   augment	   RA-­‐mediated	   differentiation	   of	   NBL	   cells,	   given	  
that	   such	   compounds	   have	   been	   shown	   to	   cause	   neuritogenesis,	   a	   cell-­‐structural	  
parameter	   of	   differentiation	   (Rogers	   et	   al.,	   1994),	   as	   well	   as	   activating	   PI3K/Akt	  
signalling	   (Shioda	  et	   al.,	   2008),	   shown	   to	  have	   a	   role	   in	  RA-­‐induced	  differentiation	  
(López-­‐Carballo	  et	  al.,	  2002).	   Indeed	  BMOV-­‐induced	  comparable	  neurite	  outgrowth	  
and	  upregulation	  of	  neural	  markers	  to	  that	  of	  RA,	  while	  increasing	  the	  effects	  of	  RA	  
alone.	  However,	  more	   importantly,	  BMOV/RA	  treatment	  caused	  synergistic	   ‘hyper-­‐
activation’	  of	  both	  Akt	  and	  Erk	  signalling,	  both	  of	  which	  were	  shown	  to	  be	  involved	  
in	   stimulating	   differentiation/cell	   senescence	   that	   persisted	   in	   the	   absence	   of	  
treatment,	  unlike	  RA,	  and	  appears	  independent	  of	  PTEN	  inhibition.	  	  
Pro-­‐senescence	   treatment	   has	   been	   suggested	   as	   a	   potential	   therapeutic	  
modality	   based	   on	   the	   well-­‐established	   issues	   of	   conventional	   chemotherapy,	  
including	   severe	   toxicity-­‐related	   side	   effects	   and	   acquired	   resistance,	   as	   well	   as	  
intransigence	  at	  clinical	  presentation	  (Nardella	  et	  al.,	  2011).	  The	  most	  common	  form	  
of	   senescence	   exhibited	   by	   cancer	   cells/precancerous	   lesions	   is	   OIS	   (Braig	   and	  
Schmitt,	   2006;	   Collado	   and	   Serrano,	   2010),	   resulting	   from	   increased	  
levels/constitutive	  activation	  of	  oncogenic	  kinase	  signalling,	  leading	  to	  the	  induction	  
of	   senescence	   through	   a	   DNA	   damage	   response	   involving	   p53/p16INK4A	   (Lin	   et	   al.,	  
1998;	  Michaloglou	   et	   al.,	   2005;	   Oikonomou	   et	   al.,	   2009;	  Wajapeyee	   et	   al.,	   2008).	  	  
While	  there	  is	  evidence	  that	  this	  phenomenon	  contributes	  to	  the	  outcome	  of	  cancer	  
therapy	   (Schmitt	   et	   al.,	   2002;	   Wu	   et	   al.,	   2007),	   it	   is	   often	   circumvented	   due	   to	  
mutations	   in	   both	   p53	   and	   p16INK4A	   that	   frequently	   occur	   in	   cancer.	   Furthermore	  
senescence	  might	  only	  be	  activated	  following	  excessive	  oncogenic	  activity	  (Sarkisian	  
et	   al.,	   2007),	   which	   might	   otherwise	   be	   tightly	   regulated	   in	   cancer	   cells,	   and	  
achieving	  such	  activation	   is	  difficult	  given	  that	  most	   forms	  of	   targeted	  therapy	  rely	  
on	   target	   inhibition	   rather	   than	   activation.	   We	   have	   shown	   that	   PTP	   inhibition,	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although	  not	  sufficient	  alone,	  can	  synergise	  with	  RA	  in	  the	  activation	  of	  Akt	  and	  Erk	  
signalling	  to	  drive	  cell	  senescence.	  We	  hypothesize	  that	  this	  effect	  is	  directly	  related	  
to	   the	   level	   of	   Akt/Erk	   activation,	   given	   that	   both	   BMOV	   and	   RA	   are	   capable	   of	  
inducing	  such	  activation	  at	  lower	  levels	  alone	  but	  fail	  to	  efficiently	  induce	  irreversible	  
differentiation/senescence.	   Furthermore	   this	   effect	   appears	   distinct	   to	   a	   recently	  
characterised	   novel	   form	   of	   senescence	   entitled	   PICS	   (Alimonti	   et	   al.,	   2010b),	  
achieved	   through	   activation	   of	   Akt	   concomitant	   to	   PTEN	   inhibition.	   In	   contrast	   to	  
PICS,	   BMOV/RA-­‐induced	   senescence	   is	   effective	   in	   the	   absence	   of	   heterozygous	  
PTEN	  mutations	  (which	  are	  infrequent	  in	  NBL),	  and	  occurs	  independently	  of	  p53	  and	  
mTOR.	  	  
	   The	   effects	   of	   BMOV/RA	   are	   potentially	   valuable	   to	   NBL	   therapy.	   Tumour	  
relapse	   is	   arguably	   the	   most	   significant	   barrier	   to	   effective	   therapy,	   given	   that	   a	  
plethora	  of	  compounds	  have	  been	  shown	  to	  effectively	  induce	  tumour	  regression	  in	  
solid	   tumours	   including	   NBL,	   but	   fail	   to	   prevent	   relapsed	   tumour	   growth.	   Thus	  
eradication	   based	   on	   a	   therapy	   whose	   effects	   are	   apparent	   following	   treatment	  
removal	   could	   potentially	   prevent	   relapse.	   To	   our	   knowledge	   little	   if	   any	   research	  
has	   focused	   on	   the	   effects	   of	   RA-­‐treatment	   following	   the	   termination	   of	   therapy,	  
raising	   a	   significant	   issue	   that	   apparently	   growth-­‐arrested	   cells	   might	   return	   to	   a	  
proliferative	  state	  in	  the	  absence	  of	  on-­‐going	  treatment.	  Although	  there	  are	  inherent	  
risks	   associated	   with	   the	   activation	   of	   RTK-­‐driven	   signalling,	   we	   have	   found	   little	  
evidence	   for	   negative	   side	   effects.	   For	   instance,	   BMOV/RA	   fails	   to	   induce	   hyper-­‐
proliferation	   associated	  with	  OIS,	  which	  might	   be	   expected	   to	   occur	   following	   the	  
activation	   of	   both	   Akt	   and	   Erk	   given	   that	   both	   are	   involved	   in	   stimulating	  
proliferation/cell-­‐survival	  (Roberts	  and	  Der,	  2007;	  Vivanco	  and	  Sawyers,	  2002).	  	  This	  
argues	   against	   the	   obvious	   issue	   that	   attempting	   to	   activate	   oncogenic	   signalling	  
would	   potentially	   unleash	   uncontrolled	   proliferation	   in	   bulk	   tumour	   cells.	  
Furthermore	   BMOV/RA	   causes	   little	   if	   any	   evidence	   of	   cytotoxicity,	   a	   commonly	  
dose-­‐limiting	  factor	  in	  the	  administration	  of	  chemotherapy.	  Of	  particular	  note	  is	  the	  
independence	  of	  p53	  to	  BMOV/RA-­‐induced	  cell	  senescence,	  despite	  the	  fact	  that	  the	  
induction	   of	   cell	   senescence	   as	   well	   as	   apoptosis	   frequently	   centres	   on	   p53	  
induction.	   This	   is	   an	   important	   point	   given	   that	   relapsed	   and	   thus	   treatment-­‐
resistant	   NBL	   is	   frequently	   characterised	   by	   p53	   mutations	   (Carr-­‐Wilkinson	   et	   al.,	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2010),	  while	  p53	  is	  also	  often	  inactivated	  by	  other	  means	  (Tweddle,	  2003).	  Lastly	  this	  
approach	  may	  be	  an	  effective	  means	  of	  therapy	  given	  that	   it	   relies	  on,	  rather	  than	  
antagonizes	   the	  molecular	  make	  up	  of	   a	   tumour,	   i.e.	   further	   stimulating	  pathways	  
that	   drive	   tumour	   maintenance	   to	   exploit	   fail-­‐safe	   mechanisms,	   as	   opposed	   to	  
inhibiting	  growth/survival-­‐signalling	  kinases,	  which	  ultimately	  results	   in	  selection	  of	  
resistant	  cells	  and/or	  off-­‐target	  effects	  (Balmanno	  et	  al.,	  2009).	  
	   One	   caveat	   is	   that	   BMOV/RA	   relies	   on	   the	   effectiveness	   of	   RA.	   Although	  
BMOV	   appears	   to	   augment	   the	   actions	   of	   RA	   we	   found	   no	   evidence	   that	   it	   can	  
sensitize	  RA-­‐resistant	  cells	  to	  RA-­‐mediated	  differentiation,	  nor	  does	  this	  effect	  occur	  
in	   all	   NBL	   cell	   lines	   which	   exhibit	   increased	   Akt	   activity,	   suggesting	   that	   further	  
studies	   are	   needed	   to	   examine	   the	   mechanisms	   of	   resistance	   to	   such	  
differentiation/senescence,	   and	   the	   transcriptional	   changes	   associated	   with	   RA	  
treatment	   that	  might	   synergise	  with	   RA/BMOV-­‐induced	   Akt	   activation	   to	   enhance	  
senescence.	  	  
The	   effects	   of	   BMOV/RA	   treatment	   and	   RA	   alone	   also	   exhibited	   variability.	  
For	  instance	  initial	  experiments	  (e.g.	  see	  figure	  3.16)	  showed	  marked	  differences	  in	  
the	  propensity	  of	  RA	  and	  BMOV/RA	   treated	  cells	   to	  undergo	  senescence,	  whereby	  
cells	  treated	  with	  RA	  alone	  would	  fully	  revert	  back	  to	  proliferative	  neuroblasts	  with	  
few	  if	  any	  senescent	  cells.	  In	  contrast	  later	  experiments	  (e.g.	  see	  figure	  3.23)	  found	  
less	  evidence	  for	  clear-­‐cut	  differences	  in	  senescence	  responses,	  and	  RA-­‐treated	  cells	  
more	  closely	  resembled	  BMOV/RA	  treated	  cells	  (esp.	  in	  SH-­‐SY5Y).	  While	  the	  reasons	  
for	   this	   are	   unclear,	   this	   may	   relate	   to	   gradual	   changes	   in	   endogenous	   and	  
BMOV/RA-­‐mediated	   Akt	   and	   Erk	   stimulation,	   which	   may	   be	   due	   to	   selective	  
pressures	   in	   cultured	   cells,	   and/or	   phenotypic	   drift	   experienced	   with	   cell	   lines.	  
However	  put	  another	  way	  this	  perhaps	  argues	  in	  favour	  that	  increased	  levels	  of	  Akt	  
signalling	  can	  induce	  senescence,	  as	  such	  an	  effect	  occurs	  following	  stimulation	  with	  
RA	   alone	   when	   this	   treatment	   causes	   abnormally	   high	   Akt	   activity.	   One	   further	  
caveat	   is	   that	   while	   initial	   experiments	   based	   on	   the	   effects	   of	   U0126/LY294002	  
suggested	   that	   both	   Akt	   and	   Erk	   were	   involved	   in	   morphological	   differentiation	  
induced	   by	   both	   RA	   and	   BMOV,	   the	   later	   experiments	   (shown	  here)	   failed	   to	   find	  
evidence	   for	   differences	   in	   morphology	   following	   U0126/PI103	   treatment.	   In	   the	  
case	  of	  the	  latter,	  the	  effects	  of	  LY294002	  aren’t	  always	  clear	  given	  its	  propensity	  for	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off-­‐target	  inhibition,	  thus	  PI103	  is	  perhaps	  a	  more	  reliable	  inhibitor	  especially	  given	  
that	   it	   exerts	   activity	   on	   both	   PI3K	   and	   mTOR	   (Fan	   et	   al.,	   2006).	   However	   these	  
differences	  may	  also	  be	  related	  to	  inhibitor	  dosage,	  which	  was	  used	  at	  a	  maximum	  
limit	   in	   earlier	   experiments;	   this	   was	   designated	   unfeasible	   in	   later	   experiments	  
however	  due	  to	  low	  seeding	  density	  and	  high	  toxicity,	  which	  would	  have	  limited	  the	  
number	  of	  cells	  to	  assay	  following	  termination	  of	  experiments,	  but	  one	  might	  predict	  
a	  more	   pronounced	   effect	   on	   senescence	   if	   such	   inhibitors	  were	   used	   at	   two	   fold	  
higher	  doses.	  	  
	   Certain	   issues	   still	   remain	   regarding	   BMOV/RA-­‐induced	   senescence	   in	  
comparison	   to	   previously	   published	   findings.	   It	   is	   unclear	   how	   BMOV/RA-­‐induced	  
senescence	   occurs	   in	   the	   absence	   of	   p53/p16INK4A,	   given	   that	   these	   proteins	   are	  
frequently	   involved	   in	   OIS	   as	   well	   as	   PICS.	   It	   is	   also	   noteworthy	   that	   BMOV/RA-­‐
induced	   senescence	   occurs	   following	   strong	   activation	   of	   Erk,	   given	   that	  MEK/Erk	  
signalling	   has	   been	   cited	   as	   a	   mechanism	   of	   RA-­‐resistance	   following	   mutational	  
inactivation	  of	  NF1	  in	  NBL	  (Hölzel	  et	  al.,	  2010).	  However	  as	  previously	  discussed	  this	  
phenomenon	  might	   be	   related	   to	   the	   duration	   and	   level	   of	   activation	   of	   Erk	   (von	  
Kriegsheim	  et	  al.,	  2009).	  Lastly	  PI3K	  has	  been	  recently	  shown	  to	   inhibit	  senescence	  
downstream	  of	  Ras	  (Kennedy	  et	  al.,	  2011),	  while	  clearly	  Akt	  and	  Erk	  are	  co-­‐activated	  
by	   BMOV/RA	   treatment	   with	   little	   consequence.	   However	   it	   is	   of	   course	   possible	  
that	  such	  effects	  are	  entirely	  cell-­‐type	  dependent.	  	  	  
	   The	   apparent	   causal	   role	   of	   Akt	   signalling	   in	   this	   senescence	   response	  
complicates	   the	   contention	   that	   Akt	   only	   contributes	   negatively	   to	   disease	  
progression	  in	  NBL	  by	  controlling	  proliferation/cell-­‐survival	  (Bender	  et	  al.,	  2011;	  Opel	  
et	   al.,	   2007).	   Targeted	   inhibition	   of	   Akt,	   which	   has	   been	   argued	   as	   a	   potential	  
strategy	   against	   NBL	   tumours	   (Li	   et	   al.,	   2010;	   Li	   and	   Thiele,	   2007),	   may	   be	   an	  
effective	  means	  of	  tumour	  eradication.	  However	  tumours	  with	  low	  Akt	  activity	  may	  
also	  benefit	  from	  augmentation	  of	  Akt,	  given	  that	  this	  could	  stimulate	  a	  senescence	  
response.	  Furthermore	  tumours	  with	  high	  Akt	  may	  also	  benefit	   from	  increased	  Akt	  
activity	   if	   this	   senescence	   response	   is	   simply	   related	   to	  a	   threshold	  of	  Akt	  activity.	  
This	   may	   already	   be	   a	   consequence	   of	   RA	   treatment	   in	   some	   tumours,	   although	  
there	  is	  no	  formal	  proof	  for	  this.	  Although	  caution	  is	  certainly	  required	  in	  suggesting	  
that	  a	  pathway	  that	  frequently	  controls	  proliferation/survival	  should	  be	  augmented,	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this	   approach	   is	   appealing	   in	   some	   ways	   as	   it	   may	   avoid	   problems	   of	   toxicity	  
associated	  with	  the	  inhibition	  of	  a	  fundamental	  signalling	  pathway	  such	  as	  PI3K/Akt,	  
as	  well	  as	  compensation	  limiting	  the	  effectiveness	  of	  Akt	  inhibition	  (Chandarlapaty	  et	  
al.,	  2011).	  Furthermore	  Akt	  inhibition	  might	  limit	  the	  effectiveness	  of	  RA	  in	  inducing	  
irreversible	   growth	   arrest	   (which	   could	   otherwise	   be	   augmented	   by	   BMOV),	  
although	   this	   could	  be	  avoided	  by	   confining	  BMOV/RA	   treatment	   to	  MRD.	  Thus	   in	  
sum	  the	  effectiveness	  of	  BMOV/RA	  certainly	  warrants	  pre-­‐clinical	   testing	  of	   such	  a	  
treatment	  combination	  against	  NBL	  tumours,	  which	  despite	  recent	  advances	   in	  the	  
understanding	   of	   pathogenesis	   is	   still	   frequently	   resistant	   to	   current	   treatments.	  
Importantly	   a	   number	   of	   related	   vanadium	   compounds	   have	   been	   shown	   to	   be	  
effective	  against	  solid	  tumours	  in	  pre-­‐clinical	  testing	  (Bishayee	  et	  al.,	  2010),	  as	  well	  
as	  being	  well	  tolerated	  in	  human	  clinical	  studies	  (Thompson	  et	  al.,	  2009),	  urging	  their	  
use	   in	   combination	  with	   RA	   treatment	   to	   potentially	   further	   improve	   NBL	   patient	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4.1.	  Introduction	  
As	  previously	  mentioned,	  conventional	  chemotherapy	  involves	  the	  induction	  of	  wide	  
scale	   DNA	   damage	   in	   rapidly	   dividing	   tumour	   cells,	   inducing	   selective	   cytotoxicity.	  
However	   this	   is	   often	   associated	   with	   considerable	   side	   effects	   related	   to	   non-­‐
specific	  toxicity	  e.g.	  due	  to	  off	  target	  effects	  on	  dividing	  cells	  of	  the	  gastrointestinal	  
tract	   and	   hair	   follicles	   for	   instance.	   Thus	   since	   the	   discovery	   of	   cancer-­‐causing	  
oncogenes	   in	   the	   early	   1980s,	   drug	   discovery	   has	   focused	   on	   targeted	   therapy	   of	  
proteins	   driving	   tumour	   progression,	   culminating	   in	   the	   FDA	   approval	   of	   the	   first	  
targeted	   therapy	   Trastuzumab	   (Herceptin)	   in	   1998,	   a	   monoclonal	   antibody	   that	  
interferes	   with	   the	   HER2/neu	   receptor	   in	   breast	   cancer.	   This	   has	   met	   with	   some	  
remarkable	   successes,	   for	   example	   the	  use	  of	   the	  BCR-­‐ABL	   fusion	  protein	   tyrosine	  
kinase	   inhibitor	   Imatinib	   mesylate	   (Gleevec),	   which	   causes	   remission	   of	   chronic	  
myeloid	  leukaemia	  (CML)	  in	  as	  high	  as	  90%	  of	  cases.	  
	   However	  this	  has	  considerable	  challenges	  in	  tumours	  of	  polygenic	  origin	  (the	  
majority	   of	   tumours),	  which	   do	   not	   present	  with	   one	   single	   target	   driving	   tumour	  
progression.	   Similarly	   although	   the	   phenomenon	   of	   oncogene	   addiction,	   whereby	  
cancer	  cells	  become	  dependent	  on	  particular	  proteins	  for	  survival,	  has	  been	  noted	  to	  
occur	   in	   tumours	   (Weinstein	   and	   Joe,	   2008),	   redundancy	  between	  growth/survival	  
signalling	   pathways	   often	  mitigates	   the	   effects	   of	   targeted	   therapy.	   Perhaps	  most	  
importantly	  tumour	  cells	  often	  develop	  resistance	  to	  targeted	  therapy,	  both	  through	  
Darwinian	   selection	  and	  direct	   adaptation,	   rendering	  drugs	   ineffective	  and	   causing	  
relapse.	   This	   has	   been	   elegantly	   demonstrated	   with	   Trastuzumab	   by	   the	   recent	  
finding	   that	   the	   tyrosine	   kinase	   SRC	   is	   a	   key	   node	   in	   both	   de	   novo	   and	   acquired	  
resistance	  to	  this	  drug,	  controlling	  alternative	  survival	  pathways	  normally	  negatively	  
regulated	  through	  dephosphorylation	  by	  the	  tumour	  suppressor	  PTEN	  (Zhang	  et	  al.,	  
2011).	  Conversely,	   inhibition	  of	  the	  survival/growth-­‐promoting	  kinase	  Akt	  has	  been	  
shown	   to	   relieve	   feedback	   suppression	   of	   multiple	   tyrosine	   kinase	   receptors	  
including	  HER3	   (Chandarlapaty	   et	   al.,	   2011).	   Lastly	   resistance	   can	  develop	   through	  
acquired	  mutations	  in	  unrelated	  proteins	  that	  confer	  a	  selective	  advantage,	  such	  as	  
in	   NBL	   where	   loss	   of	   the	   tumour	   suppressor	   NF1	   has	   been	   shown	   to	   mediate	  
resistance	  to	  RA	  (Hölzel	  et	  al.,	  2010;	  Huang	  et	  al.,	  2009).	  A	  common	  theme	  in	  all	  of	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these	  studies	  is	  the	  targeting	  of	  multiple	  kinases	  to	  alleviate	  compensatory	  survival	  
signalling.	  Although	  this	  strategy	  may	  appear	  effective	  it	  is	  presumably	  subject	  to	  the	  
same	   limitations	   of	   resistance	   and	   adaptation	   mechanisms,	   as	   well	   as	   potentially	  
incurring	   problems	   due	   to	   targeting	   multiple	   pathways	   required	   for	   normal	  
homeostasis	  and	  development,	  e.g.	  PI3K/Akt.	  	  
	   Given	   that	   a	   substantial	   majority	   of	   targeted	   therapies	   are	   aimed	   either	  
directly	   or	   indirectly	   at	   tyrosine-­‐kinases,	   the	   PTP	   family	   is	   perhaps	   an	   overlooked	  
pool	  of	  drug	  targets.	  This	  is	  not	  without	  its	  reasons,	  given	  the	  initial	  hypothesis	  that	  
PTPs	   would	   most	   likely	   represent	   tumour	   suppressors	   due	   to	   their	   ability	   to	  
negatively	   regulate	   growth-­‐factor	   receptor	   driven	   signalling	   pathways.	   However	  
findings	   such	   as	   that	   of	  MacKeigan	   et	   al.	   that	   as	  much	   as	   32%	   of	   the	   PTP	   family	  
promote	   cell-­‐survival	   signalling	   in	   cancer	   cells	   (MacKeigan	   et	   al.,	   2005),	   has	  
highlighted	   the	   PTP	   family	   as	   a	   growing	   family	   of	   potential	   targets	   (Easty	   et	   al.,	  
2006).	  
	   Since	   these	  early	  discoveries,	  a	  number	  of	  PTPs	  have	  emerged	  as	  bona	   fide	  
cancer-­‐promoting	  genes	  that	  are	  truly	  viable	  drug	  targets.	  For	  instance,	  SHP2,	  PTP1B	  	  
and	   PTPH1	   can	   all	   function	   in	   a	   positive	  manner	   to	   increase	   tumour	   growth	   (see	  
1.4.3).	  Lastly	  a	  pro-­‐tumorigenic	  function	  of	  the	  dual-­‐specificity	  phosphatase	  DUSP26	  
was	   recently	  highlighted	  by	   its	  ability	   to	   inhibit	  p53	   tumour	   suppressor	   function	   in	  
NBL	  (Shang	  et	  al.,	  2010).	  With	  the	  exception	  of	  PTPH1,	  selective	  inhibitors	  have	  been	  
developed	   for	   all	   of	   these	   phosphatases,	  making	   them	   tempting	   targets	   for	   novel	  
therapies.	   Although	   PTP	   targeting	   is	   a	   relatively	   untapped	   therapeutic	   strategy,	   it	  
would	   obviously	   be	   subject	   to	   the	   same	   limitations	   as	   the	   targeting	   of	   tyrosine	  
kinases,	  although	  perhaps	  suffering	  less	  from	  non-­‐specific	  toxicity.	  Thus	  an	  appealing	  
hypothesis	   is	   the	   notion	   that	   PTP	   inhibition	   could	   engage	   apoptotic	   pathways	   by	  
paradoxically	  stimulating	  growth-­‐factor	  receptor	  signalling	  cascades.	  Although	  there	  
is	   little	   evidence	   for	   this	   occurring	   in	   cancer,	   numerous	   examples	   exist	   whereby	  
over-­‐activation	  of	  proteins	  normally	  engaged	  in	  survival	  mechanisms	  can	  cause	  cell	  
death.	   For	   instance	   the	   increasing	   expression	   of	  Mycn,	   a	   transcription	   factor	  with	  
various	   survival/growth-­‐promoting	   roles	   when	   amplified	   in	   NBL,	   can	   paradoxically	  
sensitise	  NBL	  cells	  lacking	  Mycn	  amplification	  to	  apoptosis	  induced	  by	  chemotherapy	  
(Gamble	  et	  al.,	  2011;	  Peirce,	  2009).	  The	  serine/threonine	  kinase	  Akt,	  which	  controls	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numerous	   survival	   pathways	   in	   most	   human	   cancers,	   has	   been	   shown	   to	  
paradoxically	   sensitise	   cells	   to	   apoptosis	   mediated	   by	   reactive	   oxygen	   species	  
through	   inhibition	   of	   FoxO	   transcription	   factors	   and	   their	   ROS-­‐inhibiting	   targets	  
(Nogueira	  et	  al.,	  2008).	  This	  perhaps	  represents	  the	  most	  salient	  paradox	  of	  cancer-­‐
survival	   signalling,	   as	   inhibition	   of	   FoxO	   transcription	   factors	   has	   been	   considered	  
the	  primary	  mechanism	  by	  which	  Akt	  promotes	  cell-­‐survival	  (Brunet	  et	  al.,	  1999),	  yet	  
FoxOs	   have	   also	   been	   shown	   to	  maintain	   the	   survival	   of	   tumour-­‐initiating	   cells	   in	  
CML,	  conferring	  resistance	  to	  Imatinib	  (Naka	  et	  al.,	  2010;	  Tothova	  et	  al.,	  2007).	  
	   Thus	   we	   hypothesise	   that	   the	   inhibition	   of	   PTPs	   may	   both	   identify	   novel	  
regulators	  of	  cell-­‐survival	  within	  this	  enzyme	  group,	  as	  well	  as	  potentially	  elucidating	  
mechanisms	   by	   which	   the	   activation	   of	   kinases	   can	   actually	   promote	   cell	   death,	  
uncovering	   alternative	  methods	   to	   targeted	   therapy	   whereby	   one	   can	   exploit	   the	  
Achilles	  heal	  of	  cancer-­‐promoting	  enzymes	  and	  thus	  work	  with	  rather	   than	  against	  
deregulated	  signalling	  given	  its	  ubiquitous	  presence	  in	  cancer.	  
	  
4.2.	  Experimental	  procedures	  
4.2.1. Immunoblotting	  for	  oxidized	  PTEN	  
The	   detection	   of	   oxidised	   and	   reduced	   forms	   of	   PTEN	  was	   achieved	   as	   previously	  
described	   (Lee,	  2002).	  Specifically	  SDS-­‐PAGE	  gels	  were	  made	  with	  7.5%	  acrylamide	  
to	   facilitate	   band	   separation	   at	   the	   40-­‐70kDa	   range.	   Cells	  were	   lysed	   in	   the	   usual	  
manner	   except	   that	   40mM	  N-­‐ethylmaleomide	   (NEM)	  was	   added	   to	   lysis	   buffer	   to	  
block	   free	   sulfhydryls,	   i.e.	   preventing	   reduction	   of	   oxidised	   PTEN.	   Following	  
clarification	   lysates	   were	   then	   added	   to	   standard	   loading	   buffer	   without	   β-­‐
mercaptoethanol	  and	  separated	  without	  boiling	  in	  order	  to	  prevent	  reduction.	  	  
	  
4.2.2. Isogenic	  Mycn	  cell	  lines	  
The	   Tet21N	   cell	   line	   is	   a	   variant	   of	   the	   SHEP	   cell	   line,	   itself	   a	   subclone	  of	   SK-­‐N-­‐SH	  
cells,	  stably	  expressing	  Mycn	  using	  the	  Tet	  Off	  system	  (Lutz	  et	  al.,	  1998).	  Briefly	  the	  
Tet-­‐Off	  system	  was	  developed	  for	  the	  reversible	  activation	  of	  protein	  expression	  by	  
binding	   of	   the	   tetracycline	   transactivator	   (tTA)	   to	   DNA	   at	   a	   ‘tet’	   Operator,	   which	  
activates	   a	   coupled	   promoter	   containing	   a	   tetracycline	   response	   element	   (TRE)	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resulting	   in	  gene	  expression	   (Gossen	  and	  Bujard,	  1992).	  Addition	  of	   tetracycline	   to	  
culture	   medium	   prevents	   binding	   of	   tTA	   to	   the	   Mycn	   TRE,	   preventing	   promoter	  
transactivation.	   The	   second	  Mycn	   inducible	   cell	   line	   SK-­‐N-­‐AS	  MycnER	  works	   in	   the	  
opposite	  fashion.	  Specifically	  this	  cell	  line	  stably	  expresses	  a	  fusion	  protein	  of	  Mycn	  
and	   the	   oestrogen	   receptor,	   which	   can	   be	   activated	   by	   binding	   of	   the	   oestrogen	  
analogue	   4-­‐Hydroxytamoxifen	   (4-­‐OHT),	   activating	   transcription	   of	   Mycn	   after	  
addition	  of	  4-­‐OHT	  to	  culture	  medium	  (Koppen	  et	  al.,	  2007).	   	  The	  third	   isogenic	  cell	  
line	   is	  simply	  a	  variant	  of	  the	  Mycn	  non-­‐amplified	  cell	   line	  ACN	  (Thiele,	  2006),	   that	  
can	   stably	   expresses	  Mycn	   under	   the	   control	   of	   the	   CMV	   promoter	   at	   3	   different	  
levels,	  ACN-­‐0	   (empty	  vector),	  ACN-­‐5	   (Mycn	   low)	  and	  ACN-­‐10	   (Mycn	  high)	   cell	   lines	  
(Gualdrini	   et	   al.,	   2010),	   although	   we	   noted	   no	   difference	   in	   expression	   levels	  
between	  ACN-­‐5	  and	  ACN-­‐10.	  	  
	  
Figure	  4.1.	  Isogenic	  Mycn	  expressing	  cell	  lines.	  Cell	  lines	  Tet21N,	  ACN	  and	  SK-­‐N-­‐AS	  MycnER	  
have	  been	  engineered	  to	  either	  stably	  or	  conditionally	  express	  Mycn.	  Scale	  bar	  =	  10	  microns	  
	  
4.3.3. Detection	  of	  intracellular	  ROS	  and	  glutathione	  	  	  
Fluorescent	  dyes	  activated	  by	  ROS	  are	  a	  commonly	  used	  means	  of	  intracellular	  ROS	  
detection	   (Wardman,	   2007).	   Perhaps	   the	   most	   widely	   used	   die	   is	   2’,7’-­‐
Dichlorodihydrofluorescein	   (DCFH2),	  which	  has	  been	   in	  existence	   for	  over	  40	   years	  
(Chen	  et	  al.,	  2010c;	  Eruslanov	  and	  Kusmartsev,	  2010).	  This	  method	  of	  ROS	  detection	  
is	   relatively	  simple	   (Figure	  4.2).	  The	  non-­‐fluorescent	   lipophillic	  DCFH2	   is	  membrane	  
permeable	  in	  its	  deacetylated	  form	  DCFH2	  diacetate	  (DCFH2-­‐DA).	  	  Following	  addition	  
to	   culture	  medium	   the	   DCFH2-­‐DA	   compound	   diffuses	   across	   the	   phospholipid	   cell	  
membrane	   (1),	   where	   it	   is	   targeted	   by	   endogenous	   esterases	   to	   yield	   the	  
deacetylated	   membrane-­‐impermeable	   polar	   form	   DCFH2	   (2),	   which	   is	   oxidised	   by	  
intracellular	   ROS	   to	   yield	   the	   fluorescent	   molecule	   2’-­‐7’-­‐dichlorofluorescein	   (DCF)	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(4),	   losing	   2	   electrons	   in	   the	   process.	   Although	   used	   as	   a	   generic	   ROS	   detector,	  
DCFH2	   is	  not	  oxidised	  by	  all	  species,	   for	   instance	  the	  superoxide	  (O2.-­‐)	  anion,	  and	   is	  
most	  commonly	  used	  for	  the	  detection	  of	  H2O2	  (Chen	  et	  al.,	  2010c).	  
Dihydrorhodamine	   (DHR)	   123	  was	   used	   as	   an	   alternative	   to	  DCFDA	   for	   the	  
detection	  of	  ROS.	  DHR	  123	  works	  on	   the	  exact	   same	  principle	  as	  DCFDA,	  whereby	  
intracellular	  H202	  oxidises	  the	  non-­‐fluorescent	  chemical	  DHR	  123	  into	  the	  fluorescent	  
molecule	   rhodamine	   123,	   which	   emits	   fluorescence	   at	   534nm	   when	   excited	   at	  
502nm	  (Emmendörffer	  et	  al.,	  1990).	  Importantly	  DHR123	  has	  been	  suggested	  to	  be	  
more	   sensitive	   in	   the	   detection	   of	   ROS	   when	   compared	   with	   DCFDA.	   Briefly	   cells	  
were	   seeded	   onto	   a	   96	   well	   plate	   at	   high	   density	   (5x104).	   Cells	   were	   allowed	   to	  
adhere	   to	   their	   surface,	  and	   then	   treated	   for	  4	  hours	  with	   compounds	  of	   interest.	  
Following	  treatment,	  cells	  were	  washed	  with	  pre-­‐warmed	  HBSS	  then	  incubated	  with	  
10µM	  DHR	  123	  diluted	  in	  DMSO	  in	  fresh	  HBSS	  for	  30	  minutes	  at	  37°C.	  Following	  this	  
DHR	   loading,	   cells	   were	   washed	   with	   HBSS,	   then	   replaced	   with	   fresh	   HBSS	   and	  
fluorescence	   was	   immediately	   read	   using	   a	   FLUOstar	   OPTIMA	   plate	   reader	   (BMG	  
Labtech,	  Offenburg,	  Germany)	  microplate	   reader	  at	  an	  excitation/emission	   ratio	  of	  
492/520.	  	  
	  
Figure	  4.2.	  Mechanism	  of	  ROS	  detection	  by	  DCF	   fluorescence.	  DCFDH2-­‐DA	  enters	   the	   cell	  
membrane	  (1)	  where	  it	  is	  deacetylated	  by	  esterases	  (2)	  and	  oxidised	  to	  DCF	  by	  intracellular	  
ROS	  (3),	  generating	  a	  fluorescent	  signal	  (4).	  Note	  that	  controversies	  exist	  such	  as	  which	  ROS	  
target	   DCFDH2	   (3),	   the	   leakage	   of	   DCF	   by	   diffusion	   (5)	   as	   well	   as	   the	   membrane	  
impermeability	   of	   DCFH2	   (6)	   and	  whether	   deacetylation	  may	   occur	   prior	   to	   cell	   entry	   (7),	  
reflecting	  general	  uncertainties	  concerning	  the	  mechanism	  of	  action	  of	  such	  probes.	  Taken	  
from	  (Chen	  et	  al.,	  2010c).	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Monochlorobimane	   was	   used	   for	   the	   detection	   of	   intracellular	   glutathione	   (GSH).	  
MCB	  enters	  into	  the	  cell	  forming	  a	  fluorescent	  GSH-­‐MCB	  product	  dependent	  on	  the	  
glutathione-­‐S-­‐transferase	  activity,	  which	  catalyses	  the	  conjugation	  of	  GSH.	  GSH-­‐MCB	  
is	  thus	  indicative	  of	  the	  relative	  levels	  of	  cellular	  GSH	  (Kamencic	  et	  al.,	  2000).	  Briefly	  
cells	   were	   seeded	   in	   96	   well	   plates	   and	   treated	   as	   previously.	   However	   following	  
treatment,	   50µM	   MCB	   diluted	   in	   DMSO	   was	   added	   to	   the	   culture	   medium	   and	  
fluorescence	  was	  read	  immediately	  at	  an	  excitation/emission	  ratio	  of	  426/490.	  	  
	  
4.2.4.	  Examination	  of	  apoptosis	  following	  plasmid	  overexpression	  
To	   examine	   the	   influence	   of	   Akt	   on	   BMOV-­‐induced	   toxicity,	   we	   overexpressed	  
plasmids	  containing	  a	  dominant	  negative	  HA-­‐Akt	  DN	  (K179M)	  (Zhou	  et	  al.,	  2000)	  and	  
a	  constitutively	  active	  myr-­‐Akt	  Delta4-­‐129	   (Kohn	  et	  al.,	  1996)	   form	  of	  Akt,	  a	  gift	  of	  
Dr.	   Mien-­‐Chie	   Hung	   (Addgene	   plasmid	   16243)	   and	   Dr.	   Richard	   Roth	   (Addgene	  
plasmid	   10841)	   respectively.	   Due	   to	   the	   absence	   of	   selectable	  marker	   genes,	   cells	  
were	  co-­‐transfected	  with	  a	  CAG-­‐H	  vector	   (see	  Chapter	  3)	   containing	   the	  HLH	   gene	  
conferring	  resistance	  to	  the	  antibiotic	  hygromycin	  B.	  One-­‐day	  post	  transfection	  cells	  
were	  selected	  by	  the	  addition	  of	  hygromycin	  B	  to	  the	  culture	  medium	  (400µg/µl)	  for	  
72	  hours,	  then	  re-­‐plated	  onto	  new	  dishes	  and	  treated	  as	  normal	  for	  72	  hours.	  This	  
method	  allowed	  significant	  enrichment	  for	  transfected	  cells	  (Figure	  4.3).	  	  
In	  order	  to	  achieve	  maximal	  transfection,	  the	  lipid-­‐based	  transfection	  reagent	  
Lipofectamine™	   2000	   (L2K)	   (Invitrogen,	   Carslbad,	   CA)	   was	   used.	   Briefly	   L2K	   was	  
diluted	  in	  reduced	  serum	  Opti-­‐MEM	  medium	  and	  allowed	  to	  incubate	  for	  5	  minutes.	  
DNA	  was	   diluted	   at	   a	   ratio	   of	   2:3	  DNA:	   L2K	   in	   an	   equal	   volume	  of	  Opti-­‐MEM	  and	  
both	  mixtures	  were	  combined	  and	  incubated	  for	  20	  minutes	  before	  addition	  to	  the	  
culture	  medium.	  Media	  was	  removed	  12-­‐16	  hours	  following	  transfection.	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Figure	  4.3.	  Enrichment	   cells	  over-­‐expressing	  plasmid	  based	  on	  acute	  antibiotic	   selection.	  
Cells	   were	   co-­‐transfected	   with	   a	   vector	   encoding	   GFP	   and	   a	   vector	   containing	   the	  
hygromycin	   resistance	   gene	   then	   acutely	   selected	   for	   48	   hours	   using	   hygromycin	   B	  
(400µg/µl)	   followed	   by	   trypsinisation	   and	   reseeding.	   Surviving	   cell	   populations	   are	   highly	  
enriched	  for	  GFP	  positive	  and	  thus	  transfected	  cells.	  	  
	  
4.2.5.	  Detection	  of	  autophagy	  
The	   detection	   of	   macroautophagy	   (autophagy)	   was	   achieved	   through	   3	   methods.	  
The	  first	  made	  use	  of	  a	  plasmid	  encoding	  a	  GFP-­‐LC3	  fusion	  protein	  (A	  kind	  gift	  of	  Dr.	  
Toren	  Finkel,	  Addgene	  plasmid	  24920),	  which	  facilitates	  the	  detection	  of	  autophagy	  
due	  to	  LC3	  becoming	  conjugated	  to	  phosphatidylenimine	   (PE)	  during	   the	   induction	  
of	  autophagy	  and	  its	  localisation	  transitioning	  from	  a	  cytosolic	  to	  an	  autophagosome	  
membrane	   distribution,	   thus	   becoming	   punctate	   in	   appearance	   (Elgendy	   et	   al.,	  
2011).	   	  Here	   cells	  were	   transiently	   transfected,	   fixed	   in	   4%	  paraformaldehyde	   and	  
photographed	   under	   blue	   excitation.	   The	   second	   method	   involved	   the	   vital	   dye	  
acridine	   orange,	   which	   becomes	   protonated	   under	   acidic	   conditions,	   leading	   to	  
orange	  staining	  when	  subjected	   to	  excitation	  by	  blue	   light	   (Mains	  and	  May,	  1988).	  
Here	   cells	   were	   treated	   for	   15	   minutes	   with	   acridine	   orange	   (5µg/ml)	   diluted	   in	  
water	  and	  fixed	  in	  4%	  paraformaldehyde.	  Cells	  were	  then	  photographed	  under	  both	  
green	   and	   red	   emission.	   Although	   red	   light	   emitting	   acidic	   vesicles	   should	   be	  
detected	   under	   blue	   light,	  we	   examined	   fluorescence	   under	   each	   excitation	   beam	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and	  did	  not	  detect	  any	  red	  signal	  under	  blue	  light.	  Thus	  vesiculation	  after	  excitation	  
with	  green	  light	  was	  took	  as	  indicative	  of	  autophagy.	  Lastly	  the	  conjugation	  of	  LC3-­‐I	  
to	  LC3-­‐II	  was	  detected	  by	  immunoblotting,	  whereby	  LC3-­‐II	  migrates	  faster	  than	  LC3-­‐I	  
giving	   rise	   to	   two	   distinct	   bands.	   Here	   cells	   were	   treated	   with	   lysosomal	   peptide	  
inhibitors	  E64d	  (4µg/ml)	  and	  pepstatin-­‐A	  (2µg/ml)	  to	  block	  endogenous	  turnover	  of	  
LC3-­‐II	   in	   the	   autophagosome	   for	   4	   hours,	   followed	   by	   treatment	  with	   chemical	   of	  
interest	  for	  12	  hours.	  Cells	  were	  then	  lysed	  and	  subjected	  to	  SDS-­‐PAGE	  using	  a	  15%	  




4.3.1.	  Vanadium	  compounds	  selectively	   induce	  apoptosis	   in	  a	  cell	   line-­‐dependent	  
manner	  	  
Undoubtedly	  the	  most	  common	  approach	  to	  chemotherapy	  is	  the	  selective	  targeting	  
of	  cancer	  cells	  through	  their	  reliance	  on	  survival	  mechanisms,	  for	  instance	  oncogene	  
addiction	   (Weinstein,	   2002;	   Weinstein	   and	   Joe,	   2008),	   resulting	   from	   constitutive	  
activation	   of	   growth	   factor	   signalling.	   Although	   traditionally	   viewed	   as	   positive	  
regulators	   of	   programmed-­‐cell	   death	   through	   dampening	   growth	   factor	   signalling,	  
PTPs	  have	  been	  shown	  to	  be	  largely	  responsible	  for	  cell	  survival	  with	  an	  RNAi	  screen	  
in	  the	  cervical	  cancer	  HeLa	  cell	  line	  identifying	  33%	  of	  phosphatases	  as	  contributing	  
positively	  to	  cell	  survival	  (MacKeigan	  et	  al.,	  2005).	  Thus	  we	  sought	  to	  see	  if	  vanadium	  
compounds	   could	   act	   in	   a	   similar	   manner	   to	   conventional	   chemotherapeutics	   by	  
initiating	  a	  cytotoxic	  response	  selectively	  in	  neuroblastoma	  cells.	  	  
	   We	   noted	   previously	   that	   LAN-­‐5	   cells	   displayed	   evidence	   of	   morphological	  
apoptosis	  in	  response	  to	  VA	  as	  well	  as	  undergoing	  neuritogenesis	  (See	  section	  3.1).	  
Thus	  we	  sought	  to	  confirm	  this	  by	  analysing	  the	  sub-­‐G1	  fraction	  of	  cells	  (a	  marker	  of	  
DNA	   fragmentation	   following	  apoptosis)	   after	   treatment	  with	  VA.	  VA	   treatment	  of	  
LAN-­‐5	   cells	   significantly	   increased	   apoptosis	  while	   both	   SK-­‐N-­‐SH	   and	   SH-­‐SY5Y	   cells	  
were	   unaffected	   (Figure	   4.4,	   A).	   This	   effect	   was	   partially	   reduced	   by	   concurrent	  
treatment	   with	   RA,	   suggesting	   it	   is	   unrelated	   to	   differentiation	   and	   for	   instance	  
neurotrophin	  dependence	  (Encinas	  et	  al.,	  2000b).	  VA	  also	  failed	  to	  induce	  cell	  death	  
in	   transformed	   cells	   (293T,	   COS7)	   as	   well	   as	   glioma	   (C6)	   and	   pheochromocytoma	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(PC63)	  cells	   (Figure	  4.4A).	  This	  suggests	  VA	   induces	  highly	  selective	  cytotoxicity	   for	  
NBL	   cells,	   given	   that	   (1)	   pheochromocytoma	   is	   a	   neuroendocrine,	   neural	   crest	  
derived	   tumour	   likely	   originating	   from	   a	   common	   precursor	   to	   NBL,	   and	   (2)	   that	  
glioblastoma	   is	   a	   tumour	  of	  neuronal	  origin.	   Similarly	  non-­‐transformed	  MEFs	  were	  
unresponsive	   to	  VA	   treatment,	   reinforcing	   the	   selectivity	  of	   the	  effect	  on	  NBL	  and	  
showing	   that	   these	   normal,	   non-­‐immortalised	   cells	   are	   resistant	   to	   BMOV	   (Figure	  
4.4,	  B).	  
	   	  Further	   testing	   revealed	   that	  multiple	   cell	   lines	   (KCNR,	   Kelly,	   IMR-­‐32)	   also	  
responded	   to	   VA	   with	   cell	   death,	   with	   5µM	   dosage	   significantly	   abrogating	   cell	  
survival	  (Figure	  4.4,	  C).	  Importantly	  this	  effect	  appeared	  selective	  for	  a	  subset	  of	  NBL	  
cell	  lines,	  as	  cells	  that	  were	  unresponsive	  to	  VA	  (SK-­‐N-­‐DZ,	  SK-­‐N-­‐AS)	  failed	  to	  undergo	  
cell	  death	  at	  doses	  up	  to	  10	  fold	  higher	  (data	  not	  shown).	  Crystal	  violet	  staining	  for	  
viable	   cells	   revealed	   a	   near	   complete	   loss	   of	   surviving	   cells	   following	   6	   days	   of	  
treatment	  with	  the	  alternative	  vanadium	  compound	  BMOV	  (Figure	  4.4,	  D).	  	  VA	  was	  
also	  observed	  to	  induce	  morphological	  evidence	  of	  apoptosis,	  causing	  picnotic	  nuclei	  
as	   evidenced	   by	   DAPI	   staining	   (Figure	   4.4,	   E)	   and	   positive	   staining	   for	   propidium	  
iodide	   that	  preferentially	  marks	   cells	   that	  have	   lost	  membrane	   integrity,	   indicating	  
late-­‐stage	  apoptosis	  and/or	  necrosis.	  	  
To	   briefly	   summarise,	   both	  BMOV	  and	  VA	   cause	   cytotoxicity	   in	   a	   subset	   of	  
NBL	  cell	  lines	  by	  mechanisms	  distinct	  from	  non-­‐specific	  cell	  stress,	  e.g.	  sparing	  non-­‐
NBL	  cell	  types,	  and	  indicating	  both	  PCD	  and	  necrosis	  as	  possible	  contributing	  forms	  
of	  cell	  death.	  We	  next	  sought	  to	  characterize	  this	  response	  further	  by	  examining	  the	  
mechanism	  of	  cell	  death.	  Chemotherapeutic	  targeted	  drugs	  often	  induce	  cell	  death	  
via	   apoptosis,	   a	   mechanism	   of	   PCD	   in	   which	   cells	   undergo	   distinct	   morphological	  
changes	   including	   membrane	   blebbing,	   chromatin	   condensation,	   nuclear	  
fragmentation	  (karyorrhexis)	  and	  cell	  shrinkage.	  	  PCD	  and	  apoptosis	  generally	  occur	  
through	   activation	   by	   proteolytic	   cleavage	   of	   caspases,	   where	   stimuli	   activate	  

















Figure	   4.4.	   Vanadium	   compounds	   induce	   cytotoxicity	   in	   a	   cell-­‐line	   specific	   manner	  
selectively	   in	   NBL	   cells.	   (A)	   Sub	   G1	   analysis	   showing	   increases	   in	   the	   percentage	   of	  
apoptotic	  cells	  in	  LAN-­‐5	  cells	  treated	  for	  6	  days	  with	  VA	  (5µM),	  an	  effect	  reduced	  by	  co-­‐
treatment	   with	   RA.	   Increased	   sub	   G1	   is	   not	   exhibited	   by	   non-­‐cancerous	   transformed	  
control	   cells	   (COS-­‐7,	   293T)	   and	   neuroendocrine	   (PC-­‐63)	   and	   glial	   (C6)	   tumour	   control	  
cells.	   (B)	   BMOV	   (10µM)	   exerts	   no	   cytotoxicity	   against	   untransformed	  wild-­‐type	  mouse	  
embryonic	   fibroblasts	   treated	   for	   6	   days.	   (C)	   VA-­‐induced	   cytotoxicity	   is	   shared	   with	  
BMOV	  in	  distinct	  NBL	  cell	  lines	  (IMR-­‐32,	  KCNR,	  Kelly),	  whereas	  other	  NBL	  cell	  lines	  (SK-­‐N-­‐
DZ,	   SK-­‐N-­‐AS)	   are	   unresponsive	   to	   both	   inhibitors	   after	   the	   same	   treatment	   period	   (3-­‐6	  
days)/dosage	  (10µM).	  (D)	  Crystal	  violet	  staining	  of	  fixed	  cells	  treated	  for	  6	  days	  with	  5µM	  
VA	   revealing	   gross	   reductions	   in	   cell	   survival.	   (E)	   DAPI	   and	   propidium	   iodide	   staining	  
revealing	  morphological	   apoptosis	   characterized	   by	   picnotic	   nuclei	   (DAPI	   –	   arrows	   and	  
insets)	   and	   late-­‐stage	   apoptosis/necrosis	   (PI	   –	   arrow	   heads)	   in	   cells	   treated	   for	   3	   days	  
with	  BMOV	  (10µM).	  Scale	  bar	  =	  10	  micrometers.	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Thus	  we	  examined	  whether	  the	  effector	  caspase	  3	  was	  cleaved	  following	  treatment	  
with	  BMOV	   in	   those	  NBL	  cell	   lines	   that	   respond	  via	  cell	  death.	   Immunostaining	   for	  
cleaved	  caspase	  3	  revealed	  an	  increase	  in	  the	  proportion	  of	  cells	  expressing	  cleaved	  
caspase	   3	   in	   LAN-­‐5,	   IMR-­‐32,	   Kelly	   and	   KCNR	  NBL	   cells.	   This	   increase	   however	  was	  
fairly	  modest,	  and	  did	  not	  appear	  to	  recapitulate	  the	  extent	  of	  cell	  death	  after	  BMOV	  
treatment	   (Figure	   4.5,	   A).	   Activated	   caspase-­‐3	   positivity	   was	   observed	   to	   roughly	  
correlate	   with	   propidium	   iodide	   staining	   suggesting	   that	   cell	   death	   was	   occurring	  
predominantly	  via	  caspase	  activation	  but	  to	  a	  lesser	  extent	  via	  caspase-­‐independent	  
PCD	  and/or	  necrosis	  (Figure	  4.5.	  A).	  
	   Given	   that	  we	  observed	  propidium	   iodide	  positive	   cells	   and	   cells	   exhibiting	  
morphological	   apoptosis	   (picnotic	   nuclei)	   in	   cases	   were	   caspase	   3	   activation	   was	  
infrequent,	  we	  sought	  to	  examine	  whether	  BMOV	  induced-­‐cell	  death	  was	  dependent	  
on	   caspase	   activation	   using	   Z-­‐VAD-­‐FMK,	   a	   pan-­‐caspase	   inhibitor	   that	   irreversibly	  
binds	  to	  the	  caspase	  active	  site	  (Slee	  et	  al.,	  1996).	  	  Compound	  treatment	  with	  zVAD-­‐
FMK	   partially	   but	   significantly	   blocked	   BMOV-­‐induced	   death	   in	   KCNR	   cells	   (Figure	  
4.5,	  B).	  However	  a	   significant	   sub	  G1	   fraction	   remained	   in	   the	  presence	  of	   Z-­‐VAD-­‐
FMK,	   suggesting	   either	   that	   this	   inhibitor	   was	   not	   achieving	   full	   efficacy	   and	   thus	  
some	   apoptosis	   was	   still	   occurring,	   or	   that	   one	   component	   of	   BMOV	   induced-­‐cell	  
death	  may	  be	  PCD	  occurring	  independently	  of	  caspases	  (Kroemer	  and	  Martin,	  2005;	  
Lockshin	  and	  Zakeri,	  2004;	  Tait	  and	  Green,	  2008).	  
One	  of	  the	  most	  common	  mechanisms	  of	  PCD	  induced	  by	  chemotherapeutic	  
agents	  occurs	  via	  stress	  signalling/activation	  of	  the	  DNA	  damage	  response	  leading	  to	  
stabilization	  and	  activation	  of	  p53	   (Junttila	  and	  Evan,	  2009).	  While	  p53	   is	  generally	  
wild	  type	  at	  presentation	  in	  NBL	  (Chen	  et	  al.,	  2007),	  it	  can	  be	  frequently	  inactivated	  
via	   mechanisms	   including	   post-­‐translational	   squelching	   caused	   by	   MDM2	   (Van	  
Maerken	   et	   al.,	   2011)	   and	   mutations	   acquired	   during	   tumour	   remission	   causing	  
relapse	  (Carr-­‐Wilkinson	  et	  al.,	  2010).	  	  Thus	  we	  examined	  whether	  BMOV	  was	  causing	  
cell	   death	   through	   genotoxic	   stress	   induced	   by	   stabilization	   and	   activation	   of	   p53.	  
Immunoblotting	  revealed	  that	  standard	  and	  two-­‐fold	  higher	  doses	  of	  BMOV	  did	  not	  
lead	   to	   upregulation	   of	   p53	   (Figure	   4.5,	   C).	   In	   fact	   p53	  was	   undetectable	   in	   three	  
lines	   that	   respond	   to	   BMOV	   via	   cell	   death	   (LAN-­‐5,	   KCNR,	   IMR-­‐32)	   and	   only	  
detectable	   in	  Kelly	  cells,	  but	  at	  basal	   levels.	  Similarly	  we	  observed	  no	  effect	  of	   the	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p53	  inhibitor	  Nutlin	  (data	  not	  shown).	  This	  suggests	  that	  BMOV-­‐induced	  cell	  death	  is	  
independent	  of	  p53.	  	  
	   Stress	  and	  damage	  responses	  also	  commonly	  activate	  the	  p38	  MAPK	  family,	  
which	  positively	  regulate	  cell	  death	  (Xia	  et	  al.,	  1995).	  Thus	  we	  asked	  the	  question	  of	  
whether	   BMOV-­‐induced	   cell	   death	   was	   the	   result	   of	   p38	   MAPK	   activation.	  
Immunoblotting	   revealed	   that	   BMOV	   did	   not	   cause	   increased	   activation	   of	   p38	  
MAPK	  in	  any	  cell	  line	  (Figure	  4.5,	  D),	  further	  suggesting	  that	  BMOV	  does	  not	  exert	  its	  
cytotoxic	  effects	  via	  activation	  of	  a	  general	  cell	  stress	  response.	  	  
In	   sum,	  both	  VA	  and	  BMOV	   induce	  cell	  death	   in	  a	  cell-­‐line	  specific	  manner,	  
causing	   significant	   increases	   in	   morphological	   cell	   death/DNA	   fragmentation	   at	   a	  
dosage	   that	   is	   tolerated	   in	   genetically	   distinct	   NBL	   cells	   as	   well	   as	   non-­‐
neuroblastoma	   transformed	   and	   tumour	   cells	   and	   normal	   non-­‐tumour	   cells.	  
Furthermore	   this	   cytotoxic	   response	   elicits	   morphological	   apoptosis	   and	   necrosis	  
that	   activates	   cleaved	   caspase	  3.	  However,	   a	   caspase	   inhibitor	   study	   suggests	   that	  
caspase-­‐independent	   PCD	   is	   also	   a	   significant	   component.	   Lastly,	   BMOV	   fails	   to	  
activate	  either	  p53	  or	  p38	  MAPK,	  suggesting	  that	  this	  cytotoxic	  effect	   is	  not	  simply	  
due	   to	   non-­‐specific	   genotoxic	   stress.	   BMOV	   could	   thus	   potentially	   target	   NBL	  
tumours	   having	   mutations	   in	   the	   p53	   pathway,	   a	   frequent	   obstacle	   to	  
chemotherapy.	  	  
	  
4.3.2.	   Decreasing	   cell	   adhesion	   increases	   cell	   death	   in	   BMOV-­‐unresponsive	   cells	  
and	  reduces	  SRC	  kinase	  levels	  
Both	  SRC	  and	  FAK	  have	  been	  shown	  to	  contribute	  to	  cell	  survival	  in	  NBL,	  where	  joint	  
inhibition	  was	  found	  to	  cause	  cytotoxicity	  due	  to	  decreased	  adhesion	  and	  apoptosis	  
through	   detachment	   from	   the	   extra-­‐cellular	  matrix	   (anoikis)	   (Beierle	   et	   al.,	   2010).	  
Similarly	   FAK	   is	   a	   target	   of	   Mycn,	   where	   increased	   expression	   of	   Mycn	   causes	  
increases	   in	   the	   levels	   of	   FAK	   (Beierle	   et	   al.,	   2007)	   and	   is	   thus	   considered	   a	   good	  
target	  for	  therapy	  (Gillory	  and	  Beierle,	  2010).	  Caspase-­‐8	  was	  shown	  to	  promote	  SRC-­‐
mediated	  adhesion	  in	  NBL,	  explaining	  its	  lack	  of	  tumour-­‐suppressive	  function	  (Finlay	  
and	  Vuori,	  2007),	  while	  joint	  activation	  of	  FAK	  and	  SRC	  have	  been	  found	  to	  promote	  
α5β1	  and	  α4β1	  integrin-­‐stimulated	  NBL	  cell	  motility	  (Wu	  et	  al.,	  2008).	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Figure	  4.5.	  VA/BMOV	  induced	  cell	  death	   involves	  caspase	  activation	  but	  does	  not	   induce	  
genotoxic	   stress	   signalling.	   (A)	   ICC	   illustrating	   cleavage	   of	   caspase	   3	   following	   48	   hour	  
treatment	  with	  BMOV	   (10µM),	   note	   that	   caspase-­‐3	   activation	   generally	   fails	   to	   co-­‐localise	  
with	  propidium	  iodide	  staining	  indicating	  both	  necrosis	  and	  apoptosis.	  (B)	  KCNR	  cells	  treated	  
for	   2	   hours	   prior	   too	   and	  48	  hours	   during	  BMOV	   (10µM)	   treatment	  with	   the	  pan-­‐caspase	  
inhibitor	   z-­‐vad-­‐FMK	   (20µM),	  which	   significantly	   reduces	  BMOV-­‐induced	   cell	   death	   (sub	  G1	  
DNA	  content).	  (C)	  24-­‐hour	  BMOV	  treatment	  fails	  to	  induce	  the	  expression	  of	  p53	  or	  activate	  
p38	   MAPK	   signalling	   (D)	   illustrating	   that	   BMOV-­‐induced	   cell	   death	   is	   independent	   of	  
genotoxic	  stress	  signals.	  C	  shows	  mean	  and	  SEM	  with	  independent	  samples	  student’s	  t	  tests.	  
D	  =	  10µM	  BMOV.	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Both	   SRC	   and	   FAK	   are	   subject	   to	   regulation	   through	   reversible	   tyrosine	  
phosphorylation	   where	   a	   number	   of	   PTPs	   play	   a	   direct	   role	   both	   positively	   and	  
negatively	   regulating	   FAK/SRC	   activity.	   For	   instance	   PTP-­‐PEST	   (PTPN12)	   has	   been	  
shown	   to	  dephosphorylate	   SRC	  at	   Y416,	  preventing	   the	  phosphorylation	  of	   villin	   1	  
and	   negatively	   regulating	   cell	  migration/invasion	   (Mathew	   et	   al.,	   2008).	   PTEN	   has	  
recently	   been	   shown	   to	   directly	   dephosphorylate	   SRC,	   negatively	   regulating	   its	  
activity	  contributing	  to	  tumour	  regression	  during	  chemotherapy	  (Zhang	  et	  al.,	  2011).	  
Conversely	   PTPRA	   has	   been	   found	   to	   dephosphorylate	   SRC	   on	   Y527	   through	   its	  
interaction	   with	   integrin	   α5β3,	   activating	   SRC	   and	   positively	   regulating	   the	  
association	  of	  FAK	  and	  SRC	  (Harder	  et	  al.,	  1998).	  	  PTP1B	  has	  been	  demonstrated	  to	  
activate	  SRC,	  an	  event	  necessary	  for	  transformation	  of	  human	  breast	  epithelial	  cells	  
by	  ErbB2	  (Arias-­‐Romero	  et	  al.,	  2009).	  	  	  
	   The	  PTP	  family	  has	  a	  well-­‐defined	  role	  in	  cell	  adhesion	  (Gebbink	  et	  al.,	  1993),	  
while	   treatment	   with	   vanadium	   compounds	   has	   been	   shown	   to	   modulate	   cell	  
adhesion	  (Edwards	  et	  al.,	  1991).	  Given	  the	  fact	  that	  both	  SRC	  and	  FAK	  are	  subject	  to	  
regulation	  by	  PTPs,	  and	  are	  involved	  in	  regulating	  cell	  adhesion,	  motility	  and	  invasion	  
in	  tumour	  cells	  and	  contribute	  positively	  to	  cell	  survival	  in	  NBL,	  we	  hypothesized	  that	  
BMOV	  may	   alter	   their	   activation,	   causing	   cell	   death	   through	   anoikis.	   Indeed	  KCNR	  
cells	   are	   among	   the	   least	   adhesive	   of	   the	   panel	   of	   tested	  NBL	   cells	   and	   the	  most	  
sensitive	  to	  BMOV	  induced-­‐cytotoxicity,	  while	  SK-­‐N-­‐AS	  cells	  are	  at	  the	  opposite	  end	  
of	  the	  spectrum,	  representing	  highly	  substrate	  adherent	  cells	  with	  a	  high	  tolerance	  
to	  BMOV	  treatment.	  	  Thus	  we	  examined	  the	  expression	  and	  phosphorylation	  status	  
of	  both	  FAK	  and	  SRC	  in	  both	  BMOV-­‐sensitive	  (LAN-­‐5,	  KCNR)	  and	  BMOV-­‐unresponsive	  
(SK-­‐N-­‐AS)	  cells.	  
	   Immunoblotting	  revealed	  large	  differences	  in	  the	  expression	  of	  SRC	  and	  FAK	  
in	   BMOV-­‐responsive	   cells	   versus	   unresponsive	   cells,	   with	   SK-­‐N-­‐AS	   expressing	   high	  
levels	   of	   endogenous,	   phosphorylated	   FAK	   and	   SRC	   compared	   to	   low	   levels	   in	  
KCNR/LAN5	  cells	  (Figure	  4.6).	  BMOV	  treatment	  was	  found	  to	  further	  decrease	  both	  
total	   and	   phosphorylated	   SRC	   levels	   in	   all	   cell	   lines.	   Due	   to	   the	   high	   level	   of	   SRC	  
expression/activation	  in	  SK-­‐N-­‐AS	  cells	  the	  effect	  of	  BMOV	  was	  negligible,	  however	  in	  
the	  case	  of	  both	  LAN-­‐5/KCNR	  treatment	  with	  BMOV	  reduced	  the	  expression	  of	  total	  
and	  activated	  SRC	  to	  undetectable	  levels.	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Figure	  4.6.	  High	  expression	  of	  total	  and	  activated	  FAK	  and	  SRC	  in	  BMOV-­‐unresponsive	  SK-­‐
N-­‐AS	  cells.	  In	  each	  cell	  line	  BMOV	  (B)	  (10µM)	  treatment	  decreased	  levels	  of	  SRC	  protein	  and	  
phospho-­‐SRC,	   without	   significantly	   affecting	   FAK.	   Cells	   were	   treated	   for	   24	   hours.	   C	   –	  
control;	   R	   –	   RA;	   BR	   =	   BMOV/RA.	   Experiment	   carried	   out	   with	   M.	   Attwood	   under	   direct	  
supervision	  of	  O.Clark.	  	  
	  
Based	   on	   this	   evidence	   we	   hypothesized	   that	   high	   expression	   of	   endogenous	  
activated	  SRC	  may	  form	  a	  mechanism	  of	  resistance	  to	  BMOV.	  This	  might	  potentially	  
explain	  why	  SK-­‐N-­‐AS	  cells,	  which	  express	  high	  levels	  of	  SRC,	  are	  BMOV-­‐unresponsive,	  
while	  KCNR	  cells,	  which	  express	  low	  levels	  of	  SRC	  that	  is	  further	  decreased	  by	  BMOV,	  
are	  sensitive	  to	  its	  cytotoxic	  effects.	  Both	  low	  expression	  of	  FAK/SRC	  and	  sensitivity	  
to	   BMOV	  may	   be	   related	   to	   a	   relative	   lack	   of	   substrate	   adherence	   in	   KCNR	   cells	  
versus	  SK-­‐N-­‐AS,	  given	  that	  inhibition	  of	  SRC/FAK	  causes	  anoikis	  (Beierle	  et	  al.,	  2010).	  
Thus	   we	   attempted	   to	   test	   this	   by	   seeding	   cells	   onto	   non-­‐tissue	   culture	   treated	  
dishes,	  which	   lack	  a	  hydrophilic	   surface	  and	   therefore	   fail	   to	   facilitate	  adhesion	   to	  
the	  substratum.	  Although	  SK-­‐N-­‐AS	  cells	  were	  able	  to	  adhere	  to	  non-­‐treated	  plastic,	  
they	   exhibited	   a	  morphology	  more	   closely	   resembling	   that	   of	   adherent	   KCNR	   cells	  
when	  seeded	  onto	  treated	  plastic	  in	  terms	  of	  a	  propensity	  to	  form	  loosely	  adherent	  
spheroid	  structures	  and	  a	  more	  fusiform	  phenotype	  (Figure	  4.7,	  A).	  	  
Indeed	   seeding	   cells	   onto	   non-­‐treated	   plastic	   greatly	   reduced	   the	   levels	   of	  
endogenous	   FAK	   and	   SRC	   in	   SK-­‐N-­‐AS	   cells	   in	   terms	   of	   both	   activated	   and	   total	  
protein	   expression,	   resembling	   levels	   of	   KCNR	   cells	   seeded	   onto	   treated	   plastic	  
(Figure	   4.7,	   B,	   C).	   Activated	   FAK	   was	   also	   observed	   to	   decrease	   following	   BMOV	  
treatment	  only	  in	  SK-­‐N-­‐AS	  cells	  seeded	  onto	  non-­‐treated	  plastic,	  highly	  suggestive	  of	  
the	   fact	   that	   preventing	   substrate	   adherence	   increases	   the	   effect	   of	   BMOV	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treatment.	  However	  In	  these	  experiments	  BMOV-­‐sensitive	  KCNR	  cells	  were	  observed	  
to	   increase	   FAK	   activation	   slightly	   following	   BMOV	   treatment	   in	   both	   substrate	  
adherent	   and	   non-­‐adherent	   conditions,	   suggesting	   that	   decreased	   FAK	   activation	  
was	  not	  a	  determinant	  of	  cytotoxicity	  to	  BMOV.	   	  Levels	  of	  both	  activated	  and	  total	  
SRC	   remained	   low	   in	   KCNR	   cells	   regardless	   of	   seeding	   surface.	   Thus	   preventing	  
adequate	  substrate	  adhesion	  in	  SK-­‐N-­‐AS	  cells	  led	  to	  a	  profile	  of	  FAK/SRC	  expression	  
and	   activation	   that	   closely	   resembled	   that	   of	   KCNR	   cells	   at	   basal	   levels,	   reducing	  
protein	  expression	  and	  conferring	  sensitivity	  to	  BMOV-­‐induced	  changes	  in	  activation.	  
	   We	   next	   sought	   to	   see	   if	   the	   observed	   changes	   in	   FAK/SRC	   expression	  
correlated	   with	   changes	   in	   sensitivity	   to	   the	   cytotoxic	   effects	   of	   BMOV.	   Sub-­‐G1	  
analysis	   was	   carried	   out	   following	   BMOV	   treatment	   of	   cells	   seeded	   onto	   both	  
treated	   and	   non-­‐treated	   surfaces.	   As	   expected	   SK-­‐N-­‐AS	   cells	   failed	   to	   undergo	  
increases	   in	   the	   percentage	   of	   sub-­‐G1	   cells	   when	   seeded	   onto	   treated	   plastic,	   in	  
contrast	   to	  KCNR	   cells	   that	  underwent	   significant	   cell	   death.	  However,	  modulating	  
the	  substrate	  adherence	  by	  seeding	  onto	  non-­‐treated	  plastic	  significantly	   increased	  
the	   percentage	   of	   apoptotic	   SK-­‐N-­‐AS	   cells	   treated	   with	   BMOV	   (Figure	   4.8).	  
Importantly,	  untreated	  cells	  did	  not	  significantly	  undergo	  apoptosis	  although	  we	  did	  
note	   a	  modest	   increase,	   arguing	   against	   the	   explanation	   that	   preventing	   adhesion	  
simply	   reduces	   cell	   survival.	   Although	   KCNR	   cells	   did	   not	   further	   increase	   their	  
sensitivity	  to	  BMOV,	  this	  may	  reflect	  the	  fact	  that	  the	  levels	  of	  FAK/SRC	  are	  already	  
very	  low.	  Similarly	  the	  high	  rate	  of	  death	  seen	  in	  untreated	  KCNR	  cells	  seeded	  onto	  
non-­‐treated	   plastic	   may	   reflect	   their	   reduced	   capability	   to	   survive	   in	   suspension,	  
where	  BMOV	  may	  mimic	  this	  process	  by	  inducing	  anoikis.	  	  
To	   briefly	   summarize,	   cells	   unresponsive	   to	   BMOV	   (SK-­‐N-­‐AS)	   express	   high	  
levels	   of	   endogenous	   activated	   SRC	   and	   FAK	   compared	   with	   BMOV-­‐sensitive	   cells	  
(KCNR).	   Treatment	  with	   BMOV	   causes	   reductions	   in	   the	   levels	   of	   activated	   SRC	   in	  
KCNR	  cells,	  which	  are	  mimicked	   in	  SK-­‐N-­‐AS	  cells	  when	  their	  substrate	  adherence	   is	  
partially	   attenuated.	   This	   correlates	   with	   an	   increase	   in	   the	   sensitivity	   to	   BMOV	  
induced-­‐cytotoxicity.	   Thus	   we	   hypothesized	   that	   the	   ability	   of	   BMOV	   to	   induce	  
cytotoxicity	  may	  be	  a	  direct	  result	  of	  its	  ability	  to	  decrease	  the	  level	  of	  activated	  SRC.	  
Here	   high	   endogenous	   levels	   of	   activated	   SRC	   in	   SK-­‐N-­‐AS	   versus	   KCNR	   cells	   can	  
explain	   resistance	   to	  BMOV.	  Thus	  we	   tested	   this	  hypothesis	  by	   conducting	   sub-­‐G1	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analysis	   on	   cells	   treated	   with	   BMOV	   in	   combination	   with	   the	   SRC	   inhibitor	   PP2,	  
predicting	   that	   compound	   inhibition	   of	   SRC	   would	   augment	   BMOV	   induced-­‐
cytotoxicity	  owing	  to	  more	  effective	  inhibition.	   	  Furthermore	  PP2	  should	  mimic	  the	  
effects	  of	  BMOV,	  achieving	  increased	  cytotoxicity	  in	  KCNR	  cells	  compared	  with	  SK-­‐N-­‐
AS	  cells.	  
Although	  KCNR	  cells	  exhibited	  increased	  sensitivity	  to	  the	  SRC	  inhibitor	  PP2,	  
treatment	   alone	   failed	   to	   induce	   significant	   increases	   in	   cell	   death	   (Figure	   4.9,	   A).	  
Similarly	  compound	  treatment	  of	  KCNR	  cells	  failed	  to	  significantly	  increase	  cell	  death	  
in	  KCNR	  cells	  compared	  with	  cells	  treated	  with	  BMOV	  alone.	  Although	  SK-­‐N-­‐AS	  cells	  
were	   observed	   to	   significantly	   increase	   the	   number	   of	   sub-­‐G1	   cells	   following	  
compound	  treatment	  with	  PP2/BMOV,	  despite	  not	  undergoing	  significant	  cell	  death	  
with	  either	  inhibitor	  alone,	  this	  failed	  to	  mimic	  the	  levels	  seen	  in	  KCNR	  cells	  treated	  
with	  BMOV	  and	  was	  also	  exhibited	  by	  the	  inactive	  PP2	  analogue	  PP3	  (Figure	  4.9,	  B).	  	  
This	  evidence	  suggests	  that	  inhibition	  of	  SRC	  is	  not	  the	  primary	  determinant	  
of	  BMOV	  induced-­‐cytotoxicity,	  as	  inhibition	  of	  SRC	  did	  not	  recapitulate	  the	  effects	  of	  
BMOV,	  nor	  did	  it	  significantly	  increase	  its	  efficacy.	  Nevertheless,	  with	  KCNR,	  we	  did	  
observe	   a	   slight	   increase	   in	   cell	   death	   with	   both	   PP2	   alone	   and	   PP2/BMOV	  
treatment.	   It	   could	   be	   argued	   therefore	   that	   BMOV	   is	   already	   achieving	   near	  
maximal	   inhibition	   of	   SRC,	   and	   remaining	   cell	   survival	   is	   largely	   through	   other	  
mechanisms.	  Thus	  PP2	  may	  not	  be	  able	  to	  greatly	  alter	  the	  biochemical	  response	  of	  
NBL	   cells	   in	   terms	   of	   the	   relative	   level	   of	   total	   to	   phosphorylated	   SRC.	  
However,	  subsequent	  experiments	  demonstrated	  high	  variability	  and	  in	  some	  cases	  
undetectable	  expression	  of	  activated	  SRC	  at	  endogenous	  levels,	  raising	  doubts	  over	  
the	   initial	   hypothesis	   that	   SRC	   activation	   confers	   survival	   in	   NBL	   cells.	  We	   sort	   to	  
further	   test	   this	   hypothesis,	   by	   examining	   whether	   overexpression	   of	   dominantly	  
active	   SRC	  would	   attenuate	  BMOV-­‐induced	   cell	   death,	   however	  we	  did	  not	  obtain	  
any	   consistent	   effects	   in	   such	   experiments	   (data	   not	   shown).	   Thus	   taken	   together	  
this	   data	   argues	   against	   SRC-­‐inhibition	   being	   the	   primary	   determinant	   of	   BMOV-­‐
induced	  cytotoxicity	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Figure	   4.7.	   The	   effects	   of	   adhesion	   on	   the	   regulation	   of	   SRC/FAK	   by	   BMOV.	   Cells	   were	  
cultured	  on	  tissue	  culture	  plastic	  suitable	  to	  facilitate	  adherence	  (treated)	  or	  normal	  plastic	  
to	   prevent	   adhesion	   to	   the	   substratum	   (non-­‐treated)	   (A).	   Loss	   of	   adhesion	   dramatically	  
reduced	  the	  levels	  of	  both	  total	  and	  phosphorylated	  FAK	  protein	  and	  sensitised	  cells	  to	  the	  
dephosphorylation	  of	  FAK	  induced	  by	  BMOV	  in	  SK-­‐N-­‐AS	  and	  IMR32	  cells,	  but	  did	  not	  affect	  
KCNR	   cells	   (B).	   BMOV	   caused	   a	   decrease	   in	   phosphorylated	   SRC,	   which	   was	   further	  
augmented	  in	  SK-­‐N-­‐AS	  cells	  by	  the	  loss	  of	  adhesion	  (C).	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Figure	  4.8.	  The	  effects	  of	  adhesion	  on	  sensitivity	  to	  BMOV.	  Cells	  were	  seeded	  onto	  treated	  
and	  non-­‐treated	  plastic	  and	  analysed	  for	  sub-­‐G1	  DNA	  content	  after	  3	  days	  of	  treatment	  with	  
BMOV	   (10µM).	   The	   loss	   of	   adhesion	   following	   seeding	   onto	   untreated	   plastic	   in	   SK-­‐N-­‐AS	  




Figure	   4.9.	   Treatment	  of	   KCNR	   (A)	   and	   SK-­‐N-­‐AS	   (B)	   cells	  with	   the	   SRC	   inhibitor	   failed	   to	  
neither	  mimic	   the	   effects	   of	   BMOV	  nor	   significantly	   increase	   it	   effectiveness.	   Cells	  were	  
treated	   for	   3	   days	  with	   BMOV	   (10µM)	   prior	   to	   sub-­‐G1	   analysis.	   Although	   PP2	   (10µM)	   did	  
cause	  cytotoxicity	  in	  KCNR	  cells	  and	  not	  SK-­‐N-­‐AS	  this	  did	  not	  obtain	  statistical	  significance	  in	  
independent	  samples	  t-­‐tests.	  Similarly	  PP2	  increased	  the	  efficacy	  of	  BMOV	  but	  again	  this	  did	  
not	  obtain	   significance	   (KCNR)	  or	  was	   also	  exhibited	  by	   the	   inactive	   analogue	  PP3	   (10µM)	  
(SK-­‐N-­‐AS).	   *=	   p<0.05;	   **=p<0.005.	   Graph	   shows	   means	   and	   SEM.	   Asterisk	   above	   bars	  
represents	  condition	  versus	  DMSO	  control.	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4.3.3.	   BMOV	   upregulates	   Mycn	   protein	   levels	   independently	   of	   the	  
PI3K/Akt/mTOR	  signalling	  pathway	  	  
Amplification	  of	  Mycn,	  which	  occurs	   in	  approximately	  22%	  of	  patients,	   is	   currently	  
the	  only	  genetic	  marker	  allowing	  patient	  stratification	  in	  NBL,	  where	  high	  expression	  
contributes	   to	   tumour	   progression,	   treatment	   failure	   and	   reduced	   likelihood	   of	  
survival	   (Cohn	  and	  Tweddle,	  2004;	  Schwab,	  2004).	  Thus	   targeting	  Mycn	  to	  prevent	  
tumour	   progression	   has	   been	   the	   subject	   of	   much	   research	   (Cohn	   and	   Tweddle,	  
2004).	   However	   as	   a	   transcription	   factor	   Mycn	   has	   often	   been	   regarded	   as	  
undruggable.	  Thus	  efforts	  have	  instead	  focused	  on	  either	  targeting	  Mycn	  through	  its	  
regulatory	  pathways	  or	   through	   its	   targets	   (Bell	   et	  al.,	   2010;	  Gustafson	  and	  Weiss,	  
2010).	  
	   	  Mycn	   protein	   is	   subject	   to	  multiple	   levels	   of	   regulation	   including,	   but	   not	  
limited	   to,	   post-­‐translational	  modification.	   Here	   growth	   factor	   signalling	   pathways	  
positively	  regulate	  Mycn	  levels	  by	  preventing	  its	  degradation	  (Gustafson	  and	  Weiss,	  
2010).	   For	   example,	   PI3K	   has	   been	   shown	   to	   stabilize	  Mycn	   by	   blocking	   glycogen	  
synthase	   kinase	   3β	   (GSK3β)-­‐mediated	   phosphorylation	   and	   increasing	   its	   levels	   in	  
vitro,	  where	   inhibition	  of	   PI3K	   reduces	  Mycn	   levels	   (Chesler	   et	   al.,	   2006).	   Similarly	  
mTOR	  downregulates	  protein-­‐phosphatase	  2A	  (PP2A)	  preventing	  dephosphorylation	  
and	   ubiquitin	   targeting	   of	   MYCN	   and	   thus	   promoting	   its	   stabilisation,	   where	  
inhibition	  of	  mTOR	  has	  been	  shown	  to	  downregulate	  Mycn	  protein	  expression	  and	  
inhibits	  NBL	  growth	  both	  in	  vitro	  and	  in	  vivo	  (Johnsen	  et	  al.,	  2008).	  	  
	   We	  previously	  noted	   that	  Mycn	  protein	  expression	  was	  modestly	   increased	  
by	   BMOV	   treatment	   in	   lines	   with	  Mycn	   amplification	   (See	   Chapter	   3).	   Given	   that	  
BMOV	   activates	   Akt,	   suggestive	   of	   PI3K	   stimulation,	   one	   might	   predict	   increased	  
stabilization	   of	   Mycn.	   However	   we	   also	   noted	   that	   Mycn-­‐amplified	   cell	   lines	   are	  
particularly	   sensitive	   to	   BMOV	   (LAN-­‐5,	   IMR-­‐32,	   Kelly,	   KCNR)	   while	   we	   did	   not	  
observe	   BMOV-­‐induced	   cytotoxicity	   in	   any	   non-­‐Mycn	   amplified	   cell	   lines.	   Thus	  we	  
sought	   to	   characterize	   BMOV-­‐induced	   upregulation	   of	   Mycn	   in	   terms	   of	   the	  
responsible	  signalling	  changes	  and	  its	  role	  in	  BMOV-­‐induced	  cell	  death.	  
	   In	  order	   to	   test	   the	  hypothesis	   that	   increased	  Mycn	  protein	  expression	  was	  
due	   to	   increased	   activation	   of	   PI3K/Akt,	   we	   used	   the	   PI3K	   inhibitor	   LY294002	   in	  
combination	   with	   BMOV	   to	   test	   whether	   this	   would	   block	   changes	   in	   Mycn	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expression.	   In	   line	   with	   earlier	   findings	   Mycn	   protein	   levels	   were	   observed	   to	  
increase	   after	   BMOV	   treatment	   in	   three	   NBL	   cell	   lines	   that	   exhibit	   cytotoxicity	   in	  
response	  to	  BMOV	  (LAN-­‐5,	  Kelly,	  KCNR).	  However	  we	  observed	  similar	   increases	   in	  
the	   presence	   of	   LY294002	   (Figure	   4.10,	   A)	   in	   both	   LAN-­‐5	   and	   Kelly	   cells	   although	  
levels	   were	   slightly	   reduced	   in	   KCNR.	   Surprisingly,	   we	   observed	   a	   paradoxical	  
increase	   in	  the	   levels	  of	  phosphorylated	  Akt	   (pAkt)	  after	   treatment	  with	  LY294002.	  
Combination	  treatment	  of	  cells	  with	  both	  BMOV	  and	  LY294002	  caused	  increases	  in	  
pAkt	   in	   a	   dose	   dependent	  manner,	   causing	   dramatic	   increases	   at	   20µM.	   Similarly	  
LY294002	   failed	   to	   block	   endogenous	   Akt	   activation	   and	   instead	   caused	   slight	  
increases	   in	   pAkt	   (KCNR	   and	   Kelly).	   Although	   these	   counterintuitive	   effects	   of	  
LY294002	  precluded	  the	  test	  of	  our	  original	  hypothesis,	  this	  data	  does	  argue	  against	  
increases	  in	  Mycn	  being	  the	  result	  of	  BMOV-­‐induced	  stimulation	  of	  PI3K,	  given	  that	  
Mycn	   levels	   did	   not	   increase	   despite	   large	   increases	   in	   the	   level	   of	   pAkt	   after	  
combined	  BMOV/LY294002	  treatment,	  and	  even	  decreased	  in	  some	  instances.	  	  
Thus	   in	   order	   to	   address	   this	   question	   further,	   we	   conducted	   a	   similar	  
experiment	  with	  the	  second-­‐generation	  dual	  PI3K/mTOR	  inhibitor	  PI-­‐103,	  which	  has	  
shown	  high	  efficacy	  and	  selectivity	  towards	  its	  targets	  at	  nanomolar	  concentrations	  
(Fan	  et	  al.,	  2006).	  Treatment	  with	  PI-­‐103	  effectively	  abolished	  activation	  of	  both	  Akt	  
and	  the	  mTOR	  target	  4E-­‐BP1,	  both	  in	  the	  presence	  and	  absence	  of	  BMOV.	  However	  
despite	  this,	  increases	  in	  Mycn	  expression	  remained	  broadly	  similar	  in	  both	  pattern	  
and	  level,	  increasing	  after	  BMOV	  treatment	  and	  remaining	  at	  untreated	  levels	  in	  PI-­‐
103-­‐treated	  cells	  (Figure	  4.10,	  B).	  	  
	   179	  
	  
Figure	   4.10.	   BMOV	   upregulates	   Mycn	   protein	   expression	   independently	   of	   PI3K	   and	  
synergistically	   activates	   Akt	   in	   the	   presence	   of	   LY294002.	   (A)	   24-­‐hour	   BMOV	   (10µM)	  
treatment	  causes	  an	  increase	  in	  Mycn	  in	  three	  NBL	  cell	  lines	  sensitive	  to	  its	  cytotoxic	  effects.	  
Paradoxically,	   increased	  Akt	  activation	   is	  seen	  with	   increasing	  PI3K	   inhibitor	  LY294002	  (10-­‐
20µM),	   paralleling	   decreasing	  MYCN	   levels.	   (B)	  BMOV	   induced-­‐increases	   in	  Mycn	   occur	   in	  
the	   absence	   of	   PI3K/mTOR	   activation,	   inhibited	   by	   constant	   treatment	   with	   the	   dual	  
PI3K/mTOR	   inhibitor	   PI-­‐103	   (0.5-­‐1µM).	   Akt	   and	   4E-­‐BP1	   were	   used	   to	   assess	   activation	   of	  
PI3K	  and	  mTOR	  respectively	  due	  to	  their	  status	  as	  downstream	  effectors.	  	  
	  
The	   finding	   that	   LY294002	   in	   combination	   with	   BMOV	   increases	   the	   levels	   of	  
phosphorylated	   Akt	   beyond	   those	   seen	   with	   BMOV	   treatment	   alone	   raises	   a	  
substantial	   paradox,	   given	   that	   LY294002	   is	   a	   well-­‐established	   inhibitor	   of	   PI3K.	  
LY294002	   is	   generally	   classified	   as	   a	   ‘dirty’	   inhibitor	   due	   to	   its	   effects	   on	   other	  
kinases	   independent	   of	   PI3K.	   The	   effectiveness	   of	   mTOR	   inhibitors	   such	   as	  
rapamycin	  has	  been	  attributed	  to	  their	  propensity	  to	  inhibit	  activation	  of	  S6	  kinase	  1	  
(S6K1)	  downstream	  of	  mTOR	  (Zoncu	  et	  al.,	  2011),	  the	  phosphorylation	  and	  activation	  
of	  which	  causes	  negative	  feedback	  signalling	  to	  PI3K	  dampening	  and	  thus	  regulating	  
excessive	   output	   of	   the	   PI3K/Akt/mTOR	   pathway	   (O'Reilly	   et	   al.,	   2006).	   Thus	   we	  
hypothesised	   that	   LY294002	   may	   inhibit	   S6K1,	   which	   when	   coupled	   with	   the	  
activation	   of	   PI3K/Akt	   by	   BMOV	   would	   remove	   negative	   feedback	   regulation	  
resulting	   in	   increased	   activation.	   Thus	   we	   conducted	   immunoblotting	   towards	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phosphorylated	  S6	  ribosomal	  protein,	  which	  is	  directly	  phosphorylated	  by	  S6K1	  as	  a	  
means	  of	  examining	  S6K1	  activation	  following	  treatment	  with	  BMOV	  both	  alone	  and	  
in	  combination	  with	  LY294002.	  Indeed	  while	  BMOV	  alone	  was	  observed	  to	  activate	  
S6K1,	   correlating	  with	   increased	   activation	  of	  Akt	   as	   expected	   (i.e.	   downstream	  of	  
mTor),	  concurrent	  treatment	  with	  LY294002	  effectively	   inhibited	  S6K1	  activation	  to	  
within	   control	   levels,	   which	   correlated	   with	   an	   increase	   in	   the	   activation	   of	   Akt	  
(Figure	  4.11).	  	  
	   Taken	   together	   these	   findings	   indicate	   that	   BMOV-­‐induced	   upregulation	   of	  
Mycn	  occurs	  independently	  of	  the	  PI3K/Akt/mTOR	  pathway,	  despite	  its	  activation	  by	  
BMOV	   and	   its	   regulatory	   effect	   on	   Mycn	   levels	   in	   NBL	   cells.	   However	   this	   also	  
presents	  an	  interesting	  paradox,	  namely	  that	  BMOV	  induced	  cell	  death	  occurs	  in	  the	  
presence	  of	  heightened	  Mycn	  protein	  levels,	  as	  well	  as	  increased	  PI3K	  activity.	  Thus	  
we	   hypothesized	   that	   rather	   than	   being	   an	   unrelated	   consequence	   of	   BMOV	  
treatment,	   increased	  Mycn	   protein	   expression	  may	   actually	   be	   detrimental	   to	   cell	  
survival.	   This	   is	   an	   appealing	   hypothesis	   given	   that	   only	   those	   NBL	   cell	   lines	  
harbouring	  Mycn	  amplification	  are	  responsive	  to	  the	  cytotoxic	  effects	  of	  BMOV.	  This	  
is	   also	   pertinent	   given	   that	   forced	   expression	   of	   Mycn	   can	   confer	   sensitivity	   to	  
chemotherapeutics,	  although	  this	  phenomenon	  is	  only	  apparent	  in	  NBL	  cells	  lacking	  
Mycn	   amplification	   (Hogarty,	   2003).	   Lastly	   of	   note	   is	   the	   finding	   that	   combined	  
treatment	  with	  BMOV/LY294002	  paradoxically	  activates	  Akt	  to	  a	  greater	  extend	  than	  
BMOV	  alone	  potentially	  due	  to	  the	   inhibition	  of	  S6K1,	  which	  represents	  a	  negative	  
influence	  on	  PI3K	  activity	  downstream	  of	  Akt/mTOR.	  Given	  that	  LY294002	  has	  been	  
reported	  to	  exhibit	  very	  low	  affinity	  for	  S6K1	  (Vlahos	  et	  al.,	  1994),	  one	  possibility	  is	  
that	   this	   compound	   is	   achieving	   inhibition	   of	   the	   mTORC1	   complex	   in	   a	   similar	  
manner	   to	   rapamycin,	   thus	   still	   allowing	   phosphorylation	   of	   Akt	   at	   serine	   473	   by	  
mTORC2.	   Here	   BMOV	  may	   act	   synergistically	   by	   attenuating	   inhibition	   of	   PI3K	   by	  
LY294002,	   for	   instance	   activating	   Akt	   through	   inhibiting	   PTPs	   that	   negatively	  
regulate	  its	  activity,	  or	  activating	  mTORC2	  that	  would	  lead	  to	  phosphorylation	  of	  Akt	  
independent	  of	  PI3K.	  This	  possibility	  remains	  to	  be	  tested	  however.	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4.3.4.	  Mycn	   is	   not	   required	   for	   BMOV	   induced-­‐cytotoxicity	   nor	   does	   it	   sensitize	  
cells	  to	  BMOV	  
Mycn	  is	  thought	  to	  increase	  tumour	  aggressiveness	  by	  stimulating	  quiescent	  cells	  to	  
re-­‐enter	   the	   cell	   cycle,	   shortening	   cell	   cycle	   progression	   time	   and	   increasing	  
detachment	   from	  the	  extracellular	  matrix	   (see	  section	  1.2).	  However,	  paradoxically	  
Mycn	  also	  has	  a	  role	  in	  the	  induction	  of	  apoptosis.	  For	  instance,	  conditional	  	  
	  
Figure	  4.11.	  BMOV/LY294002	  inhibits	  S6	  kinase.	  Cells	  treated	  for	  24hr	  with	  BMOV	  (10µM)	  
and	  LY294002	  (5µM).	  While	  BMOV	  activates	  S6	  kinase	  alone	  (as	  shown	  by	  phosphorylation	  
of	   its	   target	   S6	   ribosomal	   protein),	   combined	   treatment	   with	   LY294002	   inhibits	   this	  
activation	   removing	   negative	   feedback	   of	   PI3K	   and	   thus	   correlating	   with	   increased	   Akt	  
activation.	  	  
	  
overexpression	  of	  Mycn	  in	  a	  non-­‐Mycn	  amplified	  NBL	  cell	  line	  was	  shown	  to	  sensitize	  
cells	  to	  chemotherapeutic-­‐induced	  apoptosis	  (Fulda	  et	  al.,	  2000;	  Fulda	  et	  al.,	  1999).	  
Similarly	   induction	  of	  Mycn	  expression	  by	   the	  p53	   inhibitor	  Nutlin-­‐3	  was	   shown	   to	  
enhance	  chemosensitivity	   (Peirce,	  2009).	   	  Thus	  NBL	  cells	  with	  amplified	  Mycn	  may	  
require	   aberrant	   PCD	   signalling	   in	   order	   to	   survive	   in	   the	   face	   of	   high-­‐level	  Mycn	  
expression	  (Hogarty,	  2003).	  	  
	   Based	   on	   this	   evidence,	   we	   decided	   to	   test	   the	   hypothesis	   that	   BMOV-­‐
induced	  upregulation	  of	  Mycn	  sensitizes	  cells	  to	  its	  apoptotic	  effects.	  Thus	  we	  used	  
the	   isogenic	   cell	   line	   SH-­‐EP	   Tet21N	   (Tet21N),	   which	   has	   been	   engineered	   to	  
conditionally	   express	  Mycn	   in	   the	   absence	   of	   tetracycline	   using	   the	   tet	   on/tet	   off	  
system	   (Lutz	   et	   al.,	   1998).	   Indeed	   Tet21N	   cells	   appeared	   hypersensitive	   to	   BMOV	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treatment	   specifically	   in	   the	   Tet-­‐Off/Mycn+	   condition,	   i.e.	   absence	   of	   tetracycline	  	  
(Figure	  4.12,	  A).	  	  Crucially	  BMOV	  had	  no	  visible	  effect	  on	  the	  survival	  of	  Tet21N	  cells	  
in	   the	   Tet-­‐On/Mycn-­‐	   condition	   i.e.	   in	   the	   presence	   of	   tetracycline,	   nor	   did	  
tetracycline	   itself	   display	   any	  effects	  on	   cell	   survival.	   Crystal	   violet	   staining	   for	   cell	  
viability	   revealed	  a	   statistically	   significant	  decrease	   in	   cell	   survival	   following	  BMOV	  
treatment	   only	   in	   the	   Mycn+	   condition	   (Figure	   4.12,	   B).	   However	   we	   failed	   to	  
confirm	  the	  conditional	  suppression	  of	  Mycn	  expression	  by	  immunoblotting	  (Figure	  
4.12,	   C),	   thus	   suggesting	   that	   the	   protective	   effect	   of	   tetracycline	   does	   not	   result	  
from	  its	  suppression	  of	  Mycn	  expression.	  Therefore	  although	  this	  represents	  another	  
example	  of	  cell	  death	  induced	  by	  BMOV	  associated	  with	  the	  expression	  of	  MYCN,	  it	  
does	  not	  provide	  evidence	  that	  increasing	  Mycn	  expression	  in	  this	  cell	  line	  sensitizes	  
cells	   to	   BMOV	   induced	   apoptosis,	   as	   we	   failed	   to	   conditionally	   suppress	   Mycn	  
expression.	  	  
To	  investigate	  this	  hypothesis	  further,	  we	  took	  advantage	  of	  an	  NBL	  cell	  line,	  
ACN,	   that	   has	   been	   engineered	   to	   stably	   express	   Mycn	   at	   different	   levels	   using	  
different	  plasmid	  expression	  vectors,	  namely	  ACN-­‐0,	  expressing	  vector	  alone,	  ACN-­‐5,	  
expressing	  a	  vector	  encoding	  Mycn,	  and	  ACN-­‐10,	  expressing	  a	  vector	  encoding	  Mycn	  
at	  a	  greater	  level	  of	  expression.	  We	  confirmed	  the	  levels	  of	  Mycn	  protein	  expression	  
by	  immunoblotting,	  however	  we	  failed	  to	  detect	  a	  difference	  between	  the	  levels	  of	  
Mycn	   protein	   in	   ACN-­‐5	   and	   ACN-­‐10	   cells,	   but	   did	   detect	   increased	   expression	   of	  
Mycn	   in	   both	   compared	   with	   ACN-­‐0	   (Figure	   4.13,	   A).	   	   However,	   we	   observed	  
minimal	  differences	  in	  sensitivity	  to	  BMOV	  between	  ACN-­‐0,	  ACN-­‐5	  and	  ACN-­‐10	  cells	  
(Figure	  4.13,	  B).	  	  In	  fact	  all	  three	  isogenic	  versions	  of	  ACN	  responded	  to	  BMOV	  with	  
significantly	  reduced	  cell	  survival,	  despite	  no	  detectable	  expression	  of	  Mycn	  in	  ACN-­‐0	  
cells	   (Figure	   5.13,	   C).	   This	   provides	   evidence	   against	   the	   hypothesis	   that	   an	  
upregulation	  of	  Mycn	  protein	  level	  is	  required	  for	  BMOV	  induced-­‐cytotoxicity,	  given	  
that	  ACN	  cells	  without	  Mycn	  amplification	  are	  BMOV	  sensitive.	  However	  it	  does	  not	  
exclude	   the	  possibility	   that	  BMOV	  can	  exert	   cytotoxicity	   via	  different	  mechanisms,	  
one	  of	  which	  is	  through	  an	  upregulation	  of	  Mycn.	  	  
Thus	   we	   sought	   to	   further	   answer	   this	   question	   using	   isogenic	   SK-­‐N-­‐AS-­‐
nMycER	   cells,	   which	   have	   been	   engineered	   to	   stably	   express	   Mycn	   fused	   to	   an	  
oestrogen	  responsive	  domain	  capable	  of	  binding	  to	  4-­‐OHT	  to	  stimulate	  Mycn	  activity	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(Koppen	  et	  al.,	  2007).	  	  As	  earlier	  findings	  indicated	  that	  the	  non-­‐Mycn-­‐amplified	  SK-­‐
N-­‐AS	   cells	   were	   unresponsive	   to	   BMOV	   (Section	   4.3.1),	   SK-­‐N-­‐AS-­‐nMycER	   cells	   are	  
well	  suited	  to	  answer	  the	  question	  of	  whether	  increasing	  Mycn	  expression	  sensitizes	  
NBL	   cells	   to	   BMOV.	   However,	   we	   did	   not	   detect	   differential	   sensitivity	   to	   BMOV	  
following	   treatment	  with	   4-­‐OHT	   (Figure	   4.14,	   A,	   B).	  We	   confirmed	   that	   treatment	  
with	   low	   dose	   4-­‐OHT	   increased	   the	   levels	   of	   Mycn	   protein	   (Figure	   4.14,	   C).	   This	  
therefore	  again	  argues	  against	  the	  hypothesis	  that	  BMOV	  induced-­‐cytotoxicity	  relies	  
on	   Mycn,	   given	   that	   forced	   expression	   of	   Mycn	   in	   SK-­‐N-­‐AS	   cells	   did	   not	   confer	  
sensitivity.	  
Lastly	   we	   sought	   to	   once	   again	   test	   the	   hypothesis	   that	   conditionally	  
expressing	   Mycn	   in	   the	   Tet21N	   cell	   line	   would	   sensitize	   cells	   to	   BMOV	   using	   an	  
alternative	  source	  of	  an	  identical	  cell	  line	  (a	  kind	  gift	  of	  Manfred	  Schwab,	  University	  
of	   Heidelberg).	   Although	   in	   this	   case	   tetracycline	   treatment	   suppressed	   the	  
expression	  of	  Mycn	  after	  24	  hours	  (Figure	  4.15,	  A),	  we	  observed	  the	  opposite	  effect	  
of	  BMOV	  on	  cell	  death	  when	  compared	  with	  the	  first	  Tet21N	  cell	   line,	  namely	  that	  
conditional	   expression	  of	  Mycn	  appeared	   to	  exert	   a	  protective	  effect	   (Figure	  4.15,	  
B),	  reducing	  the	  degree	  of	  cell	  death.	  	  
In	  sum,	  we	  have	  shown	  that	  while	  upregulation	  of	  Mycn	  protein	  expression	  is	  
a	  consequence	  of	  BMOV	  treatment	  that	  correlates	  with	  cytotoxicity,	  it	  is	  unlikely	  to	  
be	   a	   causative	   factor.	   Although	   a	   version	   of	   Tet21N	   cells	   expressing	   Mycn	   was	  
sensitive	   to	   BMOV,	   tetracycline	   appeared	   to	   suppress	   this	   effect	   independently	   of	  
Mycn	  levels.	  Conversely	  an	  alternative	  Tet21N	  cell	   line	  responded	  to	  BMOV	  only	   in	  
the	   presence	   of	   tetracycline	   and	   the	   absence	   of	   Mycn.	   Similarly	   SK-­‐N-­‐AS	   cells	  
remained	   unresponsive	   to	   BMOV	   regardless	   of	   Mycn	   expression,	   and	   Mycn	  
expression	  was	  not	  required	  for	  sensitivity	  to	  BMOV	  in	  the	  non-­‐Mycn	  amplified	  cell	  
line	  ACN.	  However	  one	  potential	  caveat	  of	  these	  experiments	  is	  the	  use	  of	  isogenic	  
cell	   lines	   engineered	   to	   express	  Mycn	   though	   lacking	   in	  Mycn	   amplification.	   	   This	  
situation	  may	  be	  entirely	  different	   than	   that	  of	  Mycn	  amplified	   cell	   lines,	   in	  which	  
high	  Mycn	   levels	   likely	   result	  may	  result	   in	  Mycn	  addiction,	  as	  has	  been	  evidenced	  
with	  other	  proto-­‐oncogenes	  (Weinstein	  and	  Joe,	  2008).	  In	  the	  same	  vein	  cytotoxicity	  
due	  to	  enforced	  Mycn	  expression	  has	  been	  suggested	  to	  be	  p53-­‐dependent,	  relying	  
on	  a	  DNA	  damage	   response,	  which	   is	  not	   induced	  by	  BMOV	   (Petroni	  et	   al.,	   2011).	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This	   means	   that	   while	   forced	   expression	   of	   Mycn	   may	   not	   necessarily	   enhance	  
chemosensitivity,	   interference	   with	   correct	   regulation	   of	  Mycn	   protein	   expression	  
may	  alter	  the	  ability	  of	  NBL	  cells	  to	  survive,	  although	  this	  remains	  to	  be	  proven.	  	  	  
	  
Figure	   4.12.	   Tetracycline	   treatment	  enhances	   BMOV	   induced-­‐cytotoxicity	   in	   the	   isogenic	  
cell	  line	  Tet21N	  without	  inducing	  MYCN.	  (A)	  Crystal	  violet	  staining/phase	  contrast	  images	  of	  
SH-­‐EP	  Tet21N	  cells	  pretreated	  for	  48	  hours	  with	  tetracycline	  (2.5µg/ml)	  following	  3	  days	  of	  
BMOV	  treatment	  (10µM)	  revealing	  gross	  reductions	   in	  cell	  survival	   in	  the	  Tet-­‐Off/Mycn-­‐On	  
condition	  only.	  (B)	  Independent	  samples	  t-­‐tests	  of	  OD	  absorbance	  following	  solubilisation	  of	  
crystal	   violet	   staining	   of	   Tet21N	   cells	   treated	   with	   BMOV	   (10µM)	   for	   3	   days	   showing	   a	  
statistically	   significant	   reduction	   in	   cell	   survival	   only	   in	   the	   Tet-­‐Off/Mycn-­‐On	   condition	  
(*=p<0.05).	  Error	  bars	  denote	  standard	  deviation.	  	  (C)	  Immunoblot	  for	  Mycn	  demonstrating	  
the	   presence	   of	   Mycn	   in	   the	   absence	   of	   tetracycline	   and	   a	   lack	   of	   increase	   in	   Mycn	  
expression	  at	  increasing	  doses	  of	  tetracycline.	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Figure	   4.13.	   The	   non-­‐Mycn-­‐amplified	   cell	   line	   ACN	   is	   sensitive	   to	   BMOV,	   which	   is	   not	  
enhanced	  by	  forced	  expression	  of	  Mycn.	  (A)	  Phase-­‐contrast	  images	  of	  ACN	  cells	  treated	  for	  
3	  days	  with	  BMOV	  (10µM)	  showing	  reductions	   in	  the	  number	  of	  viable	  cells	   independently	  
of	  isogenic	  Mycn	  expression.	  (B)	  Following	  3	  days	  treatment,	  cells	  were	  crystal	  violet	  stained	  
dye	  was	   solubilised	   to	  obtain	  a	   gross	   read	  out	  of	   the	  number	  of	   viable	   cells.	   Independent	  
samples	   t-­‐tests	   revealed	   BMOV	   (10µM)	   significantly	   reduced	   cell	   numbers	   in	   both	   Mycn	  
expressing	   and	  non-­‐expressing	   cells.	   (***=p<0.001).	   Error	   bars	   denote	   standard	  deviation.	  
(C)	   Immunoblot	   for	   Mycn	   confirming	   increased	   protein	   expression	   in	   ACN-­‐5/10	   cells	  
compared	  with	  ACN-­‐0	  expressing	  vector	  alone.	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Figure	   4.14.	   Forced	   expression	   of	  Mycn	   in	   an	   isogenic	   version	   of	   SK-­‐N-­‐AS	   cells	   does	   not	  
cause	  sensitivity	  to	  BMOV.	  Crystal	  violet	  stained	  (A)	  and	  phase	  contrast	  (B)	  images	  of	  SK-­‐N-­‐
AS	   nMycER	   cells	   treated	   for	   3	   days	  with	   BMOV	   (10µM)	   following	   48	   hours	   pre-­‐treatment	  
with	  4-­‐OHT	  (250nM)	  revealing	  an	  absence	  of	  cytotoxicity	   in	  either	  +/-­‐	  Mycn	  conditions.	  (C)	  
Immunoblot	   for	   Mycn	   confirming	   increases	   in	   protein	   expression	   following	   48	   hours	  
treatment	  with	  4-­‐OHT	  in	  a	  dose-­‐dependent	  manner.	  	  
	  
4.3.5.	  BMOV-­‐induced	  cell	  death	  is	  enhanced	  both	  by	  inhibition	  and	  augmentation	  
of	  Akt	  activation	  	  
We	   previously	   found	   that	   BMOV	  was	   capable	   of	   activating	   both	   Akt	   and	   Erk	   as	   a	  
single	   agent	   (See	   Chapter	   3).	   Both	   of	   these	   signalling	   effectors	   are	   capable	   of	  
inducing	   cell	   death	   or	   survival	   depending	   on	   multiple	   factors	   such	   as	   level	   and	  
duration	  of	  stimulation,	  differentiation	  status	  and	  cell	  type.	  For	  instance,	  activation	  
of	  Akt	  has	  been	  shown	  to	   induce	  cell	  death	   in	  the	  presence	  of	  heightened	  reactive	  
oxygen	  species	  (ROS)	  production	  (Nogueira	  et	  al.,	  2008).	  Similarly	  inhibiting	  Akt	  as	  a	  
means	   of	   targeted	   therapy	   has	   been	   shown	   to	   positively	   affect	   cell	   survival	   by	  
relieving	  negative	   feedback	  of	  growth	   factor	   signalling	   (Chandarlapaty	  et	  al.,	  2011)	  
and	  also	  inducing	  coping	  mechanisms	  such	  as	  autophagy	  (Fan	  et	  al.,	  2010).	  This	  is	  of	  
particular	  interest	  given	  that	  the	  PI3K/Akt	  pathway	  is	  frequently	  mutated	  in	  human	  
cancer	  and	  a	  commonly	  sought	  after	  target	  of	  therapy	  (Hennessy	  et	  al.,	  2005).	  This	  is	  
also	   true	   of	   NBL,	   where	   Akt	   activity	   has	   been	   shown	   to	   contribute	   negatively	   to	  
tumour	   progression	   (Opel	   et	   al.,	   2007).	   Inhibition	   of	   Akt	   has	   also	   been	   shown	   to	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reduce	  tumour	  growth	  in	  vitro	  and	  in	  vivo	  (Li	  et	  al.,	  2010)	  and	  inhibition	  of	  PI3K	  has	  




Figure	   4.15.	   Conditional	   suppression	   of	  Mycn	   in	   Tet21N	   cells	   does	   not	   sensitize	   cells	   to	  
BMOV.	   Tetracycline	   treatment	   (2µg/µl)	   causes	   suppression	   of	  Mycn	   levels	   after	   24	   hours	  
(A),	   however	   in	   comparison	   to	   previously	   tested	   Tet21N	   cells	   (Figure	   5.12),	   here	   BMOV	  
induces	  cytotoxicity	   in	   the	  presence	  of	   tetracycline,	  which	   in	   this	  case	   is	   in	   the	  absence	  of	  
Mycn,	  as	  shown	  by	  crystal	  violet	  staining	  of	  viable	  cells	  following	  48	  hours	  treatment	  (B).	  
	  
Similarly	   Erk	   activation	   has	   been	   shown	   to	  mediate	   cell	   survival	   of	   neuronal	   cells	  
(Scuteri	   et	   al.,	   2010)	   and	   cancer	   cells	   (Kim	   et	   al.,	   2005)	   as	   well	   as	   mediating	  
resistance	   to	   chemotherapy	   (Balmanno	   et	   al.,	   2009).	   This	   is	   again	   not	   surprising	  
given	  that	  Erk	  is	  commonly	  activated	  in	  human	  cancer	  via	  mutations	  in	  its	  upstream	  
effectors	  Ras,	  MEK	  and	  RAF	  (Montagut	  and	  Settleman,	  2009).	  However	  activation	  of	  
Erk	  has	  been	  shown	  to	  cause	  cell	  death	  induced	  by	  chemotherapeutics	  such	  as	  the	  
commonly	  used	  platinum	  based	  ‘front	  line’	  agent	  cisplatin	  (Woessmann	  et	  al.,	  2002).	  	  
This	  dichotomy	  of	   responses	   to	  Erk	   stimulation	  has	  been	   shown	   to	  depend	  on	   the	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duration	   of	   activation	   (Marshall,	   1995)	   due	   to	   differential	   interactions	   with	  
downstream	  substrates	  (von	  Kriegsheim	  et	  al.,	  2009).	  	  
	   Given	  that	  BMOV	  causes	  cell	  death	  in	  the	  presence	  of	  activated	  Akt	  and	  Erk,	  
we	   hypothesized	   that	   stimulating	   both	   of	   these	   enzymes	   in	   NBL	   cells	   reduces	   cell	  
survival.	   Thus	  we	   tested	   this	   by	   using	   inhibitors	   of	  MEK/Erk	   (U0126)	   and	   PI3K/Akt	  
(LY294002)	   and	   examining	   sub-­‐G1	   cells	   as	   a	  marker	   of	   apoptosis.	   First	   generation	  
inhibitors	   have	   often	   been	   criticized	   due	   to	   off-­‐target	   effects.	   Thus	  we	   used	   both	  
U0126	  and	  LY294002	  at	   low	  doses	   (5µM	  versus	  10-­‐20µM	  standard	  dose),	  although	  
the	  effects	  of	  LY294002	  are	  of	  course	  complicated	  by	  the	  fact	  that	  it	  was	  previously	  
found	  to	  paradoxically	  increase	  the	  activation	  of	  Akt	  in	  the	  presence	  of	  BMOV	  (See	  
Section	  5.3.3).	  Thus	  rather	   than	   inhibiting	  Akt,	  combined	  BMOV	  treatment	  actually	  
results	  in	  its	  stimulation.	  
	   Low	  dose	  treatment	  with	  both	  LY294002	  and	  U0126	  had	  no	  visible	  cytotoxic	  
effect	   alone,	   however	   remarkably	   we	   found	   that	   at	   the	   same	   dosage,	   compound	  
treatment	   of	   both	   U0126	   and	   LY294002	   induced	   synergistic	   gains	   in	   cell	   death	  
(Figure	  4.16,	  A).	  	  This	  effect	  was	  less	  dramatic	  for	  U0126,	  which	  only	  caused	  modest	  
gains	   in	   sub-­‐G1	   when	   compared	   to	   BMOV	   alone	   in	   both	   KCNR	   and	   LAN-­‐5	   cells,	  
although	   significantly	   enhancing	   cell	   death	   when	   compared	   to	   untreated	   cells	   in	  
LAN-­‐5	   despite	   a	   lack	   of	   response	   to	   BMOV.	   However	   LY294002	   significantly	  
enhanced	  the	  effects	  of	  BMOV	  alone	  in	  both	  cell	  types.	  We	  reasoned	  that	  given	  the	  
similarity	   between	   the	   effects	   of	   the	   Ras/RAF/MEK/Erk	   and	   PI3K/Akt/mTOR	  
pathway,	  redundancy	  might	  exist,	  causing	  compensatory	  survival	  signalling	  by	  Akt	  in	  
the	   presence	   of	   inhibited	   Erk	   for	   instance	   (Balmanno	   et	   al.,	   2009).	   However	  
combined	   treatment	   of	   U0126/LY294002/BMOV	   did	   not	   increase	   the	   effects	   of	  
either	   inhibitor	   alone,	   suggesting	   a	   reliance	   on	   signalling	   through	   one	   of	   these	  
pathways	   as	   a	   survival	   mechanism.	   Importantly	   compound	   treatment	   with	  
U0126/LY294002	   alone	   had	   no	   effect	   on	   cell	   death,	   arguing	   against	   the	   possibility	  
that	  cell	  death	  caused	  by	  BMOV/LY294002	  is	  simply	  the	  result	  of	  non-­‐specific	  stress	  
caused	   by	   multiple	   compound	   treatments.	   	   We	   confirmed	   the	   presence	   of	  
biochemical	   inhibition	   of	   Erk	   (U0126)	   and	   activation	   of	   Akt	   (LY294002)	   following	  
compound	  treatment	  with	  BMOV	  (Figure	  4.16,	  B).	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   We	  next	  sought	  to	  examine	  whether	  interfering	  with	  the	  regulation	  of	  major	  
growth	  factor	  signalling	  pathways	  in	  the	  presence	  of	  a	  cytotoxic	  stimuli	  (BMOV)	  was	  
causing	   non-­‐specific	   cell	   death.	   However	   sub-­‐G1	   analysis	   of	   cell	   death	   following	  
treatment	   of	   primary	   wild-­‐type	   MEFs	   revealed	   a	   complete	   absence	   of	   toxicity	  
induced	  by	  combination	  BMOV/LY294002	  or	  BMOV/U0126	  treatment	   (Figure	  4.16,	  
C).	  This	  again	  argues	  against	  the	  notion	  that	  the	  combination	  of	  these	  compounds	  is	  
simply	   exerting	   a	   battery	   of	   changes	   in	   intracellular	   signalling	   causing	   non-­‐specific	  
cell	  stress	  and	  cytotoxicity.	  	  
LY294002	  increases	  the	  cytotoxicity	  of	  BMOV.	  However	  we	  initially	  sought	  to	  
find	   out	   whether	   inhibiting	   Akt	   activation	   induced	   by	   BMOV	   would	   attenuate	   its	  
cytotoxic	   potential.	   LY294002	   was	   earlier	   shown	   to	   paradoxically	   augment	   Akt	  
activation	   in	   the	   presence	   of	   BMOV,	   thus	   arguing	   in	   favour	   of	   this	   being	   a	  
mechanism	   of	   BMOV	   induced	   cell	   death.	   However	   we	   wished	   to	   confirm	   this	   by	  
answering	  the	  earlier	  question	  of	  whether	  inhibition	  of	  Akt	  could	  block	  the	  effects	  of	  
BMOV.	   Thus	   we	   conducted	   similar	   experiments	   with	   PI-­‐103,	   a	   dual	   PI3K/mTOR	  
inhibitor	  that	  effectively	  inhibits	  PI3K	  at	  nanomolar	  concentrations	  (Fan	  et	  al.,	  2006).	  
We	  found	  that	  treatment	  of	  KCNR	  cells	  with	  PI-­‐103	  caused	  a	  cytotoxic	  response	  as	  
shown	  by	  an	  increased	  percentage	  of	  sub-­‐G1	  cells	  that	  was	  significantly	  augmented	  
after	   combined	   treatment	   with	   BMOV	   (Figure	   4.17,	   A),	   at	   doses	   that	   effectively	  
inhibited	  Akt	  activation	  (Figure	  4.17,	  B).	  Here	  increases	  in	  sub-­‐G1	  were	  additive,	  as	  
both	  BMOV	  and	  PI-­‐103	  increased	  the	  percentage	  of	  sub-­‐G1	  cells	  to	  ~20%,	  whereas	  
combined	  PI-­‐103/BMOV	   treatment	   raised	   the	  percentage	   to	  ~50%.	   Similar	   to	  both	  
LY294002	  and	  U0126,	   combined	   treatment	  of	   cells	  with	  PI-­‐103	  and	  BMOV	  did	  not	  
induce	  non-­‐selective	  toxicity,	  as	  the	  levels	  of	  sub-­‐G1	  cells	   in	  MEFS	  were	  unaffected	  
(Figure	  4.17,	  C).	  
This	   presents	   a	   possible	   paradox	   in	   that	   both	   PI-­‐103	   and	   LY294002	   cause	  
similar	   increases	   in	   cell	   death	   in	   the	   presence	   of	   BMOV,	   despite	   having	   converse	  
effects	  on	  the	  status	  of	  Akt	  signalling,	  blocking	  and	  stimulating	  it	  respectively.	  Thus	  
we	  sought	  to	  examine	  whether	  an	  alternative	  compound	  that	  stimulated	  Akt	  would	  
recapitulate	  the	  effects	  of	  BMOV/LY294002.	  Thus	  we	  conducted	  the	  same	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Figure	  4.16.	  MEK	   inhibition	  and	  Akt	  stimulation	  enhance	  BMOV-­‐induced	  cytotoxicity.	   (A)	  
Sub	  G1	  analysis	  of	  cells	  treated	  for	  48	  hours	  with	  BMOV	  (10µM),	  U0126	  (5µM)	  and	  LY294002	  
(5µM)	   indicating	   both	   compounds	   increase	   the	   effects	   of	   BMOV	   on	   cell	   death.	   (B)	  
Immunoblot	   of	   KCNR	   cells	   treated	   for	   24	   hours	   with	   BMOV,	   U0126	   and	   LY294002	   (LY29)	  
indicating	   the	   U0126	   inhibits	   BMOV-­‐induced	   Erk	   activation	   while	   LY294002	   augments	  
BMOV-­‐induced	  Akt	  activation.	  (C)	  Neither	  U0126	  nor	  LY294002	  in	  combination	  with	  BMOV	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experiment	   using	   the	   specific	   inhibitor	   of	   mTOR	   rapamycin.	   Rapamycin	   has	   been	  
shown	  to	  increase	  the	  activation	  of	  Akt	  due	  to	  a	  lack	  of	  mTOR	  mediated-­‐inhibition	  of	  
S6	   kinase	   1,	   which	   itself	   inhibits	   PI3K	   in	   a	   negative	   feedback	   loop	   (O'Reilly	   et	   al.,	  
2006),	   and	   has	   been	   used	   to	   augment	   Akt	   signalling	   in	   contexts	   where	   this	   may	  
induce	  cytotoxicity	  (Nogueira	  et	  al.,	  2008).	  	  
	   In	  line	  with	  previous	  reports,	  rapamycin	  was	  not	  cytotoxic	  alone	  and	  did	  not	  
cause	   a	   significant	   increase	   in	   the	   percentage	   of	   sub-­‐G1	   cells.	   However	   combined	  
treatment	  with	  BMOV	   increased	  the	  effects	  of	  BMOV	  on	  the	  proportion	  of	   sub-­‐G1	  
cells	   by	   ~15%,	   although	   this	   was	   not	   significant	   (Figure	   4.17,	   A).	   However	   we	  
observed	  that	  combined	  treatment	  of	  KCNR	  cells	  with	  BMOV	  and	  rapamycin	  actually	  
caused	   very	   little	   change	   in	   the	   status	   of	   Akt	   phosphorylation	   at	   the	   given	   doses	  
(Figure	  4.17,	  B).	  This	  suggests	  that	  inhibition	  of	  mTOR	  in	  KCNR	  cells	  has	  a	  negligible	  
effect	   on	   PI3K	   activation,	   and	   thus	   does	   not	   allow	   us	   to	   distinguish	   whether	  
increases	   in	  Akt	  activation	   result	   in	   increased	  cell	  death	   in	   the	  presence	  of	  BMOV.	  
Lastly	  while	  PI-­‐103/BMOV	  caused	  large	  increases	  in	  cell	  death	  in	  NBL	  cells,	  treatment	  
caused	  no	  observable	  toxicity	  in	  non-­‐tumour	  cell	  MEFs	  (Figure	  4.17,	  C).	  	  
In	  sum,	  we	  hypothesized	  that	  BMOV-­‐induced	  activation	  of	  Akt	  and	  Erk	  may	  
be	  the	  determinant	  of	  cell	  death;	  we	  have	  shown	  that	  prevention	  of	  this	  activation	  
actually	  enhances	  the	  effectiveness	  of	  BMOV.	  However	  paradoxically	  we	  also	  found	  
that	   stimulating	   Akt	   with	   a	   putative	   PI3K	   inhibitor	   similarly	   enhances	   the	  
effectiveness	  of	  BMOV.	  This	  suggests	  two	  possibilities.	  Firstly	  activation	  of	  Erk	  and	  to	  
a	   greater	   extent	  Akt	  may	  be	   an	   effective	   coping	   strategy	   that	  NBL	   cells	   employ	   in	  
order	  to	  limit	  the	  cytotoxicity	  of	  BMOV,	  that	  when	  inhibited	  significantly	  attenuates	  
resistance	  to	  cell	  death.	  This	  is	  evidenced	  by	  the	  fact	  that	  inhibiting	  both	  Erk	  and	  Akt	  
using	   U0126	   and	   PI-­‐103	   respectively	   increases	   cell	   death.	   However	   a	   second	  
possibility	   is	   that	   aberrant	   signalling	   of	   growth	   stimulatory	   pathways	   caused	   by	  
BMOV	   is	   responsible	   for	   BMOV	   induced	   cell	   death.	   This	   is	   arguably	   a	  more	   likely	  
possibility	   given	   that	   both	   increasing	   and	   decreasing	   the	   levels	   of	   Akt	   stimulation	  
using	  LY294002	  and	  PI-­‐103	  respectively	  caused	  a	  similar	  increase	  in	  cell	  death.	  	  Thus	  
inhibiting	   and	   activating	   Akt	   may	   cause	   cell	   death	   via	   opposing	   mechanisms,	  
highlighting	  a	  need	  for	  finely	  tuned	  PI3K/Akt	  signalling	  for	  cell	  survival.	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4.3.6.	  BMOV	  induced-­‐cytotoxicity	   is	  abrogated	  by	  blocking	  the	  production	  of	  ROS	  
and	  is	  augmented	  by	  attenuating	  ROS	  protection	  
ROS	   such	   as	   the	   superoxide	   anion,	   hydroxyl	   radicals	   and	   hydrogen	   peroxide	   are	  
natural	   by-­‐products	   of	   intracellular	   redox	   reactions	   that	   can	   induce	   cell	   stress	  
through	  oxidative	  damage	  of	   lipids,	  proteins,	   carbohydrates	  and	  nucleic	  acids.	  ROS	  
can	   also	   participate	   in	   intracellular	   signal	   transduction	   functioning	   as	   second	  
messengers	  and	  cause	  enzymatic	  inhibition	  through	  nucleophilic	  attack	  of	  sulphydryl	  
groups	  on	  cysteine	  residues	  (Davies,	  1995).	  	  ROS	  have	  been	  shown	  to	  contribute	  to	  
apoptosis	   triggered	   by	   chemotherapeutics	   in	   NBL	   (Marengo	   et	   al.,	   2005),	   and	  
insensitivity	  to	  ROS	  is	  a	  putative	  mechanism	  of	  chemotherapeutic	  resistance	  in	  Mycn	  
amplified	  NBL	  (de	  Tudela	  et	  al.,	  2010).	  	  
ROS	   are	   frequently	   responsible	   for	   regulation	   of	   growth	   factor	   signalling	  
including	  activation	  of	  MAPK	  (Wu	  et	  al.,	  2009),	  activation	  of	  Akt	  (Crossthwaite	  et	  al.,	  
2002),	   inhibition	  of	  FAK	   (Chiarugi	  et	  al.,	  2003)	  and	   inactivation	  of	  SRC	   (Tang	  et	  al.,	  
2005),	  with	  various	  consequences	   including	  apoptosis	  and	  differentiation.	  PTPs	  are	  
also	  major	   targets	   of	   ROS	   (den	   Hertog	   et	   al.,	   2005;	   Groen,	   2005),	   contributing	   to	  
inhibition	   through	  oxidation	  of	   their	   active	   site	   cysteine.	   Similarly	   vanadium	  based	  
PTP	   inhibitors	   have	   been	   shown	   to	   generate	   ROS	   with	   this	   being	   a	   putative	  
mechanism	  of	  action	  and	  a	  crucial	  factor	  in	  determining	  the	  sensitivity	  of	  cancer	  cells	  
to	  vanadium-­‐induced	  apoptosis	  (Wang	  et	  al.,	  2010;	  Zhang	  et	  al.,	  2003),	  although	  this	  
may	   vary	   between	   vanadium-­‐based	   compounds	   (Krejsa	   et	   al.,	   1997;	   Krejsa	   and	  
Schieven,	  1998).	  
Thus	   given	   their	   ability	   to	   cause	   apoptosis	   through	   oxidative	   stress,	   to	  
regulate	   signalling	   of	   Akt/Erk/SRC,	   form	   as	   a	   consequence	   of	   PTP	   inhibition	   by	  
vanadium	  compounds	  and	  themselves	  potently	  inhibit	  PTPs,	  ROS	  represent	  a	  highly	  
relevant	  candidate	  for	  investigation	  into	  the	  molecular	  basis	  of	  cytotoxicity	  of	  BMOV.	  
We	   first	   sought	   to	   determine	   the	   level	   of	   intracellular	   ROS	   following	   BMOV	  
treatment	   in	   BMOV-­‐sensitive	   NBL	   cells,	   using	   the	   fluorescence-­‐based	   ROS	   dye	  
DCFDA,	   which	   ultimately	   forms	   the	   highly	   fluorescent	   molecule	   DCF	   through	  
oxidation	   by	   ROS,	   generating	   a	   fluorescent	   signal	   corresponding	   to	   the	   levels	   of	  
intracellular	  ROS	  (Eruslanov	  and	  Kusmartsev,	  2010)	  (see	  Figure	  4.2).	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Figure	  4.17.	   Inhibition	  of	   PI3K	  and	  mTOR	  enhance	  BMOV-­‐induced	   cell	   death.	   (A)	   Sub-­‐G1	  
analysis	   showing	   the	   effects	   of	   the	   PI3K/mTOR	   inhibitor	   PI-­‐103	   (500nM)	   and	   the	   mTOR	  
inhibitor	   rapamycin	   (100nM)	   on	   KCNR	   cells,	   both	   of	   which	   increased	   BMOV-­‐induced	   cell	  
death.	   (B)	   Immunoblot	   of	   KCNR	   cells	   treated	   with	   BMOV	   and	   PI-­‐103,	   which	   inhibits	   Akt	  
phosphorylation,	  and	  Rapamycin	  (Rap)	  which	  failed	  to	  increase	  Akt	  phosphorylation.	  (C)	  PI-­‐
103/BMOV-­‐induced	  toxicity	  is	  specific	  to	  NBL	  cells,	  as	  MEFs	  do	  not	  increase	  the	  levels	  of	  sub-­‐
G1	  cells.	  	  
	  
Short-­‐term	   treatment	   with	   BMOV	   in	   Kelly	   cells	   was	   observed	   to	   cause	   modest	  
increases	   (50%)	   in	   DCF	   signal	   intensity	   beyond	   untreated	   control	   cells	   at	   standard	  
dosage	  capable	  of	   inducing	  cell	  death	   (10µM)	  while	   inducing	  greater	   changes	  with	  
increasing	  dosage	  (200µM)	  more	  in	  line	  with	  that	  generated	  from	  a	  positive	  control	  
treatment	  of	  pervanadate,	  which	  has	  been	  suggested	  to	  generate	  much	  higher	  levels	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of	   ROS	   than	   BMOV	   through	   irreversible	   inactivation	   of	   PTPs	   (Krejsa	   et	   al.,	   1997)	  
(Figure	  4.18).	  However,	   figure	  5.18	   is	   just	  a	   representative	  example	  and	   in	   fact	  we	  
noted	  very	  high	  variability	  in	  this	  assay,	  making	  statistical	  comparisons	  difficult.	  The	  
laboratory	   has	   not	   yet	   been	   able	   to	   understand	   or	   control	   this	   variability.	  
Furthermore	  given	  the	  high	  level	  of	  fluorescence	  in	  untreated	  control	  cells,	  changes	  
induced	  by	  low	  dose	  BMOV	  may	  be	  too	  subtle	  for	  detection	  in	  this	  assay.	  	  
Thus	   we	   attempted	   identical	   experiments	   using	   an	   alternative	   fluorescent	  
dye	   DHR	   123,	   which	   has	   been	   suggested	   to	   exhibit	   greater	   sensitivity	   than	   DCF	  
(Emmendörffer	  et	  al.,	  1990).	  Here	  BMOV	  treatment	  again	  induced	  modest	  (30%)	  but	  
significant	  increases	  in	  fluorescence	  intensity	  beyond	  that	  of	  untreated	  control	  cells	  
in	   both	   Kelly	   and	   SK-­‐N-­‐AS	   cells,	   despite	   the	   latter	   exhibiting	   little	   phenotypic	  
response	   to	  BMOV	   (Figure	   4.19).	  We	  previously	   observed	   a	   synergistic	   increase	   in	  
BMOV-­‐induced	   cytotoxicity	   with	   the	   PI3K	   inhibitor	   LY294002	   (LY29),	   despite	   no	  
evidence	   of	   PI3K	   inhibition	   when	   used	   in	   combination	   with	   BMOV	   (see	   section	  
5.3.5).	  Both	   LY29	  and	   the	   inactive	  analogue	  LY303511	  have	  been	  demonstrated	   to	  
induce	   toxicity	   independent	   of	   the	   PI3K/Akt	   pathway	   by	   stimulating	   intracellular	  
H202,	  which	  in	  turn	  activates	  MAPKs	  leading	  to	  tumour	  necrosis	  factor	  (TNF)-­‐related	  
apoptosis-­‐inducing	  ligand	  (TRAIL)-­‐mediated	  cell	  death	  (Shenoy	  et	  al.,	  2009).	  
Thus	   we	   sought	   to	   examine	   whether	   LY29	   was	   further	   increasing	   ROS	  
following	   BMOV	   treatment,	   leading	   to	   enhanced	   cytotoxicity.	   Similarly	  we	   used	   in	  
the	   same	  manner	   L-­‐buthionine-­‐S,R-­‐	   sulfoximine	   (BSO),	   which	   depletes	   cells	   of	   the	  
antioxidant	   glutathione	   by	   inhibiting	   	   an	   enzyme	   involved	   in	   its	   production	   by	   γ-­‐
glutamylcysteine	  synthetase.	  BSO	  would	  be	  expected	   to	   increase	  ROS	   (Marengo	  et	  
al.,	  2008).	  Interestingly	  LY29	  induced	  significant	  increases	  in	  ROS	  alone	  in	  Kelly	  cells,	  
beyond	  that	  of	  BMOV	  (Figure	  4.19).	  However	  while	  BSO	  did	  not	   induce	  statistically	  
significant	   increases	   in	   ROS,	   contrary	   to	   previous	   reports	   (Marengo	   et	   al.,	   2008).	  
Compound	  BSO/BMOV	  treatment	  did	  cause	  higher	  ROS	  levels	  than	  BMOV	  treatment	  
alone,	  although	  this	  did	  not	  attain	  statistical	  significance	  (Figure	  4.19).	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Figure	   4.18.	   BMOV	   induces	   increases	   in	   ROS.	   Representative	   graph	   of	   DCF	   fluorescence	  
signal	  normalized	  to	  untreated	  control	  cells	  (A)	  and	  microscopic	  (10x	  objective)	  images	  (B)	  of	  
Kelly	   NBL	   cells	   treated	   for	   2	   hours	   with	   BMOV	   (10	   and	   200µM)	   or	   for	   10	   minutes	   with	  
pervanadate	  (1mM)	  in	  one	  single	  experiment.	  	  
	  
Given	  that	  antioxidant	  defence	  systems	  have	  been	  shown	  to	  positively	  maintain	  the	  
survival	   of	   cancer	   cells,	   mediating	   therapeutic	   resistance	   (Denicola	   et	   al.,	   2011;	  
Diehn	  et	  al.,	  2009;	  Raj	  et	  al.,	  2011),	  we	  sought	  to	  examine	  whether	  BMOV	  treatment	  
alone	  or	   in	   combination	  with	   LY29	  or	  BSO	  affected	   levels	   of	  ROS	  detoxification	  by	  
examining	   relative	  amounts	  of	  GSH	   following	   treatment	  using	   the	   fluorescent	  GSH	  
dye	  MCB.	   Indeed	   following	  14	  hours	  of	   treatment,	   a	  period	  of	   time	   that	  preceded	  
cell	   death,	   all	   treatments	   were	   found	   to	   significantly	   reduce	   the	   levels	   of	   GSH	  
relative	  to	  untreated	  control	  cells	  in	  both	  Kelly	  and	  SK-­‐N-­‐AS	  cells	  (Figure	  4.20).	  While	  
reductions	   in	   MCB	   signal	   intensity	   were	   low	   in	   cells	   treated	   with	   BMOV	   alone,	  
combination	   treatment	   of	   BSO/BMOV	   caused	   much	   larger	   decreases,	   over	   and	  
above	  that	  of	  BSO	  alone.	  	  
In	  order	  to	  determine	  whether	  increases	  in	  ROS	  production	  were	  responsible	  
for	  BMOV	  induced-­‐cytotoxicity,	  we	  conducted	  viability	  analysis	  of	  cells	  treated	  with	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BMOV	  in	  the	  presence	  of	  the	  reducing	  agent	  NAC	  in	  order	  to	  block	  ROS	  production.	  
BMOV	  was	  found	  to	  cause	  a	  50%	  reduction	  in	  the	  number	  of	  viable	  LAN-­‐5	  cells	  after	  
6	   days	   of	   treatment.	   However,	   compound	   treatment	   with	   low	   dose	   NAC	   almost	  
completely	  abolished	  this	  reduction	  in	  viability,	  with	  BMOV	  treated	  cells	  returning	  to	  
levels	  of	  vehicle	  treated	  control	  (Figure	  4.21,	  A).	  This	  effect	  however	  did	  not	  extend	  
to	   KCNR	   cells,	   in	   which	   treatment	   with	   NAC	   further	   increased	   the	   cytotoxicity	   of	  
BMOV.	   During	   these	   initial	   studies	   we	   observed	   substantial	   toxicity	   at	   commonly	  
used	  doses	  of	  NAC,	  precluding	  higher	  dose	  analysis.	  However,	  pH	  adjustment	  of	  NAC	  
prior	  to	  its	  addition	  substantially	  reduced	  its	  own	  toxic	  effects	  in	  KCNR	  cells,	  allowing	  
analysis	   of	   higher	   dose	   treatment.	   Here	   sub-­‐G1	   analysis	   using	   higher	   dose	   NAC	  
revealed	   a	   near	   complete	   blockade	   of	   the	   cytotoxic	   effects	   of	   BMOV,	   where	  
compound	   treatment	   significantly	   abolished	   BMOV	   induced	   increases	   in	   apoptotic	  
cells	   (Figure	  4.21,	  B).	   Similarly	  NAC	   treatment	   significantly	   decreased	  BMOV/LY29-­‐
induced	   cytotoxicity,	   although	   this	   did	   not	   fully	   return	   to	   the	   levels	   of	   untreated	  
control	  cells	  (Figure	  4.21,	  C).	  	  
The	  ability	  of	  the	  reducing	  agent	  NAC	  to	  abrogate	  the	  effects	  of	  BMOV	  on	  cell	  
death	  is	  suggestive	  of	  a	  functional	  role	  for	  ROS	  in	  BMOV	  induced-­‐cytotoxicity.	  Thus	  
we	  sought	  to	  examine	  whether	  preventing	  protection	  from	  ROS	  would	  augment	  the	  
effects	   of	   BMOV.	   Importantly	   glutathione	   has	   been	   found	   to	   be	   upregulated	   in	  
tumour	   cells,	   where	   BSO	   has	   been	   shown	   to	   enhance	   the	   efficacy	   of	   multiple	  
chemotherapeutics	  by	  increasing	  basal	  ROS	  levels	  in	  multiple	  tumours	  including	  NBL	  
(Lewis-­‐Wambi	  et	  al.,	  2008;	  Marengo	  et	  al.,	  2008).	  Sub-­‐G1	  analysis	  revealed	  that	  BSO	  
significantly	   augmented	   BMOV-­‐induced	   cytotoxicity	   in	   KCNR	   cells	   (Figure	   4.22	   A).	  
This	   response	   occurred	   at	   doses	   of	   BSO	   far	   lower	   than	   commonly	   used,	   and	   ones	  
that	   induced	  no	  visible	   toxicity	  alone.	  This	   suggests	  a	   synergism	  between	  BSO	  and	  
BMOV.	   Importantly,	   compound	   treatment	   of	   primary	   wild-­‐type	   MEFs	   failed	   to	  
stimulate	   apoptosis,	   suggesting	   this	   sensitivity	   to	   enhanced	   ROS	   levels	   in	   the	  
presence	  of	  BMOV/BSO	  is	  a	  feature	  of	  tumour	  cells	  as	  previously	  documented	  (Wang	  
et	  al.,	  2010).	   Lastly	  we	  wished	   to	  examine	  whether	  GSH	  was	   indeed	  counteracting	  
the	  effects	  of	  BMOV	  by	  performing	  a	  rescue	  experiment	  in	  which	  cells	  were	  treated	  
with	  BMOV	  in	  the	  presence	  of	  GSH	  ethyl	  ester,	  in	  order	  to	  increase/prevent	  BMOV-­‐
induced	   decreases	   of	   GSH.	   Indeed	   the	   addition	   of	   GSH	   ethyl	   ester	   significantly	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blocked	  BMOV-­‐induced	  toxicity	  in	  KCNR	  cells,	  suggesting	  a	  causal	  role	  for	  inhibition	  
of	  GSH	  synthesis.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  4.19.	  BMOV	  and	  LY29	  cause	  significant	  increases	  in	  ROS.	  DHR	  fluorescence	  intensity	  
normalized	  to	  untreated	  control	  cells	  following	  4	  hours	  treatment	  with	  BMOV	  (10µM),	  LY29	  
(5µM),	   or	   4	   hours	   following	   24	  hours	   pre-­‐treatment	  with	  BSO	   (10µM).	  While	   BSO	  did	   not	  
induce	   significant	   ROS	   production,	   combined	   treatment	   with	   BMOV	   did	   cause	   modest	  
increases	   in	  ROS	   levels	  beyond	  BMOV	  alone.	  Mean	   from	  3	   independent	  experiments	  each	  
with	  triplicate	  samples;	  Error	  bars	  denote	  SEM;	  independent	  samples	  t-­‐tests.	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Figure	   4.20.	   BMOV,	   LY29	   and	  BSO	   cause	   reductions	   in	   the	   level	   of	  GSH	   as	  measured	   by	  
decreases	  in	  fluorescence	  intensity	  of	  MCB.	  Cells	  treated	  for	  14	  hours	  with	  BMOV	  (10µM)	  
and	   LY29	   (5µM)	   or	   14	   hours	   following	   12	   hours	   pre-­‐treatment	   with	   BSO.	   Mean	   signal	  
intensity	  relative	  to	  untreated	  control	  cells	  from	  5	  independent	  experiments	  each	  containing	  
3	  independent	  samples.	  Graphs	  show	  means	  and	  SEM	  with	  independent	  samples	  t-­‐tests.	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Figure	   4.21.	   Preventing	   ROS	   production	   NAC	   attenuates	   BMOV-­‐induced	   increases	   in	  
apoptosis.	   (A)	   LAN-­‐5	   and	   KCNR	   cells	   treated	   for	   6	   and	   3	   days	   with	   BMOV	   (10µM)	   in	   the	  
presence	  or	  absence	  of	  concurrent	  NAC	  treatment	  (100µM).	  Following	  crystal	  violet	  staining	  
dye	   was	   solubilised	   to	   assess	   gross	   cell	   viability,	   showing	   attenuation	   of	   BMOV	   induced	  
cytotoxicity	  by	  NAC	  in	  the	  case	  of	  LAN-­‐5	  only.	  (B)	  KCNR	  cells	  treated	  for	  3	  days	  with	  BMOV	  
(10µM)	   in	   the	   presence	   or	   absence	   of	   concurrent	   NAC	   (5mM,	   pH	   7.2)	   treatment	   were	  
subjected	  to	   flow	  cytometry	  analysis	  of	  sub	  G1	  content	  revealing	  a	  significant	   reduction	   in	  
the	  cytotoxic	  effects	  of	  BMOV	  by	  NAC.	  (C)	  As	  (B)	  except	  for	  LY29	  (5µM)/BMOV	  treatment.	  	  
	  
In	   sum,	   BMOV	   is	   capable	   of	   causing	   increases	   in	   intracellular	   ROS	   as	   well	   as	  
decreases	   in	   GSH.	   While	   these	   are	   modest	   and	   non-­‐selective,	   i.e.	   occurring	   in	  
unresponsive	  SK-­‐N-­‐AS	  cells,	   they	  appear	  at	   least	  partly	  causative	   in	  BMOV-­‐induced	  
cytotoxicity,	   since	  blocking	  ROS	  with	   the	   reducing	  agent	  NAC	  prevents	   increases	   in	  
cell	  death.	  Furthermore,	  reducing	  ROS	  protection	  using	  the	  glutathione	  inhibitor	  BSO	  
enhances	  the	  efficacy	  of	  BMOV,	  although	  this	  may	  be	  through	  preventing	  reduction	  
of	   vanadate	   to	   vanadyl	   (see	   section	   4.4).	   Lastly,	   synergistic	   increases	   in	   cell	   death	  
caused	  by	  compound	  BMOV/LY2942002	  treatment	  similarly	  appear	  ROS-­‐dependent	  
as	  they’re	  significantly	  blocked	  by	  NAC	  and	  correlate	  with	  further	  decreases	  in	  GSH	  
and	  increases	  in	  ROS.	  	  
	  
4.3.7.	   BMOV	   causes	   additive	   reductions	   in	   cell	   survival	   in	   conjunction	   with	  
PI3K/mTOR	  inhibition	  by	  preventing	  the	  induction	  of	  autophagy	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Macroautophagy	   (autophagy)	   is	   a	   lysosomal	   degradation	   pathway	   for	   the	  
breakdown	   of	   intracellular	   organelles	   and	   macromolecules.	   It	   functions	  
predominantly	   as	   a	   survival	   pathway,	   recycling	   cellular	   components	   in	   periods	   of	  
nutrient	   deprivation	   or	   stress,	   to	  maintain	  metabolic	   homeostasis.	   Autophagy	   has	  
long	   been	   considered	   a	   ‘double-­‐edged	   sword’	   in	   cancer,	   due	   to	   its	   converse	  
functions	  in	  promoting	  and	  suppressing	  cell	  survival	  (White	  and	  Dipaola,	  2009).	  For	  
instance,	   tumour	  cells	  capable	  of	  circumventing	  apoptosis	  can	  survive	   long	  periods	  
of	  stress/deprivation	  by	  activating	  autophagy,	   in	  the	  absence	  of	  adequate	  nutrition	  
and	  sustainable	  mitogenic	  signalling.	  However	  paradoxically	  autophagy	  defects	  such	  
as	   loss	   of	   the	   essential	   gene	   beclin1	   are	   often	   observed	   in	   many	   cancers,	   and	   in	  
contrast	   to	   its	   pro-­‐survival	   functions,	   autophagy	   can	   cause	   autophagic	   cell	   death	  
(Kroemer	   and	   Levine,	   2008),	   thought	   to	   be	   an	   alternative	   form	   of	   PCD	   distinct	   to	  
apoptosis	  (Bröker	  et	  al.,	  2005).	  	  
	  
Figure	   4.22.	   BMOV-­‐induced	   toxicity	   in	   KCNR	   cells	   is	   augmented	   by	   inhibition	   of	   GSH	  
synthesis.	   (A)	   Cells	   treated	   for	   3	   days	   with	   BMOV	   (10µM)	   or	   BMOV/BSO	   (10µM)	   and	  
analysed	   fro	   sub-­‐G1	   content	   by	   flow	   cytometry.	   (B)	   BMOV/BSO	   treatment	   is	   non-­‐toxic	   in	  
non-­‐tumour	   cell	  MEFs	   treated	   or	   the	   same	  period	  with	   BMOV/BSO	   (BMOV	  on	   graph).	   (C)	  
BMOV-­‐induced	   increases	   in	   sub-­‐G1	  KCNR	   cells	   are	   significantly	   blocked	  by	   the	   addition	   of	  
GSH	  ethyl	  ester	  	  (2mM)	  (referred	  to	  in	  graph	  as	  GSH).	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There	  have	  been	  a	  number	  of	   recent	  elegant	  demonstrations	  of	   this	  phenomenon.	  
For	   instance,	   Yang	   et	   al.	   showed	   that	   pancreatic	   tumours	   rely	   on	   autophagy	   for	  
survival,	   exhibiting	   high	   basal	   rates	   of	   autophagy	   which	   when	   inhibited	   using	  
chloroquine,	  elevated	  ROS/DNA	  damage	  and	  growth	  suppression	  both	  in	  vitro	  and	  in	  
vivo	   (Yang	   et	   al.,	   2011).	   Similarly	   expression	   of	   oncogenic	   Ras	   triggers	   autophagy,	  
which	  when	  rendered	  defective	  causes	  mitochondrial	  damage	  and	  reduced	  oxygen	  
consumption,	   suggesting	  autophagy	  maintains	  mitochondrial	   functionality	   required	  
for	   survival	   under	   starvation	   (Guo	   et	   al.,	   2011).	   Conversely	   Elgendy	   et	   al.	   showed	  
that	   the	   induction	   of	   autophagic	   proteins	   noxa	   and	   beclin-­‐1	   by	   oncogenic	   Ras	  
actually	  triggers	  autophagic	  cell	  death	  independent	  of	  caspase	  activation	  (Elgendy	  et	  
al.,	  2011).	   Indeed	  such	  Ras	  driven	  autophagic	  cell	  death	  has	  been	  demonstrated	  to	  
be	   a	   feature	   of	   NBL	   tumours,	   and	   cited	   as	   a	   possible	  mechanism	   of	   spontaneous	  
regression	  given	  that	  high	  Ras	  expression	  is	  actually	  a	  positive	  prognostic	  marker	  in	  
NBL	  (Kitanaka	  et	  al.,	  2002).	  	  
	   Adding	  further	  confusion	  to	  the	  matter,	  Fan	  et	  al.	   recently	  showed	  that	  the	  
inhibition	   of	   the	   PI3K/Akt/mTOR,	   which	   drives	   proliferation/survival	   in	   therapy-­‐
resistant	  glioma,	  actually	  promotes	  autophagy	  as	  a	  survival/coping	  mechanism	  (Fan	  
et	  al.,	  2010).	  Here	  it	  was	  shown	  that	  the	  dual	  PI3K/mTOR	  inhibitor	  PI-­‐103	  as	  well	  as	  
the	   mTOR	   inhibitor	   rapamycin	   caused	   the	   induction	   of	   autophagy,	   inhibitors	   of	  
which	   caused	   apoptosis	   in	   a	   cooperative	   manner.	   Importantly	   chloroquine	  
synergised	   with	   a	   novel	   PI3K	   inhibitor	   in	   vivo	   to	   cause	   tumour	   regression.	   While	  
taken	   together	   these	   findings	  are	  paradoxical,	   i.e.	  one	  would	  predict	  autophagy	   to	  
be	  activated	  by	  PI3K/Akt	   in	  order	   for	   cancer	   cells	   to	   survive	  unrelenting	  mitogenic	  
signals	   in	   the	   face	  of	   sparse	  nutrition,	   this	  points	   to	   the	  possibility	   that	  autophagy	  
may	   contribute	   to	   cell	   survival	   following	   inhibition	   of	   growth	   factor	   signalling,	   a	  
common	  target	  of	  therapy.	  	  
	   We	  previously	  demonstrated	  additive	   increases	   in	  cell	  death	  when	  the	  dual	  
PI3K/mTOR	   inhibitor	   PI-­‐103	   was	   used	   in	   combination	   with	   BMOV	   (section	   4.3.5).	  
However	   this	   again	   presented	   a	   paradox	   given	   that	   increasing	   Akt	   also	   led	   to	  
synergistic	   cell	   death,	   possibly	   suggesting	   that	   an	   alternative	   mechanism	   i.e.	   one	  
independent	   of	   canonical	   downstream	   PI3K/Akt	   targets,	   may	   be	   mediating	   these	  
effects.	  Thus	  we	  hypothesised	  that	  PI-­‐103	  may	   in	  similarity	  to	   its	  effects	  on	  glioma	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cells	   cause	   the	   induction	  of	  autophagy	  as	  a	   survival	  mechanism	   in	   the	  presence	  of	  
inhibited	   PI3K/mTOR,	   which	   may	   be	   suppressed	   by	   BMOV	   due	   to	   its	   putative	  
activation	   of	   various	   RTK-­‐driven	   growth	   factor	   signalling	   pathways,	   leading	   to	  
enhanced	   cell	   death.	   Thus	   we	   sought	   to	   examine	   the	   role	   of	   autophagy	   in	   this	  
context.	  
	   Microtubule-­‐associated	   protein	   1A/1B-­‐light	   chain	   3	   (LC3)	   is	   expressed	  
diffusely	  throughout	  the	  cytoplasm.	  During	  autophagy,	  autophagosome	  engulfment	  
causes	  conjugation	  of	  cytosolic	  LC3	  (LC3-­‐I)	  to	  PE,	  forming	  LC3-­‐III	  and	  resulting	  in	  its	  
autophagosome-­‐membrane	  recruitment	  and	  punctate	  distribution	  (Mizushima	  et	  al.,	  
2010).	  Thus	  the	  expression	  pattern	  of	  GFP-­‐tagged	  LC3	  is	  indicative	  of	  the	  activation	  
of	  autophagy,	  i.e.	  due	  to	  transitioning	  from	  diffuse	  to	  punctate	  GFP	  localisation.	  	  
	   We	  first	  sought	  to	  examine	  whether	  PI-­‐103	  causes	  autophagy	  in	  U87	  glioma	  
cells	   as	   shown	   by	   punctate	   LC3,	   in	   line	   with	   recent	   reports	   (Fan	   et	   al.,	   2010).	  
However	  we	   failed	   to	  detect	  any	  gross	   changes	   in	   the	  proportion	  of	  punctate	  GFP	  
cells	  in	  PI-­‐103	  treated	  U87	  cells	  transfected	  with	  GFP-­‐LC3	  (Figure	  4.23,	  A).	  Increased	  
punctate	  GFP	  was	  neither	  observed	  in	  BMOV	  treated	  cells	  nor	  cells	  treated	  with	  the	  
alternative	   PI3K	   inhibitor	   LY294002,	   ruling	   out	   the	   explanation	   that	   PI-­‐103	   was	  
actually	  suppressing	  autophagy.	  Similarly	   the	  NBL	  cell	   line	  Kelly	  also	   failed	  to	  show	  
any	  evidence	  of	   increased	  punctate	  GFP	   in	  any	  treatment	  condition	  (Figure	  4.23B),	  
and	  neither	  cell	  type	  showed	  a	  degree	  of	  puncta	  that	  matched	  other	  reports	  e.g.	  Fan	  
et	  al.	  
	   This	  suggests	  that	  autophagy	  may	  not	  be	  being	  activated	  in	  either	  glioma	  or	  
NBL	  cells	  in	  response	  to	  PI3K	  inhibition.	  However	  given	  that	  this	  goes	  against	  recent	  
reports,	  we	   sought	   to	   confirm	   this	  using	  an	  alternative	  method.	  Thus	  we	  used	   the	  
green	   fluorescent	   dye	   acridine	   orange,	   which	   becomes	   protonated	   in	   response	   to	  
lysosomal	   acidification,	   emitting	   a	   signal	   that	   can	   be	   preferentially	   detected	   at	  
588nm,	   i.e.	   increasing	   punctate	   red	   staining	   in	   the	   presence	   of	   autophagy	   (Mains	  
and	   May,	   1988).	   	   In	   contrast	   to	   LC3-­‐GFP,	   acridine	   orange	   reliably	   detected	   the	  
presence	   of	   autophagy	   in	   PI-­‐103	   treated	   U87	   cells	   (data	   not	   shown),	   thus	   this	  
method	  was	  used	  to	  test	  the	  original	  hypothesis	  that	  PI-­‐103-­‐induced	  autophagy	  may	  
occur	  in	  NBL	  cells.	  	  
	   203	  
	   Indeed	  Kelly	  cells	  actually	  displayed	  high	  rates	  of	  basal	  autophagy,	  as	  shown	  
by	  acridine	  orange	  staining,	  although	  this	  was	  not	  affected	  by	  PI3K	   inhibition	  using	  
PI-­‐103	   or	   Akt-­‐stimulation	   using	   LY29	   (Figure	   4.24).	   Remarkably	   BMOV	   treatment	  
suppressed	  the	  induction	  of	  autophagy	  both	  in	  basal	  situations	  and	  in	  response	  to	  PI-­‐
103	  treatment.	  However	  a	  significant	  caveat	  is	  that	  we	  failed	  to	  detect	  red	  staining	  
following	   excitation	   with	   blue	   fluorescent	   light,	   which	   has	   been	   suggested	   to	   be	  
specific	  for	  acidic	  organelles	  such	  as	  autophagosomes.	  Instead	  staining	  was	  detected	  
by	  red	  emission	  following	  green	  excitation,	  which	  could	  be	  potentially	   indicative	  of	  
RNA.	  However	   the	  punctate	   staining	  observed	   in	   the	   red	   channel,	  which	  exhibited	  
greater	   signal	   intensity	   than	   diffuse	   red	   staining	   suggests	   that	   we	  may	   indeed	   be	  
detecting	  acidic	  vesicles	  on	  this	  channel.	  The	  only	  other	  possible	  explanation	  for	  this	  
pattern	  of	  staining	   is	  that	  acridine	  orange	  may	  in	  this	  case	  be	  detecting	  RNA	  stress	  
granules,	  which	  have	  been	  shown	  to	  occur	  following	  transformation	  by	  an	  ALK	  fusion	  
protein	  (Fawal	  et	  al.,	  2011),	  although	  this	  seems	  less	  likely.	  	  
As	   previously	   mentioned	   the	   staining	   of	   autophagic	   vesicles	   by	   acridine	  
orange	   shown	   above	   may	   be	   artifactual,	   or	   may	   represent	   RNA	   granules.	  
Furthermore	   acridine	   orange	   is	   considered	   by	   some	   to	   be	   insufficient	   evidence	   of	  
autophagy	   given	   that	   this	   procedure	   stains	   acidic	   vesicles	   only,	   which	   include	  
lysosomes	  as	  well	   as	  autophagosomes	   (Mizushima	  et	  al.,	  2010).	  Thus	   to	   retest	   the	  
hypothesis	   that	  BMOV	  may	  suppress	  PI-­‐103-­‐mediated	   induction	  of	  autophagy	  by	  a	  
different	   assay,	   we	   conducted	   immunoblotting	   for	   LC3.	   As	   previously	   mentioned	  
during	   the	   formation	   of	   autophagosomes,	   LC3	   becomes	   conjugated	   to	   PE	   to	   form	  
LC3-­‐II,	  which	   can	  be	   visualised	  as	   a	  distinct	  band	   that	  migrates	   slightly	   faster	   than	  
LC3-­‐I	  during	  SDS-­‐PAGE	  due	  to	  its	  hydrophobicity.	  We	  were	  able	  to	  detect	  both	  forms	  
of	  LC3	  (I/II)	  by	  SDS-­‐PAGE	  in	  untreated	  NBL	  cells.	  As	  hypothesised,	  treatment	  with	  PI-­‐
103	  caused	  an	  induction	  of	  autophagy	  as	  shown	  by	  an	  increase	  in	  the	  level	  of	  LC3-­‐II,	  
as	   did	   a	   positive	   control	   of	   rapamycin,	   which	   should	   cause	   autophagy	   through	  
inhibition	  of	  mTOR.	  Remarkably	  BMOV	  was	  able	  to	  suppress	  both	  rapamycin	  and	  PI-­‐
103-­‐mediated	   increases	   in	   LC3-­‐II,	   causing	   levels	   to	   return	   to	   that	   of	   untreated	  
control	  cells	  (Figure	  4.25).	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Figure	   4.23.	   LC3-­‐GFP	   revealing	   a	   lack	   of	   autophagy	   in	   both	   U87	   glioma	   and	   Kelly	  
neuroblastoma	   cells	   in	   response	   to	   PI3K/mTOR	   inhibition.	   Cells	   were	   transiently	  
transfected	  with	  a	  GFP	  tagged	  LC3	  expression	  vector	  24	  hours	  prior	  to	  inhibitor	  treatment,	  
however,	   neither	   U87	   (A)	   nor	   Kelly	   (B)	   cells	   exhibited	   punctate	   GFP	   expression	   after	   72	  
hours	  of	  treatment	  with	  PI-­‐103	  (500nM),	  LY294002	  (5µM)	  or	  BMOV	  (10µM).	  Magnification	  =	  
63x	  objective	  lens.	  B	  =	  2x	  enlargement.	  DMSO	  =	  vehicle	  control.	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Thus	  this	  provides	  tentative	  evidence	  that	  at	   least	  one	  mechanism	  by	  which	  BMOV	  
may	   be	   enhancing	   the	   efficacy	   of	   PI-­‐103	   is	   by	   attenuating	   autophagy	   activated	   by	  
PI3K/mTOR	   inhibition,	   and	   thus	   preventing	   autophagic	   cell	   survival	   by	   stimulating	  
alternative	  growth	  factor	  signalling	  pathways	  e.g.	  RAF/MEK/Erk.	  This	  parallels	  similar	  
findings	  in	  glioma	  (Fan	  et	  al.,	  2010).	  	  
	  
4.3.8.	  The	  effects	  of	  BMOV	  on	  apoptosis	  appear	  independent	  of	  PTEN	  
We	  previously	  documented	  VA/BMOV	  mimetic	  effects	  of	  the	  specific	  PTEN	  inhibitor	  
VO-­‐OH	  Pic	  in	  terms	  of	  synergistically	  activating	  Erk	  and	  Akt	  signalling	  in	  combination	  
with	   retinoic	   acid,	   as	   well	   as	   inducing	   neuritogenesis	   at	   micromolar	   ranges	   (See	  
section	  3.3.7).	  However	  given	  the	   lack	  of	  effect	  at	  nanomolar	  ranges,	  at	  which	  this	  
inhibitor	   has	   previously	   been	   documented	   to	   specifically	   inhibit	   PTEN	   over	   other	  
phosphatases	   (Alimonti	   et	   al.,	   2010b;	   Rosivatz	   et	   al.,	   2006),	   we	  were	   reluctant	   to	  
conclude	   that	   PTEN	   is	   the	   primary	   determinant	   of	   the	   response	   of	   NBL	   cells	   to	  
vanadium	  compounds.	  	  
Nevertheless,	   in	  order	   to	   falsify	   this	   hypothesis,	  we	  wished	   to	   examine	   the	  
response	   of	   NBL	   cells	   that	   undergo	   cell	   death	   when	   treated	   with	   vanadium	  
compounds	  to	  the	  PTEN	  inhibitor	  VO-­‐OH	  Pic.	  Thus	  we	  tested	  its	  effects	  over	  short-­‐
term	   treatment	   periods	   on	   KCNR	   cells.	   Treatment	   of	   NBL	   cells	   with	   VO-­‐OH	   Pic	  
matched	   the	   effects	   of	   BMOV	   in	   inducing	   cytotoxicity	   at	   a	   similar	   concentration	  
range	   (Figure	   4.26).	   In	   fact	   VO-­‐OH	   Pic	  was	   shown	   to	   induce	   broad	   and	   acute	   cell	  
death	   at	   concentrations	   in	   which	   BMOV	   had	   little	   effect,	   as	   shown	   by	   cell	  
morphology.	   However,	   crucially,	   VO-­‐OH	   Pic	   failed	   to	   induce	   cell	   death	   at	  
concentrations	   lower	   than	  5µM,	  a	   ten	   fold	  higher	  dose	   than	   that	  used	   in	  previous	  
publications,	   suggesting	   this	   effect	  may	  not	   be	  due	   to	   specific	   PTEN	   inhibition	  but	  
more	  broad	  PTP	  inhibition	  by	  vanadate	  delivery	  and/or	  the	  production	  of	  ROS.	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Figure	   4.24.	   BMOV	   may	   suppress	   autophagy	   as	   shown	   by	   acridine	   orange	   staining.	   (A)	  
Kelly	   NBL	   cells	   treated	   for	   3	   days	   with	   PI-­‐103	   (500nM)	   or	   LY29	   (5µM)	   with	   and	   without	  
BMOV	   (10µM),	   then	   stained	   with	   acridine	   orange	   (5µg/ml)	   for	   15	   minutes	   and	  
photographed	   when	   excited	   with	   green	   light.	   Potential	   autophagosomes	   (arrows)	   were	  
detected	  in	  all	  conditions	  but	  were	  significantly	  suppressed	  following	  BMOV	  treatment.	  63x	  
objective	  magnification.	  (B)	  Mean	  percentage	  of	  autophagosome-­‐containing	  cells,	  as	  judged	  
by	  the	  presence	  of	  at	  least	  10	  red	  puncta	  (white	  arrows	  in	  A).	  Error	  bars	  denote	  SEM	  (N=2).	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Figure	  4.25.	  BMOV	  inhibits	  PI-­‐103/Rapamycin-­‐induced	  increases	  in	  LC3-­‐II.	  The	  Induction	  of	  
LC3-­‐II	   indicative	   of	   autophagy	   can	   be	   visualised	   as	   a	   distinct	   band	   below	   LC3-­‐I.	   15-­‐hour	  
treatment	  with	   both	   PI-­‐103	   (1µM)	   and	   rapamycin	   (200nM)	   caused	   significant	   increases	   in	  
LC3-­‐II,	  which	  were	  completely	  blocked	  by	  concomitant	  treatment	  with	  BMOV	  in	  both	  Kelly	  
(A)	   and	   KCNR	   (B)	   cells.	   Note	   that	   PI-­‐103	   also	   decreases	   LC3-­‐I,	   which	   is	   not	   abrogated	   by	  
BMOV,	   however	   it	   is	   unknown	   whether	   restoration	   of	   LC3-­‐I	   is	   required	   to	   suppress	  
autophagy.	  
	   	  
We	  previously	  demonstrated	  a	  synergistic	  induction	  of	  cell	  death	  in	  NBL	  cells	  treated	  
with	   BMOV	   following	   depletion	   of	   GSH	   using	   BSO	   (See	   section	   4.3.6),	   despite	  
minimal	  evidence	  of	   increased	  ROS	   following	  compound	  BSO/BMOV	  treatment.	  To	  
further	  explore	  the	  possibility	  that	   inhibition	  of	  PTEN	  may	  be	  a	  determinant	  of	   the	  
cytotoxic	   response	  of	  NBL	  cells	   to	  BMOV,	  we	  examined	  whether	  PTEN	   inactivation	  
by	   oxidation	   may	   account	   for	   the	   combined	   effects	   of	   BMOV/BSO.	   As	   previously	  
discussed,	   oxidation	  of	   the	   PTP	   active-­‐site	   cysteine	   (Cys)	   is	   a	  major	  mechanism	  by	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which	   PTPs	   are	   physiologically	   inhibited	   by	   ROS	   (See	   section	   1.4).	   PTEN	   itself	   has	  
been	   shown	   to	   be	   subject	   to	   reversible	   oxidation.	   For	   instance,	   Lee	   et	   al.	  
demonstrated	   that	   hydrogen	   peroxide	   (H2O2)	   treatment	   of	   PTEN	   in	   vitro	   caused	  
inactivation	   via	   oxidation	   due	   to	   cross-­‐linking	   between	   the	   conserved	   active	   site	  
Cys124	  with	  Cys71	   (Lee,	  2002),	  a	  process	   that	   is	  negatively	  regulated	  by	  thioredoxin.	  
More	  importantly	  GSH	  was	  recently	  shown	  to	  negatively	  regulate	  PTEN	  oxidation	  by	  
directly	  reducing	  oxidised	  PTEN	  in	  mammalian	  cells	  (Kim	  et	  al.,	  2010).	  Here	  genetic	  
knockdown	   of	   the	   catalytic	   subunit	   of	   glutamate	   cysteine	   ligase	   (GCLc),	   a	   rate-­‐
limiting	  enzyme	  in	  GSH	  synthesis,	   increased	  oxidation	  of	  PTEN	  and	  phosphorylation	  
of	  Akt	  following	  growth	  factor	  stimulation.	  
Thus	   we	   reasoned	   that	   given	   the	   evidence	   that	   BMOV	   is	   capable	   of	  
stimulating	   growth	   factor-­‐receptor	   driven	   signalling	   pathways	   (e.g.	   PI3K/Akt)	  most	  
likely	  by	  PTP	   inhibition,	   combined	   treatment	  with	  BSO	  may	  augment	   this	  effect	  by	  
preventing	   the	   reduction	  and	   thus	  activation	  of	  PTEN,	  contributing	   to	   its	   inhibition	  
and	   thus	   further	   boosting	   PI3K/Akt	   signalling.	   Crucially	   this	  would	   predict	   that,	   A)	  
BSO	  treatment	  causes	  the	  inactivation	  of	  PTEN,	  which	  could	  be	  further	  inhibited	  by	  
BMOV	   treatment	   explaining	   the	   cytotoxicity	   of	   BSO/BMOV,	   B)	   BSO-­‐induced	   PTEN	  
inactivation	  augments	  BMOV	  driven	  PI3K/Akt	  activation,	  which	  may	  also	  contribute	  
towards	   cell	   death	   if	   PTEN	   inhibition/Akt	   activation	   is	   causatively	   linked	   to	   BMOV	  
induced	  toxicity.	  
	   In	  order	  to	  examine	  oxidation	  of	  PTEN	  in	  the	  presence	  of	  BSO,	  we	  conducted	  
immunoblotting	  for	  PTEN	  under	  non-­‐reducing	  conditions,	  which	  have	  been	  shown	  to	  
identify	  both	  oxidised	  and	  reduced	  forms	  of	  PTEN	  due	  to	  their	  different	  migrational	  
speeds	  during	  SDS-­‐PAGE	  (Lee,	  2002).	  BSO	  treatment	  of	  two	  NBL	  PTEN-­‐expressing	  cell	  
lines	  (KCNR/SK-­‐N-­‐SH)	  (see	  section	  3.3.7)	  failed	  to	  cause	  PTEN	  oxidation	  as	  evidence	  
by	   immunoblotting	   (Figure	   4.27,	   A).	   Here	   only	   the	   reduced	   form	   of	   PTEN	   was	  
detected.	  We	  also	  failed	  to	  detect	  oxidised	  PTEN	  following	  BMOV	  treatment,	  as	  well	  
as	   combined	   BMOV/BSO	   treatment,	   suggesting	   that	   despite	   increasing	  
ROS/decreasing	   antioxidant	   defences,	   neither	   compound	   was	   able	   to	   oxidise	   and	  
inactivate	   PTEN.	   Importantly	   the	   detection	   of	   oxidised	   PTEN	   was	   verified	   using	  
Hydrogen	   peroxide.	   Thus	   this	   suggests	   that	   augmentation	   of	   BMOV-­‐induced	   cell	  
death	  by	  BSO	  does	  not	  result	  from	  concomitant	  inactivation/inhibition	  of	  PTEN.	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We	  next	  sought	  to	  examine	  whether	  BMOV/BSO	  treatment	  caused	  activation	  
of	  PI3K/Akt.	   Immunoblotting	   for	  phosphorylated	  Akt	  also	  did	  not	  provide	  evidence	  
for	   further	   significant	   activation	   of	   Akt	   induced	   by	   BMOV	   after	   combination	  
treatment	  with	  BSO	   (Figure	  4.27,	  B).	   Thus	   this	  provides	   further	  evidence	   that	  BSO	  
treatment	  of	  NBL	  cells	  does	  not	  cause	  inactivation	  of	  PTEN,	  as	  this	  would	  most	  likely	  
result	   in	   attenuation	   of	   PI3K/Akt	   suppression	   by	   PTEN	   and	   thus	   increased	   Akt	  
activation	  in	  cells	  treated	  with	  BSO	  both	  alone	  and	  with	  BMOV.	  This	  also	  shows	  that	  
the	  greatly	   enhanced	   cytotoxic	   effect	  of	  BSO/BMOV	   treatment	   is	   not	   the	   result	   of	  
enhanced	  Akt	  stimulation.	  
In	  sum	  this	  data	  provides	   little	  evidence	  for	  the	   involvement	  of	  PTEN	  in	  the	  
cytotoxic	   response	   of	   NBL	   cells	   to	   vanadium	   compound	   treatment.	   Although	   the	  
PTEN	  inhibitor	  VO-­‐OH	  Pic	  was	  able	  to	  induce	  cytotoxicity,	  this	  effect	  failed	  to	  extend	  
to	   nanomolar	   doses.	   Of	   course	   this	  may	   reflect	   the	  wild	   type	   PTEN	   status	   of	   NBL	  
cells,	  given	  the	  lack	  of	  evidence	  for	  genetic	  mutations/deletions	  in	  PTEN,	  as	  VO-­‐OH	  
Pic	   has	   been	   suggested	   to	   only	   induce	   cell	   senescence	   in	   cells	   harbouring	  
hemizygous	  deletions	  of	  PTEN	  (Alimonti	  et	  al.,	  2010b),	  but	  NBL	  cell	  lines	  expressing	  
low	  levels	  of	  PTEN	  (e.g.	  SK-­‐N-­‐AS/SK-­‐N-­‐DZ)	  were	  found	  to	  be	  unresponsive	  to	  either	  
BMOV	  or	  VO-­‐OH	  Pic	   treatment	   (data	  not	  shown).	  Similarly	   it	  has	  been	  argued	  that	  
due	   to	   its	  hydroxypicolinic	  acid	   scaffolding,	  VO-­‐OH	  Pic	  achieves	   selective	   inhibition	  
by	  specifically	  binding	  to	  the	  wide	  active	  site	  cleft	  of	  PTEN,	  in	  contrast	  to	  BMOV	  that	  
has	  been	  shown	   to	  deliver	  vanadate	   to	   the	  active	   site	  of	  generic	  PTPs	   (Mak	  et	  al.,	  
2010).	  However	  it	  is	  difficult	  to	  conceive	  that	  NBL	  cells	  require	  a	  ten	  fold	  higher	  dose	  
of	  VO-­‐OH	  Pic	  to	  achieve	  PTEN	  inhibition	  at	  similar	  efficacy	  to	  other	  mammalian	  cells	  
such	  as	  adipocytes/fibroblasts,	  as	  well	  as	  prostate	  cancer	  cells,	  which	  have	  all	  been	  
shown	   to	  be	   subject	   to	   PTEN	   inhibition	   after	   500nM	  VO-­‐OH	  Pic	   treatment.	   	   It	   has	  
been	  argued	   that	  VO-­‐OH	  Pic	  would	   still	   selectively	   target	  PTEN	  at	  higher	  doses	   (R.	  
Woscholski,	  personal	  communication),	  however	  it	  cannot	  be	  dismissed	  that	  here	  VO-­‐
OH	   Pic	  may	   simply	   also	   degenerate	   into	   vanadate	   and	   thus	   non-­‐selectively	   inhibit	  
PTPs.	  Thus	  in	  sum,	  PTEN	  does	  not	  appear	  to	  be	  the	  primary	  determinant	  of	  BMOV-­‐
induced	  cell	  death.	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Figure	  4.26.	  The	  PTEN	  inhibitor	  VO-­‐OH	  Pic	  induces	  cytotoxicity	  similar	  to	  BMOV,	  but	  only	  
above	   2.5µM.	   KCNR	   cells	   were	   treated	   for	   48	   hours	   with	   various	   doses	   of	   the	  
organovanadium	   compound	   BMOV	   and	   the	   selective	   PTEN	   inhibitor	   VO-­‐OH	   Pic	   and	   cell	  
death	  was	  analysed	  by	  grossly	  comparing	  morphology	  to	  that	  of	  untreated	  control	  cells.	  VO-­‐
OH	   PIC	   induced	   cytotoxicity	   more	   effectively	   than	   BMOV	   at	   a	   two	   fold	   lower	   dosage,	  
however	   this	   effect	   failed	   to	   extend	   to	   the	   nanomolar	   dosages	   at	   which	   this	   inhibitor	   is	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Figure	  4.27.	  BSO	  treatment	  fails	  to	  neither	   inactivate	  PTEN	  by	  oxidation	  nor	   increase	  Akt	  
stimulation.	   (A)	   Immunoblotting	   under	   non-­‐reducing	   conditions	   reveals	   the	   presence	   of	   a	  
lower	  band	  indicative	  of	  the	  oxidised	  form	  of	  PTEN	  following	  5-­‐minute	  stimulation	  with	  H2O2	  
(2mM)	  but	  not	  after	  24-­‐hour	  stimulation	  with	  either	  BMOV	  (10µM)	  or	  BSO	  (10µM)	  alone	  or	  
in	   combination	   in	   PTEN	   expression	   KCNR	   and	   SK-­‐N-­‐SH	   cells.	   (B)	   Immunoblot	   showing	   a	  
failure	  of	  BSO	  to	  increase	  BMOV	  stimulated	  Akt	  activation	  in	  both	  SK-­‐N-­‐SH	  and	  KCNR	  cells,	  
although	  the	  latter	  also	  failed	  to	  be	  stimulated	  by	  H2O2	  despite	  its	  ability	  to	  inactive	  PTEN.	  	  
	  
4.3.9.	   Cytotoxicity	   by	   BMOV	   is	   not	   significantly	   induced	   by	   Akt	   activation	   or	  
inhibition	  in	  BMOV-­‐resistant	  cells	  
Contrary	   to	   its	  well	   characterised	  role	  as	  a	  pro-­‐survival	   factor	   in	  a	   range	  of	  human	  
cancers,	   Akt	   has	   been	   shown	   to	   have	   an	   ‘Achilles	   heel’	   whereby	   increases	   in	   its	  
phosphorylation	  lead	  to	  downstream	  deactivation	  of	  FoxO	  transcription	  factors	  and	  
sestrin	  3	  (a	  FoxO	  target),	  resulting	  in	  reductions	  in	  the	  capability	  to	  detoxify	  cellular	  
ROS,	  thus	  leading	  to	  oxidative	  apoptosis	  (Nogueira	  et	  al.,	  2008).	  We	  have	  shown	  that	  
BMOV	  can	   induce	   increases	   in	  Akt	  phosphorylation	  and	  ROS	  production	  as	  well	   as	  
decreases	   in	   the	   levels	   of	   a	   major	   antioxidant	   GSH,	   that	   has	   a	   crucial	   role	   in	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countering	   increased	   ROS	   levels.	   	   Furthermore	   LY29	   was	   observed	   to	   amplify	   the	  
cytotoxic	   effects	   of	   BMOV	   while	   also	   increasing	   Akt	   phosphorylation	   and	   causing	  
ROS	   increases	  and	  GSH	  decreases	  alone	  and	   in	  combination	  with	  BMOV.	  Lastly	  we	  
failed	   to	   observe	   changes	   in	   Akt	   phosphorylation	   induced	   by	   BMOV	   in	   cells	   that	  
failed	  to	  undergo	  phenotypic	  changes	  (SK-­‐N-­‐AS,	  SK-­‐N-­‐DZ),	  although	  the	  former	  were	  
not	  resistant	  to	  BMOV	  mediated	  ROS	  increases.	  These	  results	  begged	  the	  question	  of	  
whether	  ROS	  and	  Akt	  played	  a	  causal,	   cooperative	   relationship	   in	  BMOV-­‐mediated	  
cytotoxicity,	   whereby	   BMOV-­‐mediated	   increases	   in	   Akt	   phosphorylation	   sensitises	  
cells	   to	   the	   toxic	   effects	   of	   ROS,	   also	   increased	   by	   BMOV,	   by	   limiting	   ROS	  
detoxification.	   Indeed	   such	   an	   effect	   has	   been	   demonstrated	   to	   result	   from	  
rapamycin-­‐mediated	   Akt	   phosphorylation	   and	   phenethyl	   isothiocyanate-­‐mediated	  
ROS	  production	  in	  ovarian	  cancer	  cells	  (Nogueira	  et	  al.,	  2008).	  	  
	   Thus	   we	   manipulated	   Akt	   activity	   in	   BMOV-­‐unresponsive	   SK-­‐N-­‐AS	   cells	   by	  
over-­‐expressing	  plasmids	  encoding	  a	  dominant	  negative	  Akt	  mutant	  (DN	  Akt),	  which	  
blocks	  Akt	   activation	  due	   to	   a	   point	  mutation	   in	   the	  ATP-­‐binding	  domain	   (K179M)	  
(Franke	   et	   al.,	   1995),	   as	   well	   as	   a	   dominant	   active	   version	   of	   Akt,	   which	   is	  
constitutively	   active	   due	   to	   the	   presence	   of	   a	   SRC	  myristoylation	   signal	   (Myr	   Akt)	  
(Kohn	   et	   al.,	   1996).	   We	   confirmed	   the	   expression	   of	   both	   plasmids	   following	  
transient	  transfection	  and	  acute	  selection	  via	  immunoblotting	  for	  HA	  (Both	  plasmids	  
were	  HA-­‐tagged),	  although	  this	  was	  considerably	  higher	  for	  Myr	  Akt	  compared	  with	  
DN	  Akt	  (Figure	  4.28).	  Furthermore	  Myr	  Akt	  caused	  highly	  significant	  increases	  in	  Akt	  
activity	  beyond	  control	  levels	  and	  relative	  to	  Akt	  protein	  levels	  (Figure	  4.28).	  	  
We	   next	   conducted	   sub-­‐G1	   analysis	   of	   apoptosis	   following	   transient	  
overexpression	  of	  DN/Myr	  Akt	  in	  SK-­‐N-­‐AS	  cells	  after	  BMOV	  treatment.	  Although	  Myr	  
Akt	  was	  found	  to	  increase	  apoptosis	  following	  BMOV	  treatment,	  this	  did	  not	  attain	  
statistical	  significance,	  in	  contrast	  to	  DN	  Akt,	  which	  actually	  enhanced	  the	  effects	  of	  
BMOV	   to	   a	   greater	   degree	   than	   Myr	   Akt	   (Figure	   4.29),	   similar	   to	   the	   effect	   of	  
combined	   BMOV/PI-­‐103	   treatment.	   However	   this	   effect	   exhibited	   high	   inter-­‐
experimental	  variability.	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Figure	   4.28.	   Immunoblotting	   for	   phosphorylated	   Akt	   and	   HA.	   SK-­‐N-­‐AS	   cells	   were	   co-­‐
transfected	  with	   either	  DN	  or	  Myr	  Akt	   and	  a	   vector	   encoding	   resistance	   to	  hygromycin	  B,	  
followed	   by	   acute	   selection	   for	   48	   hours	   in	   the	   presence	   of	   hygromycin	   (400µg/ml),	  
reseeding	  and	  24	  hour	  treatment	  with	  BMOV	  (10µM).	  	  
	  
This	   suggests	   that	  high	   levels	  of	  Akt	  activation	  are	  associated,	  but	  not	  sufficient	   to	  
sensitize	   cells	   to	   BMOV	   treatment,	   arguing	   against	   the	   hypothesis	   that	   BMOV-­‐
resistance	  is	  caused	  by	  low	  Akt	  activation.	  
	  
4.4.	  Discussion	  
PTPs	   have	   been	   shown	   to	   contribute	   to	   cell	   survival	   and	   therapeutic	   resistance	  
(MacKeigan	  et	  al.,	  2005),	  and	   individual	  PTPs	  such	  as	  DUSP26	  and	  SHP2	  have	  been	  
highlighted	   as	   potential	   oncogenes	   in	   NBL	   (Bentires-­‐Alj	   et	   al.,	   2004;	   Shang	   et	   al.,	  
2010).	  Thus	  we	  sought	  to	  test	  the	  efficacy	  of	  PTP	  inhibition	  as	  a	  means	  of	   inducing	  
selective	   apoptosis	   in	   NBL	   cells.	   In	   doing	   so	   we	   have	   shown	   that	   the	   broad	   PTP	  
inhibitor	  BMOV	  causes	   selective	  apoptosis	   in	  a	   subset	  of	  NBL	   cell	   lines.	   This	  effect	  
does	  not	  appear	  to	  involve	  either	  p53/p38	  MAPK,	  as	  we	  did	  not	  detect	  induction	  or	  
activation	   of	   these	   proteins	   respectively,	   although	   we	   did	   not	   examine	   p53	  
phosphorylation	  that	  may	  occur.	  Remarkably	  this	  effect	  is	  associated	  with	  enhanced	  
activity	  of	  Akt,	  despite	  its	  normal	  role	  in	  mediating	  cell	  survival.	  Both	  apoptosis	  and	  
Akt	   activity	   are	   dramatically	   enhanced	   by	   co-­‐treatment	   with	   LY294002	   due	   to	  
apparent	  inhibition	  of	  negative	  feedback	  regulation	  of	  PI3K/Akt.	  Furthermore	  these	  
effects	  were	  shown	  to	  result	  from	  a	  change	  in	  REDOX	  state,	  where	  BMOV	  was	  shown	  
	   214	  
to	   increase	   ROS	   and	   decrease	   the	   antioxidant	   GSH,	   while	   NAC/GSH-­‐ethyl	   ester	  
treatment	  abrogated	  apoptosis	  and	  inhibition	  of	  GSH	  synthesis	  augmented	  it.	  Lastly	  
we	   hypothesised	   that	   resistance	   to	   BMOV	   exhibited	   by	   SK-­‐N-­‐AS	   cells	  might	   result	  
from	   low	   levels	   of	   Akt	   activity,	   however	   constitutive	   activation	   of	   Akt	   failed	   to	  
effectively	   sensitize	   cells	   to	   BMOV,	   although	   it	   did	   cause	   an	   increase	   in	   BMOV-­‐
induced	  apoptosis.	  Thus	   in	  sum	  these	  data	  suggests	   that	  BMOV	   is	  able	   to	   increase	  
Akt	  activity	  and	  ROS	  production	  as	  well	  as	   target	   the	  ROS	  detoxification	  system	  to	  
cause	   ROS-­‐dependent	   apoptosis,	   showing	   that	   in	   contrast	   to	   the	  well	   known	   pro-­‐
survival	  functions	  of	  Akt,	  its	  activity	  is	  actually	  associated	  with	  cell	  death	  in	  this	  case.	  	  
	  
	  
Figure	   4.29.	   	   Overexpression	   of	   constitutively	   active	   Akt	   does	   not	   significantly	   sensitize	  
BMOV-­‐resistant	  SK-­‐N-­‐AS	  cells	  to	  apoptosis.	  Sub-­‐G1	  analysis	  of	  cells	  over-­‐expressing	  either	  
DN	  or	  Myr	  Akt	  treated	  for	  3	  days	  with	  10µM	  BMOV.	  Myr	  Akt	  failed	  to	  significantly	  sensitize	  
cells	   to	   BMOV	   treatment,	   although	   DN	   Akt	   did.	   Mean	   and	   SEM	   of	   4	   independent	  
experiments.	  	  
	  
The	  PI3K/Akt	  pathway	  is	  arguably	  the	  most	  important	  signalling	  pathway	  in	  tumour	  
initiation	  and	  maintenance,	  governing	  diverse	  roles	  from	  cell	  survival,	  proliferation,	  
migration	  and	  angiogenesis	  (Vivanco	  and	  Sawyers,	  2002).	  The	  PIK3CA	  gene	  encoding	  
the	  p110a	  catalytic	  sub-­‐unit	  of	  PI3K	  is	  a	  frequent	  target	  of	  activating-­‐mutations	  and	  
amplification	  and	  the	  negative	  regulator	  of	  Akt	  PTEN	  is	  one	  of	  the	  most	  frequently	  
mutated	   tumour	   suppressor	   genes	   identified	   to	   date	   (Salmena	   et	   al.,	   2008).	   This	  
extends	   to	   NBL	  where	   Akt	   activation	   is	   a	   negative	   prognostic	  marker	   (Opel	   et	   al.,	  
2007),	  and	  inhibition	  of	  both	  PI3K	  (Bender	  et	  al.,	  2011)	  and	  Akt	  (Li	  et	  al.,	  2010)	  have	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emergent	  efficacy	  in	  NBL	  treatment.	  While	  PI3K/Akt	  inhibition	  is	  certainly	  worthy	  of	  
consideration	  in	  NBL	  (Brodeur,	  2010;	  Li	  and	  Thiele,	  2007),	   it	   is	  not	  without	  caveats.	  	  	  	  	  	  
First,	   there	   is	   considerable	   redundancy	   between	   both	   PI3K	   isoforms	   themselves	  
(Foukas	  et	  al.,	  2010)	  and	  other	  signalling	  pathways	  such	  as	  MEK/Erk	  (Mendoza	  et	  al.,	  
2011),	   which	   can	   directly	   compensate	   for	   each	   other	   by	   the	   activation	   of	   joint	  
targets	  (She	  et	  al.,	  2010).	  In	  fact	  PI3K/Akt	  inhibition	  has	  been	  shown	  to	  directly	  result	  
in	   an	   adaptive	   response	   by	   relieving	   negative	   feedback	   suppression	   of	   oncogenic	  
RTKs	  such	  as	  HER2	  (Chandarlapaty	  et	  al.,	  2011;	  Serra	  et	  al.,	  2011).	  Thus	  as	  with	  other	  
kinase	   targets,	   therapeutic	   resistance	   as	   well	   as	   off-­‐target	   effects	   associated	   with	  
inhibition	  of	  such	  an	  integral	  pathway	  are	  obvious	  concerns	  (Zoncu	  et	  al.,	  2011).	  
	   The	  ability	  of	  an	  enzyme	  like	  Akt	  to	  regulate	  a	  diverse	  plethora	  of	  substrates	  
potentially	   exposes	   it	   to	   an	   ‘Achilles	   heel’.	   For	   instance,	   inhibition	   of	   FoxO	  
transcription	   factors,	   although	   a	   key	   pro-­‐survival	   function	   of	   Akt	   (Brunet	   et	   al.,	  
1999),	  causes	  downregulation	  of	  sestrin	  3,	   limiting	  ROS	  detoxification	  and	  resulting	  
in	  apoptosis	   (Nogueira	  et	  al.,	  2008).	  This	  suggests	  that	  targets	  negatively	  regulated	  
by	  Akt	  otherwise	  potentially	  maintain	  survival	  of	  cancer	  cells	  in	  the	  face	  of	  oxidative	  
stress	  (Naka	  et	  al.,	  2010;	  Tothova	  et	  al.,	  2007),	  often	  induced	  by	  chemo	  and	  radiation	  
therapy.	   This	   research	   highlights	   a	   potential	   strategy	   whereby	   increasing	   Akt	  
activation	   may	   actually	   hinder	   cell	   survival	   when	   accompanied	   by	   increased	   ROS	  
production.	   Indeed	   oncogenic	   transformation	   is	   accompanied	   by	   concomitant	  
increases	   in	   molecules	   mediating	   ROS	   detoxification	   (Denicola	   et	   al.,	   2011),	  
suggesting	   a	   requirement	   for	   antioxidants	   in	   the	   prevention	   of	   ROS-­‐mediated	   cell	  
death	  of	  tumour	  cells.	  	  
We	  have	  characterised	  such	  a	  dual	  function	  of	  BMOV,	  which	  through	  broadly	  
inhibiting	  PTPs	  results	  in	  enhanced	  kinase	  activity	  of	  Akt,	  while	  also	  causing	  increases	  
in	  ROS	  and	  reduced	  glutathione	  protection.	  This	  approach	  allows	  further	  modulation	  
allowing	   increased	   efficacy.	   For	   instance,	   limiting	   the	   ROS	   defence	   system	   by	  
compound	  treatment	  with	  BSO	  dramatically	  augments	  apoptosis	  induced	  by	  BMOV.	  
Similarly	   although	   commonly	  described	   as	   a	   PI3K	   inhibitor,	   by	  preventing	  negative	  
feedback	  suppression	  of	  PI3K	  through	  S6	  kinase	  inhibition	  the	  compound	  LY294002	  
increases	  the	  effects	  of	  BMOV	  on	  Akt	  activity,	  also	  enhancing	  apoptosis.	  Remarkably	  
these	   compounds	   though	   effective	   at	   inducing	   apoptosis	   in	   NBL	   cells	   show	   no	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toxicity	   against	   non-­‐neoplastic	   dividing	   cells,	   likely	   reflecting	   the	   fact	   that	   this	  
approach	   specifically	   targets	   NBL	   cells	   due	   to	   their	   sensitivity	   to	   ROS	   and	  
requirement	   for	   tightly	   regulated	  PI3K/Akt	   signalling.	  This	   latter	  point	   is	   reinforced	  
by	   the	   fact	   that	   PI3K	   inhibition	   also	   enhances	   BMOV-­‐induced	   apoptosis,	   providing	  
tentative	  evidence	  that	  NBL	  cells	  rely	  on	  a	  finely	  balanced	  or	  ‘just	  right’	  regulation	  of	  
Akt	  activity	  for	  cell	  survival,	  evidence	  for	  which	  has	  been	  demonstrated	  in	  the	  case	  
of	  Wnt	   signalling	   in	   colorectal	   cancer,	   dubbed	   the	  Goldilocks	   hypothesis	   (A.	   Clark,	  
personal	   communication).	   However	   this	   may	   also	   simply	   reflect	   entirely	   different	  
functions	   of	   Akt,	   for	   instance	   PI3K	   inhibition	   likely	   upregulates	   pro-­‐apoptotic	  
proteins	   enhancing	  most	   chemotherapeutic	   agents	   (Bender	   et	   al.,	   2011).	  We	  have	  
also	  provided	  preliminary	  evidence	  that	  BMOV	  can	  suppress	  autophagy,	  a	  putative	  
mechanism	  of	   cell	   survival	   in	   response	   to	   PI3K/mTOR	   inhibition	   (Fan	   et	   al.,	   2010),	  
providing	  one	  possible	  mechanism	  for	  enhancement	  of	  cell	  death	  by	  PI-­‐103/BMOV.	  
This	  is	  an	  interesting	  subject	  for	  further	  investigation,	  given	  the	  lack	  of	  well-­‐tolerated	  
autophagy	   inhibitors	   and	   the	   suggestion	   that	   autophagy	   inhibition	   may	   be	   an	  
effective	  form	  of	  therapy.	  	  
	   Importantly	   this	   approach	  may	   circumvent	   acquired	   therapeutic	   resistance,	  
the	  most	  common	  limitation	  of	  targeted	  therapy,	  because	  BMOV	  treatment	  actually	  
takes	   advantage	   of	   rather	   than	   working	   against	   the	   basal	   state	   of	   NBL	   cells,	   i.e.	  
having	   increased	   Akt	   activity,	   and	   instead	   exploits	   an	   Achilles	   heel.	   The	   lack	   of	   a	  
requirement	  for	  p53	  in	  BMOV-­‐induced	  apoptosis	  is	  also	  a	  useful	  feature,	  given	  that	  
p53	   often	   becomes	   mutated	   following	   chemotherapy,	   leading	   to	   relapse	   in	   NBL	  
(Carr-­‐Wilkinson	  et	  al.,	  2010).	  BMOV	  also	  targets	  a	  dependence	  on	  ROS	  homeostasis	  
exhibited	  by	  cancer	  cells,	  which	  have	  much	  higher	   levels	  of	  ROS	  and	  therefore	  rely	  
more	  heavily	  on	  antioxidant	  defences	  (Raj	  et	  al.,	  2011).	  One	  interesting	  point	  is	  that	  
CSCs,	   whose	   existence	   has	   been	   hypothesised	   to	   drive	   tumour	   recurrence	   in	   NBL	  
(Hansford	   et	   al.,	   2007),	   have	   been	   shown	   to	   rely	   more	   heavily	   on	   antioxidant	  
defences	   against	   ROS	   (Diehn	   et	   al.,	   2009)	   as	  well	   as	   FoxOs	   (Naka	   et	   al.,	   2010)	   for	  
survival,	   allowing	   us	   to	   speculate	   that	   this	   therapy	   may	   be	   particularly	   effective	  
against	  CSCs	  in	  NBL.	  	  
	   An	  obvious	  caveat	  is	  that	  this	  approach	  is	  not	  equally	  effective	  in	  all	  NBL	  cell	  
lines,	  as	  they	  exhibit	  differential	  sensitivity	  to	  BMOV.	  While	  the	  reasons	  for	  this	  need	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to	  be	  investigated	  further,	  future	  studies	  may	  elucidate	  candidate	  PTPs	  that	  could	  be	  
mediating	  therapeutic	  resistance,	  which	  may	  be	  more	  highly	  expressed	  and/or	  active	  
in	   BMOV-­‐resistant	   cells.	   Alternatively,	   this	   may	   simply	   reflect	   the	   known	  
heterogeneity	   in	   the	   molecular	   make	   up	   of	   NBL	   tumours	   and	   their	   derived	   lines,	  
whereby	  some	  tumour	  cells	  may	  rely	  on	  correct	  Akt	  and	  ROS	  regulation	  more	  than	  
others.	  	  
One	  further	  caveat	  that	  was	  briefly	  raised	  is	  that	  the	  ability	  of	  NAC/GSH-­‐ethyl	  
ester	   to	   abrogate	   the	   effects	   of	   BMOV	  may	   simply	   reflect	   the	  propensity	   of	   these	  
reducing	   agents	   to	   reduce	   oxidised	   and	   thus	   activated	   vanadium	   (V)	   TO	   (IV),	  
lowering	   its	  potency	   (with	  the	  converse	  argument	  applying	  to	  BSO).	  While	   it	   is	  not	  
possible	   to	   rule	   this	   out,	   there	   are	   a	   number	   of	   counter	   arguments.	   Firstly	   if	   BSO	  
were	   to	   increase	   oxidised	   vanadium	   increasing	   its	   potency,	   one	   would	   expect	   an	  
increase	   in	   Akt	   activation	   in	   BSO/BMOV	   treated	   cells	   versus	   BMOV	   treated	   cells	  
alone,	  which	  was	  not	  observed.	  In	  the	  same	  vein	  we	  found	  no	  evidence	  for	  toxicity	  
of	  BSO/BMOV	  on	  MEFs,	  which	  one	  would	  predict	  to	  occur	  if	  BSO	  simply	  altered	  the	  
dosage	  of	   vanadium	   (as	   toxicity	  was	   observed	  with	  BMOV	   treatment	   greater	   than	  
50µM).	  Lastly	  the	  finding	  that	  BMOV	  increases	  ROS	  and	  decreases	  GSH	  also	  provides	  
supporting	   evidence	   to	   the	   rescue	   experiments	   with	   NAC/GSH-­‐ethyl	   ester,	  
suggesting	   that	   an	   altered	   redox	   state	   is	   at	   least	   partially	   responsible	   for	   these	  
effects.	  
	  	  It	  is	  also	  noteworthy	  that	  BMOV	  causes	  increases	  in	  the	  expression	  of	  Mycn.	  
Given	   that	  Mycn	   is	   the	  best-­‐characterised	  negative	  prognostic	  marker	   in	  NBL,	   one	  
might	  expect	  that	  any	  agent	  capable	  of	  increasing	  Mycn	  levels	  might	  increase	  rather	  
than	  reduce	  cell	   survival.	  While	   it	   is	  of	  course	  possible	   that	   increases	   in	  Mycn	  may	  
play	  a	  causal	  role	  in	  apoptosis	  due	  to	  the	  well	  characterised	  effects	  of	  forced	  Mycn	  
expression	   leading	   to	   apoptosis	   in	  NBL	   cells,	  we	  detected	   little	  direct	   evidence	   for	  
this.	   It	   remains	   to	   be	   seen	   whether	   increasing	   Mycn	   in	   cells	   already	   harbouring	  
amplified	   and	   thus	   high	   level	  Mycn	   results	   in	   either	   survival	   or	   apoptosis,	   but	   this	  
could	   be	   tested	   using	   a	   knockdown	   approach.	   In	   sum	   the	   efficacy	   of	   BMOV	  
treatment	   clearly	   warrants	   further	   investigation,	   including	   preclinical	   testing,	   and	  
suggests	   that	   BMOV	   either	   alone	   or	   in	   combination	   with	   LY294002	   or	   BSO,	   may	  
represent	  an	  effective,	  novel	  therapy	  in	  NBL	  treatment.	  	  













Chapter	  5.	  The	  expression	  profile	  of	  the	  PTP	  
gene	  family	  in	  neuroblastoma	  cells	  and	  its	  














	   219	  
5.1.	  Introduction	  
Gene-­‐expression	   analysis	   has	   become	   an	   important	   tool	   in	   providing	   preliminary	  
evidence	  for	  causal	  roles	  of	  proteins	  in	  diverse	  cell	  biological	  processes.	  For	  example,	  
the	  genes	  of	  important	  proteins,	  most	  notably	  ‘house	  keeping’	  proteins	  with	  roles	  in	  
general	   homeostasis,	   are	   expressed	   at	   higher	   levels	   than	   genes	   encoding	   proteins	  
with	   a	   less	   crucial,	   or	  more	   specialised	   functions.	   Real-­‐time	   (RT)	   qPCR	   is	   the	  most	  
reliable	   method	   of	   analysing	   gene	   expression	   due	   to	   its	   sensitivity	   and	   therefore	  
ability	   to	   detect	   low	   levels	   of	   mRNA,	   as	   well	   as	   its	   capacity	   for	   high-­‐throughput	  
analysis,	   increasing	   the	   possible	   power	   of	   experiments.	   As	   changes	   in	   gene	  
expression	  are	  crucial	  to	  differences	  in	  cell	  growth,	  differentiation	  and	  survival,	  RT-­‐
qPCR	   is	   ideally	   suited	   to	   identify	   candidate	   proteins	   involved	   in	   tumorigenesis	   or	  
tumour	  maintenance	  in	  cancer.	  For	  instance	  oncogenic	  transformation	  often	  results	  
in	   increased	   expression	   of	   genes	   encoding	   receptor-­‐tyrosine	   kinases,	   leading	   to	  
increases	  in	  protein	  level	  and	  altered	  signal	  transduction	  (Blume-­‐Jensen	  and	  Hunter,	  
2001).	   While	   targets	   of	   genomic	   amplification	   such	   as	   Mycn	   will	   show	   drastic	  
changes	   in	   gene	   expression	   reflecting	   their	   importance	   in	   tumour	   cell	   survival	  
(Schweigerer	  et	  al.,	  1990).	  Similarly,	  subtypes	  of	  tumours	  can	  be	  delineated	  based	  on	  
the	  differential	  expression	  pattern	  of	  a	  gene	  set,	  as	  has	  been	  shown	  with	  TrkA	  and	  
TrkB-­‐expressing	  NBL	  tumours	  (Schulte	  et	  al.,	  2005).	  
	   As	  well	  as	  general	  changes	  associated	  with	  transformation,	  gene	  expression	  
profiling	   has	   been	   conducted	   in	   NBL	   following	   treatment	   with	   differentiation	  
induction	  agents	  such	  as	  RA	  (Yuza	  et	  al.,	  2003)	  and	  NGF	  (Oe	  et	  al.,	  2005),	  in	  order	  to	  
identify	  candidate	  proteins	  mediating	  differentiation.	  For	   instance	  the	  upregulation	  
of	   a	   given	   protein	   following	   treatment	   with	   RA	  may	   be	   causal,	   indicating	   that	   its	  
expression	   is	   required	   to	   initiate/maintain	   differentiation,	   though	   this	   requires	  
functional	   validation.	   As	   previously	  mentioned,	   for	   the	  most	   part	   PTPs	   have	   been	  
regarded	  as	  a	  tumour-­‐suppressor	  ‘enriched’	  family	  given	  their	  negative	  regulation	  of	  
oncogenic	   kinases.	   However	   such	   a	   view	   has	   become	   out-­‐dated	   given	   that	   a	  
substantial	   proportion	   of	   PTPs	   maintain	   a	   positive	   role	   in	   tumour	   initiation	   and	  
progression	  by	  regulating	  cell	  survival	  and	  therapeutic	  resistance	  (MacKeigan	  et	  al.,	  
2005).	  Furthermore,	  a	  recent	  report	  conducted	  gene-­‐expression	  profiling	  on	  PTPs	  in	  
	   220	  
association	  with	  transformation	  by	  the	  HER2	  oncogene	  in	  breast	  cancer,	  identifying	  
numerous	   alterations	   in	   PTP	   expression	   both	   positive	   and	   negative	   as	   a	   result	   of	  
HER2	  modulation	  (Lucci	  et	  al.,	  2010).	  	  
	   So	  far	   little	  research	  has	  been	  carried	  out	   into	  the	  role	  of	  PTPs	   in	  NBL.	  One	  
study	   that	   compared	   the	   expression	   of	   genes	   in	   NBL	   tumours	   to	   that	   of	   fetal	  
neuroblasts,	  the	  cell-­‐of-­‐origin	  in	  NBL,	  only	  documented	  two	  PTPs,	  PTPRD	  and	  PTPRK	  
that	   were	   differentially	   regulated.	   However,	   given	   that	   numerous	   reports	   have	  
identified	   a	   host	   of	   PTPs	   as	   having	   roles	   in	   cancer	   (Julien	   et	   al.,	   2011),	   one	  might	  
expect	  numerous	  gene	  expression	  alterations	  to	  take	  place	  between	  untransformed	  
cells	   and	   NBL	   cells.	   Thus	   as	   a	   first,	   albeit	   preliminary	   step,	   we	   sought	   to	   analyse	  
differences	   in	   PTP	   gene	   expression	   between	   normal	   nervous	   system	   tissue	   and	   a	  
range	  of	  NBL	  cell	  lines,	  to	  highlight	  potential	  oncogenes	  and	  tumour	  suppressors.	  For	  
instance,	   tumour	   suppressor	   PTPs	   could	   be	   acting	   as	   a	   barrier	   to	   tumorigenesis	  
through	   mechanisms	   such	   as	   growth	   suppression	   and	   execution	   of	   apoptosis.	  
Conversely	  other	  PTPs	  may	  be	  promoting	  tumour	  formation	  and	  progression	  e.g.	  by	  
negatively	  regulating	  tumour	  suppressive	  proteins	  or	  through	  direct	  interaction	  with	  
proteins	   involved	   in	  motility,	   proliferation	   or	   survival.	   Furthermore	   given	   that	   the	  
phenotypic	   consequences	   of	   inhibition	   of	   the	   PTP	   family	   segregates	   NBL	   cell	   lines	  
into	   neuritogenic,	   apoptotic	   and	   resistant	   groups	   (Chapters	   3-­‐4),	   we	   wished	   to	  
understand	  whether	   certain	   PTPs	  may	   be	   differentially	   expressed	  within	   each	   cell	  
group,	   highlighting	   possible	   effector	   pathways	   or	   mechanisms	   of	   therapeutic	  
resistance.	  	  
	  
5.2.	  Experimental	  procedures	  
5.2.1. qPCR	  array	  
For	   generating	   PTP	   gene	   expression	   profiles,	   we	   made	   use	   of	   a	   semi-­‐automated	  
qPCR	  platform	  generously	  made	  available	  to	  us	  by	  Dr.	  Rob	  Hooft	  van	  Huijsduijnen	  at	  
Merck-­‐Serono	   Pharmaceuticals	   AG,	   Geneva,	   Switzerland.	   This	   was	   a	   collaboration	  
within	   the	   FP6	  Network	   PTPNET.	  With	   the	   exception	  of	   the	  RNA	   isolation	   and	   the	  
final	  data	  analysis,	  Dr.	  Fanny	  Schmidt	  carried	  out	  all	  of	  the	  RT-­‐QPCR	  assays.	  384	  well	  
plates	   were	   filled	   with	   Qiagen	   primers	   for	   the	   entire	   PTP	   family	   as	   well	   as	   four	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different	  house-­‐keeping	  genes	  (HKGs)	  -­‐	  Actin,	  Canx,	  Psmb3	  and	  Hbms.	  Cross	  point	  or	  
threshold	  cycle	  values	  (Ct),	  representing	  the	  number	  of	  cycles	  required	  to	  reach	  a	  set	  
threshold	  of	  fluorescence	  intensity,	  were	  obtained	  for	  each	  sample	  by	  normalizing	  to	  
the	   average	   of	  HKGs	   using	   the	   equation	   2-­‐ΔCt,	  where	   ΔCt	   =	   Ct	   (sample)	   –	  Mean	  Ct	  
(reference	   genes).	   Ct	   values	   were	   extracted	   using	   Fast	   7900	   SDS	   2.2.2	   software	  
(Applied	  Biosystems,	  Life	  Technologies,	  Carslbad,	  CA,	  USA).	  Results	  are	  displayed	  as	  a	  
percentage	   of	   expression	   compared	   to	   the	  HKG	   set	   i.e.	  %2-­‐ΔCt,	   e.g.	   a	   value	   of	   100	  
denotes	   the	   same	   expression	   as	   the	   HGKs	   whereas	   50	   denotes	   a	   2	   fold	   lower	  
expression	  level.	  All	  RNA	  was	  isolated	  in	  triplicate	  at	  different	  time	  points,	  with	  the	  
exception	  of	  non-­‐neoplastic	  neural	  tissue	  samples	  that	  were	  a	  kind	  gift	  of	  Mr.	  Simon	  
Picker	   (adult	  cortex)	  and	  Dr.	  Francesca	  Menghi	   (Fetal	  –	  26	  weeks	  gestation/adult	  –	  
26	  years	  cerebellum),	  and	  were	  originally	  either	  isolated	  from	  primary	  biopsy	  tissue	  
or	  purchased	  commercially	   (BioChain,	  Hayward,	  CA,	  USA	  -­‐	   	  CB6	  (adult	  cerebellum),	  
No.	   R1234039-­‐50;	   CBF3	   (fetal	   cerebellum),	  No.	   R1244039-­‐50),	   respectively.	  Where	  
applicable,	  non-­‐neoplastic	  neural	  tissue	  expression	  was	  pooled,	  by	  combining	  values	  
for	  each	  tissue	  type	  (adult	  and	  fetal	  cerebellum	  and	  adult	  cortex)	  and	  expressing	  a	  
mean	   value	   for	   non-­‐neoplastic	   neural	   tissue	   overall	   (referred	   to	   as	   brain),	   to	  
generate	  a	  rough	  estimate	  of	  ‘normal’	  e.g.	  non-­‐neoplastic	  expression	  levels.	  
Although	  the	  Qiagen	  PTP	  primers	  have	  not	  been	  strictly	  normalised	  to	  each	  
other	  in	  terms	  of	  efficiency,	  they	  are	  expected	  to	  be	  similar.	  For	  example,	  research	  
by	   Viktoria	   Tchtchelnitksi	   compared	   similar	   qPCR	   data	   of	   murine	   PTPs	   against	   an	  
exon	   array	   and	   obtained	   very	   comparable,	   relative	   gene	   expression	   profiles	  
(V.Tchetchelnitski,	  UCL	  PhD	  Thesis).	  
	  
5.2.2. Statistical	  analysis	  and	  clustering	  
Clustering	  analysis	  was	  completed	  using	  MeV	  software	   (V4.7)	   in	  collaboration	  with	  
Mr	  Simon	  Picker	   (ICH,	  UCL).	  Clustering	  dendrograms	  were	  created	  by	  sub-­‐grouping	  
cell	   lines	   into	   non-­‐neoplastic	   neural	   tissue	   (adult	   cortex,	   fetal	   cerebellum,	   adult	  
cerebellum),	  glioblastoma	  (U118,	  T98G),	  unresponsive	  NBL	  (IPhNB1,	  SK-­‐N-­‐BE(2),	  SK-­‐
N-­‐AS,	   SK-­‐N-­‐DZ),	   neuritogenic	   NBL	   (SK-­‐N-­‐SH,	   SH-­‐SY5Y,	   LAN5)	   and	   apoptotic	   NBL	  
(KCNR,	   IMR32,	   Kelly).	   Between	   subjects	   student’s	   t-­‐tests	  were	   computed	   for	   each	  
comparison	  between	  NBL	  groups	  only,	  with	  a	  predetermined	  p	  value	  of	  0.05.	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5.3. Results	  
5.3.1. qPCR	  Expression	  profiling	  of	  PTPs	  in	  NBL	  cell	  lines	  
We	  previously	  hypothesised	  that	  the	  in	  line	  with	  recent	  evidence	  (Julien	  et	  al.,	  2011;	  
MacKeigan	   et	   al.,	   2005),	   the	   PTP	   family	   would	   harbour	   a	   number	   of	   genes	   either	  
crucial	   or	   detrimental	   to	   cell	   survival.	   This	   is	   a	   crucial	   question	   given	   the	   relative	  
paucity	  of	  data	  concerning	   the	   role	  of	  PTPs	   in	  NBL.	  Thus	  we	  sought	   to	  analyse	   the	  
expression	  of	  the	  entire	  PTP	  family	  in	  a	  range	  of	  NBL	  lines.	  	  
One	   main	   aim	   of	   this	   task	   was	   to	   highlight	   PTPs	   that	   are	   differentially	  
expressed	   in	   NBL	   lines,	   depending	   on	   the	   response	   profiles	   of	   the	   cells	   to	   PTP	  
inhibitors.	  For	  example,	  if	  a	  PTP	  is	  strongly	  expressed	  in	  BMOV-­‐responsive	  lines	  and	  
weakly	  in	  BMOV-­‐unresponsive	  lines,	  then	  this	  might	  provide	  initial,	  indirect	  evidence	  
for	  a	  role	  in	  the	  effects	  of	  BMOV	  treatment.	  Similarly	  this	  approach	  could	  potentially	  
rule	  out	  a	  number	  of	  PTPs	  expressed	  at	  very	  low	  levels,	  given	  that	  they	  are	  unlikely	  
to	   be	   targeted	   by	   vanadium.	   Lastly	   this	   approach	   could	   also	   generate	   hypotheses	  
concerning	   the	  wider	   role	   of	   PTPs	   in	  NBL	   tumorigenesis,	   by	   highlighting	   candidate	  
oncogenic	  and	  tumour-­‐suppressive	  PTPs	  based	  on	  expression	  profiles	  in	  comparison	  
to	  non-­‐neoplastic	  tissue.	  
	   Thus	  we	  conducted	  qPCR	  on	  triplicate	  samples	  of	  every	  original	  NBL	  cell	  line	  
(I.e.	  non-­‐isogenic)	  used	   in	   the	  present	   study,	   including	  BMOV-­‐responsive	   (SH-­‐SY5Y,	  
SK-­‐N-­‐SH,	  LAN5,	   IMR32,	  KCNR,	  Kelly)	  and	  BMOV	  unresponsive	   (SK-­‐N-­‐BE(2),	  SK-­‐N-­‐AS,	  
SK-­‐N-­‐DZ,	   IPhNB1).	   Here	   responsiveness	   was	   defined	   based	   on	   phenotypic	   criteria	  
established	   in	   chapters	   4-­‐5,	  whereby	   responsive	   cells	   undergo	   either	   apoptosis	   or	  
neuritogenesis	   following	   5-­‐10µM	   treatments	   with	   either	   BMOV	   or	   VA,	   while	  
unresponsive	   cells	   are	   phenotypically	   resistant	   at	   such	   doses.	   	   Furthermore	   as	   a	  
comparison	   against	   a	   distinct	   neural	   tumour	   type,	   cell	   lines	   derived	   from	   the	   CNS	  
solid	   tumour	   glioblastoma	   (T98G,	  U118)	  were	   included.	   This	   inclusion	  may	  help	   to	  
rule	   out	   non-­‐NBL	   specific	   PTPs	   as	   well	   as	   highlighting	   more	   general	   changes	   in	  
expression	  in	  cancer.	  Lastly	  as	  a	  comparison,	  central	  nervous	  system	  tissue	  isolated	  
from	  both	  fetal	  and	  adult	  cerebellum	  as	  well	  as	  adult	  cortex	  was	  included.	  Although	  
not	  an	  ideal	  point	  of	  comparison,	  given	  the	  sympathoblastic	  origin	  of	  NBL,	  one	  might	  
	   223	  
expect	   reduced	   expression	   for	   instance	   of	   a	   tumour-­‐suppressor	   gene	   in	   tumour	  
derived	  neuroblasts	  when	  compared	  with	  normal	  nervous	  system	  tissue.	  	  
In	  sum,	  the	  proceeding	  analysis	  has	  provided	  a	  platform	  by	  which	  to	  generate	  
hypotheses	   concerning	   the	   role	   of	   individual/sub	   groups	   of	   PTPs	   in	   NBL	  
tumorigenesis	   and	   the	   response	   to	   PTP	   inhibition,	   by	   highlighting	   differentially	  
expressed	  PTPs	  in	  sub	  groups	  of	  NBL,	  as	  well	  as	  in	  NBL	  tumours	  when	  compared	  to	  
normal	   central	   nervous	   system	   (Table/figure	   5.1).	   The	   specific	   conclusions	   of	   this	  
analysis	  and	  its	  relation	  to	  experimental	  results	  from	  chapters	  3-­‐4	  will	  be	  discussed	  
in	  the	  remainder	  of	  this	  chapter.	  	  
	  
5.3.2.	   Relative	   expression	   of	   PTPs	   in	   NBL	   compared	   with	   known	   alterations	   in	  
human	  cancer	  
In	   order	   to	   assess	   the	   general	   relevance	   of	   this	   expression	   profiling	   data	   set,	   we	  
sought	  to	  compare	  our	  analyses	  with	  known	  alterations	   in	  human	  cancer.	  Clearly	  a	  
large	   number	   of	   PTPs	   have	   been	   demonstrated	   to	   be	   involved	   in	   positive	   and	  
negative	  aspects	  of	  tumorigenesis/	  tumour	  maintenance	  (Julien	  et	  al.,	  2011;	  Ostman	  
et	  al.,	  2006),	  however	  for	  the	  most	  part	  it	  is	  unclear	  whether	  these	  PTPs	  are	  involved	  
in	   NBL	   pathogenesis.	   Similarly,	   to	   our	   knowledge	   this	   is	   the	   first	   gene	   expression	  
analysis	  of	  the	  entire	  PTP	  gene	  family	  in	  NBL	  to	  date,	  thus	  an	  indication	  of	  PTPs	  that	  
are	  significantly	  up/downregulated	  when	  compared	  with	  non-­‐neoplastic	  tissue	  may	  
at	   least	   hint	   at	   the	   involvement	   of	   novel	   PTPs.	   Firstly	   we	   sought	   to	   identify	  
potentially	  oncogenic	  PTPs	  by	   indexing	  PTPs	  that	  were	  upregulated	   in	  one	  or	  more	  
NBL	   cell	   lines	   in	   comparison	   to	   pooled	   non-­‐neoplastic	   neural	   tissue	   (adult	  
cortex/cerebellum,	   fetal	   cerebellum).	   In	   total	   we	   identified	   15	   PTPs	   that	   were	  
expressed	   more	   highly	   in	   tumour	   samples	   compared	   with	   non-­‐neoplastic	   neural	  
tissues	  (Figure	  5.2).	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Epm2a 8.35 3.89 9.81 0.49 1.34 1.06 2.02 0.88 1.58 3.18 1.35 1.97 1.15 1.71 0.84 
Ptpdc1 7.83 3.91 10.33 0.34 0.98 2.27 2.73 1.69 5.53 3.10 1.17 3.30 5.25 3.56 1.25 
Cdkn3 0.97 4.10 1.28 0.00 0.00 8.97 0.02 6.24 0.01 0.01 0.00 0.01 0.01 6.10 4.08 
Ptpmt1 19.95 23.66 37.24 0.59 0.39 7.41 0.85 
11.4
4 0.44 0.58 0.43 1.17 1.06 5.53 9.35 
Dusp2
3 9.85 15.00 14.81 0.66 1.83 4.27 0.00 0.64 0.04 5.65 3.27   0.00 0.01 0.02 
Mtm1 5.36 5.57 7.96 0.00 0.00 0.34 0.00 0.31 0.00 0.00 0.00 0.00 0.00 0.19 0.12 
Mtmr1 11.37 5.85 9.14 0.04 0.04 1.89 0.13 1.95 0.14 0.16 0.08 0.16 0.15 2.23 1.79 










4 17.59 14.66 7.50 
19.1
6 
Mtmr3 11.98 9.45 10.40 1.56 3.01 7.41 2.15 2.15 2.80 2.70 2.01 2.02 2.59 3.21 3.38 








1 20.94 26.22 22.65 
10.1
2 
Mtmr6 46.30 17.82 36.29 1.59 2.31 11.52 2.35 6.46 3.68 1.72 1.58 4.97 4.25 10.19 8.54 
Mtmr7 23.64 8.69 25.92 0.00 0.01 1.23 1.16 0.24 1.72 0.68 0.19 0.19 1.84 0.51 2.00 
Mtmr9 0.45 0.26 0.50     0.15 0.00 0.15 0.01 0.00 0.00 0.01 0.00   0.19 
Mtmr11 44.82 28.80 33.91 2.07 3.65 3.66 7.56 5.41 8.35 10.01 6.04 11.68 10.22 4.73 4.83 
Mtmr12 1.21 0.69 0.21 0.14 0.13 0.06 0.02 0.79 0.05 0.05 0.02 0.11 0.13 0.11 0.10 
Mtmr10 35.63 13.54 31.62 2.30 4.03 4.23 3.11 3.98 3.59 2.41 2.93 2.39 2.30 3.09 4.49 
Sbf1 27.28 11.05 32.22 0.31 0.78 0.60 0.60 2.23 0.98 1.19 0.95 0.98 1.11 2.05 1.62 
Sbf2 40.55 13.84 20.30 8.73 
10.2




2 19.76 14.97 6.45 
10.6
0 
Tns1 33.71 47.38 36.03 0.78 3.15 3.94 2.67 3.48 4.22 4.59 2.23 3.55 4.41 2.69 1.60 
Tns3 13.53 5.86 5.87 0.00 0.08 0.91 0.56 4.09 0.40 0.72 1.39 0.70 0.34 0.84 1.73 




2 1.65 0.25 2.70 3.62 1.32 8.89 2.95 2.66 3.11 1.82 
Cdc25a 1.44 0.33 0.45 0.51 0.13 0.01 0.02 0.89 0.00 0.02 0.59         
Cdc25
b 0.71 1.28 0.41 0.19 0.12 12.20 0.37 2.80 1.20 1.41 0.36 1.35 1.93 9.20 9.54 












2 22.46 14.91 8.92 
13.9
7 
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Ptpn1 0.07 0.41 0.03 1.92 1.47 1.46 2.35 1.98 3.62 2.08 1.22 1.15 1.94 2.99 4.10 
Ptpn2 0.10 0.07 0.17     0.10 0.00 0.06 0.00 0.00     0.00 0.07 0.05 
Ptpn6 23.64 31.05 68.58 5.80 
18.0
3 8.67 4.35 8.60 8.64 8.32 9.25 4.15 10.06 9.45 
10.1
8 
Ptpn11 2.13 0.58 1.00 0.00 0.00 0.68 0.01 0.02 0.28 0.01 0.01 0.02 0.01 0.04 3.06 










8 22.01 20.65 19.41 
20.6
2 
Ptpn12 11.91 7.58 8.79 1.29 2.73 3.40 4.94 5.00 3.78 5.87 3.43 6.99 5.71 6.33 3.98 
Ptpn22 31.75 62.73 59.49 0.33 1.83 17.46 1.63 
18.3
7 1.82 3.56 0.88 1.38 1.70 11.20 8.58 
Ptpn18 2.07 1.46 5.62 0.27 6.35 0.01 0.10 0.01 0.11 0.00 0.27 0.20 0.55 0.01 0.01 
Ptpn4 0.48 0.29 0.33 0.02 0.04 0.18 0.11 0.33 0.31 0.03 0.02 0.07 0.06 0.33 0.07 
Ptpn3 54.02 26.15 141.70 0.72 0.35 2.75 3.27 3.01 2.21 2.86 1.37 3.06 3.76 3.29 2.61 
Ptpn21 
5.5241
8 1.95736 3.10907   0.00 0.16 0.08 2.25 0.00 0.00 0.02 0.00 0.04 2.78 0.31 
Ptpn14 7.04 7.53 7.85 0.18 1.01 1.85 1.02 2.65 0.54 2.45 1.15 2.17 2.14 1.57 1.19 
Ptpn13 11.30 7.96 3.20 4.30 6.94 0.15 0.07 6.86 0.12 0.23 8.15 0.04 0.03 0.71 0.08 
Ptpn20 17.92 23.91 10.23 0.32 0.22 4.33 1.29 5.38 3.29 1.47 0.71 6.59 1.47 6.39 8.10 
Ptpn23 10.32 5.89 9.23 5.21 
13.0
7 6.24 3.96 3.52 7.43 11.81 
10.9
9 11.20 10.81 6.37 6.61 
Ptpn7 0.08 0.06 0.07       0.04   0.06     0.02       
Ptprc 9.41 1.70 6.15 0.01 0.01   0.06 
74.8
6 0.01 0.01 0.01 0.01   0.05   




6 5.20 6.14 2.54 3.19 16.98 6.63 
Ptprd 8.64 39.76 38.13 0.01 2.15 0.15 0.30 0.34 1.43 0.28 0.11 0.10 0.10 0.73 0.46 








3 24.96 23.53 27.22 
27.5
8 
Ptprk 6.77 5.13 5.52 2.48 
13.5
8 0.65 0.22 4.10 1.68 0.01 0.27   0.01 0.53 1.21 
Ptprm 27.09 47.75 22.34 0.92 3.14 0.33 0.04 1.02 0.30 0.17 0.35 1.24 0.67 0.59 1.16 
Ptprt 32.28 19.53 2.97   0.01 0.24 0.03 0.02 0.02 0.02     0.03 0.13   
Ptprq 1.70 1.11 0.8882 0.42 0.14 1.81 2.04 1.44 0.78 1.70 0.43 0.07 1.58 3.57 4.83 
Ptpro 1.29 1.18 0.20 0.00 0.01 0.02 0.01   0.03 0.00   0.00 0.06 0.01 0.09 
Ptprb 37.67 61.12 2.30 0.00 0.21 2.07 2.74 4.53 2.68 1.86 0.12 0.43 1.08 3.90 2.67 
Ptprj 9.80 3.16 14.71 0.02 0.01 0.09 0.20 0.16 0.02 0.02 0.21 0.02 0.02 0.02 0.02 
Ptprh 9.75 6.62 4.78 0.00 0.00 0.33 0.00 1.16 0.00 0.00 0.00 0.00 0.00 0.11 0.28 
Ptpra 0.27 0.05 0.17 0.24 0.58 1.17 0.28 0.32 0.62 0.07 0.06 0.16 0.59 0.01 0.68 
Ptpre 112.46 67.45 84.20 4.21 
11.4




7 18.50 8.44 13.52 14.12 16.49 
20.6
0 
Ptprg 17.07 11.74 9.69 0.11 2.82 0.18 0.83 3.06 0.01 1.57 3.03 3.81 2.31   0.10 
Ptprz1 67.60 85.79 50.08 3.38 
10.0
9 6.66 1.52 6.31 3.94 1.01 4.17 1.07 1.16 7.92 
10.7
3 
Ptprr 159.75 206.58 116.85   0.01 1.01   0.08 0.01         0.03   




9 4.08 0.66 1.62 2.75 1.84 1.60 3.47 
Ptprn 51.64 12.54 1.53 0.00 0.00 1.11 0.02 0.03 1.55 0.18 0.01 0.28 0.11 0.02   
Ptprn2 33.96 1.72 4.90 0.01 0.00 4.71 1.98 2.62 1.19 1.70 0.17 0.37 1.65 4.04 8.30 
Ptprv 58.28 14.37 6.82 0.09 0.11 4.84 2.94 0.12 3.69 3.77 0.56 1.53 1.78 2.12 1.94 
















Table	   5.1.	   Expression	   profile	   of	   PTPs	   in	   glioblastoma	   and	   NBL	   as	   well	   as	   in	   brain	   and	  
cerebellar	  tissue.	  Values	  indicate	  mRNA	  levels	  relative	  to	  the	  expression	  of	  4	  HKGs	  (%).	  Blue	  
cells	  ≥5<10;	  Green	  cells	  ≥10<20;	  Red	  cells	  ≥20.	  Missing	  values	  indicate	  an	  undetectable	  PCR	  
product	   after	   40	   cycles.	   Samples	   are	   grouped	   by	   non-­‐neoplastic	   neural	   tissue	   (adult	  
cortex/cerebellum,	   fetal	   cerebellum),	   glioblastoma	   (T98G,	   U118),	   NBL	   vanadium	  
unresponsive	   (IPhNB1,	   SK-­‐N-­‐AS,	   SK-­‐N-­‐DZ,	   SK-­‐N-­‐BE(2))	   and	  NBL	   responsive	   (SH-­‐SY5Y,	   SK-­‐N-­‐
SH,	  LAN5,	  KCNR,	  IMR32,	  Kelly),	  as	  defined	  in	  experimental	  procedures.	  	  
	  
Although	   these	   PTPs	   were	   rarely	   uniformly	   upregulated,	   this	   may	   suggest	   that	  
certain	  PTPs	  may	  be	  involved	  in	  the	  formation	  or	  survival	  of	  genetically	  distinct	  NBL	  
tumours.	   Thus	  14	  PTPs	  were	   shown	   to	  be	  overexpressed	   in	  one	  or	  more	   cell	   lines	  
versus	  brain.	  However	  excluding	  glioblastoma,	  only	  6	  PTPs	  remained	  in	  this	  data	  set,	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namely	   PTPRC,	   PTPRF,	   CDC25b,	   CDKN3,	   DUSP3	   and	   DUSP10.	   This	   provides	   a	  
relatively	   small	   number	   of	   potentially	   oncogenic	   PTPs	   suitable	   for	   further	  
investigation.	  
	   We	   reasoned	   that	   as	   well	   as	   overexpressed	   PTPs,	   genes	   that	   were	   highly	  
expressed	  in	  NBL	  cell	  lines	  regardless	  of	  non-­‐neoplastic	  neural	  tissue	  expression	  may	  
also	   harbour	   functions	   in	   NBL,	   i.e.	   reliance	   for	   cell	   survival,	   given	   that	   high	  
expression	  is	  generally	  indicative	  of	  an	  important	  function	  e.g.	  HKGs.	  Thus	  we	  sought	  
to	   examine	   PTPs	   with	   high	   expression	   levels	   (e.g.	   20%	   of	   HKGs).	   Although	   not	  
surprisingly	  this	  yielded	  a	  large	  number	  of	  PTPs,	  exclusion	  of	  PTPs	  highly	  expressed	  
in	  less	  than	  two	  cell	  lines	  yielded	  a	  much	  smaller	  group,	  containing	  PTP4A1,	  PTP4A2,	  
MTMR4,	  PTPN9,	  PTPRS,	  PTPRE	  and	  ACP1	   (Figure	  5.3).	   Thus	   such	  PTPs	  may	  also	  be	  
vital	   to	   NBL	   cells	   reflecting	   their	   broader	   expression	   in	   the	   nervous	   system.	  
Interestingly	   PTPRS,	   a	   type	   IIa	   PTP	   was	   expressed	   at	   very	   high	   levels	   uniformly	  
throughout	  NBL	  cell	  lines,	  despite	  very	  low	  expression	  of	  the	  highly	  homologous	  type	  
IIB	  PTPRD.	  
	   Lastly	  we	   sought	   to	  highlight	  possible	   tumour-­‐suppressive	  PTPs	  by	   indexing	  
PTPs	  with	  an	  expression	  value	  less	  than	  that	  of	  control	  tissue	  in	  one	  or	  more	  NBL	  cell	  
lines.	   Clearly	   this	   is	   a	   pertinent	   question	   given	   that	   as	   negative	   regulators	   of	  
oncogenic	  kinase	  signalling,	  PTPs	  were	  originally	  hypothesised	  as	  putative	  hallmark	  
tumour	   suppressors.	   However,	   the	   identification	   of	  bona	   fide	   tumour	   suppressors	  
has	  been	  less	  successful	  than	  envisaged,	  and	  no	  such	  genes	  have	  been	  identified	  in	  
NBL	  to	  date.	  We	  found	  that	  24	  PTPs	  were	  expressed	  at	  very	  low	  levels	  in	  comparison	  
to	   control	   tissue	   (Figure	  5.4),	   including	  genes	   for	  which	  a	   tumour	   suppressive	   role	  
has	  been	  demonstrated	   in	  other	  cancers	  such	  as	  PTPRD	  and	  PTPRJ	   (see	  below).	  Of	  
note	  is	  that	  two	  PTPs,	  PTPRK	  and	  PTPN18	  were	  expressed	  at	  low	  levels	  in	  NBL	  cells	  
only	  and	  thus	  excluded	  from	  this	  data	  set	  that	  included	  glioblastoma.	  However	  this	  
identification	   is	   potentially	   more	   useful	   as	   these	   genes	   may	   function	   as	   tumour	  
suppressors	  specific	  to	  NBL.	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Figure	   5.2.	   Highly	   expressed	   PTPs	   in	   NBL	   versus	   non-­‐neoplastic	   neural	   tissue.	   Graph	  
depicting	  gene	  expression	  levels	  of	  individual	  PTPs	  with	  higher	  expression	  values	  relative	  to	  
4	  HKGs	  when	  compared	  with	  pooled	  central	  nervous	  system	  tissue.	  Note	  that	  glioblastoma	  
cell	  lines	  (T98G,	  U118)	  are	  also	  shown	  as	  a	  comparison	  to	  NBL.	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Figure	  5.3.	  Highly	  expressed	  PTPs	  in	  multiple	  NBL	  cell	  lines.	  Graph	  depicting	  PTPs	  that	  are	  
expressed	  over	   a	   cut	  off	   value	  of	   20%	  of	  4	  HKGs	   in	   two	  or	  more	  NBL	   cell	   lines.	  Note	   that	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Thus	  in	  sum	  we	  have	  identified	  a	  number	  of	  PTPs	  that	  are	  differentially	  regulated	  in	  
NBL	  when	  compared	  with	  a	   reasonably	  matched	   (albeit	  non	  SA)	  comparison	  tissue	  
type.	  On	  one	  hand	  we	  have	   identified	  PTPs	   that	  are	  either	  upregulated	   in	  NBL	  cell	  
lines,	  or	  expressed	  at	  very	  high	  levels,	  suggesting	  a	  potentially	  oncogenic	  or	  at	  least	  
important	  role	   in	  NBL	  cell	  function.	  On	  the	  other	  we	  have	  shown	  that	  a	  number	  of	  
PTPs	   are	   expressed	   at	   very	   low	   levels,	   despite	   expression	   in	   the	   nervous	   system,	  
suggestive	  of	  a	  potential	  tumour	  suppressive	  function	  in	  NBL.	  Interestingly	  a	  number	  
of	  such	  genes	  have	  already	  been	  identified	  as	  being	  differentially	  expressed	  or	  even	  
functionally	   involved	   in	   other	   human	   cancers,	   and	   in	   some	   cases	   linked	   to	   the	  
regulation	  of	  signal	   transduction	  (Table	  5.2).	  This	  bolsters	  the	  suggestion	  that	  such	  
genes	   may	   be	   important	   in	   NBL	   pathogenesis,	   and	   are	   thus	   highly	   pertinent	  
candidates	  for	  functional	  analysis.	  	  
	   For	  instance	  we	  observed	  overexpression	  of	  the	  DSPs	  DUSP7,	  DUSP3,	  DUSP4	  
and	  CDKN3,	  all	  of	  which	  have	  been	  observed	  to	  be	  similarly	  overexpressed	  in	  a	  range	  
of	   other	   cancers	   (Henkens	   et	   al.,	   2008;	   Lee	   et	   al.,	   2000;	   Levy-­‐Nissenbaum	   et	   al.,	  
2003a;	  Levy-­‐Nissenbaum	  et	  al.,	  2003b;	  Wang	  et	  al.,	  2003).	  Perhaps	  of	  more	  interest	  
is	   the	   very	   high	   expression	   of	   the	   phosphatase	   of	   regenerating	   liver	   (PRL)	   family	  
genes	  PTP4A1/2,	  which	  have	  been	  shown	  by	  numerous	  groups	  to	  be	  upregulated	  in	  
a	  number	  of	  cancers,	  where	  they	  are	  thought	  to	  contribute	  to	  growth	  and	  metastasis	  
for	  instance	  by	  the	  regulation	  of	  Rho	  family	  GTPases	  (Fiordalisi	  et	  al.,	  2006;	  Peng	  et	  
al.,	   2004;	   Polato	   et	   al.,	   2005;	   Zeng	   et	   al.,	   2003).	   Studies	   have	   also	   shown	   that	  
targeting	  PRLS	  with	  inhibitors,	  RNAi	  and	  monoclonal	  antibodies	  has	  significant	  anti-­‐
cancerous	  effects	  (Guo	  et	  al.,	  2008;	  Pathak	  et	  al.,	  2002;	  Stephens	  et	  al.,	  2008).	  	  
A	  significant	  number	  of	  RPTPs	  were	  expressed	  at	  high	  or	  low	  levels	  in	  our	  NBL	  
screen.	   For	   instance,	   we	   observed	   lower	   expression	   versus	   non-­‐neoplastic	   neural	  
tissue	   of	   PTPRG	   and	   PTPRH,	   extending	   similar	   observations	   from	   other	   cancers	  
(Nagano	   et	   al.,	   2003;	   van	   Doorn	   et	   al.,	   2005).	   Of	   note	  was	   the	   low	   expression	   of	  
PTPRJ,	  a	  fairly	  well	  defined	  tumour-­‐suppressor	  (Ruivenkamp	  et	  al.,	  2002),	  which	  has	  
also	   been	   shown	   to	   directly	   interact	   with	   Erk	   as	   well	   as	   negatively	   regulating	   Akt	  
signalling	   (Omerovic	   et	   al.,	   2010;	   Sacco	   et	   al.,	   2009).	   Similarly	   low	   expression	   of	  
PTPRK	   was	   also	   observed	   in	   line	   with	   similar	   findings	   of	   mutations	   and	   loss	   of	  
heterozygosity	  (LOH)	  (Nakamura	  et	  al.,	  2003;	  Zhang	  et	  al.,	  1998).	  Low	  expression	  of	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PTPRK	  has	  also	  been	  reported	  in	  primary	  NBL	  tumours	  (De	  Preter	  et	  al.,	  2006),	  and	  is	  
clearly	   an	   interesting	   target	   for	   functional	   analyses	   given	   its	   proven	   ability	   to	  
negatively	  regulate	  β-­‐catenin	  	  (Novellino	  et	  al.,	  2008),	  which	  has	  been	  suggested	  to	  
play	  a	  role	  in	  NBL	  pathogenesis	  (Maris	  et	  al.,	  2007).	  	  
	   PTPRT	  was	  also	  expressed	  at	  low	  levels	  in	  this	  screen,	  which	  was	  one	  of	  the	  
first	  RPTPs	   to	  be	  shown	  to	  have	  a	   tumour	  suppressor	   function	   in	  colorectal	  cancer	  
(Wang	  et	  al.,	  2004),	  and	  has	  also	  been	  shown	  to	  dephosphorylate	  STAT3	  as	  well	  as	  
controlling	  cell	  adhesion	  (Yu	  et	  al.,	  2008;	  Zhang	  et	  al.,	  2007),	  suggesting	  similarity	  to	  
PTPRD	   (See	   Chapter	   3).	   One	   last	   noteworthy	   mention	   is	   the	   remarkably	   high	  
expression	  of	  PTPRS.	  As	  mentioned	  PTPRS	  is	  a	  type	  IIa	  RPTP	  from	  the	  same	  family	  as	  
PTPRD,	  both	  of	  which	  are	  generally	  expressed	  at	  similar	  levels	  and	  share	  functional	  
homology	   (Pulido	   et	   al.,	   1995).	   Although	   little	  work	   has	   been	   done	   on	   the	   role	   of	  
PTPσ	   in	  cancer,	  numerous	  studies	  hint	  at	  a	  possible	  role	   in	  NBL.	  For	   instance	  PTPσ	  
was	  shown	  to	  directly	  dephosphorylate	  receptors	  for	  the	  neurotrophins,	  suppressing	  
NGF-­‐dependent	  neurite	  outgrowth,	  a	  process	  that	  could	  be	  detrimental	  to	  NBL	  cell	  
differentiation	   (Faux	  et	  al.,	   2007).	   Similarly	  a	   recent	   study	  documented	   the	   role	  of	  
PTPσ	   in	   synaptic	   organisation	   through	   its	   interaction	   with	   TrkC	   (Takahashi	   et	   al.,	  
2011).	  Although	  not	  as	  well	  defined	  as	  TrkA/B,	  TrkC	  expression	  has	  been	  suggested	  
to	  contribute	  favourably	  to	  NBL	  prognosis	  (Brodeur	  et	  al.,	  2009),	  as	  has	  been	  shown	  
for	  breast	  cancer	  (Blasco-­‐Gutierrez,	  2007).	  Thus	  this	  RPTP	  is	  certainly	  an	  interesting	  
target	  for	  functional	  analysis.	  	  
	  












	   	   	   	  
ACP1	   High	  expression	   -­‐	   -­‐	   -­‐	  
DUSP3	   Overexpression	   Overexpression	  
(Henkens	  et	  al.,	  2008)	  
Cervical	   -­‐	  
DUSP4	   Overexpression	   Overexpression	   Breast	   -­‐	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(Wang	  et	  al.,	  2003)	  
DUSP5	   Downregulation	   -­‐	   -­‐	   -­‐	  
DUSP7	   Overexpression	   Overexpression	  
(Levy-­‐Nissenbaum	  et	  
al.,	  2003a;	  Levy-­‐
Nissenbaum	  et	  al.,	  
2003b)	  
Leukaemia	   -­‐	  
DUSP8	   Overexpression	   -­‐	   -­‐	   -­‐	  
DUSP10	   Overexpression	   -­‐	   -­‐	   -­‐	  
DUSP19	   Downregulation	   -­‐	   -­‐	   -­‐	  
DUSP22	   Downregulation	   -­‐	   -­‐	   -­‐	  
CDC14a	   Downregulation	   -­‐	   -­‐	   -­‐	  
CDKN3	   Overexpression	   Overexpression	  (Lee	  
et	  al.,	  2000)	  






EPM2a	   Downregulation	   -­‐	   -­‐	   -­‐	  
MTM1	   Downregulation	   -­‐	   -­‐	   -­‐	  
MTMR1	   Downregulation	   -­‐	   -­‐	   -­‐	  
MTMR4	   High	  expression	   -­‐	   -­‐	   -­‐	  
MTMR7	   Downregulation	   -­‐	   -­‐	   -­‐	  
MTMR10	   Downregulation	   -­‐	   -­‐	   -­‐	  
PTP4A1	   High	  expression	   Overexpression	  
(Stephens	  et	  al.,	  
2008)	  
Overexpression	  and	  




al	  and	  CRC	  
p130CAS	  cleavage,	  
Rho	  GTPase	  
activation	  and	  Akt	  
signalling	  (Daouti	  
et	  al.,	  2008),	  (Zeng	  
et	  al.,	  2003),	  
(Stephens	  et	  al.,	  
2008)	  
	  
PTP4A2	   High	  expression	   Overexpression	  




Akt	  and	  Erk	  
signalling	  
(Stephens	  et	  al.,	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Overexpression	  and	  
association	  with	  
metastasis	  (Zeng	  et	  
al.,	  2003)	  
2008)	  
SBF1	   Downregulation	   -­‐	   -­‐	   -­‐	  
TNS1	   Downregulation	   -­‐	   -­‐	   -­‐	  
TNS3	   Downregulation	   -­‐	   -­‐	   -­‐	  
Non-­‐receptor	  
PTPs	  
	   	   	   	  
PTPN9	   High	  expression	   -­‐	   -­‐	   -­‐	  
PTPN3	   Downregulation	   Overexpression	  (Wu	  
et	  al.,	  2006)	  
Gastric	   -­‐	  
PTPN14	   Downregulation	   Somatic	  mutation	  





PTPN18	   Downregulation	   Aberrant	  splicing	  
(Guimarães	  et	  al.,	  
2006)	  
Thyroid	   -­‐	  
PTPN23	   Overexpression	   -­‐	   -­‐	   -­‐	  
Receptor	  PTPs	   	   	   	   	  
PTPRB	   Downregulation	   Overexpression	  
(Foehr	  et	  al.,	  2006;	  
Goldmann	  et	  al.,	  





PTPRC	   Overexpression	   -­‐	   -­‐	   -­‐	  
PTPRD	   Downregulation	   Methylation,	  somatic	  
mutation	  and	  
microdeletion	  of	  
5’UTR	  (Veeriah	  et	  al.,	  
2009),	  (Solomon	  et	  







(Veeriah	  et	  al.,	  
2009)	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al.,	  2008)	  




PTPRG	   Downregulation	   Somatic	  mutation,	  
methylation	  and	  LOH	  
(Cheung	  et	  al.,	  2008;	  
Wang	  et	  al.,	  2004)	  
Downregulation	  (Liu	  
et	  al.,	  2002;	  van	  
Niekerk	  and	  Poels,	  
1999;	  Vezzalini	  et	  al.,	  
2007)	  
Methylation	  (van	  
Doorn	  et	  al.,	  2005;	  











PTPRH	   Downregulation	   Downregulation	  
(Nagano	  et	  al.,	  2003)	  
Liver	   -­‐	  
PTPRJ	   Downregulation	   LOH	  and	  missense	  
mutation	  
(Ruivenkamp	  et	  al.,	  
2002)	  
	  SNP	  and	  LOH	  
(Ruivenkamp	  et	  al.,	  
2002),	  SNP	  (Iuliano	  











(Kovalenko	  et	  al.,	  
2000;	  Sacco	  et	  al.,	  
2009;	  Tarcic	  et	  al.,	  
2009)	  
PTPRK	   Downregulation	   Downregulation	  
(McArdle	  et	  al.,	  
2001;	  Zhang	  et	  al.,	  
1998)	  







(Novellino	  et	  al.,	  
2008)	  
	   236	  
PTPRM	   Downregulation	   Downregulation	  
(Burgoyne	  et	  al.,	  







et	  al.,	  2002)	  
PTPRN	   Downregulation	   -­‐	   -­‐	   -­‐	  
PTPRR	   Downregulation	   -­‐	   -­‐	   -­‐	  
PTPRS	   High	  expression	   Somatic	  mutation	  
(Korff	  et	  al.,	  2008)	  
CRC	   EGFR	  signalling	  
	  
PTPRT	   Downregulation	   Somatic	  mutation	  




EGFR,	  paxillin	  and	  
STAT3	  signalling	  
(Zhang	  et	  al.,	  2007;	  
Zhao	  et	  al.,	  2010)	  
PTPRV	   Downregulation	   -­‐	   -­‐	   -­‐	  
Class	  III	  
phosphatases	  
	   	   	   	  
CDC25b	   Upregulation	   -­‐	   -­‐	   -­‐	  
CDC25c	   Upregulation	   -­‐	   -­‐	   -­‐	  
	  
Table	  5.2.	  Expression	  alteration	  of	  PTPs	  in	  NBL	  qPCR	  screen	  and	  their	  relation	  to	  published	  
alterations/functional	  analyses	  in	  other	  cancers.	  Table	  documents	  the	  findings	  of	  the	  qPCR	  
PTP	  screen,	  where	  applicable	  studies	  have	  been	  referenced	  documenting	  evidence	  of	  gene	  
involvement	  in	  other	  cancer	  types.	  Expression	  levels	  are	  in	  comparison	  to	  CNS	  neural	  tissue,	  
where	  high	  expression	  indicates	  that	  both	  NBL	  and	  non-­‐neoplastic	  neural	  tissue	  expressed	  a	  
given	   gene	   at	   similar	   levels,	   whereas	   overexpression	   (and	   conversely	   downregulation)	  
denotes	  a	  difference	  between	  NBL	  and	  non-­‐neoplastic	  neural	   tissue,	  although	   it	   should	  be	  
noted	  that	  CNS	  tissue	  is	  distinct	  from	  SNS	  tissue	  (from	  which	  NBL	  is	  derived).	  Where	  known,	  
an	   indication	  of	  possible	  molecular	  events	  concerning	  tumour	   function	  has	  been	  specified.	  
LOH	  –	  loss	  of	  heterozygosity.	  CRC	  -­‐	  Colorectal	  cancer.	  For	  further	  discussion	  see	  (Julien	  et	  al.,	  
2011).	  
	  
In	  sum	  a	  number	  of	  PTPs	  have	  been	  shown	  to	  be	  highly	  expressed,	  upregulated	  and	  
downregulated	  in	  NBL	  in	  comparison	  to	  normal	  tissue.	  A	  number	  of	  such	  expression	  
alterations	   agree	   with	   published	   data	   concerning	   the	   expression	   of	   PTPs	   in	   other	  
human	   cancers.	   Furthermore	   a	   number	   of	   PTPs	   with	   roles	   in	   relevant	   biological	  
processes	  such	  as	  regulation	  of	  motility,	  adhesion	  and	  signal	  transduction	  have	  been	  
documented	  as	  functionally	   involved	  in	  cancer	  suppression/formation,	  allowing	  the	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generation	  of	  hypotheses	  concerning	  functionality	   in	  NBL.	  As	  well	  as	  extending	  the	  
findings	  of	  the	  known	  cancer	  phosphatome,	  the	  expression	  of	  PTPs	  whose	  function	  
in	   cancer	   is	   currently	   unknown	   was	   also	   altered,	   hinting	   at	   further	   targets	   for	  
exploration	  in	  NBL.	  	  
	  
5.3.2. Clustering	  analysis	  
We	  previously	  documented	  stark	  differences	  in	  the	  responsiveness	  of	  NBL	  cell	   lines	  
to	   PTP	   inhibition	   using	   BMOV/VA	   (See	   chapters	   4-­‐5).	   We	   wished	   to	   understand	  
whether	   these	   differences	   might	   reflect	   actual	   expression	   levels	   of	   a	   particular	  
subset	   of/individual	   PTPs,	   whereby	   comparatively	   high	   expression	   PTPs	   whose	  
inhibition	   is	   required	   for	   BMOV/VA	   responsiveness	   may	   confer	   resistance	   to	   the	  
effects	   of	   these	   compounds.	   Although	   the	   converse	   argument	   may	   also	   apply	  
whereby	  high	  expression	  of	  PTPs	  may	  confer	  sensitivity,	  given	  that	  cells	  may	  rely	  on	  
that	  high	  expression	  for	  survival/maintenance	  of	  an	  undifferentiated	  state.	  Thus	  we	  
sought	  to	  conduct	  an	  unbiased	  clustering	  analysis	  based	  on	  our	  expression	  profile	  of	  
92	  PTPs,	  grouping	  cell	   lines	   that	  were	  either	  unresponsive	   to	  BMOV,	  or	   those	   that	  
responded	   to	   BMOV	   by	   either	   undergoing	   neuritogenesis	   or	   apoptosis,	   as	   well	   as	  
non-­‐neoplastic	  neural	  tissue	  and	  glioblastoma	  cells	  (GBM).	  	  
	   As	   expected	  we	   observed	   strong	   clustering	   of	   non-­‐neoplastic	   neural	   tissue	  
(group	   1,	   light	   green	   bar)	   compared	  with	   all	   tumour	   lines,	   as	  well	   as	   clustering	   of	  
GBM	   lines	   (group	  2,	   blue	  bar)	   versus	  NBL	   lines,	   although	   this	  was	  not	   as	  dramatic	  
(Figure	  5.5).	   Interestingly	  we	  did	  observe	  weak	  clustering	  of	  neuritogenic	  NBL	   lines	  
(group	   4,	   yellow	  bar).	   However	   clustering	  was	   not	   particularly	   observed	   for	   either	  
unresponsive	  NBL	  lines	  (group	  3,	  red	  bar)	  or	  apoptotic	  NBL	  lines	  (group	  5,	  dark	  green	  
bar),	   which	   did	   not	   form	   unified	   subgroups.	   In	   fact	   half	   of	   the	   unresponsive	   NBL	  
group	  segmented	  on	  the	  BMOV-­‐responsive	  half	  of	  the	  dendrogram,	  at	  the	  opposite	  
end	   to	   Non-­‐neoplastic	   neural	   tissue/GBM	   cells,	   suggesting	   little	   deviation	   in	   their	  
expression	  pattern	  compared	  with	  responsive	  cells.	  	  
Given	  that	  the	  extent	  of	  our	  qPCR	  profile	  was	  confined	  to	  only	  92	  genes,	  i.e.	  
the	  PTP	  family	  only,	  which	  comprise	  a	  broad	  range	  of	  functions	  and	  substrates,	  we	  
reasoned	   that	   this	   analysis	   was	   unlikely	   to	   reveal	   large	   differences	   between	   the	  
entire	  PTP	  family	  within	  NBL	  cell	  lines,	  which	  share	  similar	  lineages.	  Thus	  we	  sought	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to	  conduct	  a	  an	  unbiased	  statistical	  analysis	  comparing	  individual	  sub	  groups	  of	  NBL	  
cells	   in	  order	  to	   identify	   individual	  PTPs	  whose	  differential	  expression	  might	  reflect	  
differences	  in	  the	  responsiveness	  of	  cells	  to	  PTP	  inhibition.	  	  
Indeed	   between	   subjects	   t-­‐tests	   revealed	   a	   small	   number	   of	   genes	   whose	  
expression	   was	   significantly	   different	   in	   BMOV-­‐unresponsive,	   BMOV-­‐Neuritogenic	  
and	  BMOV-­‐Apoptotic	  cell	  lines	  (Figure	  5.6).	  An	  overall	  comparison	  between	  BMOV-­‐
unresponsive	   cells	   (SK-­‐N-­‐AS,	   SK-­‐N-­‐DZ,	   IPhNB1,	   SK-­‐N-­‐BE(2))	   and	   BMOV-­‐responsive	  
cells	  (SH-­‐SY5Y,	  SK-­‐N-­‐SH,	  LAN5,	  IMR32,	  Kelly,	  KCNR)	  revealed	  a	  statistically	  significant	  
difference	   in	   the	  expression	  of	   3	   genes	   (3%).	   Specifically	  PTPN5	   and	  DUSP26	  were	  
expressed	  at	  higher	  levels	  in	  unresponsive	  cells	  versus	  responsive	  cells	  (p=0.035	  and	  
0.019	  respectively),	  while	  PTPN23	  had	  the	  opposite	  profile	  (p=0.017)	  (Figure	  5.6A).	  	  
A	   comparison	   between	   unresponsive	   cells	   and	   neuritogenic	   cells	   revealed	  
differences	  in	  the	  overall	  expression	  of	  7	  genes	  (8%).	  Specifically	  DUSP19	  (p=0.042),	  
PTP4A3	   (p=0.017),	  MTMR10	   (p=0.019)	   and	  PTPRB	   (p=0.043)	  were	   all	   expressed	   at	  
higher	   levels	   in	   BMOV-­‐unresponsive	   cells	   versus	   those	   that	   undergo	   neurite	  
extension	   in	  response	  to	  BMOV,	  while	  PTPN23	  (p=0.008)	  and	  PTPRO	   (p<0.001)	  had	  
the	   opposite	   profile	   (Figure	   5.6B).	   	   The	   same	   comparison	   between	   unresponsive	  
cells	   and	   those	   that	   undergo	   apoptosis	   in	   response	   to	   BMOV	   failed	   to	   yield	   any	  
genes	   that	   were	   differentially	   expressed	   at	   a	   statistically	   significant	   level.	   	   Lastly	  
BMOV-­‐neuritogenic	  and	  BMOV-­‐apoptotic	  groups	  showed	  differential	  expression	  of	  3	  
genes	  (3%),	  namely	  DUSP7	  (p=0.019)	  and	  PTPRO	  (P=0.03),	  which	  were	  expressed	  at	  
higher	  levels	  in	  the	  latter	  group,	  and	  SSH1	  (P=<0.001)	  that	  had	  the	  opposite	  profile	  
(Figure	  5.6C).	  	  
	  
5.4.	  Discussion	  
Gene	  expression	  analysis	   is	  an	   important	  tool	   in	  elucidating	  underlying	  effectors	  of	  
tumorigenesis	   and	   the	   mechanism	   of	   action	   of	   targeted	   therapy.	   So	   far	   little	  
research	  has	  been	  done	  on	  the	  role	  of	  the	  phosphatome	  in	  NBL	  tumours,	  and	  while	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Figure	  5.5.	  Clustering	  dendrogram	  of	  qPCR	  expression	  from	  92	  PTP	  genes.	  Strong	  clustering	  
was	  observed	   for	  non-­‐neoplastic	  neural	   tissue	  cells,	  however	  NBL	  cells	   failed	   to	  cluster	  on	  
the	   basis	   of	   their	   responsiveness	   to	   BMOV.	   Cell	   lines	   grouped	   as	   either	   unresponsive	   to	  
BMOV	  (BMOV-­‐UNR),	  or	  those	  that	  responded	  to	  BMOV	  by	  either	  undergoing	  neuritogenesis	  
(BMOV-­‐Neu)	  or	  apoptosis	  (BMOV-­‐apo),	  as	  well	  as	  non-­‐neoplastic	  neural	  tissue	  (control)	  and	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the	   present	   study	   has	   broadly	   demonstrated	   a	   role	   for	   PTPs	   in	   suppressing	  
differentiation	  and	  promoting	  cell	  survival	  via	  non-­‐specific	  PTP	  inhibition,	  the	  actual	  
drivers	  of	  these	  effects	  remain	  unknown.	  Thus	  we	  have	  conducted	  qPCR	  analysis	  of	  
gene	  expression	  of	   the	  whole	  PTP	  gene	  family	   in	  multiple	  NBL	  cell	   lines,	  as	  well	  as	  
comparison	  groups	  of	  an	  alternative	  neural	  tumour	  glioblastoma,	  and	  non-­‐neoplastic	  
neural	   tissue.	   Although	   the	   analysis	   of	   this	   sample	   set	   has	   been	   fairly	   limited,	   a	  
number	   of	   interesting	   points	   can	   be	   drawn	   from	   this	   data	   set.	   Firstly	   several	  
candidate	  tumour	  suppressors	  have	  been	  highlighted	  in	  both	  NBL	  and	  glioblastoma.	  
This	   is	   based	   on	   stark	   differences	   between	   expression	   of	   certain	   PTPs	   in	   non-­‐
neoplastic	   and	   tumour	   cells.	   Interestingly	   several	   of	   these	   PTPs	   such	   as	   PTPRT,	  
PTPRG,	   PTPN3	   and	   PTPN13	   (Wang	   et	   al.,	   2004)	   and	   PTPRH	   (Keane	   et	   al.,	   1996),	  
function	  as	  tumour	  suppressors	   in	  other	  cancers,	  but	  have	  not	  been	  the	  subject	  of	  
functional	  studies	   in	  NBL.	  Overexpression	  studies,	  which	  would	  be	  relatively	  simple	  
to	  carry	  out,	  might	  reveal	  a	  growth	   inhibitory	  or	  apoptosis-­‐promoting	  role	  for	  such	  
PTPs,	  as	  well	  as	  highlighting	  unknown	  substrates	  whose	  activity	  would	  be	  increased	  
by	  the	  loss	  of	  such	  tumour	  suppressors.	  	  
At	  the	  opposite	  end	  of	  the	  spectrum,	  several	  PTPs	  are	  very	  highly	  expressed	  
in	  comparison	  to	  the	  candidate	  tumour-­‐suppressive	  PTPs,	  as	  well	  as	  to	  levels	  seen	  in	  
non-­‐neoplastic	   neural	   cells.	   Follow-­‐up	   studies	   from	   this	   gene	   set	   could	   potentially	  
highlight	  PTP	  oncogenes,	  of	  which	  very	  few	  have	  been	  identified	  to	  date,	  especially	  
in	  NBL.	  This	  is	  based	  on	  the	  hypothesis	  that	  genes	  that	  are	  very	  highly	  expressed	  in	  
tumour	  cells	  are	  often	  crucial	  for	  the	  maintenance	  of	  cell	  survival	  or	  the	  suppression	  
of	  differentiation.	   This	   is	   especially	   so	   for	  enzymes	   involved	   in	   signal	   transduction,	  
which	   is	   likely	   to	   remain	  at	   steady-­‐state	  equilibrium	   following	  neurogenesis.	  Given	  
the	   crucial	   involvement	  and	  high	  expression	  of	  PTPs	   in	  general	  within	   the	  nervous	  
system	   (Paul	  and	  Lombroso,	  2003),	   it	   is	   curious	   that	   certain	  PTPs	  are	  expressed	  at	  
even	  higher	   levels	   in	  neural	   tumour	   cells.	   In	   some	  cases	   these	  genes	  have	  already	  
been	  demonstrated	  to	  play	  functional	  roles	  in	  cancer,	  such	  as	  the	  PRL	  phosphatases.	  
Two	  of	  these,	  PRL1	  and	  PRL2,	  were	  very	  highly	  expressed,	  albeit	  at	  lower	  levels	  than	  
non-­‐neoplastic	  neural	  tissue,	  and	  have	  been	  shown	  to	  contribute	  towards	  metastatic	  
spread	  and	  survival	   signalling	  via	  Akt	   regulation	   (Stephens	  et	  al.,	  2008;	  Zeng	  et	  al.,	  
2003).	   Another	   interesting	   target	   is	  PTPRS,	   which	  was	   very	   highly	   expressed	   in	   all	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NBL	   cell	   lines,	   despite	   expression	   of	   type-­‐IIa	   family	   members	   PTPRF	   and	   PTPRD,	  
which	  have	  high	  homology	  and	  similar	  functions	  (Pulido	  et	  al.,	  1995),	  being	  low	  and	  
very	  low,	  respectively.	  Of	  particular	  interest	  is	  the	  fact	  that	  PTPσ	  has	  recently	  been	  
shown	   to	   interact	   with	   TrkC	   (Takahashi	   et	   al.,	   2011),	   itself	   highly	   expressed	   in	  
favourable	  NBL	   tumours	  and	  with	  a	  putative	   role	   in	  differentiation	   (Brodeur	  et	  al.,	  
1997;	  Edsjo	  et	  al.,	  2001).	  	  
	  	   Thus	   these	   genes	   provide	   targets	   for	   follow	   up	   studies,	   such	   as	   siRNA	  
knockdown	   experiments,	  which	   could	   potentially	   demonstrate	   a	   driver	   function	   in	  
NBL	   tumour	   formation/maintenance.	   Of	   note	   is	   that	   the	   dual-­‐specificity	  
phosphatases	  (DUSPs)	  are	  particularly	  enriched	  in	  this	  group,	  e.g.	  Dusp4,	  7,	  10,	  8	  and	  
3.	   DUSPs	   are	   considered	   promising	   candidates	   as	   cancer	   targets	   (Pulido	   and	   van	  
Huijsduijnen,	  2008a),	  and	  one	  such	  enzyme	  DUSP26	  has	  been	  shown	  to	  function	  as	  a	  
cancer	   promoting	   PTP	   in	   NBL	   (Shang	   et	   al.,	   2010).	   A	   possible	   oncogenic	   role	   of	  
several	   DUSPs	   has	   also	   recently	   been	   demonstrated	   by	   genome-­‐wide-­‐association	  
studies	  (J.	  Maris,	  personal	  communication).	  	  
In	   terms	   of	   the	   second	   question	   addressed,	   i.e.	   whether	   the	   response	   to	  
BMOV/VA	  could	  delineate	  NBL	  cell	   lines,	   this	  analysis	  has	  not	  provided	  a	  definitive	  
answer	  or	  hint	  at	  the	  underlying	  functional	  targets	  of	  inhibition.	  While	  we	  were	  able	  
to	  perform	  clustering	  analysis,	  NBL	  sub	  groups	  i.e.	  those	  responding	  to	  PTP	  inhibition	  
by	   undergoing	   neurite-­‐outgrowth,	   apoptosis	   or	   not	   bearing	   any	   response	   did	   not	  
cluster	  based	  on	   the	  any	  one	  subset	  of	   the	  PTP	   family.	  This	   is	  not	   surprising	  given	  
that	  a	  host	  of	  genes	  beyond	  PTPs	  are	  likely	  involved	  in	  these	  mechanisms.	  However	  
it	  is	  certainly	  interesting	  that	  a	  small	  number	  of	  PTPs	  have	  a	  statistically	  significantly	  
different	   expression	   pattern	   between	   BMOV-­‐phenotype	   subgroups.	   For	   instance,	  
DUSP26	   was	   expressed	   at	   higher	   levels	   on	   average	   in	   BMOV-­‐unresponsive	   cells	  
versus	   responsive	   cells.	   This	   is	   certainly	   noteworthy	   given	   that	   this	   dual-­‐specificity	  
phosphatase	  is	  the	  only	  PTP	  that	  has	  been	  shown	  to	  have	  a	  functional	  oncogenic	  role	  
in	  NBL,	  acting	  as	  a	  p53	  phosphatase	  and	  causing	  chemoresistance	  in	  NBL	  cells	  (Shang	  
et	   al.,	   2010).	   Although	   we	   found	   little	   evidence	   of	   p53-­‐dependence	   in	   BMOV-­‐
induced	  apoptosis	  (See	  chapter	  4),	  this	  gene	  would	  still	  be	  an	  interesting	  candidate	  
for	   further	   investigation.	   PTPN23	   was	   found	   to	   be	   expressed	   at	   two-­‐fold	   higher	  
levels	  in	  cell	  lines	  that	  respond	  to	  BMOV	  by	  undergoing	  neurite	  extension	  compared	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with	   unresponsive	   cells,	   possibly	   hinting	   at	   an	   involvement	   of	   this	   PTP	   in	   neurite	  
extension,	  i.e.	  conferring	  resistance	  when	  highly	  expressed.	  
	  
Figure	   5.6.	   Significantly	   differential	   expression	   of	   PTPs.	   Graphs	   showing	   means	   and	  
standard	   deviation	   of	   genes	   exhibiting	   statistically	   significant	   expression	   between	   BMOV-­‐
unresponsive	   versus	   BMOV-­‐responsive	   cells	   (A),	   BMOV-­‐unresponsive	   and	   BMOV-­‐
neuritogenic	  cells	  (B)	  and	  BMOV-­‐neuritogenic	  and	  BMOV-­‐apoptotic	  cells	  (C).	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This	   gene	   was	   also	   expressed	   at	   high	   levels	   in	   NBL	   cells	   compared	   with	   non-­‐
neoplastic	   neural	   tissue,	   making	   it	   another	   candidate	   for	   further	   investigation.	  
PTP4A3	  was	  another	  gene	  differentially	  expressed	  between	  these	  two	  subgroups,	  in	  
the	   opposite	   manner,	   representing	   an	   interesting	   candidate	   in	   mediating	   BMOV-­‐
resistance	  given	  that	  this	  PTP	  is	  heavily	  implicated	  in	  pro-­‐cancer	  functions	  (Kim	  et	  al.,	  
2004;	  Polato	  et	  al.,	  2005;	  Zeng	  et	  al.,	  2003).	  Lastly	  SSH1	  exhibited	  a	  remarkably	  low	  
expression	   in	   cells	   that	   respond	   to	   BMOV	   by	   undergoing	   apoptosis	   versus	  
neuritogenesis,	   making	   it	   an	   interesting	   candidate	   in	   explaining	   this	   difference	   in	  
phenotypic	  response.	  	  
	   This	  analysis	  is	  certainly	  not	  without	  caveats	  however.	  For	  instance	  significant	  
differences	  may	   in	  some	  cases	  be	  artefacts	  of	   low	  standard	  deviation	  observed	  for	  
PTPs	  expressed	  at	  very	   low	   levels,	  e.g.	  PTPRO,	  where	  differences	   in	  expression	  are	  
unlikely	   to	   be	   of	   consequence	   given	   that	   overall	   expression	   is	   very	   low.	   It	   is	   also	  
entirely	  subject	  to	  speculation	  whether	  differences	  of	   less	  that	  1	  fold	   in	  expression	  
(observed	   for	   the	   majority	   of	   statistically	   significant	   comparisons),	   would	   have	   a	  
noticeable	   effect	   on	   responsiveness	   to	   PTP	   inhibition.	   Furthermore	   differential	  
sensitivity	  may	  not	   simply	  be	  a	   function	  of	  differential	   gene	  or	  protein	  expression,	  
for	  example	  KCNR	  cells	  and	  SH-­‐SY5Y	  cells	  both	  respond	  to	  PTP	  inhibition	  in	  a	  similar	  
biochemical	   manner	   but	   leading	   to	   highly	   different	   phenotypic	   consequences,	  
presumably	  reflecting	  differences	  in	  their	  underlying	  molecular	  make-­‐up.	  Similarly	  it	  
is	  not	  well	  understood	  how	  broad	  PTP	   inhibitors	  may	  differently	   inhibit	  PTP	   family	  
members,	  for	  instance	  one	  PTP	  may	  be	  highly	  expressed	  while	  another	  expressed	  at	  
lower	   levels,	   but	   the	   latter	  may	   actually	   be	  more	   effectively	   inhibited	   due	   to	   that	  
lower	  level	  of	  expression,	  or	  even	  a	  higher	  sensitivity	  to	  the	  inhibitor.	  Another	  caveat	  
is	   the	   lack	  of	  uniformity	  within	  subgroups	  of	  NBL	   lines,	   for	  example	  KCNR	  cells	  are	  
more	   sensitive	   to	   BMOV	   than	   LAN-­‐5	   cells,	   though	   both	   have	   an	   apoptotic	  
component	   of	   cells	   following	   treatment.	   Furthermore	   the	   latter	   cell	   line	   also	  
undergoes	  neuritogenesis	  following	  BMOV	  treatment,	  further	  complicating	  matters.	  
Thus	  it	  may	  be	  necessary	  to	  expand	  this	  data	  set	  by	  testing	  an	  even	  greater	  number	  
of	  cell	  lines	  and	  thus	  increasing	  the	  sample	  size	  and	  power	  of	  statistical	  comparisons.	  
However	   at	   the	   very	   least	   this	   analysis	   has	   provided	   some	   putative	   targets	   for	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knockdown	  experiments	  and	  specific	  inhibitors,	  which	  may	  provide	  a	  more	  definitive	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As	   a	   diverse	   group	   of	   enzymes	   with	   the	   capacity	   for	   the	   regulation	   of	   cell	  
differentiation,	  survival	  and	  proliferation,	  PTPs	  are	  an	  emergent	  source	  of	  targets	  for	  
investigation	  into	  the	  pathogenesis,	  maintenance,	  and	  treatment	  of	  cancer	  (Julien	  et	  
al.,	  2011;	  Ostman	  et	  al.,	  2006).	  Despite	  the	  fact	  that	  NBL	  has	  been	  classified	  as	  the	  
most	  common	  and	  deadly	  solid	  tumour	  of	   infancy,	   initiating	  much	  research	   into	   its	  
underlying	  causes	  and	   targets	   for	   intervention	   (Brodeur,	  2003;	   Janoueix-­‐Lerosey	  et	  
al.,	  2010;	  Maris,	  2010;	  Maris	  et	  al.,	  2007),	  very	  few	  bona	  fide	  oncogenes	  and	  tumour	  
suppressors	   with	   a	   driving	   role	   in	   oncogenesis/tumour	   maintenance	   have	   been	  
identified.	   Thus	   as	   an	   untapped	   source	   of	   such	   agents,	  we	   sought	   to	   examine	   the	  
role	  of	  PTPs	  in	  this	  cancer	  focussing	  primarily	  on	  the	  capacity	  of	  PTPs	  to	  potentially	  
suppress	  differentiation	  and	  apoptosis,	  thus	  providing	  therapeutic	  targets.	  	  
	   To	  précis	  this	  investigation,	  we	  have	  shown	  that	  PTPs	  in	  general	  harbour	  the	  
capacity	  to	  suppress	  both	  differentiation	  and	  apoptosis,	  revealing	  that	  use	  of	  broad	  
PTP	   inhibitors	   is	   a	   potentially	   viable	   therapeutic	   intervention.	   When	   used	   in	  
combination	  with	   an	   established	   differentiation-­‐induction	   agent	   RA,	   PTP	   inhibitors	  
can	  cause	   irreversible	  senescence,	  while	  when	  used	  as	  single	  agents	  PTP	   inhibitors	  
can	  cause	  potent	  but	  selective	  apoptosis	   in	  a	  significant	  number	  of	  tumour-­‐derived	  
cell	  lines.	  Furthermore,	  we	  have	  sought	  to	  examine	  the	  molecular	  underpinnings	  of	  
these	   effects,	   finding	   that	   the	   capacity	   of	   PTP	   inhibitors	   to	   relieve	   suppression	   of	  
RTK-­‐driven	  signalling	  pathways	  actually	  appears	  beneficial	  in	  mediating	  the	  effects	  of	  
senescence	   and	   apoptosis,	   causing	   strong	   and	   sustained	   activation	   of	   PI3K/Akt	  
signalling	  when	  combined	  with	  RA,	  and	  lower	  level	  activation	  of	  PI3K/Akt	  signalling	  
in	  combination	  with	  altered	  ROS	  homeostasis,	  respectively.	  Finally	  we	  have	  provided	  
at	   least	   a	   preliminary	   investigation	   into	   a	   putative	   sub-­‐set	   of	   PTPs	   that	   may	   be	  
particularly	  involved	  in	  such	  processes,	  which	  when	  combined	  with	  recent	  advances	  
in	  the	  generation	  of	  more	  specific	  PTP	   inhibitors	   (Ferreira	  et	  al.,	  2006;	  Hellmuth	  et	  
al.,	   2008;	   Heneberg,	   2009;	   Jiang	   and	   Zhang,	   2008;	   Zhang	   and	   Zhang,	   2007),	   could	  
lead	   to	   more	   effective	   targeted	   therapy	   in	   NBL.	   The	   most	   salient	   point	   of	   these	  
findings	   is	   the	   dichotomy	   of	   senescence/differentiation	   and	   apoptosis,	   as	  
consequences	  of	  vanadium	  compounds	  depending	  on	  putative	  effects	  of	  RA	  (Figure	  
6.1).	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Figure	  6.1.	  Summary	  of	  the	  distinct	  effects	  of	  BMOV	  in	  different	  NBL	  cell	  lines.	  (A)	  BMOV	  
as	  a	  single	  agent	  causes	  Akt	  activation	  along	  with	  altered	  REDOX	  homeostasis	  characterised	  
by	   ROS	   production	   and	   GSH	   downregulation,	   sensitising	   cells	   to	   oxidative	   apoptosis.	   (B)	  
BMOV	  causes	  activation	  of	  Akt	  and	  Erk	  downstream	  of	  putative	  RTK	  signalling	  which	  when	  
coupled	  with	   RA-­‐induced	   transcriptional	   changes	   causes	   hyperactivation,	   driving	   cells	   into	  
senescence.	  
	  
Perhaps	  the	  most	  noteworthy	  point	  of	  this	  study	  is	  that	  PI3K/Akt	  signalling	  has	  been	  
shown	   to	   suffer	   from	   two	   ‘Achilles	   heels’,	   namely	   the	   propensity	   to	   drive	   cell	  
senescence	   when	   activated	   and	   sustained	   at	   high	   levels,	   and	   the	   propensity	   to	  
selectively	  kill	  NBL	  cells	  in	  the	  presence	  of	  heightened	  ROS	  production	  and	  a	  lowered	  
capacity	   to	   detoxify	   intracellular	   ROS.	   Both	   findings	   are	   paradoxical	   given	   that	  
deregulation	   of	   PI3K/Akt	   signalling	   is	   a	   frequent	   and	   often	   crucial	   event	   in	  
oncogenesis,	   and	   such	   signalling	   generally	   promotes	   proliferation	   and	   cell	   survival	  
rather	  than	  mitigating	  such	  behaviour	  (Hennessy	  et	  al.,	  2005;	  Paez	  and	  Sellers,	  2003;	  
Vivanco	   and	   Sawyers,	   2002).	   However	   such	   strategies	   are	   appealing	   given	   that	  
targeting	   an	   ‘Achilles	   heel’	   of	   cancer	   may	   not	   be	   subject	   to	   the	   same	   issues	  
associated	   with	   targeted	   therapy	   against	   oncogenic	   drivers,	   i.e.	   direct	   adaptation	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through	  pathway	  redundancy	  and/or	  evolution	  through	  Darwinian	  selection,	  which	  
ultimately	  results	   in	  tumour	  relapse	  and	   intransigence	  to	  therapy	  (Balmanno	  et	  al.,	  
2009;	  Chandarlapaty	  et	   al.,	   2011;	   Serra	  et	   al.,	   2011;	   She	  et	   al.,	   2010;	   Zhang	  et	   al.,	  
2011).	   Indeed	   targeting	   events	   associated	   with,	   but	   not	   crucial	   to,	   oncogenic	  
transformation,	   i.e.	  adaptive	  changes	  such	  as	  the	  reliance	  on	  tight	  regulation	  of	  an	  
intracellular	  signalling	  cascade	  or	  stress	  events	  such	  as	  ROS	  production,	  might	  show	  
greater	  selectivity	  than	  broadly	  targeting	  dividing	  cells	  (Raj	  et	  al.,	  2011).	  
	   These	   therapeutic	   strategies	   are	   of	   course	   not	   without	   their	   caveats.	   For	  
instance	   although	   Akt	   has	   been	   shown	   to	   negatively	   regulate	   the	   lifespan	   of	  
leukaemia-­‐initiating	   cells	   (Naka	   et	   al.,	   2010;	   Tothova	   et	   al.,	   2007),	   there	   is	   still	  
concern	  that	  efforts	  to	  augment	  such	  an	  anomalous	  feature	  of	  Akt	  signalling	  might	  
have	   negative	   consequences	   such	   as	   driving	   proliferation	   of	   bulk	   tumour	   cells	   for	  
instance.	   However	   we	   have	   provided	   good	   evidence	   that	   although	   vanadium	  
compounds	  with	  any	  combination	  of	  second	  agent	  stimulate	  activation	  of	  both	  Akt	  
and	  Erk,	  there	  is	  little	  if	  any	  effect	  on	  cell	  proliferation	  and	  no	  discernible	  effects	  on	  
non-­‐neoplastic	   cells.	   Furthermore	   there	   are	   certainly	   concerns	   over	   using	   broad	  
inhibitors	   due	   to	   the	   potential	   for	   off-­‐target	   effects.	  While	   one	   cannot	   deny	   that	  
vanadium	  compounds	  could	  potentially	  have	  unwanted	  side	  effects	  due	  to	  inhibiting	  
an	  entire	  enzyme	  family	  that	  carries	  out	  vital	  functions	  in	  cell	  biology,	  again	  we	  have	  
found	  no	  evidence	  for	  acute	  non-­‐specific	  toxicity	  in	  non-­‐neoplastic	  cells.	  	  
Although	   BMOV	  was	   shown	   to	   be	   slightly	   less	   potent	   than	   VA	   (requiring	   a	  
two	   fold	   dosage	   increase	   to	   achieve	   comparable	   effects),	   the	   introduction	   of	  
vanadium	  compounds	  containing	  organic	  scaffolds	  was	  designed	  historically	  to	  limit	  
toxicity-­‐related	   side	   effects	   such	   as	   gastrointestinal	   disturbances	   often	   cited	   as	   a	  
dosage-­‐limiting	   factor	   in	   the	   administration	   of	   vanadium	   compounds	   to	   patients	  
(Thompson	  et	  al.,	  2009).	  	  BMOV	  also	  has	  much	  better	  uptake	  in	  vivo	  than	  vanadium	  
salts.	   This	   also	   highlights	   an	   advantage	   of	   the	   use	   of	   vanadium	   compounds	   as	  
anticancer	  agents	  given	  that	  a	  number	  of	  such	  compounds	  have	  already	  been	  tested	  
on	  human	  patients	  for	  treatment	  of	  type	  2	  diabetes	  (Domingo,	  2002;	  Thompson	  et	  
al.,	   2009).	   Not	   only	   this	   but	   pre-­‐clinical	   studies	   have	   highlighted	   the	   efficacy	   of	  
vanadium	  compounds	  on	  a	  number	  of	  solid	  tumours	  (Bishayee	  et	  al.,	  2010).	  Thus	  we	  
are	  at	  a	  standpoint	  in	  which	  based	  on	  mounting	  in	  vitro	  evidence	  BMOV	  could	  easily	  
	   249	  
be	   tested	   on	   preclinical	   models	   of	   NBL,	   such	   as	   the	   TH-­‐Mycn	   transgenic	   mouse	  
model,	  which	  causes	  Mycn-­‐driven	   tumours	  highly	   similar	   to	  primary	  NBL	   (Weiss	  et	  
al.,	  1997).	  	  
	   The	   present	   study	   has	   also	   ruled	   out	   potential	   candidates	   for	   further	  
investigation	  in	  NBL,	  a	  significant	  feature	  given	  the	  paucity	  of	  knowledge	  concerning	  
NBL	   pathogenesis.	   For	   instance,	   we	   have	   provided	   evidence	   that	   PTPRD	   does	   not	  
harbour	  a	  tumour	  suppressor	  function	  in	  NBL,	  despite	  reports	  of	  genetic	  associations	  
between	  its	  expression,	  mutation	  and	  deletion	  and	  the	  development	  of	  NBL	  (Nair	  et	  
al.,	  2008;	  Stallings	  et	  al.,	  2006).	  This	  perhaps	  highlights	  a	  general	  issue	  in	  the	  field	  of	  
cancer	   biology	   that	   downregulation/genetic	  mutations	   often	   occur	   as	   ‘passengers’	  
downstream	   of	   ‘driver’	   mutations,	   and	  may	   yield	   false	   positives	   in	   the	   search	   for	  
therapeutic	  targets.	  Furthermore	  no	  evidence	  has	  been	  found	  for	  a	  role	  of	  PTEN	  in	  
NBL	  pathogenesis,	  despite	  its	  widespread	  function	  as	  a	  tumour	  suppressor	  in	  other	  
human	   cancers	   (Salmena	   et	   al.,	   2008).	   In	   fact	   despite	   gross	   differences	   in	   PTEN	  
protein	  expression	  exhibited	   in	  NBL	  cell	   lines,	  we	  did	  not	  find	  evidence	  for	  obvious	  
differences	  between	  endogenous	  Akt	  activity,	  suggesting	  that	  the	  PI3K/Akt	  pathway	  
might	  be	   regulated	  by	  other	   rate-­‐limiting	   factors	   in	  NBL.	   	   Similarly	   the	   finding	   that	  
Mycn	   expression	   can	   still	   undergo	   large	   decreases	   following	   BMOV/RA	   treatment	  
despite	   high	   levels	   of	   Akt	   activity	   also	   potentially	   reveals	   that	   targeting	   Mycn	  
through	   inhibition	   of	   enzymes	   preventing	   its	   degradation	   (Gustafson	   and	   Weiss,	  
2010;	   Otto	   et	   al.,	   2009)	   (i.e.	   in	   this	   case	   PI3K	   (Chesler	   et	   al.,	   2006)),	   may	   not	   be	  
necessary	   given	   that	   (a)	   RA,	   already	   used	   for	   the	   treatment	   of	   MRD	   potently	  
decreases	  Mycn	  expression,	  (b)	  PI3K	  activity	  can	  exist	  independently	  of	  Mycn	  levels.	  	  
	   One	   further	   limitation	  of	   the	  present	   study	   is	   that	   it	   is	   as	   yet	  unclear	  as	   to	  
why	  certain	  NBL	  cell	  lines	  either	  respond	  or	  fail	  to	  respond	  to	  vanadium	  compound	  
treatment,	   and	   furthermore	  why	   some	   are	   particularly	   susceptible	   to	   one	   form	  of	  
response	   such	   as	   pro-­‐senescence/differentiation	   (e.g.	   SH-­‐SY5Y),	   while	   others	   to	  
another	   form	   such	   as	   apoptosis	   (e.g.	   KCNR).	   Obviously	   therapeutic	   resistance	   is	  
almost	   unanimously	   experienced	   with	   targeted	   therapy,	   and	   often	   poorly	  
understood,	  and	  it	  is	  very	  likely	  that	  BMOV	  treatment	  would	  not	  be	  equally	  effective	  
in	   all	   NBL	   tumours,	   given	   their	   well-­‐characterised	   heterogeneity	   and	   the	   sheer	  
number	  of	  genetic	  alterations	  associated	  with	  high-­‐stage	  NBL.	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   It	   is	   still	   unclear	   how	   BMOV	   exerts	   such	   different	   effects	   of	   differentiation	  
and	  apoptosis.	  This	  is	  highlighted	  by	  the	  fact	  that	  BMOV-­‐responsive	  cell	  lines	  such	  as	  
KCNR	   seem	   to	   undergo	   apoptosis	   in	   response	   to	   BMOV	   as	   a	   single	   agent,	   yet	   RA	  
exerts	   a	   seemingly	   neuro-­‐protective	   effect,	   limiting	   cytotoxicity.	   One	   possibility	   is	  
that	   these	   effects	   depend	   on	   the	   level	   of	   activity	   of	   Akt	   and/or	   Erk	   (which	   is	   far	  
greater	   in	   the	   case	   of	   BMOV/RA	   versus	   BMOV	   alone),	   as	   this	   has	   been	   shown	   to	  
affect	   substrate	   interactions	   (von	  Kriegsheim	  et	  al.,	   2009).	  However	   LY29/BMOV	   is	  
also	  capable	  of	   inducing	  high	   levels	  of	  Akt	  activity,	  which	   result	   in	  cell	  death.	  Thus	  
one	  might	  hypothesise	  that	  RA	  may	   limit	   the	  production	  of	  ROS	  and/or	  changes	   in	  
GSH	  synthesis.	  While	  this	   is	  a	  distinct	  possibility,	   it	  will	  always	  be	  difficult	  to	  gain	  a	  
complete	  understanding	  of	  the	  effects	  of	  combination	  BMOV/RA	  treatment	  as	  both	  
agents	  instigate	  wide	  scale	  molecular	  changes	  in	  transcription	  and	  post-­‐translational	  
modification	  of	  proteins.	   The	  mechanism	  of	   action	  of	  RA	   is	   still	   surprisingly	  poorly	  
understood	  despite	  its	  use	  in	  the	  clinic	  for	  over	  ten	  years.	  	  
One	   minor	   irritation	   during	   this	   investigation	   was	   the	   fact	   that	   the	  
effectiveness	  of	  VA/BMOV	  treatments	  on	  distinct	  cell	  lines	  varied	  slightly	  throughout	  
the	  3-­‐year	  study.	  For	  instance	  cell	   lines	  such	  as	  IMR32,	  which	  responded	  acutely	  to	  
BMOV	  treatment	  by	  undergoing	  apoptosis,	  failed	  to	  undergo	  a	  phenotypic	  response	  
at	   some	  points.	   Furthermore	  BMOV/RA-­‐induced	  Akt/Erk	   stimulation	  also	  exhibited	  
variability	   where	   both	   the	   endogenous	   and	   RA-­‐mediated	   activation	   of	   both	  
pathways	  gradually	  went	  up	  from	  barely	  detectable	  levels	  to	  significant	  levels	  as	  the	  
study	   progressed,	   while	   the	   senescence	   responses	   varied	   in	   that	   SH-­‐SY5Y	   cells	  
became	  more	  responsive	  to	  RA	  and	  less	  responsive	  to	  BMOV/RA,	  initiating	  the	  noted	  
later	  change	   in	  dosage	  of	  BMOV	  treatment.	  Unfortunately	  these	  vagaries	  elicit	   few	  
obvious	   explanations.	   One	   might	   of	   course	   accept	   that	   the	   number	   of	   factors	  
involved	   in	   mammalian	   cell	   culture	   (e.g.	   substratum,	   serum	   content,	   serial	  
passaging)	   might	   introduce	   a	   certain	   level	   of	   inevitable	   variability	   into	   these	  
experiments.	   Such	   variability	   might	   also	   stem	   however	   from	   actual	   instances	   of	  
acquired	  resistance,	  for	  instance	  where	  cells	  might	  gradually	  increase	  their	  tolerance	  
to	   oxidative	   stress.	   However,	   we	   feel	   it	   unlikely	   that	   this	   is	   occurring	   because	  
passage	   numbers	   for	   the	   cells	   were	   monitored	   and	   new	   cell	   batches	   were	   used	  
regularly	   throughout	   the	   study.	   Finally,	   it	   is	   possible	   that	   batch	   variations	   in	   the	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chemicals	  themselves	  may	  have	  had	  a	  part	  to	  play,	  although	  no	  clear	  evidence	  of	  this	  
was	  apparent.	  
Another	   noted	   caveat	   concerning	   the	   use	   of	   vanadium	   compounds	   is	   that	  
they	  have	  been	  described	  to	  achieve	  a	  number	  of	  effects	  distinct	  from	  PTP	  inhibition	  
such	  as	  oxidative	  stress,	  inhibition	  of	  ATPases	  and	  transcriptional	  changes	  (See	  figure	  
1.5.3).	   Thus	   it	   is	   possible	   that	   the	   effects	   described	   in	   the	   present	   study	   occur	  
independently	   of	   PTPs.	   However	   there	   are	   a	   number	   of	   counter	   points	   to	   this	  
argument.	   First,	   we	   detected	   no	   evidence	   of	   p53/p38	  MAPK	   induction/activation,	  
suggesting	   that	   oxidative	   stress	   and/or	  DNA	   damage	   is	   not	   occurring.	   Second,	   the	  
activation	  of	  Akt	  and	  Erk	  would	  be	  predicted	  to	  occur	  following	  PTP	  inhibition,	  due	  
to	  relief	  of	  negative	  feedback	  regulation	  of	  RTKs.	  Lastly	  the	  effects	  described	  in	  the	  
present	   study	   were	   often	   modest,	   such	   as	   the	   production	   of	   ROS	   or	   the	  
accumulation	  of	  pTyr,	  suggesting	  that	  at	  the	  given	  dosage	  vanadium	  compounds	  are	  
capable	  of	  showing	  selectivity	  towards	  specific	  targets.	  However	  the	  mechanism	  of	  
action	  of	  such	  compounds	  is	  clearly	  of	  interest,	  and	  will	  undoubtedly	  be	  the	  subject	  
of	  on	  going	  investigations.	  
	   One	   important	   task	   is	   to	   better	   understand	   the	   specific	   PTPs	   crucial	   to	   the	  
response	   to	   BMOV	   and/or	   BMOV/RA	   therapy.	   While	   we	   have	   undertook	   some	  
analysis	  to	  this	  end,	  i.e.	  conducting	  a	  qPCR	  screen	  and	  computing	  clustering	  analysis,	  
again	   it	   is	   difficult	   to	   go	   beyond	   speculation	   at	   this	   stage	   as	   to	   which	   PTPs	   are	  
required	   for	   these	   responses.	   Not	   only	   this	   but	   the	   general	   difficulty	   in	   designing	  
specific	  PTP	  inhibitors	  based	  on	  the	  highly	  conserved	  active	  site	  structure	  present	  in	  
PTPs	  would	  still	  present	  a	  significant	  barrier	  to	  specific	  targeted	  therapy.	  Setting	  this	  
aside,	  the	  functional	  relevance	  of	  individual	  PTPs	  to	  differentiation/apoptosis	  might	  
be	   deciphered	   based	   on	   whole	   PTPome	   siRNA	   screening,	   whereby	   siRNA	   libraries	  
targeted	  towards	  PTPs	  would	  reveal	  the	  effects	  of	  specific	   loss	  of	  function	  for	  each	  
gene	  on	  either	  differentiation,	  which	  might	  be	  achieved	  through	  a	  high-­‐throughput	  
platform	   analysing	  morphological	   changes,	   or	   apoptosis,	   which	   could	   be	   assessed	  
based	  on	  cell	   survival	  assays.	   It	   is	  also	   important	   to	  understand	  the	   interactions	  of	  
BMOV	  and	  RA.	  Given	  that	  RA	  exerts	  large-­‐scale	  transcriptional	  changes,	  these	  could	  
be	   correlated	   with	   potential	   BMOV	   targets	   for	   instance	   PTPs	   that	   function	   as	  
negative	   regulators	  of	  RA-­‐target	   suppressors.	   The	  actual	   targets	  of	  BMOV	  could	  at	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the	   same	   time	   be	   better	   understood	   through	   use	   of	   2D-­‐gel	   electrophoresis	   or	  
quantitative-­‐phosphoproteomics	   through	   stable	   isotope	   amino	   acid	   labelling	   in	  
culture	   and	   mass	   spectrometry,	   revealing	   widespread	   protein	   expression	   and	  
activation	   changes	   influenced	   by	   BMOV	   treatment.	   The	   hypothesis	   that	   BMOV	  
treatment	  causes	  activation	  of	  RTKs	  could	  easily	  be	  tested	  using	  an	  RTK	  array.	  Once	  
targets	   are	   better	   understood	   resistance	   to	   BMOV	   may	   be	   potentially	   revealed	  
through	   mechanisms	   such	   as	   mutations	   in	   targets	   or	   differential	   expression	   of	  
negative	  regulators.	  Resistance	  could	  actually	  be	  potentially	  modelled	  by	  analysis	  of	  
changes	  in	  protein	  expression/activation	  following	  continual	  exposure	  to	  BMOV	  and	  
sub-­‐cloning	  of	  resistant	  cells	  (Engelman	  et	  al.,	  2007;	  Janne	  et	  al.,	  2009).	  
	  Furthermore	   a	   number	   of	   PTPs	   were	   expressed	   at	   very	   low	   levels	   in	   this	  
study,	   potentially	   ruling	   them	  out	   for	   involvement	   in	   these	   effects.	   Lastly	   another	  
conceptually	  interesting	  exercise	  would	  be	  to	  compare	  the	  expression	  of	  PTPs	  based	  
on	  our	  qPCR	  data	  with	  their	  prognostic	  value	  based	  on	  the	  oncogenomics	  databases	  
(http://home.ccr.cancer.gov/oncology/oncogenomics),	   whereby	   statistically	  
significant	  differences	  in	  5	  year	  EFS	  rates	  based	  on	  PTP	  gene	  expression	  might	  reveal	  
further	  candidates	  for	  functional	  analysis,	  Although	  it	  is	  difficult	  to	  infer	  causality	  in	  
survival	   based	   simply	   on	   the	   fact	   that	   inhibition	   	   of	   PTPs	   causes	   a	   potentially	  
therapeutic	  benefit,	  such	  prognostic	  analyses	  would	  still	  be	  a	  valid	  starting	  point.	  	  
	   A	   perhaps	   crucial	   benefit	   when	   discussing	   the	   viability	   of	   vanadium	  
compounds	  as	  targeted	  therapies	  in	  NBL	  is	  that	  their	  use	  would	  essentially	  be	  drug	  
redeployment.	  Such	  redeployment	  is	  at	  an	  advantage	  when	  compared	  with	  entirely	  
novel	   agents	   due	   to	   the	   wealth	   of	   knowledge	   concerning	   clinical	   factors.	   For	  
example,	  a	  number	  of	  vanadium	  compounds	  have	  been	  tested	  clinically	  for	  the	  use	  
of	   type	   2	   diabetes,	   some	   under	   late	   stage	   clinical	   trials.	   This	   provides	   invaluable	  
information	   as	   to	   toxicity	   issues	   and	   dosage	   requirements/limitations,	  which	   have	  
already	  been	   instrumental	   in	  generating	  compounds	  such	  as	  BMOV	  and	  BEOV	  that	  
are	  generally	  well	  tolerated	  clinically.	  Furthermore	  due	  to	  the	  ongoing	  efforts	  of	  the	  
diabetes	   field	   new	   compounds	   are	   frequently	   being	   generated,	   which	   may	   have	  
similar	  efficacy.	   Lastly	  as	  previously	  discussed	  a	  number	  of	  preclinical	   studies	  have	  
been	  carried	  out	  describing	  vanadium	  compounds	  as	  cytotoxic	  agents	   (Bishayee	  et	  
al.,	  2010),	  many	  of	  which	  actually	  predate	  the	  discovery	  of	  PTPs.	  Thus	  as	  with	  many	  
	   253	  
agents	   that	  have	  both	  been	   redeployed	   from	   the	   treatment	  of	  other	  diseases	   and	  
entered	  the	  clinic	  prior	  to	  an	  understanding	  of	  their	  mechanism	  of	  action	  (including	  
RA	  itself),	  basic	  research	  will	  undoubtedly	  go	  hand	  in	  hand	  with	  translational	  studies.	  	  	  
	   Thus	  in	  sum,	  the	  present	  study	  has	  provided	  evidence	  of	  a	  crucial	  role	  for	  the	  
PTP	  family	  in	  both	  the	  differentiation	  and	  survival	  of	  NBL	  cells.	  We	  have	  devised	  at	  
least	   three	   novel	   therapeutic	   combinations	   (BMOV/RA,	   BMOV/BSO,	  
BMOV/LY294002)	  worthy	  of	  pre-­‐clinical	   testing	   for	   instance	   in	   the	  aforementioned	  
TH-­‐Mycn	  transgenic	  mouse	  or	   in	  NBL	  xenografts,	  and	  provided	  molecular	  evidence	  
for	   the	  basis	  of	   their	  effects	  on	  differentiation/senescence	  and	  apoptosis.	  Not	  only	  
this	  but	  we	  have	   shown	   that	  by	   increasing	   the	   levels	  of	  Akt	  activation	  with	  BMOV	  
one	   can	   paradoxically	   limit	   cell	   growth	   and	   survival,	   concomitant	  with	   RA-­‐induced	  
transcriptional	  changes	  and/or	  Akt	  activation	  or	  and	  BMOV-­‐induced	  ROS	  production,	  
respectively.	  This	  is	  despite	  the	  evidence	  that	  the	  PI3K/Akt	  pathway	  can	  contributes	  
negatively	   toward	   NBL	   patient	   survival	   (Opel	   et	   al.,	   2007)	   and	   increases	   cell	  
survival/proliferation	  in	  other	  contexts	  (Bender	  et	  al.,	  2011),	  raising	  a	  point	  that	  is	  at	  
least	  conceptually	  worthy	  of	  interest.	  Lastly	  we	  have	  initiated	  expression	  profiling	  of	  
the	  entire	  PTPome	   in	  a	  panel	  of	  both	  Mycn	  amplified	  and	  non-­‐amplified	  NBL	  cells,	  
providing	  useful	  information	  both	  in	  the	  delineation	  of	  the	  effects	  of	  PTP	  inhibition,	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